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ABSTRACT	  
Adeno-­‐associated	  virus	  (AAV)	  is	  a	  small	  non-­‐pathogenic	  human	  DNA	  parvovirus.	  
The	   AAV	   life	   cycle,	   which	   includes	   transcriptional	   regulation,	   DNA	   replication,	  
assembly	  and	  site-­‐specific	   integration,	   is	  orchestrated	  by	  AAV’s	   four	  Rep	  proteins.	  
Structurally,	  these	  proteins	  share	  a	  AAA+	  domain	  characteristic	  of	  the	  SF3	  family	  of	  
helicases,	  with	   the	   larger	   Rep68	   and	  Rep78	   additionally	   containing	   an	  N-­‐terminal	  
origin-­‐binding	  domain	  (OBD)	  that	  specifically	  binds	  and	  nicks	  DNA.	  The	  combination	  
of	   these	   domains	   is	   the	   basis	   for	   the	   remarkable	  multi-­‐functionality	   displayed	   by	  
Rep68	   and	   Rep78.	   To	   date,	   structural	   studies	   of	   Rep68	   and	   Rep78	   have	   been	  
limited	   by	   the	   tendency	   of	   these	   proteins	   to	   aggregate	   when	   purified.	   Here,	   we	  
describe	   a	   fully	   functional	   Rep	   mutant	   that	   does	   not	   aggregate	   even	   at	   high	  
concentrations	  and	  use	   this	  mutant	   to	   investigate	   the	  structural	   requirements	   for	  
Rep	   functions.	   We	   demonstrate	   that	   one	   of	   the	   determinants	   regulating	   the	  
oligomerisation	   of	   the	   Rep	   proteins	   lies	   in	   the	   linker	   connecting	   the	   helicase	  
domain	  and	  OBD.	  We	  also	  identify	  a	  series	  of	  key	  residues	  at	  the	  interface	  between	  
Rep	   monomers	   and	   show	   that	   mutating	   them	   has	   drastic	   effects	   both	   on	   the	  
oligomerisation	   and	   functionality	   of	   the	   Rep	   proteins.	   Importantly,	   these	  
oligomerisation-­‐deficient	  mutants	  do	  not	  support	  the	  AAV	  life-­‐cycle	  and	  fail	  to	  bind	  
DNA	   efficiently,	   an	   important	   Rep	   function	   necessary	   for	   DNA	   nicking,	  
transcriptional	  regulation,	  viral	  DNA	  replication	  and	  site-­‐specific	  integration.	  
Finally,	   understanding	   the	   molecular	   details	   of	   Rep	   and	   its	   functions	   will	  
contribute	   to	   the	   development	   of	   new	   AAV-­‐based	   vectors	   that	   exploit	   the	   Rep-­‐
mediated	   integration	  mechanism	   and	   potentially	   have	   a	   lower	   risk	   of	   insertional	  
mutagenesis	  than	  retroviral	  vectors.	  In	  the	  last	  chapter,	  we	  describe	  an	  AAV	  vector	  
for	   testing	   the	   safety	   and	   feasibility	   of	   AAV-­‐mediated	   targeted	   gene	   addition	   in	  
induced	  pluripotent	   stem	   (iPS)	   cells	  within	   the	   therapeutic	   context	  of	  SCID-­‐X1,	  an	  
immunodeficiency	  caused	  by	  mutations	  in	  the	  common	  gamma	  chain	  gene.	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  repeats	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  Modified	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DNA	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   Double	  strand	  break	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   Double-­‐stranded	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E1	   	   E1	  protein	  of	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HeLa	   	  	   Henrietta	  Lacks	  (Human	  epitheloid	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   Homologous	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HRP	   	   Horseradish	  Peroxidase	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   Hematopoietic	  stem	  cells	  
HSPG	   	   Heparan	  sulphate	  proteoglycan	  
HSV-­‐1	   	   Herpes	  simplex	  virus	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HUH	   	   His-­‐hydrophobic-­‐His	  
IL-­‐2	   	   Interleukin	  2	  
IL2RG	   	   IL-­‐2	  receptor	  common	  gamma	  chain	  
Ile,	  I	   	   Isoleucine	  
iPSCs	   	   Induced	  pluripotent	  stem	  cells	  
ITR	   	   Inverted	  terminal	  repeat	  
LB	   	   Lysogeny	  broth	  
LTag	   	   Large	  T	  antigen	  of	  SV40	  
Lys,	  K	   	   Lysine	  
LTR	   	   Long	  terminal	  repeat	  
MBP	   	   Maltose-­‐binding	  protein	  
Mbs85	  	   Myosin-­‐binding	  subunit	  85	  
MCM	   	   Minichromosome	  maintenance	  complex	  
MOI	   	   Multiplicity	  of	  infection	  
MRN	   	   Mre11,	  Rad50,	  Nbs1	  complex	  
mRNA	   	   Messenger	  RNA	  
MVM	   	   Minute	  virus	  of	  mice	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NEB	   	   New	  England	  Biolabs	  
NHEJ	   	   Non-­‐homologous	  end-­‐joining	  
NTP	   	   Nucleoside	  triphosphate	  
OBD	   	   Origin	  binding	  site	  
OD	   	   Oligomerisation	  domain	  
ORF	   	   Open	  reading	  frame	  
ori	   	   Origin	  of	  replication	  
PAGE	  	   	   Poly-­‐acrylamide	  gel	  electrophoresis	  
PBS	  	   	   Phosphate	  buffered	  saline	  
PCR	   	   Polymerase	  chain	  reaction	  
PCNA	   	   Proliferating	  nuclear	  antigen	  
PEI	   	   Polyethylinimine	  
PFA	  	   	   Paraformaldehyde	  
Phe,	  F	   	   Phenylalanine	  
PIDs	   	   Primary	  immunodeficiencies	  
PLA2	   	   Phospholipase	  A2	  
POLD	   	   DNA	  polymerase	  delta	  
PPP1R12C	   Protein	  phosphatase	  I	  regulatory	  inhibitor	  subunit	  12C	  
PV	   	   Papilloma	  virus	  
qPCR	   	   Quantitative	  real-­‐time	  PCR	  
rAAV	   	   Recombinant	  AAV	  vectors	  
RCR	   	   Rolling	  circle	  replication	  
RBS	   	   Rep	  binding	  site	  
RE	   	   Restriction	  enzyme	  
Rep*	   	   Rep-­‐C151S	  (mutation	  of	  cysteine	  151	  to	  serine)	  
Rep68*	   Rep68-­‐C151S	  
RFC	   	   Replicating	  factor	  C	  
RGENs	  	   RNA-­‐guided	  engineered	  nucleases	  
RNA	   	   Ribonucleic	  acid	  
RT	   	   RT	  Reverse	  transcriptase	  
scAAVs	  	   Self-­‐complementary	  AAVs	  
SCID-­‐X1	   X-­‐linked	  severe	  combined	  immunodeficiency	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Ser,	  S	   	   Serine	  
S.e.m.	   	   Standard	  error	  of	  the	  mean	  
SF3	   	   Superfamily	  3	  of	  helicases	  
ssDNA	   	   Single-­‐stranded	  DNA	  
SV40	   	   Simian	  virus	  40	  
TAE	   	   Tris-­‐acetate-­‐EDTA	  
TALENs	   Transcription	  activator-­‐like	  effector	  nucleases	  
TEMED	  	   N,N,N’,N’-­‐tetramethylethylenediamine	  
TRS	   	   Terminal	  resolution	  site	  
Trp,	  W	  	   Tryptophan	  
TYLCV	   	   Tomato	  yellow	  leaf	  curl	  virus	  
Tyr,	  Y	   	   Tyrosine	  
Val,	  V	   	   Valine	  
VA	  RNA	   Viral	  associated	  RNA	  
VRs	   	   Variable	  regions	  
WAS	   	   Wiskott-­‐Aldrich	  syndrome	  
WPRE	   	   Woodchuck	  Posttranscriptional	  Regulatory	  Element	  
WT	   	   Wild	  type	  
ZFNs	   	   Zinc-­‐finger	  nucleases	  
Zn	   	   Zinc	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CHAPTER	  1: INTRODUCTION	  
1.1 ADENO-­‐ASSOCIATED	  VIRUS	  
1.1.1 Adeno-­‐associated	  virus	  –	  a	  historical	  overview	  
Adeno-­‐associated	  virus	  (AAV)	  was	  first	  discovered	  50	  years	  ago	  as	  a	  contaminant	  
of	   adenovirus	   stocks	   (Atchison	   et	   al.	   1965;	   Hoggan	   et	   al.	   1966).	   It	   was	   initially	  
described	   as	   a	   defective	   small	   virus-­‐like	   particle,	   serologically	   distinct	   from	  
adenovirus,	   which	   was	   infectious	   in	   humans	   but	   required	   co-­‐infection	   by	  
adenovirus	  to	  replicate.	  It	  was	  soon	  noticed	  that	  other	  viruses,	  such	  as	  herpes	  virus,	  
could	  also	  support	  productive	  AAV	  replication	  (Blacklow	  et	  al.	  1970).	  Early	  research,	  
inspired	  by	  the	  molecular	  biology	  studies	  on	  bacteriophages,	  focussed	  on	  dissecting	  
the	  AAV	  genome	  structure.	  It	  was	  noted	  that	  the	  AAV	  genome	  was	  DNA,	  that	  it	  was	  
packaged	   as	   a	   linear	   single	   strand	   of	   either	   plus	   or	  minus	   sense	   (Crawford	   et	   al.	  
1969;	  Rose	  et	  al.	  1969)	  and	  that	  the	  minus	  sense	  DNA	  was	  the	  template	  for	  mRNA	  
transcription	   (Carter	   et	   al.	   1975).	   The	   three	   structural	   proteins	   of	   AAV	   were	  
identified	  soon	  after	  and	  termed	  VP1,	  VP2	  and	  VP3	  (Johnson	  et	  al.	  1971;	  Rose	  et	  al.	  
1971).	  Further	  studies	  into	  the	  structure	  of	  the	  AAV	  DNA	  revealed	  that	  it	  contained	  
inverted	  palindromic	  repeats	  that	  could	  form	  complex	  secondary	  structures	  (Carter	  
et	  al.	  1972;	  Gerry	  et	  al.	  1973;	  Koczot	  et	  al.	  1973;	  Berns	  and	  Kelly	  1974)	  and	  serve	  as	  
origin	  of	  replication,	  leading	  to	  the	  first	  models	  of	  AAV	  replication	  (Denhardt	  et	  al.	  
1976;	   Straus	   et	   al.	   1976;	   Tattersall	   and	  Ward	   1976;	   Hauswirth	   and	   Berns	   1977).	  
Direct	  sequencing	  of	  the	  AAV	  termini	  (Lusby	  et	  al.	  1980)	  confirmed	  the	  presence	  of	  
inverted	   terminal	   repeats	   (ITRs)	   that	   could	   form	   T-­‐shaped	   hairpins.	   In	   the	   same	  
period,	  a	  mechanism	  for	  packaging	  of	  single	  stranded	  progeny	  DNA	  into	  preformed	  
capsids	  was	  described	  (Myers	  and	  Carter	  1980),	  and	  the	  basic	  transcriptional	  map	  
of	  AAV	  was	   defined	   (Laughlin	   et	   al.	   1979;	  Green	   and	  Roeder	   1980;	  Marcus	   et	   al.	  
1981).	   Furthermore,	   it	   was	   observed	   that	   AAV	   could	   establish	   latent	   infection	   in	  
cells	   in	   the	  absence	  of	  helper	  virus	  by	   integrating	   into	  the	  host	  genome,	  and	  that	  
infectious	  AAV	   could	   be	   rescued	   from	   these	   cells	   upon	   infection	  with	   adenovirus	  
(Hoggan	  1972;	  Cheung	  et	  al.	  1980).	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Significant	   progress	   in	   the	   field	   came	   from	   the	   development	   of	   the	   first	   AAV	  
molecular	  clones	  in	  the	  early	  1980s	  (Samulski	  et	  al.	  1982;	  Laughlin	  et	  al.	  1983)	  and	  
from	  the	   sequencing	  of	   its	  genome	   in	  1983	   (Srivastava	  et	  al.	  1983).	  At	   this	  point,	  
genetic	  analysis	  of	  the	  AAV	  genome	  was	  possible	  (Hermonat	  et	  al.	  1984;	  Tratschin	  
et	  al.	  1984a),	  and	   it	  was	  confirmed	  that	  the	   ITRs	  are	  the	  origin	  of	  AAV	  replication	  
and	  act	   in	  cis.	   In	  addition,	   two	   large	  open	  reading	   frames	   (ORF),	  coding	   for	  trans-­‐
acting	   functions,	   were	   identified	   within	   the	   AAV	   genome:	   the	   left	   half	   of	   the	  
genome	   was	   necessary	   for	   replication,	   while	   the	   right	   half	   coded	   for	   the	   capsid	  
proteins.	  These	  discoveries	  paved	  the	  way	   for	   the	  development	  of	  AAV	  as	  a	  gene	  
therapy	  vector.	  	  
The	  first	  recombinant	  vectors	  (rAAVs)	  were	  produced	  by	  co-­‐transfecting	  an	  ITR-­‐
flanked	   transgene-­‐containing	   plasmid	   and	   a	   construct	   coding	   for	   Rep	   and	   Cap	   in	  
adenovirus-­‐infected	   cells	   (Hermonat	   and	  Muzyczka	   1984;	   Tratschin	   et	   al.	   1984b).	  
These	   early	   vectors	   were	   contaminated	   with	   wild	   type	   (WT)	   AAV	   and	   heat-­‐
inactivated	  adenovirus,	  nevertheless	  they	  showed	  that	  it	  was	  possible	  to	  transduce	  
cells	  to	  achieve	  transgene	  expression	  from	  foreign	  DNA	  packaged	  in	  AAV	  particles.	  
Further	   refinements	   in	   AAV	   vector	   production	   (Samulski	   et	   al.	   1989;	   Flotte	   et	   al.	  
1995)	   that	   allowed	   for	   the	   generation	   of	   vector	   stocks	   free	   of	   WT	   AAV	   and	  
adenovirus	  contaminants	   led	  to	   the	   first	   in	  vivo	  gene	  therapy	  study	  using	  rAAV	   in	  
1993	  (Flotte	  et	  al.	  1993).	  This	  was	  followed	  few	  years	  later	  by	  the	  initiation	  of	  the	  
first	  clinical	   trial	   in	  cystic	   fibrosis	  patients	   (Flotte	  et	  al.	  2003).	   In	  the	   last	  20	  years,	  
the	  study	  of	  AAV-­‐based	  vectors	  for	  gene	  therapy	  has	  attracted	  a	  lot	  of	  interest	  and	  
the	   field	   has	   expanded	   rapidly,	   generating	   a	   vast	   amount	   of	   knowledge	   that	  
translated	  into	  numerous	  clinical	  trials.	  
In	   parallel	   to	   the	   development	   of	   AAV	   vectors	   for	   gene	   therapy	   studies,	  
investigations	  were	  ongoing	  to	  characterise	  the	  integration	  of	  AAV	  in	  the	  host	  cell	  
genome.	   The	   initial	   observations	   on	   latency	   were	   confirmed	   in	   several	   cell	   lines	  
using	  both	  WT	  and	  recombinant	  AAV	  (Laughlin	  et	  al.	  1986;	  McLaughlin	  et	  al.	  1988).	  
Remarkably,	   the	   analysis	   of	   the	   WT	   AAV	   integration	   sites	   revealed	   that	   most	  
integration	  events	  mapped	  to	  a	  site	  on	  human	  chromosome	  19,	  which	  was	  termed	  
AAVS1	  (Kotin	  et	  al.	  1990;	  Kotin	  et	  al.	  1991;	  Samulski	  et	  al.	  1991;	  Kotin	  et	  al.	  1992).	  
The	   determinants	   for	   site-­‐specific	   integration	   were	   uncovered	   soon	   after	   and	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included	   the	   large	   Rep	   proteins	   (Balague	   et	   al.	   1997;	   Surosky	   et	   al.	   1997),	   and	  
sequences	  shared	  by	  AAVS1	  and	   the	  viral	   ITRs,	  namely	   the	  Rep	  binding	  site	   (RBS)	  
and	  the	  terminal	  resolution	  site	  (TRS)	  present	   in	  the	  AAVS1	  site,	  and	  the	  viral	  RBS	  
(Weitzman	   et	   al.	   1994;	   Urcelay	   et	   al.	   1995;	   Linden	   et	   al.	   1996a).	   It	   was	   initially	  
thought	   that	   both	   WT	   and	   recombinant	   AAV	   could	   integrate	   site-­‐specifically	  
(Samulski	  et	  al.	  1989).	  However,	   it	   later	  became	  clear	   that	   in	   the	  absence	  of	  Rep,	  
AAV	   vectors	   only	   persist	   as	   circular	   episomes	   (Schnepp	   et	   al.	   2003)	   or	   integrate	  
randomly	   at	   very	   low	   frequency	   (Walsh	   et	   al.	   1992;	   Kearns	   et	   al.	   1996).	   Recent	  
developments	   in	   the	   study	   of	   AAV	   integration,	   facilitated	   by	   the	   advent	   of	  more	  
advanced	   PCR-­‐based	   technologies,	   are	   now	   shedding	   additional	   light	   on	   the	  
mechanism	  of	  integration	  (reviewed	  in	  section	  1.1.3.8).	  
Today,	  despite	  the	  fact	  that	  much	  remains	  to	  be	  learned	  about	  AAV,	  research	  on	  
the	  basic	  virology	  of	  AAV	  is	  overshadowed	  by	  its	  promise	  as	  a	  gene	  therapy	  vector.	  
The	  process	  of	  AAV	  site-­‐specific	  integration	  and	  its	  implications,	  including	  whether	  
site-­‐specific	  integration	  is	  actually	  part	  of	  the	  AAV	  life	  cycle	  or	  a	  mere	  consequence	  
of	   the	   biochemical	   activities	   of	   the	   Rep	   proteins,	   for	   instance,	   are	   starting	   to	  
become	   more	   accessible	   as	   advanced	   DNA	   sequencing	   technologies	   become	  
available.	   Furthermore,	   the	   remarkable	   multi-­‐functionality	   of	   the	   Rep	   proteins	  
(Mendelson	  et	  al.	  1986;	  Im	  and	  Muzyczka	  1990)	  and	  the	  mechanisms	  by	  which	  they	  
orchestrate	   the	  AAV	   life	   cycle	  are	   still	   under	   investigation.	  Understanding	   the	   full	  
extent	   of	   their	   versatile	   biochemical	   properties,	   including	   their	   ability	   to	   site-­‐
specifically	  bind	  and	  nick	  DNA	  substrates,	  may	   reveal	  an	  exciting	  biotechnological	  
potential.	  Finally,	  the	  study	  of	  the	  interactions	  between	  AAV	  and	  its	  helper	  viruses	  
may	  provide	  insights	  into	  virus-­‐virus	  interactions,	  an	  undervalued	  aspect	  of	  biology	  
that	   could	   have	   important	   implications	   in	   human	   health	   are	   only	   beginning	   to	  
emerge	  (Virgin	  2014).	  
1.1.2 AAV	  –	  the	  virus	  
1.1.2.1 Taxonomy	  
AAV	  belongs	   to	   the	  Parvovirus	   family,	  which	   includes	  all	   small,	  non-­‐enveloped,	  
linear	   single-­‐stranded	   DNA	   viruses.	   The	   Parvoviridae	   are	   remarkably	   widespread	  
throughout	   the	   animal	   kingdom,	   and	   are	   further	   classified	   into	   the	   subfamilies	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Parvovirinae,	   infecting	   vertebrates,	   and	   Densovirinae,	   infecting	   arthropods	  
(Tattersall	  2006).	  AAV	  is	  further	  classified	  into	  the	  dependovirus	  genus,	  based	  on	  its	  
dependence	  on	  helper	  functions	  provided	  by	  other	  DNA	  viruses,	  such	  as	  adenovirus	  
or	  herpesvirus,	  to	  complete	  a	  productive	  replication	  cycle.	  	  
To	  date	  thirteen	  AAV	  serotypes	  (AAV1	  to	  13)	  have	  been	  described	  (Srivastava	  et	  
al.	  1983;	  Muramatsu	  et	  al.	  1996;	  Chiorini	  et	  al.	  1997;	  Rutledge	  et	  al.	  1998;	  Chiorini	  
et	  al.	  1999b;	  Gao	  et	  al.	  2002;	  Gao	  et	  al.	  2004;	  Mori	  et	  al.	  2004;	  Schmidt	  et	  al.	  2006;	  
Schmidt	  et	  al.	  2008a;	  Schmidt	  et	  al.	  2008b),	  and	  serological	  studies	  have	  detected	  
antibodies	  against	  AAV	   in	  human	  and	  non-­‐human	  primates	   (Blacklow	  et	  al.	   1968;	  
Chirmule	  et	   al.	   1999;	   Kerr	   and	   Linden	  2006;	  Calcedo	  et	   al.	   2009).	   Furthermore,	   a	  
vast	  number	  of	  cap	   gene	   sequences	  have	  been	   identified	   in	  primate	   tissues.	  AAV	  
sequences	   have	   also	   been	   described	   for	   other	   mammals	   (dogs,	   pigs,	   cows	   and	  
horses)	  and	  in	  birds.	  The	  current	  taxonomy	  of	  AAV	  is	  based	  on	  cap	  gene	  sequence	  
similarity,	  as	  it	  is	  clear	  that	  each	  isolate	  does	  not	  represent	  a	  distinct	  serotype.	  AAV	  
sequences	  have	  been	  grouped	   into	   six	   clades	   (A-­‐F)	   and	   two	  clonal	   isolates	   (AAV4	  
and	  AAV5)	  (Gao	  et	  al.	  2004).	   It	   is	  noteworthy	  that	  most	  of	  the	  knowledge	  on	  AAV	  
biology	  comes	  from	  AAV2,	  which	  is	  the	  most	  extensively	  studied	  AAV	  serotype	  and	  
also	  the	  focus	  of	  this	  thesis.	  	  
1.1.2.2 Genome	  structure	  
The	  AAV	  genome	  (Figure	  1)	  is	  a	  single	  stranded	  linear	  DNA	  (ssDNA)	  molecule	  of	  
4.7kb;	   both	   plus	   and	  minus	   strands	   are	   infectious	   (Samulski	   et	   al.	   1987)	   and	   are	  
packaged	  with	  equal	  efficiency	  into	  separate	  preformed	  capsids	  (King	  et	  al.	  2001).	  
ITRs	  –	  imperfect	  palindromic	  sequences	  that	  self-­‐anneal	  to	  form	  T-­‐shaped	  hairpins	  
(Lusby	  et	  al.	  1980)	  –	  flank	  the	  AAV	  genome	  and	  provide	  all	  the	  cis-­‐acting	  elements	  
necessary	  for	  replication,	  packaging	  and	  integration	  (Samulski	  et	  al.	  1989),	  including	  
the	  RBS	  and	  the	  TRS.	  	  
The	  AAV	  genome	  contains	   two	  major	  ORFs:	   the	   left	  ORF	  encodes	   for	   the	  non-­‐
structural	   Rep	   proteins,	   while	   the	   structural	   Cap	   proteins	   are	   encoded	   from	   the	  
right	   ORF	   (Srivastava	   et	   al.	   1983)	   (Figure	   1).	   An	   additional	   open	   reading	   frame,	  
located	  within	   the	  VP2	  coding	  sequence,	  encodes	   for	  a	  protein	   involved	   in	  capsid	  
assembly	   called	   assembly-­‐activating	   protein	   (AAP)(Sonntag	   et	   al.	   2010).	   AAV	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exploits	  a	  combination	  of	  different	  promoters	  (p5,	  p19	  and	  p40,	  identified	  by	  their	  
relative	   position	   in	   the	   viral	   genome),	   alternative	   splicing	   and	   non-­‐conventional	  
start	   codons	   to	  make	   the	  most	   of	   its	   limited	   coding	   capacity	   (Lusby	   et	   al.	   1980;	  
Marcus	  et	  al.	   1981;	  Qiu	  et	  al.	   2006).	   The	  p5	  promoter	  gives	   rise	   to	   the	   large	  Rep	  
proteins,	  Rep78	  and	  Rep68,	  while	  the	  p19	  promoter	  controls	  the	  expression	  of	  the	  
smaller	  Rep52	  and	  Rep40.	  All	  the	  capsid	  proteins,	  VP1,	  VP2	  and	  VP3,	  are	  expressed	  




Figure	  1:	  AAV	  genome,	  genes,	  transcriptional	  units	  and	  proteins.	  	  
The	  genome	  of	  AAV	  is	  a	  single-­‐stranded	  DNA	  molecule	  that	  is	  flanked	  by	  T-­‐shaped	  ITRs.	  It	  contains	  
three	  ORFs:	   the	   REP	  ORF	   coding	   for	   the	   non-­‐structural	   Rep	   proteins,	   the	   Cap	  ORF	   coding	   for	   the	  
structural	  capsid	  proteins	  and	  the	  AAP	  ORF.	  There	  are	  three	  promoters,	   identified	  by	  their	  relative	  
position	  in	  the	  genome:	  p5,	  p19	  and	  p40.	  The	  p5	  promoter	  controls	  the	  expression	  of	  the	  large	  Rep	  
proteins	  Rep78	  and	  the	  spliced	  variant	  Rep68.	  The	  p19	  gives	   rise	   to	   the	  small	  Rep	  proteins	  Rep52	  
and	  Rep40.	  The	  p40	  promoter	  controls	  the	  three	  capsid	  proteins	  VP1,	  VP2	  and	  VP3,	  as	  well	  as	  the	  
AAP.	  There	   is	  a	   single	   splice	  donor	   site	  and	   two	  splice	  acceptor	   sites,	  one	  of	  which	   (2228)	   is	  used	  
most	  frequently.	  Alternative	  splicing	  and	  non-­‐conventional	  start	  codons	  (for	  VP2	  and	  AAP)	  allow	  the	  
generation	  of	  8	  proteins	  (coloured	  boxes).	  All	  the	  AAV	  mRNAs	  use	  a	  single	  polyA	  tail	  located	  at	  the	  
right	  end	  of	  the	  genome.	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1.1.2.3 Capsid	  structure	  
The	   AAV	   capsid	   protects	   the	   infectious	   AAV	   genome	   throughout	   the	   AAV	   life	  
cycle.	   However,	   the	   capsid	   is	   more	   than	   a	   simple	   shell,	   it	   provides	   important	  
functions	  necessary	  for	  the	  correct	  trafficking	  of	  the	  virus.	  These	  functions	  include	  
host	  cell	  recognition	  and	  binding,	  entry	  and	  trafficking	  to	  the	  nucleus,	  release	  of	  the	  
viral	   genome	   at	   the	   appropriate	   time	   and	   place,	   egress	   from	   the	   host	   cell,	   and	  
escape	  from	  immune	  surveillance	  (Agbandje-­‐McKenna	  and	  Kleinschmidt	  2011).	  The	  
AAV	   4.7kb	   genome	   is	   packaged	   inside	   a	   small	   T=1	   icosahedral	   capsid	   of	   around	  
260Å	   (26nm)	   in	  diameter.	  A	   total	  of	  60	   copies	  of	  VP1,	  VP2	  and	  VP3,	   in	  a	   ratio	  of	  
1:1:10,	   form	   the	   AAV	   virion.	   The	   three	   structural	   proteins	   have	   an	   identical	   C-­‐
terminal	  sequence,	   involved	  in	  most	  capsid	  functions,	  although	  VP1	  and	  VP2	  have	  
additional	   functionally	   relevant	   N-­‐terminal	   amino	   acids	   (AAs).	   The	   unique	   N-­‐
terminal	  VP1	   residues	  contain	  a	  phospholipase	  A2	   (PLA2)	  activity	   that	   is	  necessary	  
for	  endosomal	  escape	  (Girod	  et	  al.	  2002;	  Sonntag	  et	  al.	  2006;	  Stahnke	  et	  al.	  2011),	  
while	  the	  shared	  VP1/VP2	  sequence	  contains	  a	  nuclear	   localisation	  signal	   (Grieger	  
et	  al.	  2006b;	  Xiao	  and	  Samulski	  2012).	  In	  addition,	  AAV	  capsids	  have	  been	  shown	  to	  
have	  a	  pH-­‐dependent	  protease	  activity,	  although	   its	  role	   in	  viral	   infection	  remains	  
unclear	  to	  date	  (Salganik	  et	  al.	  2012).	  
The	  capsid	  structures	  of	  AAV	  serotypes	  1	  to	  9	  have	  been	  solved	  (Xie	  et	  al.	  2002;	  
Walters	  et	  al.	  2004;	  Padron	  et	  al.	  2005;	  Miller	  et	  al.	  2006;	  Nam	  et	  al.	  2007;	  Quesada	  
et	  al.	  2007;	  Lerch	  et	  al.	  2010;	  Ng	  et	  al.	  2010;	  DiMattia	  et	  al.	  2012),	  but	  only	  the	  VP3	  
common	   region	  has	   been	  observed.	   The	   additional	   VP1	   and	  VP2	   residues	   appear	  
disordered,	  and	   it	  has	  been	  suggested	   that	   they	  are	   situated	  on	   the	   inside	  of	   the	  
capsid	   (Kronenberg	  et	  al.	  2005).	  Part	  of	   the	  VP3	   structure,	   consisting	  of	  an	  eight-­‐
stranded	  antiparallel	  β-­‐barrel	  core	  and	  a	  short	  α-­‐helix	  is	  highly	  conserved	  amongst	  
AAV	   serotypes.	   The	   majority	   of	   the	   VP3	   protein	   sequence,	   however,	   is	   made	   of	  
loops	  that	  connect	  the	  core	  β-­‐strands,	   including	  regions	  that	  account	  for	  serotype	  
variability	   (Agbandje-­‐McKenna	   and	   Kleinschmidt	   2011).	   These	   regions,	   called	  
variable	  regions	  (VRs),	  are	  exposed	  on	  the	  outside	  of	  the	  capsid	  and	  are	  associated	  
with	  the	  capsid	  functional	  roles,	  including	  receptor	  binding	  and	  tissue	  tropism,	  and	  
also	  determine	  capsid	  antigenicity.	  This	   is	  of	  particular	  relevance	  for	  the	  design	  of	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gene	   therapy	  vectors	   that	   target	  disease-­‐specific	   tissues	  or	   cell	   types	   (Drouin	  and	  
Agbandje-­‐McKenna	  2013).	  
The	  assembled	  icosahedral	  capsid	  structure	  brings	  together	  VP	  subunits	  at	  two-­‐,	  
three-­‐	  and	  five-­‐fold	  symmetry	  axis.	  The	  two-­‐fold	  axis,	  formed	  by	  the	  interaction	  of	  
two	   VP	   monomers,	   creates	   a	   depression	   in	   the	   capsid	   surface	   and	   has	   been	  
suggested	   to	   be	   involved	   in	   structural	   changes	   occurring	   during	   endosomal	  
trafficking	  (Nam	  et	  al.	  2011).	  Three	  VP	  subunits	  strongly	   interact	  at	  the	  three-­‐fold	  
axis	  of	  symmetry,	  implicated	  in	  receptor	  binding	  and	  antibody	  recognition,	  to	  form	  
protrusions	  surrounding	  a	  central	  depression	  (Agbandje-­‐McKenna	  and	  Kleinschmidt	  
2011).	  Finally,	  the	  five-­‐fold	  axis	  interaction	  creates	  a	  central	  channel	  surrounded	  by	  
a	  depression,	  and	  is	  the	  only	  point	  of	  contact	  between	  the	  inside	  and	  the	  outside	  of	  
the	  capsid.	  The	  packaging	  of	  the	  viral	  DNA	  and	  the	  externalisation	  of	  the	  VP1/VP2	  
enzymatic	  functions	  are	  thought	  to	  occur	  at	  this	  interface	  (Kronenberg	  et	  al.	  2005;	  
Bleker	  et	  al.	  2006).	  	  
1.1.3 The	  AAV	  life	  cycle	  
	  Despite	   its	   relatively	   simple	   genomic	   architecture,	   AAV	   has	   a	   complex	   and	  
tightly	  regulated	  life	  cycle,	  consisting	  of	  a	  latent	  phase	  in	  the	  absence	  of	  helper	  co-­‐
infection	  and	  a	  productive	  replicative	  phase	  in	  its	  presence	  (Figure	  2).	  In	  both	  cases,	  
the	   infectious	   AAV	   particles	   are	   trafficked	   to	   the	   nucleus,	   where	   the	   DNA	   is	  
released	  from	  the	  capsid	  (see	  section	  1.1.3.2).	  Under	  permissive	  conditions,	  such	  as	  
co-­‐infection	   with	   adenovirus	   or	   herpes	   simplex	   virus	   (HSV),	   the	   AAV	   DNA	   will	  
undergo	  several	   rounds	  of	   replication	   (see	  section	  1.1.3.4)	  before	  being	  packaged	  
into	  newly	   formed	   capsids	   (see	   section	  1.1.3.5).	  Under	  non-­‐permissive	   conditions	  
AAV	   will	   remain	   latent	   in	   the	   cell,	   either	   episomally	   or	   integrated	   in	   the	   host	  
genome	  through	  a	  mechanism	  that	  requires	  the	  Rep	  proteins	  (discussed	  in	  section	  
1.1.3.8).	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Figure	  2:	  The	  AAV	  life	  cycle.	  	  
The	   AAV	   life	   cycle	   is	   divided	   between	   productive	   infection	   in	   the	   presence	   of	   helper	   virus	  
(adenovirus	  in	  the	  picture)	  and	  latent	  infection	  in	  its	  absence.	  (I)	  The	  AAV	  particle	  enters	  the	  cell	  by	  
receptor-­‐mediated	   endocytosis	   and	   (II)	   is	   trafficked	   through	   the	   endosomal	   system	   to	   (III)	   the	  
nuclear	  membrane	   (discussed	   in	   section	   1.1.3.2).	   (IV)	   After	   translocation	   to	   the	   nucleus,	   the	   viral	  
DNA	   is	  released	  and	  (V)	  undergoes	  several	  rounds	  of	  replication	  (section	  1.1.3.4)	  before	  being	  (VI)	  
packaged	  in	  pre-­‐formed	  capsids	  and	  (VII)	  egressing	  from	  the	  cell	  (section	  1.1.3.5).	  In	  the	  absence	  of	  
helper	  functions,	  the	  AAV	  particle	  reaches	  the	  nucleus	  where	  it	  can	  establish	  latency	  by	  (A)	  forming	  
a	  stable	  circular	  episome	  or	  (B)	  by	  integrating	  into	  the	  human	  genome	  (discussed	  in	  section	  1.1.3.8).	  
In	  the	  event	  of	  helper	  virus	  superinfection,	  (C)	  the	  AAV	  genome	  can	  be	  rescued	  from	  its	  latent	  state	  
and	   undergo	   productive	   replication.	   The	   relative	   sizes	   of	   the	   elements	   of	   this	   diagram	   are	   not	   in	  
scale	  but	  are	  adapted	  for	  clarity.	  
	  	  
1.1.3.1 AAV	  infection	  in	  humans	  
Despite	   widespread	   AAV	   infection	   of	   the	   human	   population	   (Chirmule	   et	   al.	  
1999;	  Erles	  et	  al.	  1999;	  Calcedo	  et	  al.	  2009),	  it	  is	  widely	  accepted	  that	  human	  AAV	  
infection	   is	   not	   linked	   to	   any	   pathology	   (Kerr	   and	   Linden	   2006).	   The	   lack	   of	  
pathogenicity	  has	  hindered	  the	  study	  of	  the	  viral	  life	  cycle	  in	  vivo,	  and	  most	  of	  our	  
knowledge	  of	  the	  AAV	  life	  cycle,	  comes	  from	  tissue	  culture	  studies.	  A	  few	  studies,	  
however,	  have	  attempted	  to	  investigate	  WT	  AAV	  infection	  in	   its	  human	  host.	  AAV	  
has	  been	   isolated	   from	  several	   tissues	   that	  are	  common	  sites	  of	   infection	  by	  AAV	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helper	   viruses,	   including	   respiratory,	   gastrointestinal	   and	   genital	   tract	   tissues	  
(Blacklow	   et	   al.	   1967;	   Bantel-­‐Schaal	   and	   zur	   Hausen	   1984;	   Friedman-­‐Einat	   et	   al.	  
1997).	  Another	  study	  detected	  AAV	  sequences	  in	  the	  muscle	  (Tezak	  et	  al.	  2000),	  a	  
site	   where	   helper	   virus	   infection	   is	   not	   expected	   and	   thus	   could	   represent	   a	  
potential	   reservoir	   for	  AAV	   latency.	  None	  of	   these	   studies,	   however,	   investigated	  
whether	  the	  viral	  DNA	  was	  present	  as	  an	  episome	  or	  had	  integrated	  into	  the	  host	  
genome.	  More	   recently,	   the	   group	   of	   Philip	   Johnson	   characterised	   the	  molecular	  
structure	  of	  AAV	  isolated	  from	  tonsil	  and	  adenoids	  as	  well	  as	  from	  spleen	  and	  lung	  
tissues	  (Chen	  et	  al.	  2005;	  Schnepp	  et	  al.	  2005;	  Schnepp	  et	  al.	  2009).	  In	  these	  tissues,	  
AAV	  genomes	  only	  persisted	  as	  circular	  episomes	  that	  could	  be	   isolated	  and	  were	  
shown	   to	   be	   infectious	   upon	   transfection	   in	   the	   presence	   of	   adenovirus.	   Finally,	  
epidemiological	  studies	  have	  attempted	  to	  correlate	  AAV	  infections	  with	  protection	  
from	  certain	  cancers	  or	  with	  infertility,	  however	  contrasting	  conclusions	  have	  been	  
reached	  (Kerr	  and	  Linden	  2006).	  	  
1.1.3.2 Attachment,	  entry	  and	  intracellular	  trafficking	  
AAV	  infection	  begins	  with	  the	  attachment	  of	  the	  infectious	  viral	  particles	  to	  host	  
cell	  surface	  receptors.	  Different	  AAV	  serotypes	  have	  been	  shown	  to	  use	  distinct	  cell	  
surface	   glycans	   as	   primary	   receptors	   (Agbandje-­‐McKenna	   and	   Kleinschmidt	   2011;	  
Nonnenmacher	  and	  Weber	  2012),	  and	   thus	  can	   infect	  a	  variety	  of	   tissues	   in	   vivo.	  
Heparan	   sulphate	   proteoglycan	   (HSPG)	   was	   the	   first	   AAV	   receptor	   identified	  
(Summerford	  and	  Samulski	  1998),	  and	  binds	  AAV2,	  AAV3	  and	  AAV6.	  AAV2	  variants	  
based	  on	  sequences	  detected	   in	  humans,	  however,	  do	  not	  bind	  HSPG,	   suggesting	  
that	   AAV2	   binding	   to	   HSPG	   is	   a	   tissue	   culture	   adaptation	   (Chen	   et	   al.	   2005),	  
highlighting	  a	  potential	  limitation	  of	  tissue	  culture	  studies.	  A	  specific	  capsid	  region	  
at	   the	   three-­‐fold	  axis	  of	   symmetry	  seems	   to	  be	   the	  site	   for	   receptor	  binding,	  and	  
differences	   in	   this	   region	   are	   responsible	   for	   cell	   surface	   glycan	   specificity	  
(Agbandje-­‐McKenna	   and	   Kleinschmidt	   2011).	   Following	   primary	   receptor	  
attachment,	   AAV	   particles	   interact	   with	   secondary	   co-­‐receptors	   before	   being	  
internalised.	   Co-­‐receptors	   are	   generally	   proteins	   rather	   than	   glycans,	   and	   include	  
integrins,	  fibroblast	  growth	  factor	  receptor,	  hepatocyte	  growth	  factor	  receptor,	  and	  
laminin	   (Agbandje-­‐McKenna	   and	   Kleinschmidt	   2011;	   Nonnenmacher	   and	   Weber	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2012).	   Furthermore,	   it	   has	   been	   suggested	   that	   following	   attachment,	   the	   AAV	  
capsid	   undergoes	   conformational	   changes	   that	   could	   facilitate	   interaction	   with	  
secondary	   receptors	   (Levy	   et	   al.	   2009).	   The	   AAV	   particles	   are	   then	   internalised	  
through	   endocytosis.	   Different	   internalisation	   pathways	   have	   been	   described	   for	  
AAV2.	  While	  clathrin-­‐mediated	  endocytosis	  has	   long	  been	  thought	  to	  be	  the	  main	  
pathway,	   recent	   observations	   suggest	   that	   the	   clathrin-­‐independent	   carriers/GPI-­‐
enriched	  endocytic	  compartment	  (CLIC/GEEC)	  pathway	  might	  also	  play	  a	  significant	  
role	  (Nonnenmacher	  and	  Weber	  2011).	   In	  addition,	  AAV5	  can	  also	  be	   internalised	  
through	  caveolar	  endocytosis	  (Bantel-­‐Schaal	  et	  al.	  2009).	  	  
The	   intracellular	   trafficking	   of	   AAV	   to	   the	   nucleus	   is	   a	   slow	   and	   rate-­‐limiting	  
process	   (Agbandje-­‐McKenna	   and	   Kleinschmidt	   2011;	   Nonnenmacher	   and	   Weber	  
2012).	   AAV	   particles	   have	   been	   shown	   to	   localise	   to	   early,	   late	   and	   recycling	  
endosomes,	  as	  well	  as	  lysosomes.	  In	  addition,	  transport	  to	  the	  Golgi	  apparatus	  has	  
also	   been	   reported.	   However,	   it	   is	   not	   entirely	   clear	   which	   pathway	   leads	   to	  
efficient	  infection,	  and	  serotype	  differences	  are	  expected.	  Endosomal	  processing	  is	  
necessary	  for	  efficient	  AAV	  transduction,	  and	  causes	  conformational	  changes	  to	  the	  
AAV	   capsid,	   possibly	   inducing	   the	   externalisation	   of	   the	   PLA2	   domain	   of	   VP1	  
(Nonnenmacher	  and	  Weber	  2012).	  Further	  modifications	  of	  the	  capsid	  occur	  after	  
escape	  into	  the	  cytoplasm,	  including	  the	  exposure	  of	  the	  nuclear	  localisation	  signal	  
present	   in	   VP1	   and	  VP2.	   Inhibition	   of	   capsid	   phosphorylation	   (Zhong	   et	   al.	   2008)	  
and	   ubiquitination	   (Yan	   et	   al.	   2002)	   has	   also	   been	   suggested	   to	   increase	  
transduction	  efficiency,	  although	  the	  precise	  mechanisms	  behind	  this	  effect	  are	  not	  
clear.	   The	   viral	   particles	   are	   then	   transported	   to	   the	   nucleus,	   where	   a	   series	   of	  
poorly	  understood	  events	  take	  place.	  First,	  the	  virus	  translocates	  across	  the	  nuclear	  
membrane	   via	   the	   nuclear	   pore	   complex,	   in	   a	   process	   mediated	   by	   the	   nuclear	  
localisation	  signal	  present	  in	  VP1	  and	  VP2	  (Grieger	  et	  al.	  2006b;	  Popa-­‐Wagner	  et	  al.	  
2012)	  and	   interactions	  with	   the	  nuclear	  pore	  components	   (Nicolson	  and	  Samulski	  
2014).	   Once	   in	   the	   nucleus,	   the	   intact	   viral	   particle	   is	   rapidly	   transported	   to	   the	  
nucleolus,	   from	   where	   it	   can	   be	   mobilised	   into	   the	   nucleoplasm	   (Johnson	   and	  
Samulski	   2009).	   Finally,	   the	   AAV	   genome	   is	   released	   by	   an	   unknown	  mechanism	  
(Agbandje-­‐McKenna	  and	  Kleinschmidt	  2011;	  Nonnenmacher	  and	  Weber	  2012).	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While	   the	  understanding	  of	  AAV	  trafficking	  through	  the	  host	  cell	  has	   improved	  
significantly	   over	   the	   last	   years,	  many	   important	   details	   remain	   to	   be	   elucidated.	  
Several	   aspects	   of	   AAV	   biology,	   however,	   complicate	   these	   analyses.	   First,	   most	  
studies	   have	   been	   carried	   out	   in	   the	   absence	   of	   helper	   virus,	   thus	   reflecting	   the	  
initiation	  of	   a	   latent	   infection	   rather	   than	  a	  productive	  one.	   In	   addition,	   host	   cell	  
infection	  by	  a	  helper	  virus	   is	   likely	  to	  change	  the	  overall	  cellular	  environment	  and	  
therefore	   could	   have	   consequences	   on	   the	   trafficking	   of	   AAV.	   Furthermore,	   it	   is	  
plausible	   that	   the	   trafficking	  pathway	  used	  by	  AAV	  will	   be	  dependent	  on	   the	   cell	  
type	  being	  infected	  and	  the	  multiplicity	  of	  infection	  (MOI)	  used	  to	  infect	  that	  cell,	  as	  
well	  as	  the	  AAV	  serotype.	  Finally,	  only	  a	  fraction	  of	  the	  AAV	  particles	  that	  enter	  a	  
cell	  is	  infectious.	  This	  phenomenon	  is	  particularly	  marked	  for	  rAAV	  vectors	  (Zeltner	  
et	  al.	  2010),	  which	  have	  been	  used	  in	  all	  trafficking	  studies.	  Distinguishing	  between	  
the	   infectious	   particles	   that	   will	   cause	   productive	   viral	   replication	   and	   the	   non-­‐
infectious	  ones	  is	  a	  significant	  challenge	  that	  has	  not	  been	  resolved.	  	  
1.1.3.3 Gene	  expression	  and	  transcriptional	  regulation	  
Once	  the	  DNA	  is	  released	  inside	  the	  nucleus,	  the	  ssDNA	  genome	  is	  converted	  to	  
dsDNA,	  a	  prerequisite	  for	  transcription	  and	  gene	  expression	  (Ferrari	  et	  al.	  1996).	  As	  
described	  above,	   three	  viral	  promoters,	   identified	  by	   their	   relative	  position	   in	   the	  
genome,	  give	  rise	  to	  6	  overlapping	  RNAs	  (see	  Figure	  1)	  (Qiu	  et	  al.	  2006).	  In	  AAV2,	  all	  
these	  RNAs	  are	  polyadenylated	  at	  the	  same	  site	  at	  the	  right	  end	  of	  the	  genome,	  and	  
contain	   a	   single	   intron	   that	   can	   use	   one	   of	   two	   closely	   located	   splice	   acceptors.	  
Unspliced	  p5-­‐	  and	  p19-­‐derived	  messengers	  code	  for	  Rep78	  and	  Rep52,	  respectively,	  
while	  their	  spliced	  counterparts	  encode	  for	  Rep	  68	  and	  Rep40.	  Two	  spliced	  mRNAs	  
generated	   from	   the	  p40	  promoter	   generate	   the	   structural	   proteins	  VP1,	  VP2	   and	  
VP3.	  The	  mRNA	  generated	  using	  the	  preferred	  splice	  acceptor	  site	  gives	  rise	  to	  VP3	  
and,	   through	   the	   use	   of	   a	   non-­‐conventional	   start	   codon,	   to	   VP2.	   The	   larger	   VP1	  
protein	  is	  translated	  from	  the	  minor	  spliced	  message.	  	  
Despite	  the	  fact	  that	  AAV	  RNAs	  are	  stable,	  their	  relative	  abundance	  and	  the	  ratio	  
of	  spliced	  to	  unspliced	  RNAs,	  as	  well	  as	  their	  temporal	  order	  of	  appearance	  during	  
an	   infection,	   are	   tightly	   regulated	   (Mouw	   and	   Pintel	   2000).	   During	   a	   productive	  
infection,	   i.e.	   during	   co-­‐infection	  with	   a	   helper	   virus,	   p5-­‐generated	   RNAs	   are	   the	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first	  to	  appear,	  followed	  by	  p19	  transcripts,	  ensuring	  efficient	  replication	  of	  the	  AAV	  
DNA.	  The	  p19-­‐generated	  RNAs	  accumulate	  to	  higher	  levels	  than	  those	  from	  p5,	  and	  
later	  during	  the	  infection	  the	  p40	  transcripts	  form	  the	  majority	  of	  AAV	  RNA	  species,	  
skewing	  the	  equilibrium	  towards	  the	  production	  of	  new	  infectious	  particles	  rather	  
than	   replication.	   In	  addition,	   the	   ratio	  of	   spliced	   to	  unspliced	  RNAs	  also	   increases	  
during	  infection.	  	  
In	  the	  absence	  of	  helper	  virus	  co-­‐infection,	  expression	  of	  the	  AAV	  genes	  is	  very	  
low	   (Laughlin	   et	   al.	   1986;	   Trempe	   and	   Carter	   1988),	   and	   the	   viral	   promoters	   are	  
repressed	  by	  the	  combined	  action	  of	  the	  Rep	  proteins	  and	  cellular	  factors	  such	  as	  
YY1	  and	  MLTF	  (Labow	  et	  al.	  1986;	  Beaton	  et	  al.	  1989;	  Chang	  et	  al.	  1989;	  Shi	  et	  al.	  
1991;	   Weger	   et	   al.	   1997).	   The	   levels	   of	   p5-­‐generated	   transcripts	   are	   optimal	   to	  
support	  Rep-­‐mediated	  integration	  into	  the	  host	  genomic	  DNA,	  but	  sufficiently	   low	  
to	   prevent	   Rep-­‐mediated	   rescue	   of	   the	   integrated	   DNA.	   The	   Rep-­‐mediated	  
repression	   of	   the	   p5	   promoter	   has	   been	   shown	   to	   require	   both	   the	   RBS	   in	   p5	  
(McCarty	  et	  al.	   1994a)	  and	   the	  ATPase	  activity	  of	  Rep	   (Kyostio	  et	  al.	   1995),	  while	  
repression	  of	  the	  p19	  promoter	  only	  depends	  on	  the	  ATPase	  activity	  (Kyostio	  et	  al.	  
1994;	  Horer	  et	  al.	  1995).	  Upon	  helper	  virus	  co-­‐infection,	   the	   repression	  of	   the	  p5	  
promoter	  by	   the	  cellular	   transcription	   factors	  YY1	  and	  MLTF	   is	   lifted	   (Chang	  et	  al.	  
1989;	   Shi	   et	   al.	   1991),	   leading	   to	   a	   controlled	   transactivation	   of	   all	   the	   viral	  
promoters	  to	  achieve	  the	  correct	  protein	  expression	  (Labow	  et	  al.	  1986;	  McCarty	  et	  
al.	  1991;	  Pereira	  and	  Muzyczka	  1997a;	  Pereira	  and	  Muzyczka	  1997b;	  Weger	  et	  al.	  
1997;	  Lackner	  and	  Muzyczka	  2002).	  The	  Rep	  proteins	  have	  been	  shown	  to	  act	  both	  
as	  transcriptional	  activators	  and	  repressors	  (Labow	  et	  al.	  1986;	  Pereira	  et	  al.	  1997),	  
whereby	  a	  feedback	  loop	  has	  been	  suggested	  to	  maintain	  a	  precise	  ratio	  of	  p19	  to	  
p5	   transcripts.	   More	   specifically,	   Rep	   binding	   to	   either	   the	   ITR	   or	   the	   p5	   RBS	  
mediates	   activation	   of	   p19	   and	   p40	   transcription,	   while	   expression	   from	   the	   p5	  
promoter	  is	  enhanced	  through	  Rep	  binding	  to	  the	  ITR	  RBS	  and	  repressed	  by	  the	  p5	  
RBS.	  The	  small	  Rep	  proteins,	  Rep40	  and	  Rep52,	  can,	  in	  turn,	  lift	  repression	  from	  the	  
p5	  promoter.	  In	  addition,	  the	  large	  Rep	  proteins	  have	  also	  been	  shown	  to	  increase	  
the	   ratio	   of	   spliced	   to	   unspliced	   RNAs	   through	   binding	   to	   an	   extended	   RBS,	  
provided	  either	  by	  the	  p5	  promoter	  or	  the	  ITR	  (Qiu	  and	  Pintel	  2002).	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1.1.3.4 DNA	  replication	  
	  The	   basic	   model	   for	   parvovirus	   and	   AAV	   replication	   was	   described	   several	  
decades	  ago	  (Straus	  et	  al.	  1976;	  Tattersall	  and	  Ward	  1976),	  and	  it	   is	  still	  accepted	  
today	   (Ward	  2006).	  The	  mode	  of	   replication	   is	  often	   referred	   to	  as	   rolling	  hairpin	  
replication,	   a	  modified	   version	   of	   plasmid	   rolling	   circle	   replication,	   and	   implies	   a	  
strand	  displacement	  mechanism	  (Figure	  3).	  	  
	  
	  
Figure	  3:	  Rolling	  hairpin	  replication	  of	  AAV	  DNA.	  	  
The	   free	   3’-­‐OH	   provided	   by	   the	   self-­‐annealed	   ITR	   (a)	   serves	   as	   the	   primer	   for	   DNA	   replication	  
mediated	   by	   the	   cellular	   machinery	   (b).	   The	   right	   ITR	   is	   replicated	   by	   strand	   displacement,	  
generating	  a	  ds	  molecule	  covalently	  linked	  by	  the	  left	  ITR	  (c).	  Rep	  binds	  at	  the	  RBS	  in	  the	  left	  ITR	  (d)	  
and	   nicks	   at	   the	   nearby	   TRS	   site	   (e)	   to	   allow	   the	   terminal	   resolution	   of	   the	   left	   ITR	   (f).	   The	  
complementary	  ITR	  sequences	  at	  the	  right	  end	  of	  the	  genome	  fold	  back	  (g),	  freeing	  a	  new	  3’-­‐OH	  that	  
can	  be	  used	  for	  another	  round	  of	  replication	  by	  strand	  displacement	  (h)	  that	  generates	  a	  new	  ss	  AAV	  
genome	  and	  a	  ds	  molecule	  covalently	  linked	  by	  the	  right	  ITR	  (i).	  These	  molecules	  can	  then	  be	  used	  
for	  another	  round	  of	  replication	  (grey	  arrows)	  or	  potentially	  could	  serve	  as	  packaging	  templates.	   If	  
the	   refolding	  of	   the	   right	   ITR	  occurs	  prior	   to	   the	   terminal	   resolution	  of	   the	   left	   ITR	   (j)	   followed	  by	  
replication	   by	   strand	   displacement,	   a	   dimeric	   replication	   intermediate	   that	   is	   detectable	   in	  
replication	   assays	   can	   be	   formed	   (k).	   By	   subsequent	   RBS	   binding	   and	   TRS	   nicking	   the	   dimeric	  
intermediate	  can	  re-­‐enter	  the	  replication	  cycle.	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The	   first	   step	   in	   replication	   consists	   of	   the	   second-­‐strand	   synthesis:	   the	   self-­‐
annealed	  ITR	  on	  the	  3’	  end	  of	  the	  genome	  serves	  as	  a	  primer	  for	  unidirectional	  DNA	  
synthesis	   (Figure	   3,	   a	   and	   b),	   resulting	   in	   a	   double-­‐stranded	  molecule	   covalently	  
linked	   at	   one	   side	   (Figure	   3c).	   The	   replication	   of	   the	   original	   ITR,	   or	   terminal	  
resolution,	  requires	  binding	  to	  the	  RBS	  (Figure	  3d)	  and	  nicking	  at	  the	  TRS	  (Figure	  3e)	  
by	  the	  large	  Rep	  proteins	  generating	  a	  new	  free	  base-­‐paired	  3’-­‐OH	  group	  for	  DNA	  
synthesis	  through	  the	   ITR	  (Figure	  3f).	  This	  results	   in	  a	  double-­‐stranded	   linear	  DNA	  
molecule,	  the	  monomeric	  replicative	  intermediate.	  Both	  ends	  can	  then	  fold	  back	  to	  
form	  double	  hairpinned	  structures	  (Figure	  3g),	  and	  another	  round	  of	  replication	  by	  
strand	  displacement	  can	  start	   (Figure	  3h).	  At	   the	  end	  of	  each	  cycle	  of	   replication,	  
two	  DNA	  molecules	  are	  generated:	  a	  double	  stranded	  one	  with	  one	  end	  covalently	  
closed	   (as	   in	   Figure	   3c),	   and	   a	   progeny	   single	   strand	   molecule	   (Figure	   3i).	   In	  
addition,	   if	   completion	   of	   refolding	   and	   strand	   displacement	   at	   one	   end	   occurs	  
before	   the	   terminal	   resolution	   at	   the	   other	   end	   (Figure	   3,	   j	   and	   k),	   a	   dimeric	  
intermediate	   formed	  by	   two	  genomes	   in	  a	  head-­‐to-­‐head	  or	   tail-­‐to-­‐tail	  orientation	  
can	  be	  generated	  (Figure	  3k).	  This	  mode	  of	  replication	  leads	  to	  an	  inversion	  of	  part	  
of	   the	   ITR	   sequence	   during	   each	   round	   of	   replication,	   generating	   two	   alternative	  
conformations	  designed	  as	  flip	  and	  flop	  (Lusby	  et	  al.	  1980).	  It	  is	  still	  unknown	  which	  
of	  the	  possible	  DNA	  molecules	  constitutes	  the	  template	  for	  packaging.	  
The	  essential	  elements	  required	  for	  the	  efficient	  replication	  of	  AAV	  DNA	  include	  
the	   viral	   origin	   of	   replication	   (the	   ITRs)	   (Hauswirth	   and	   Berns	   1977;	   Lusby	   et	   al.	  
1980),	  the	  large	  Rep	  proteins	  (Rep78	  or	  Rep68)	  (Im	  and	  Muzyczka	  1990)	  and	  factors	  
provided	   by	   helper-­‐virus	   infected	   cell	   extracts	   (Hong	   et	   al.	   1992;	   Ni	   et	   al.	   1994;	  
Ward	  and	  Berns	  1996).	  Rep	  binds	  to	  the	  RBS	  present	  in	  the	  ITR,	  and	  makes	  further	  
contact	  with	  a	  sequence	  in	  the	  hairpin	  termed	  RBS’	  (Snyder	  et	  al.	  1993;	  Chiorini	  et	  
al.	  1994b;	  McCarty	  et	  al.	  1994b;	  Ryan	  et	  al.	  1996).	  Following	  binding,	  Rep	  unwinds	  
the	   ITR	   stem	   in	   an	   ATP-­‐dependent	   reaction	   to	   expose	   a	   single-­‐stranded	   TRS	   for	  
nicking	  (Brister	  and	  Muzyczka	  2000;	  Smith	  and	  Kotin	  2000).	   In	  addition,	  Rep	  could	  
also	   provide	   the	   helicase	   activity	   necessary	   to	   unwind	   the	   ITR	   to	   allow	   its	  
replication	   after	   terminal	   resolution	   (Zhou	   et	   al.	   1999;	   Ward	   et	   al.	   2001).	   The	  
structure	   of	   the	   ITR,	   rather	   than	   its	   exact	   sequence,	   appears	   to	   be	   particularly	  
important	   for	   terminal	   resolution	   (Lefebvre	   et	   al.	   1984;	   Bohenzky	   et	   al.	   1988).	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Indeed,	  mutations	  of	  the	  ITR	  that	  maintain	  the	  overall	  hairpin	  structure,	  but	  that	  do	  
not	  affect	  the	  RBS’	  sequence,	  are	  still	  replicated.	  	  
Plasmids	  that	  contain	  the	  full	  AAV	  genome	  are	  infectious;	  when	  transfected	  into	  
cells	   that	   are	   subsequently	   infected	  with	   adenovirus,	   infectious	   AAV	   is	   produced	  
(Samulski	  et	  al.	  1982).	  The	   replication	  products	  obtained	   from	  these	  plasmids	  are	  
indistinguishable	  from	  those	  observed	  after	  AAV	  infection.	  The	  viral	  sequences	  are	  
rescued	  from	  the	  plasmid	  DNA	  by	  a	  Rep-­‐mediated	  mechanism	  involving	  nicking	  at	  
the	   ITR	   and	   replication	   by	   strand	   displacement	   (Samulski	   et	   al.	   1982).	   A	   similar	  
mechanism	   is	   thought	   to	   provide	   the	   basis	   for	   the	   release	   of	   the	   viral	   DNA	  
integrated	   into	   the	   host	   cell	   genome	   through	   Rep-­‐mediated	   integration	   after	  
adenovirus	   infection	   (discussed	   in	   section	   1.1.3.8).	   Deletions	   at	   one	   end	   of	   the	  
genome	   (up	   to	   113	  bases)	   are	   repaired;	   clones	   containing	   such	  deletions	   are	   still	  
infectious	   and	   the	   replication	   products	   contain	   full-­‐length	   hairpins	   in	   both	   sides	  
(Samulski	   et	   al.	   1983).	   Simultaneous	   deletions	   in	   both	   ITRs,	   on	   the	   other	   hand,	  
cannot	   be	   repaired.	   Interestingly,	   a	   plasmid	   containing	   shorter	   deletions	   of	   55	  
nucleotides	  on	  both	  ends	  of	  the	  AAV	  sequences	  does	  not	  support	  rescue	  of	  the	  viral	  
genome,	  but	  the	  presence	  of	  the	  RBS	  and	  TRS	  is	  sufficient	  to	  initiate	  replication	  of	  
the	  entire	  plasmid,	  indicating	  that	  RBS	  and	  TRS	  act	  as	  minimal	  origins	  of	  replication	  
(Hong	  et	  al.	  1992).	  
In	  vitro,	  complete	  AAV	  replication	  can	  be	  achieved	  using	  the	  host	  proteins	  DNA	  
polymerase	  delta	   (POLD),	   the	  proliferating	  nuclear	  antigen	   (PCNA),	   the	   replicating	  
factor	   C	   (RFC)	   and	   the	   minichromosome	   maintenance	   complex	   (MCM)	   in	  
combination	   with	   the	   large	   Rep	   proteins	   (Nash	   et	   al.	   2008).	   In	   cells,	   and	   in	   the	  
presence	  of	  helper	  virus,	  the	  situation	  is	  necessarily	  more	  complex.	  The	  replication	  
of	  AAV,	  similarly	  to	  many	  DNA	  viruses,	  takes	  place	  in	  specialised	  replication	  centres	  
in	  the	  nucleus	  of	  infected	  cells,	  where	  AAV	  and	  helper	  virus	  proteins	  interact	  with	  
several	  cellular	  proteins	  to	  efficiently	  replicate	  the	  AAV	  DNA	  (Vogel	  et	  al.	  2013).	  The	  
composition	   of	   the	  AAV	   replication	   centres	   is	   not	   fixed	   during	   the	   life	   cycle:	   it	   is	  
likely	   to	   change	   spatially	   and	   temporally	   over	   the	   course	   of	   replication	   and	   also	  
depends	   on	   helper	   virus	   functions.	   Both	   adenoviruses	   and	   herpes	   viruses	   are	  
efficient	   helpers	   of	   AAV	   replication	   (discussed	   in	   more	   detail	   in	   section	   1.1.3.6).	  
Other	   viruses,	   such	   as	   vaccinia	   virus	   (Schlehofer	   et	   al.	   1986)	   and	   papilloma	   virus	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(Walz	   et	   al.	   1997)	   have	   also	   been	   shown	   to	   be	   able	   to	   support	   AAV	   replication,	  
suggesting	  that	  the	  helper	  viruses	  alter	  the	  cellular	  environment	  and	  make	  the	  cell	  
permissive	  for	  AAV	  replication,	  rather	  than	  providing	  specific	  replication	  functions.	  
Accordingly,	   cell	   treatment	   with	   certain	   genotoxic	   agents	   can	   render	   cells	  
permissive	   for	   sub-­‐optimal	   AAV	   replication	   in	   the	   absence	   of	   helper	   viruses	  
(Yakobson	  et	  al.	  1987;	  Yalkinoglu	  et	  al.	  1988;	  Yakobson	  et	  al.	  1989).	  
1.1.3.5 Packaging	  and	  egress	  from	  the	  cell	  
The	  VP	   subunits	   that	   form	   the	  AAV	  capsid	  assemble	   into	  empty	   capsids	   in	   the	  
nucleoli	   of	   infected	   cells	   (Wistuba	  et	   al.	   1997),	  where	   they	   interact	  with	   the	  AAP	  
(Sonntag	   et	   al.	   2010).	   The	   progeny	   ssDNA	   is	   then	   slowly	   translocated	   into	   the	  
preformed	   capsid	   (Myers	   and	  Carter	   1980).	   The	   ITRs	   act	   as	  minimal	   cis	  elements	  
(McLaughlin	   et	   al.	   1988),	   although	   the	   precise	   packaging	   signal	   has	   not	   yet	   been	  
identified.	   The	   small	   Rep	   proteins,	   and	   in	   particular	   their	   helicase	   function,	   are	  
required	   for	   the	   efficient	   encapsidation	   of	   viral	   DNA	   and	   the	   accumulation	   of	  
ssDNA,	  which	  correlates	  with	  an	  increase	  in	  DNA-­‐containing	  particles	  (Chejanovsky	  
and	  Carter	  1989;	  King	  et	  al.	  2001).	  
The	   egress	   of	   AAV	   particles	   from	   cells	   is	   very	   poorly	   characterised.	   Like	  most	  
non-­‐enveloped	   viruses,	   AAV	   is	   thought	   to	   be	   released	   from	   infected	   cells	   after	  
accumulation	   of	   viral	   particles	   and	   lysis	   of	   nuclear	   and	   cellular	   membranes.	  
However,	   infectious	   AAV	   particles	   can	   be	   detected	   in	   the	   tissue	   culture	  medium	  
before	   the	   appearance	   of	   a	   cytopathogenic	   effect	   (CPE)	   in	   AAV-­‐producing	   cells,	  
although	   the	   degree	   of	   secretion	   varies	   amongst	   serotypes	   (Vandenberghe	   et	   al.	  
2010).	   In	   addition,	   active	   nuclear	   exit	   of	   viral	   capsids	   and	   outward	   transport	  
associated	  with	  virion	  maturation	  has	  been	  demonstrated	   for	  another	  parvovirus,	  
the	  minute	  virus	  of	  mice	  (MVM)	  (Valle	  et	  al.	  2006;	  Bar	  et	  al.	  2013),	  suggesting	  the	  
possible	   existence	   of	   an	   alternative	   release	   pathway	   that	   may	   be	   functionally	  
relevant	  for	  AAV	  as	  well.	  	  
1.1.3.6 Helper	  functions	  
Only	  a	  subset	  of	  helper	  virus	  proteins	   is	  necessary	  for	  complete	  support	  of	  the	  
AAV	   life	   cycle;	   the	  best	   characterised	  are	   the	  helper	   functions	  of	  adenovirus	   (Ad)	  
and	  herpes	  simplex	  virus	  1	  (HSV-­‐1)	  (Geoffroy	  and	  Salvetti	  2005;	  Vogel	  et	  al.	  2013).	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In	  the	  case	  of	  Ad,	  the	  helper	  factors	  necessary	  to	  support	  AAV	  replication	  are	  the	  
viral	  proteins	  E1A,	  E1b55K,	  E2A,	  E4orf6,	  and	  the	  viral	  associated	  RNA	  (VA	  RNA).	  The	  
E1A	   protein	   activates	   the	   transcription	   of	   adenoviral	   early	   genes	   and,	   similarly,	  
induces	  transcription	  of	  the	  AAV	  Rep	  ORF	  (Chang	  et	  al.	  1989).	  The	  E1b55K	  and	  the	  
E4orf6	  proteins	   form	  a	  complex	   that	  plays	  a	   role	   in	   the	  nuclear	  export	  and	   in	   the	  
metabolism	   of	   AAV	   mRNA	   (Mouw	   and	   Pintel	   2000),	   as	   well	   as	   in	   second-­‐strand	  
synthesis	   (Ferrari	   et	   al.	   1996).	   In	   addition,	   the	   E1b55K/E4orf6	   enhances	   AAV	  
replication	   by	   degrading	   the	   Mre11	   complex	   (MRN)	   (Schwartz	   et	   al.	   2007).	   The	  
MRN	  complex,	  composed	  of	  Mre11,	  Rad50,	  and	  Nbs1	  is	  a	  conserved	  multi-­‐protein	  
complex	  that	  is	  involved	  in	  DNA	  damage	  sensing	  and	  repair	  (D'Amours	  and	  Jackson	  
2002).	  E2A	  encodes	  for	  the	  DNA-­‐binding	  protein	  (DBP)	  and	  supports	  multiple	  steps	  
of	   the	   viral	   life	   cycle,	   including	   transcriptional	   regulation,	   mRNA	   processing,	   and	  
replication	   (Janik	   et	   al.	   1989;	  Ward	   et	   al.	   1998).	   Finally,	   the	   VA	   RNAs	   have	   been	  
shown	  to	  maintain	  AAV	  protein	  translation	  (Janik	  et	  al.	  1989).	  
The	  helper	  functions	  encoded	  by	  HSV-­‐1,	  unlike	  those	  of	  Ad,	  include	  proteins	  that	  
are	   also	   necessary	   for	   HSV-­‐1	   replication.	   These	   include	   the	   helicase-­‐primase	  
complex	  encoded	  by	  UL5,	  UL8	  and	  UL52,	  and	  the	  DNA	  binding	  protein	  ICP8,	  product	  
of	   the	   UL29	   gene	   (Weindler	   and	   Heilbronn	   1991).	   The	   role	   of	   UL52	   was	   later	  
revised,	  as	  it	  was	  shown	  that	  its	  primase	  activity	  is	  not	  required	  for	  AAV	  replication	  
(Slanina	  et	  al.	  2006).	  Further	  investigations	  also	  revealed	  that	  the	  ICP8	  protein	  plays	  
a	  similar	  role	  to	  the	  adenoviral	  DBP	  in	  enhancing	  AAV	  replication,	  and	  additionally	  
localises	   to	  AAV	   replication	   centres	   and	   can	   bind	   Rep78	   in	   vitro	   (Heilbronn	   et	   al.	  
2003;	   Stracker	   et	   al.	   2004).	   The	   HSV-­‐1	   DNA	   polymerase	   complex	   formed	   by	   the	  
polymerase	  UL30	  and	  the	  dsDNA	  binding	  protein	  UL42,	  has	  been	  shown	  to	  enhance	  
AAV	   replication	   (Alazard-­‐Dany	   et	   al.	   2009).	   Furthermore,	   the	   HSV-­‐1	   polymerase	  
UL30	   can	   replicate	   the	   AAV	   genome	   efficiently	   in	   vitro,	   replacing	   the	   cellular	  
replication	   machinery	   (Ward	   et	   al.	   2001).	   HSV-­‐1	   proteins	   involved	   in	   the	  
transcriptional	   regulation	  of	   the	  AAV	  proteins	   have	   also	   been	   identified	   (Alazard-­‐
Dany	  et	  al.	  2009).	  Finally,	  a	  recent	  report	  described	  how	  MRN	  degradation,	  which	  is	  
beneficial	   to	   AAV	   replication	   in	   the	   presence	   of	   adenovirus,	   is	   detrimental	   when	  
AAV	  replication	  is	  supported	  by	  HSV-­‐1	  (Millet	  et	  al.	  2015).	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1.1.3.7 AAV	  interactions	  with	  cellular	  factors	  
Several	   cellular	   proteins	   have	   been	   described	   that	   interact	   with	   the	   Rep	  
proteins,	  with	   the	  AAV	   genome,	   or	  more	   generally	   involved	   in	   the	  AAV	   life	   cycle	  
(Vogel	  et	  al.	  2013).	  The	  exact	  contributions	  of	  many	  of	  these	  host	  proteins	  to	  the	  
AAV	   life	   cycle,	   however,	   are	  not	   known.	   Furthermore,	   the	   range	  of	   host	   proteins	  
involved	   is	   different	   depending	   on	   which	   helper	   functions	   are	   present.	   Proteins	  
identified	   include	   factors	   involved	   in	   DNA	   replication,	   transcriptional	   regulation,	  
DNA	   repair	   and	   DNA	   damage	   response	   (DDR),	   and	   RNA	  metabolism.	   In	   addition,	  
cytoplasmic	  and	  mitochondrial	  proteins	  have	  also	  been	  found	  to	  interact	  with	  Rep.	  
Some	  of	   the	  best-­‐characterised	  host	   factors	   required	   for	   the	  AAV	   life	  cycle	  are	  
involved	   in	   DNA	   replication.	   In	   vitro,	   POLD,	   PCNA,	   RFC,	   and	  MCM,	   together	  with	  
Rep,	  are	  sufficient	  to	  replicate	  AAV	  DNA	  (Nash	  et	  al.	  2008).	  In	  the	  presence	  of	  HSV-­‐
1	  co-­‐infection,	   it	   is	   thought	   that	   the	  HSV-­‐1	  polymerase	  can	  substitute	  POLD.	  DNA	  
binding	   proteins,	   either	   cellular	   (RPA)	   or	   viral	   (DBP	   for	   Ad	   and	   ICP8	   for	   HSV-­‐1),	  
further	  enhance	  the	  in	  vitro	  replication	  (Ward	  et	  al.	  1998;	  Stracker	  et	  al.	  2004).	  The	  
high	  mobility	  group	  protein	  1	  (HMG1)	  has	  been	  suggested	  to	  support	  Rep	  activities,	  
and	   thus	   is	   likely	   to	   be	   involved	   in	   AAV	   replication	   (Costello	   et	   al.	   1997).	  On	   the	  
other	   hand,	   FKBP52,	   a	   protein	   that	   binds	   the	   D-­‐region	   within	   the	   viral	   ITRs,	   has	  
been	   shown	   to	   inhibit	   replication	   by	   blocking	   second	   strand	   synthesis	   in	   the	  
absence	  of	  helper	  virus	  (Qing	  et	  al.	  2001).	  In	  addition,	  the	  AAV	  genome,	  and	  likely	  
its	  replication	  intermediates,	  are	  recognised	  by	  proteins	  of	  the	  DNA	  repair	  and	  DDR	  
machineries	  (Vogel	  et	  al.	  2013).	  In	  particular,	  components	  of	  the	  MRN	  complex	  and	  
of	  the	  ATM/DNA-­‐PK	  signalling	  pathways	  have	  both	  been	  shown	  to	  be	  recruited	  to	  
AAV	  replication	  centres.	  However,	  whether	  these	  pathways	  of	  DNA	  damage	  sensing	  
and	  repair	  are	  beneficial	  or	  detrimental	  to	  the	  viral	  replication	  is	  not	  always	  trivial,	  
and	  may	  depend	  on	  the	  helper	  virus	  present.	  For	  example,	  the	  knock-­‐down	  of	  MRN	  
has	  been	  shown	   to	  have	  opposite	  effects	   in	   the	  presence	  of	  adenovirus	  or	  HSV-­‐1	  
(Schwartz	  et	  al.	  2007;	  Millet	  et	  al.	  2015).	  In	  addition,	  DDR	  proteins	  have	  also	  been	  
shown	  to	   interact	  with	   recombinant	  AAV	  vectors	   in	   the	  absence	  of	  helper	  viruses	  
(Choi	  et	  al.	  2006;	  Cervelli	  et	  al.	  2008).	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1.1.3.8 Latent	  infection	  and	  Rep-­‐mediated	  integration	  
In	  the	  absence	  of	  helper	  virus,	  the	  expression	  of	  Rep	  proteins	  is	  minimal	  and	  the	  
AAV	   genome	   is	   not	   replicated.	   Nevertheless,	   long-­‐term	   persistence	   of	   AAV	  
genomes	   has	   been	   widely	   described	   (Schultz	   and	   Chamberlain	   2008).	   Two	   main	  
mechanisms	   for	   this	   long-­‐lasting	   persistence	   have	   been	   identified:	   Rep-­‐mediated	  
site-­‐specific	   integration	   and	   episomal	   persistence	   (McCarty	   et	   al.	   2004).	   Rep-­‐
mediated	   integration,	   however,	   is	   difficult	   to	   study	   in	   vivo	   and	   has	   only	   been	  
observed	  in	  tissue	  culture.	  Thus,	  the	  significance	  of	  this	  phenomenon	  in	  the	  AAV	  life	  
cycle	  remains	  unclear.	  	  
In	   the	   early	   1990’s,	   the	   identification	   of	   viral-­‐cellular	   junctions	   in	   cell	   lines	  
latently	   infected	   with	   AAV	   led	   to	   the	   surprising	   observation	   that	   the	   cellular	  
sequences	   all	  mapped	   to	   one	   region	   on	   the	   long	   arm	  of	   human	   chromosome	  19	  
(Kotin	   et	   al.	   1990;	   Kotin	   et	   al.	   1991;	   Samulski	   et	   al.	   1991).	   This	   target	   locus,	  
subsequently	   termed	   AAVS1,	   contains	   an	   actively	   transcribed	   and	   ubiquitously	  
expressed	   gene	   that	   encodes	   for	   the	   protein	   phosphatase	   I	   regulatory	   inhibitor	  
subunit	  12C	  (PPP1R12C),	  also	  know	  as	  myosin-­‐binding	  subunit	  85	  (MBS85)	  (Dutheil	  
et	  al.	  2000;	  Lamartina	  et	  al.	  2000b).	  MBS85,	  like	  other	  MBS	  proteins,	  participates	  in	  
the	  regulation	  of	  the	  myosin	  light	  chain	  phosphatase	  that	  governs	  the	  actin-­‐myosin	  
assembly	  and	  disassembly.	  The	  MBS85	  gene	  is	  closely	  linked	  to	  three	  genes,	  TNNI3,	  
TNNT1	   and	   EPS8L1,	   which	   are	   also	   involved	   in	   the	   regulation	   of	   actin-­‐myosin	  
interactions	   (Dutheil	   et	   al.	   2000).	   Interestingly,	   orthologues	   of	   the	   human	  AAVS1	  
locus	  have	  been	   identified	   in	  non-­‐human	  primates	  and	   in	   rodents	   (Samulski	  et	  al.	  
1991;	  Dutheil	  et	  al.	  2004).	  
	  Integration	   into	   AAVS1	   is	   not	   observed	   when	   cells	   are	   transduced	   with	   viral	  
vectors	  devoid	  of	  Rep	  (Walsh	  et	  al.	  1992),	  but	  can	  be	  restored	  when	  the	  large	  Rep	  
proteins	   are	   provided	   in	   trans	   (Balague	   et	   al.	   1997;	   Surosky	   et	   al.	   1997).	   Further	  
studies	   of	   AAVS1	   reveal	   that	   it	   contains	   functional	   homologues	   of	   the	   viral	   RBS	  
(Weitzman	  et	  al.	   1994)	  and	  TRS	  motifs	   (Urcelay	  et	  al.	   1995),	   located	   immediately	  
upstream	  of	  the	  MBS85	  translation	  start	  codon;	  these	  cellular	  motifs	  are	  necessary	  
and	  sufficient	  to	  mediate	  integration	  (Giraud	  et	  al.	  1994;	  Linden	  et	  al.	  1996a).	  The	  
only	  cis-­‐acting	  viral	   sequence	  necessary	   for	   integration	   is	   the	  viral	  RBS,	  which	  can	  
be	  provided	  by	  the	  ITRs	  or	  the	  p5	  promoter	  (Young	  and	  Samulski	  2001;	  Philpott	  et	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al.	   2002;	   Guilbaud	   et	   al.	   2008).	   Despite	   several	   studies	   characterising	   AAV	  
integrants	  at	  a	  molecular	  level,	  the	  definition	  of	  a	  consensus	  proviral	  structure	  has	  
been	  hindered	  by	  the	  absence	  of	  a	  standardised	  experimental	  strategy	  (Dutheil	  and	  
Linden	  2006).	  Most	  of	  the	  integrants	  described	  to	  date	  are	  proximal	  to	  the	  TRS	  and	  
RBS	   motifs,	   although	   integrated	   AAV	   sequences	   have	   also	   been	   found	   at	   a	  
significant	  distance.	  In	  addition,	  while	  bi-­‐allelic	  integration	  has	  not	  been	  observed,	  
extensive	  rearrangements	  of	  the	  MBS85	  gene,	  as	  well	  as	  deletions	  of	  parts	  of	  the	  
viral	  sequences,	  are	  common	  (Dutheil	  and	  Linden	  2006).	  Importantly,	  a	  more	  recent	  
study	   observed	   that	   the	   integration	   event	   causes	   the	   partial	   duplication	   of	   the	  
MBS85	  sequences,	  and	   that	   the	  duplicated	   sequences	  are	  maintained	   in	   the	  5’-­‐3’	  
orientation	   (Henckaerts	   et	   al.	   2009).	   Together,	   these	   observations	   led	   to	   the	  
proposition	   of	   a	   model	   for	   AAV	   integration	   that	   parallels	   that	   of	   AAV	   DNA	  
replication	   (Figure	  4)	   (Linden	  et	  al.	  1996b;	  Henckaerts	  et	  al.	  2009).	   In	  a	   first	   step,	  
simultaneous	  binding	  of	  the	  cellular	  and	  viral	  RBS	  by	  Rep	  brings	  the	  AAV	  donor	  DNA	  
in	  close	  proximity	  to	  AAVS1	  (Weitzman	  et	  al.	  1994).	  Subsequently,	  the	  Rep	  protein	  
(bound	  to	  the	  cellular	  RBS)	  nicks	  the	  target	  cellular	  TRS,	  creating	  a	  free	  3’-­‐OH	  group	  
that	   serves	   as	   a	   primer	   for	  DNA	   replication	  by	   the	   cellular	   replication	  machinery.	  
The	   next	   step	   implies	   a	   template	   switch	   to	   a	   nearby	   AAV	   genome,	   creating	   a	  
junction	  with	  the	  left	  ITR,	  followed	  by	  one	  or	  more	  rounds	  of	  replication	  of	  the	  AAV	  
genome.	  The	  newly	  replicated	  viral	  DNA	  is	  then	  presumably	  ligated	  to	  the	  displaced	  
strand.	   Finally,	   the	   integration	   can	  be	   completed	  by	   the	   introduction	  of	   a	   second	  
nick	  in	  the	  template	  strand	  followed	  by	  replication	  of	  the	  newly	  generated	  cellular-­‐
viral	  sequences,	  resulting	  in	  a	  partial	  duplication	  of	  the	  AAVS1	  sequence.	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Figure	  4:	  Model	  for	  Rep-­‐mediated	  integration.	  	  
(I)	   Rep	   binds	   to	   the	   cellular	   RBS	   and	   inserts	   a	   strand-­‐specific	   nick	   at	   the	   TRS	   in	   AAVS1.	   (II)	   DNA	  
synthesis	  by	  strand	  displacement	  is	  initiated	  at	  the	  nicked	  TRS.	  (III)	  The	  replication	  switches	  template	  
onto	   AAV.	   (IV)	   Occasional	   second	   template	   strand	   switch-­‐back	   onto	   AAVS1	   generate	   an	   inverted	  
repeat.	  (V)	  Ligation	  between	  AAV	  and	  the	  displaced	  strand.	  (V	  and	  VI)	  Rep-­‐mediated	  nicking	  at	  the	  
bottom	  strand	  stimulates	  repair	  of	  the	  non-­‐complementary	  strand.	  (VII)	  AAV	  site-­‐specific	  integration	  
results	  in	  partial	  duplication	  of	  MBS85	  sequences.	  Adapted	  from	  (Henckaerts	  et	  al.	  2009).	  
	  
In	   recent	   years,	   the	   development	   of	   high-­‐throughput	   sequencing	   technologies	  
combined	   with	   improved	   PCR	   techniques,	   has	   allowed	   unbiased	   genome-­‐wide	  
studies	   of	   viral	   integration	   patterns	   (Schmidt	   et	   al.	   2007;	   Paruzynski	   et	   al.	   2010),	  
including	   those	   of	   AAV.	   On	   one	   side,	   the	   results	   of	   these	   studies	   confirmed	   the	  
random	   pattern	   of	   rAAV	   integration,	   but	   on	   the	   other	   side	   they	   challenged	   the	  
notion	  of	  site-­‐specific	  integration	  of	  WT	  AAV	  (Huser	  et	  al.	  2010;	  Janovitz	  et	  al.	  2013;	  
Huser	   et	   al.	   2014;	   Petri	   et	   al.	   2015).	   In	   the	   first	   of	   these	   studies,	   Huser	   and	  
colleagues	   reported	   that	   less	   than	   10%	   of	  WT	   AAV	   integration	   sites	   detected	   in	  
HeLa	   cells	  were	   in	  AAVS1	   or	   its	   proximity	   (Huser	   et	   al.	   2010).	   Two	   other	   studies	  
investigated	   AAV	   integration	   in	   HeLa	   cells:	   one	   reported	   that	   up	   to	   45%	   of	  
integration	   sites	  were	   in	  AAVS1	   (Janovitz	  et	   al.	   2013),	  while	   the	  other	   reported	  a	  
value	  of	  13%	  (Petri	  et	  al.	  2015).	   In	  addition,	   two	  very	  recent	  reports	  assessed	  the	  
	   35	  
WT	   AAV	   integration	   profile	   in	   diploid	   human	   fibroblasts,	   and	   found	   that	   2.5%	  
(Huser	  et	  al.	  2014)	  and	  9%	   (Petri	  et	  al.	  2015)	  of	   the	   integration	   sites	  were	  within	  
AAVS1.	  In	  spite	  of	  significant	  differences	  in	  the	  experimental	  procedures,	  a	  general	  
picture	  has	  emerged	  from	  these	  studies.	  First,	  it	  is	  clear	  that	  WT	  AAV	  integration	  is	  
not	   as	   site-­‐specific	   as	   initially	   hypothesised.	   Second,	   most	   of	   the	   integration	  
hotspots	   that	   were	   analysed	   revealed	   the	   presence	   of	   RBS-­‐like	   and/or	   TRS-­‐like	  
sequences,	  although	  AAVS1	  was	  the	  only	  hotspot	  that	  was	  consistently	  identified	  in	  
all	   the	   studies.	   The	   putative	   RBS	   of	   some	   of	   the	   most	   frequent	   hotspots	   were	  
shown	  to	  bind	  Rep68	  in	  vitro	  (Huser	  et	  al.	  2010;	  Petri	  et	  al.	  2015)	  and,	  remarkably,	  
Rep	  was	   also	   shown	   to	   be	   able	   to	   nick	   supercoiled	  DNA	   plasmids	   containing	   the	  
RBS-­‐TRS	   sequences	   from	   some	  of	   the	  most	   frequent	   hotspots	   (Petri	   et	   al.	   2015).	  
Thus,	   these	   data	   suggest	   that	   integration	   in	   sites	   other	   than	   AAVS1	   could	   be	  
mediated	  by	  the	  same	  Rep-­‐dependent	  mechanism	  responsible	  for	   integration	  into	  
AAVS1.	  The	  frequency	  of	  integration	  in	  sites	  containing	  an	  RBS	  and	  an	  appropriately	  
spaced	  TRS	  could	  be	  determined	  by	  cellular	  rather	  than	  viral	  factors.	  In	  particular,	  it	  
was	   described	   that	   an	   open	   chromatin	   status	   correlates	   with	   an	   increased	  
frequency	  of	  integration	  (Huser	  et	  al.	  2014).	  
The	  episomal	  mode	  of	  AAV	  persistence	  has	  been	  most	  extensively	   investigated	  
in	  the	  context	  of	  recombinant	  AAV	  vectors	  devoid	  of	  Rep,	  both	  in	  vitro	  and	  in	  vivo	  
(McCarty	  et	  al.	  2004;	  Schultz	  and	  Chamberlain	  2008).	  Following	  the	  second-­‐strand	  
synthesis	  by	  the	  cellular	  repair	  machinery	  and/or	  the	  annealing	  of	  complementary	  
AAV	   +	   and	   –	   strands,	   linear	   dsDNA	   molecules	   circularise	   and	   can	   undergo	  
concatamerisation.	   In	   this	   form,	   episomal	   vector	   genomes	   have	   been	   shown	   to	  
persist	  long-­‐term	  in	  several	  tissues.	  Very	  low	  frequency	  integration	  of	  AAV	  vectors	  
has	  also	  been	  reported	  (McCarty	  et	  al.	  2004;	  Schultz	  and	  Chamberlain	  2008)	  and	  it	  
has	  been	  suggested	  that	  non-­‐homologous	  recombination	  at	  double-­‐strand	  breaks	  is	  
the	  primary	  mechanism	  of	  this	  unspecific	  integration	  (Miller	  et	  al.	  2004).	  
1.1.4 AAV	  as	  a	  vector	  for	  gene	  therapy	  
In	   recent	   years,	   AAV	   has	   become	   one	   of	   the	   most	   promising	   vectors	   being	  
developed	   for	   gene	   therapy	   applications.	   In	   particular,	   the	   long-­‐term	   (episomal)	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persistence	  in	  vivo	  and	  the	  lack	  of	  pathogenicity	  associated	  with	  WT	  AAV	  infections	  
have	  made	  it	  an	  attractive	  candidate	  as	  gene	  therapy	  vector.	  	  
Recombinant	  AAV	  vectors,	  evolved	  from	  the	  initial	  vectors	  developed	  in	  the	  mid	  
1980s	  (Hermonat	  and	  Muzyczka	  1984;	  Tratschin	  et	  al.	  1984b),	  are	  devoid	  of	  the	  Rep	  
and	   Cap	   genes	   and	   are	   therefore	   replication	   deficient.	   The	   typical	   AAV	   vector	  
consists	  of	  a	  transgene	  expression	  cassette	  (of	  maximum	  4.5kb)	  flanked	  by	  the	  viral	  
ITRs,	  which	  are	  the	  only	  cis-­‐acting	  elements	  necessary	  for	  replication	  and	  packaging	  
(Carter	  2004).	  The	  viral	  Rep	  and	  Cap	  proteins,	  as	  well	  as	  the	  helper	  virus	  functions	  
necessary	  for	  the	  efficient	  viral	  replication	  and	  packaging	  are	  provided	  in	  trans.	  The	  
most	   common	   and	   efficient	   AAV	   vector	   production	   protocol	   is	   based	   on	   triple	  
transfection	   of	   293T	   cells	   with	   a	   vector	   plasmid,	   a	   Rep-­‐Cap	   plasmid	   and	   an	   Ad	  
helper	  plasmid	  (Wright	  2009).	  While	  this	  strategy	  allows	  for	  efficient	  production	  of	  
rAAVs,	   the	   infectivity	  of	   the	   viral	   vectors	  produced	   is	   still	   significantly	   lower	   than	  
that	  observed	  for	  WT	  AAV	  (Zeltner	  et	  al.	  2010).	  The	  need	  for	  a	  good	  manufacturing	  
practice	   (GMP)-­‐compatible	   and	   scalable	   production	   method	   has	   led	   to	   the	  
development	   of	   alternative	   production	   platforms,	   such	   as	   HEK293	   cell	   lines	   that	  
grow	  in	  suspension	  in	  serum-­‐free	  medium	  (Park	  et	  al.	  2006;	  Durocher	  et	  al.	  2007;	  
Hildinger	  et	  al.	  2007),	  the	  baculovirus	  expression	  system	  in	  insect	  cells	  (Virag	  et	  al.	  
2009),	   adeno-­‐AAV	   hybrids	   (Zhang	   et	   al.	   2009),	   and	   the	   use	   of	   a	   recombinant	  
herpesvirus	   system	   (Clement	   et	   al.	   2009).	   The	   most	   common	   strategies	   used	   to	  
purify	   AAV	   particles	   are	   column	   chromatography	   and	   ultracentrifugation	   through	  
non-­‐ionic	  iodixanol	  gradients	  (Grieger	  et	  al.	  2006a).	  
Over	  the	  years,	  a	  number	  of	  advances	  in	  the	  understanding	  of	  the	  biology	  of	  the	  
virus	   and	   of	   AAV	   vectors	   have	   translated	   into	   important	   developments	   for	   the	  
production	  of	  rAAVs.	  Beyond	  the	  discovery	  of	  the	  cis-­‐	  and	  trans-­‐acting	  elements	  of	  
the	   AAV	   genome	   (Hermonat	   et	   al.	   1984;	   Tratschin	   et	   al.	   1984a),	   the	  
characterisation	   of	   the	   minimal	   adenovirus	   helper	   functions	   allowed	   the	  
development	  of	  helper	  plasmids	  carrying	   the	  adenovirus	   functions,	  abolishing	   the	  
usage	   of	   WT	   Ad	   in	   the	   AAV	   production	   protocols	   and	   resulting	   in	   Ad-­‐free	   rAAV	  
stocks	   (Grimm	   et	   al.	   1998;	   Matsushita	   et	   al.	   1998;	   Xiao	   et	   al.	   1998).	   Another	  
significant	   advance	  was	   the	   understanding	   that	   limited	   Rep	   protein	   expression	   is	  
beneficial	  to	  the	  virus	  and	  allows	  for	  increased	  rAAV	  production	  (Li	  et	  al.	  1997).	  One	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of	  the	  most	  significant	  advances	  was	  the	  development	  of	  a	  cross-­‐packaging	  system	  
that	  enables	  the	  packaging	  of	  AAV2	  vector	  genomes	  (i.e.	  containing	  the	  ITRs	  from	  
serotype	   2)	   into	   other	   AAV	   capsids	   (Rabinowitz	   et	   al.	   2002),	   allowing	   the	   direct	  
comparison	  of	  the	  in	  vivo	  tropism	  of	  different	  AAV	  capsids	  (Rabinowitz	  et	  al.	  2002;	  
Zincarelli	   et	   al.	   2008).	   This	   work	   was	   particularly	   relevant,	   as	   one	   of	   the	   ideal	  
features	  of	  a	  gene-­‐therapy	  vector	   is	   cell-­‐type	  or	   tissue	  specificity	   in	  gene	  delivery	  
and	  different	  AAV	  capsids	  have	  been	  shown	  to	  display	  different	  tissue	  tropisms	   in	  
vivo.	  Moreover,	   this	  made	  possible	   the	   selection	  of	  natural	  or	   rationally	  designed	  
AAV	   capsids	   with	   specific	   characteristics	   and	   tissue	   specificities,	   enabling	   the	  
generation	  of	  libraries	  for	  directed	  evolution	  of	  capsids	  with	  the	  desired	  properties	  
(Vandenberghe	  et	  al.	  2009).	  Another	  remarkable	  advance	  was	  the	  development	  of	  
double-­‐stranded	   self-­‐complementary	   AAVs	   (scAAVs)	   that	   bypass	   the	   need	   for	  
second-­‐strand	   synthesis	   once	   uncoated,	   thus	   allowing	   for	   a	   faster	   onset	   of	  
transgene	   expression	   (McCarty	   2008).	   While	   this	   is	   a	   very	   desirable	   property,	  
scAAVs	   packaged	   as	   dimer	   genomes	   can	   only	   accommodate	   half	   of	   the	   already	  
limited	   size	   of	   AAV	   vector	   genomes,	   and	   thus	   have	   a	   limited	   field	   of	   application.	  
Finally,	   efforts	   towards	   increasing	   the	   capacity	   of	   rAAVs	   have	   led	   to	   the	  
development	   of	   dual	   vectors	   that	   use	   two	   separate	   AAVs	   to	   achieve	   transgene	  
expression	  (Ghosh	  and	  Duan	  2007).	  
The	  desirable	  properties	  of	  rAAVs	  and	  the	  above-­‐mentioned	  advances	  in	  vector	  
design	   and	   production	   have	  made	  AAV	   a	   suitable	   candidate	   for	   gene	   therapy.	   In	  
recent	  years,	  following	  numerous	  pre-­‐clinical	  studies	  in	  animal	  models	  ranging	  from	  
mice	   to	   non-­‐human	   primates,	   rAAVs	   have	   entered	   into	   several	   clinical	   trials	  
(Mueller	  and	  Flotte	  2008;	  High	  and	  Aubourg	  2011;	  Grieger	  and	  Samulski	  2012).	  The	  
initial	   trials	   investigated	   the	   use	   of	   rAAVs	   to	   treat	   monogenic	   disorders	   such	   as	  
cystic	  fibrosis	  (Flotte	  et	  al.	  2003)	  and	  haemophilia	  B	  (Kay	  et	  al.	  2000),	  and	  showed	  
very	   good	   safety	   profiles.	   However,	   in	   these	   initial	   trials,	   the	   expression	   of	   the	  
transgene	  was	  limited	  and	  transient,	  most	  likely	  due	  to	  an	  immune	  response	  to	  the	  
AAV2	  capsid.	  Subsequent	   trials	  have	   targeted	  more	   immuno-­‐privileged	  sites,	   such	  
as	   the	   central	   nervous	   system	   or	   the	   retina.	  More	   recently,	   thanks	   to	   the	   cross-­‐
packaging	   technology	   described	   above,	   clinical	   studies	   are	  moving	   towards	   using	  
different	   capsid	   serotypes	   to	   improve	   tissue	   targeting	  and	   to	   reduce	   the	   immune	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responses.	   Today,	   one	   rAAV	   product	   has	   reached	   the	   market	   in	   Europe	   (Yla-­‐
Herttuala	  2012),	  and	  several	  ongoing	  clinical	   trials	  are	  exploring	   the	  use	  of	   rAAVs	  
for	  the	  treatment	  of	  a	  growing	  number	  of	  diseases.	  	  
	  
1.2 	  AAV	  REP	  AND	  VIRAL	  MULTIFUNCTIONAL	  PROTEINS	  
1.2.1 AAV	  Rep	  proteins	  
1.2.1.1 The	  Rep	  proteins	  and	  their	  role	  during	  the	  AAV	  life	  cycle	  
The	   genome	   of	   AAV	   has	   evolved	   a	   single	   open	   reading	   frame	   coding	   for	   the	  
master	   regulatory	   proteins,	   the	   Rep	   proteins,	   which	   are	   responsible	   for	  
orchestrating	  every	  step	  in	  the	  viral	   life	  cycle.	  There	  are	  four	  Rep	  isoforms	  (Figure	  
5),	   named	   after	   their	   molecular	   weight	   on	   denaturing	   acrylamide	   gels:	   Rep78,	  
Rep68,	   Rep52	   and	   Rep40.	   As	   explained	   in	   section	   1.1.3.3,	   they	   are	   generated	  
through	  the	  usage	  of	  the	  p5	  and	  p19	  viral	  promoters	  and	  alternative	  splicing.	  The	  
Rep	  proteins,	   in	  particular	   the	   large	  Rep	  proteins	  Rep68	  and	  Rep78,	   are	   versatile	  
multi-­‐domain	   proteins,	   and	   are	   a	   good	   example	   of	   viral	  multi-­‐functional	   proteins	  
that	  have	  evolved	  under	  space	  constraints	  to	  combine	  several	  enzymatic	  functions	  




Figure	  5:	  The	  Rep	  proteins	  of	  AAV.	  	  
Schematic	   diagram	   showing	   the	   domain	   architecture	   of	   the	   four	   Rep	   proteins	   of	   AAV.	   The	   OBD,	  
containing	  DNA	  binding	  and	  endonuclease	  activities	  is	  shown	  in	  green;	  the	  central	  helicase	  domain	  
characteristic	  of	  SF3	  helicases	  is	  shown	  in	  blue,	  and	  the	  zinc-­‐finger	  domain	  is	  shown	  in	  red.	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The	  Rep	  proteins	  are	  important	  for	  the	  transcriptional	  regulation	  of	  AAV,	  helper	  
virus	   and	   cellular	   genes,	   ensuring	   that	   the	   cellular	   environment	   is	   prepared	   for	  
efficient	   replication	   of	   the	   viral	   genome	   or	   for	   the	   establishment	   of	   latency	  
(McCarty	  et	  al.	  1991;	  Hermonat	  1994;	  Horer	  et	  al.	  1995;	  Kyostio	  et	  al.	  1995;	  Pereira	  
et	  al.	  1997;	  Weger	  et	  al.	  1997;	  Needham	  et	  al.	  2006;	  Dutheil	  et	  al.	  2009;	  Dutheil	  et	  
al.	  2014).	  Transcriptional	  regulation	  can	  be	  achieved	  by	  direct	  binding	  to	  the	  RBS	  or	  
other	   regulatory	   DNA	   sequences,	   and	   possibly	   through	   interactions	   with	   other	  
proteins.	  The	   large	  Rep	  proteins	  Rep78/68	  are	  essential	   for	   the	   replication	  of	   the	  
AAV	  genome:	  their	  interaction	  with	  the	  RBS	  and	  the	  TRS	  is	  the	  basis	  of	  the	  terminal	  
resolution	   of	   the	   ITRs	   and	   the	   regeneration	   of	   the	   3’-­‐OH	   group	   for	   subsequent	  
rounds	   of	   replication	   (Ward	   2006).	   Furthermore,	   Rep78/68	   are	   required	   for	   site-­‐
specific	   integration	   of	   the	   viral	   genome	   into	   AAVS1	   and	   the	   rescue	   of	   the	   viral	  
genome	   from	   AAVS1	   following	   helper	   virus	   superinfection	   (Dutheil	   and	   Linden	  
2006).	   The	   small	   Rep	   proteins	   Rep52	   and	   Rep40,	   in	   addition	   to	   their	   role	   in	  
transcriptional	   regulation,	   are	   important	   for	   the	   accumulation	   of	   single	   stranded	  
genomes	   and	   their	   efficient	   packaging	   into	   preformed	   capsids	   (King	   et	   al.	   2001).	  
Finally,	   besides	   the	   well-­‐characterised	   functional	   roles	   described	   above,	   the	   Rep	  
proteins	  are	  likely	  to	  have	  additional	  and,	  as	  yet,	  undiscovered	  functions	  in	  the	  AAV	  
life	   cycle.	   Rep	   interactions	   with	   cellular	   proteins,	   for	   example,	   remain	   poorly	  
characterised,	  and	  are	  likely	  to	  play	  significant	  roles	  in	  the	  viral	  life	  cycle,	  including	  
some	  that	  could	  improve	  the	  efficacy	  of	  AAV	  vectors	  for	  gene	  therapy.	  
1.2.1.2 Rep	  domains	  and	  their	  enzymatic	  properties	  
Three	   major	   domains	   are	   combined	   to	   form	   the	   largest	   of	   the	   Rep	   proteins,	  
Rep78:	  an	  amino-­‐terminal	  origin	  binding	  domain	  (OBD),	  a	  central	  helicase	  domain	  
and	   a	   carboxy-­‐terminal	   Zn-­‐finger	   domain.	   A	   short	   interdomain	   linker	   (∼20	   amino	  
acids)	  of	  unknown	  function	  connects	  the	  OBD	  and	  helicase	  domains.	  All	  the	  other	  
Rep	  proteins	  are	  a	  combination	  of	  these	  functional	  domains:	  Rep68	   is	   identical	  to	  
Rep78	   but	   lacks	   the	   Zn-­‐finger	   domain;	   Rep52	   combines	   helicase	   and	   Zn-­‐finger	  
domains;	  and	  finally,	  Rep40	  only	  contains	  the	  helicase	  (Figure	  5).	  Interestingly,	  this	  
core	  domain	  that	   is	  present	   in	  all	   four	  Rep	   isoforms	   is	   the	  most	  conserved	  region	  
amongst	  parvoviral	  non-­‐structural	  proteins	  (Astell	  et	  al.	  1987).	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1.2.1.3 Origin	  binding	  domain	  
The	  amino-­‐terminal	  domain	  of	  Rep,	  encompassing	  residues	  1-­‐208	  and	  shared	  by	  
Rep68	   and	   Rep78,	   is	   termed	   OBD	   and	   carries	   sequence-­‐specific	   DNA	   binding	  
activity	   as	   well	   as	   strand-­‐	   and	   sequence-­‐specific	   endonuclease	   activity	   (Im	   and	  
Muzyczka	  1990;	  Owens	  et	  al.	  1993;	  Chiorini	  et	  al.	  1994a;	  McCarty	  et	  al.	  1994a).	  In	  
addition,	   it	  has	  also	  been	  shown	  to	  have	  a	  ligase	  function	  (Smith	  and	  Kotin	  2000).	  
The	   structure	   of	   AAV	   serotype	   5	   Rep	  OBD	   (residues	   1-­‐197)	   has	   been	  determined	  
with	  and	  without	  RBS-­‐containing	  DNA	  (Hickman	  et	  al.	  2002;	  Hickman	  et	  al.	  2004).	  
The	  structural	  data	  reveal	  how,	  despite	   its	   limited	  size	  (∼20kD),	  the	  OBD	  interacts	  
with	  several	  DNA	  substrates,	  including	  the	  RBS,	  the	  RBS’	  and	  the	  TRS.	  
The	  OBD	   is	   responsible	   for	   the	   specific	   binding	   of	   Rep	   to	   RBS-­‐containing	   DNA	  
substrates,	   including	   the	   viral	   ITRs	   and	   p5	   promoter,	   as	   well	   as	   the	   cellular	  
integration	   site	   AAVS1	   (McCarty	   et	   al.	   1994a;	   Weitzman	   et	   al.	   1994).	   The	   RBS	  
consists	   of	   multiple	   direct	   5’-­‐GCTC-­‐3’	   repeats	   that	   are	   recognised	   through	   both	  
major	   and	   minor	   groove	   interactions	   with	   a	   specialised	   interface	   of	   the	   OBD	  
(Hickman	  et	  al.	  2004).	  Each	  OBD	  can	  make	  contact	  with	  two	  adjacent	  repeats,	  and	  
each	  repeat	  can	  be	  recognised	  by	  two	  separate	  OBD	  molecules	  on	  opposite	  sides	  of	  
the	   DNA,	   forming	   a	   spiral	   around	   the	   RBS.	   The	   RBS	   sequences	   of	   different	   AAV	  
serotypes	  and	  of	  AAVS1	  are	  related	  but	  not	  identical.	  They	  all	  contain	  at	  least	  two	  
perfect	  GCTC	  repeats	  and	  additional	  imperfect	  repeats,	  yet	  the	  relative	  position	  of	  
the	  base	  substitutions	   in	   the	   imperfect	   repeats	  varies.	  The	  viral	  p5	  promoter	  also	  
contains	   a	   RBS	   that	   is	   efficiently	   bound	   by	   Rep,	   but	   it	   only	   contains	   one	   perfect	  
GCTC	   repeat	  and	   several	   imperfect	   repeats	   (McCarty	  et	  al.	  1994a).	   In	  addition,	   in	  
silico	  analyses	  of	  the	  human	  genome	  have	  revealed	  several	  RBS	  homologues,	  some	  
of	  which	  have	  been	  shown	  to	  have	  the	  potential	  to	  be	  bound	  by	  Rep	  (Wonderling	  
and	  Owens	  1997;	  Lamartina	  et	  al.	  2000a;	  Huser	  et	  al.	  2010;	  Petri	  et	  al.	  2015).	  Thus,	  
the	  OBD-­‐RBS	   interaction	   is	   specific	  but	   tolerates	   some	  degree	  of	   flexibility,	  which	  
may	   be	   important	   for	   some	   of	   the	   Rep	   functions,	   such	   as	   the	   transcriptional	  
regulation	   of	   different	   promoters	   (Batchu	   et	   al.	   1994;	   Horer	   et	   al.	   1995).	   In	   the	  
context	  of	  the	  viral	  ITR,	  the	  OBD	  makes	  further	  contacts	  with	  the	  RBS’,	  defined	  by	  
the	   5’-­‐CTTTG-­‐3’	   motif	   at	   the	   tip	   of	   one	   of	   the	   internal	   palindromes	   (Ryan	   et	   al.	  
1996;	  Hickman	  et	  al.	  2004).	  Importantly,	  the	  position	  of	  the	  RBS’	  relative	  to	  the	  TRS	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is	  maintained	   in	  both	  the	   flip	  and	   flop	  orientations	  of	   the	   internal	  palindromes	  of	  
the	  ITR.	  During	  replication	  and	  site-­‐specific	   integration,	  RBS	  binding	  is	  followed	  by	  
nicking	   at	   the	   TRS.	   Importantly,	   the	   binding	   positions	   Rep	   asymmetrically	   on	   the	  
ITR,	   and	   the	   correct	   alignment	   is	   necessary	   for	   the	   subsequent	   nicking	   reaction	  
(Brister	   and	  Muzyczka	  2000).	   Furthermore,	   the	   spacing	  between	   the	  RBS	  and	   the	  
TRS	   also	   appears	   to	   be	   of	   pivotal	   importance	   for	   the	   efficient	   nicking	   at	   the	   TRS	  
(Brister	  and	  Muzyczka	  2000;	  Lamartina	  et	  al.	  2000a).	  Binding	  to	  the	  RBS’,	  while	  not	  
essential	  for	  the	  nicking	  reaction,	  has	  been	  shown	  to	  increase	  its	  efficiency	  (Ryan	  et	  
al.	  1996;	  Brister	  and	  Muzyczka	  2000).	  
Structurally,	   the	   AAV	   Rep	   OBD	   belongs	   to	   the	   HUH	   family	   of	   endonucleases,	  
described	  in	  further	  detail	  below.	  The	  core	  of	  the	  AAV	  OBD	  consists	  of	  a	  5-­‐stranded	  
anti-­‐parallel	  β	  sheet	  that	  contains	  the	  canonical	  HUH	  motif,	  flanked	  on	  each	  side	  by	  
three	  helices	  (Hickman	  et	  al.	  2002)	  (Figure	  6).	  Facing	  the	  two	  histidine	  residues	  of	  
the	  HUH	  motif	  and	  forming	  the	  endonuclease	  enzymatic	  pocket,	  is	  helix	  αD,	  which	  
contains	  the	  catalytically	  active	  tyrosine	  (Y156	  in	  AAV2	  Rep).	  The	  surface	  involved	  in	  
RBS’	  binding	  is	  opposite	  the	  active	  site,	  while	  the	  region	  in	  between	  is	  important	  for	  
RBS	  binding	  and	  positions	  the	  TRS	  towards	  the	  active	  site	  (Hickman	  et	  al.	  2004).	  
	  
	  
Figure	  6:	  Crystal	  structure	  of	  the	  AAV5	  Rep	  OBD.	  	  
The	  structure	  shows	  the	  five	  central	  anti-­‐parallel	  strands,	  with	  the	  characteristic	  HUH	  motif	  located	  
in	  the	  central	  strand	  and	  highlighted	  in	  red.	  This	  motif	  is	  facing	  the	  active	  site	  tyrosine	  located	  in	  one	  
of	  the	  α-­‐helices,	  also	  highlighted	  in	  red.	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  Like	  all	  HUH	  endonucleases,	  Rep	  catalyses	  ssDNA	  nicking	  and	   joining	  using	  the	  
catalytically	   active	   tyrosine	   for	   a	   transesterification	   reaction	   that	   creates	   a	   5’-­‐
phosphotyrosine	  intermediate	  and	  a	  free	  3’-­‐OH	  (Im	  and	  Muzyczka	  1990;	  Snyder	  et	  
al.	   1990;	  Davis	  et	   al.	   2000;	   Smith	  and	  Kotin	  2000).	   In	   the	   case	  of	  AAV,	   the	  newly	  
generated	  3’-­‐OH	  is	  used	  to	  prime	  replication	  of	  the	  ITR.	  Because	  the	  TRS-­‐containing	  
DNA	  in	  AAV	  is	  double-­‐stranded,	  the	  endonuclease	  reaction	  must	  occur	  in	  two	  steps.	  
The	   first	   step	   is	   the	  unwinding	  of	   the	   ITR	   to	   expose	   the	   TRS:	   this	   reaction	   is	  ATP	  
dependent,	  requires	  the	  DNA	  helicase	  activity	  of	  Rep,	  and	  leads	  to	  the	  extrusion	  of	  
a	   stem-­‐loop	   structure	  exposing	   the	  nicking	   site	   in	   the	   loop	   (Brister	  and	  Muzyczka	  
1999;	   Davis	   et	   al.	   2000).	   The	   second	   step	   is	   the	   actual	   nicking	   reaction,	  which	   is	  
strand-­‐	   and	   sequence-­‐specific	   and	   requires	   a	   divalent	   metal	   ion,	   but	   is	   ATP	  
independent	  (Brister	  and	  Muzyczka	  1999;	  Smith	  and	  Kotin	  2000).	  The	  TRS	  sequence	  
recognised	  and	  cleaved	  by	  Rep	  is	  3’-­‐GGT/TGA-­‐5’	  and	  is	  well	  conserved	  within	  AAV	  
serotypes	   and	  AAVS1	   (Brister	   and	  Muzyczka	   1999).	   As	   it	   is	   the	   case	   for	   the	   RBS	  
sequence,	   a	   certain	   degree	   of	   flexibility	   is	   tolerated	   (Brister	   and	  Muzyczka	   2000;	  
Lamartina	  et	  al.	  2000a).	  The	  only	  exception	   is	   the	   ITR	  of	  AAV5,	   in	  which	  both	   the	  
TRS	   sequence	  and	   the	  distance	   from	  the	  RBS	  are	  different	   (Chiorini	  et	  al.	  1999a).	  
Unsurprisingly,	  AAV2	  Rep	   supports	   the	   replication	  of	   other	  AAV	   serotypes	   except	  
for	  that	  of	  AAV5	  (Costello	  et	  al.	  1997;	  Chiorini	  et	  al.	  1999a).	  
1.2.1.4 Helicase	  domain	  
The	   helicase	   domain	   of	   Rep,	   shared	   by	   all	   the	   Rep	   isoforms,	   contains	   helicase	  
and	   ATPase	   activities,	   as	   well	   as	   a	   nuclear	   localisation	   signal	   (Im	   and	   Muzyczka	  
1990;	   Yang	   et	   al.	   1992;	   Smith	   and	   Kotin	   1998;	   Cassell	   and	   Weitzman	   2004).	   As	  
explained	  previously,	  the	  helicase	  function	  of	  the	  large	  Rep	  proteins	  is	  necessary	  to	  
allow	  efficient	  TRS	  nicking.	  In	  addition,	  Rep	  is	  capable	  of	  unwinding	  the	  ITR	  to	  allow	  
re-­‐initiation	   and	   the	   replicated	   dsDNA	   genome	   for	   continued	   replication	   in	   vitro,	  
although	   it	   is	   possible	   that	   other	   helicases	   are	   involved	   in	   this	   process	   in	   vivo.	  
Furthermore,	   the	  helicase	  activity	  of	   the	  small	  Rep	  proteins	  Rep52/40	   is	  essential	  
for	  the	  efficient	  packaging	  of	  AAV	  DNA.	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Like	   all	   helicases,	   AAV	   Rep	   couples	   nucleotide	   hydrolysis	   to	   unidirectional	  
translocation	  along	  nucleic	  acid	  molecules	  (Singleton	  et	  al.	  2007;	  Patel	  et	  al.	  2011).	  
More	   specifically,	   Rep	   belongs	   to	   the	   superfamily	   3	   (SF3)	   of	  multimeric	   helicases	  
which	  includes	  multifunctional	  proteins	  found	  mainly	  in	  small	  DNA	  and	  RNA	  viruses	  
(reviewed	  in	  further	  detail	  below)	  (Gorbalenya	  and	  Koonin	  1993;	  Hickman	  and	  Dyda	  
2005).	   This	   family	   of	   helicases	   has	   3’→5’	   direction	   of	   unwinding	   and	   is	  
characterised	  by	  four	  conserved	  motifs	  clustered	  in	  a	  short	  stretch	  of	  ∼	  100	  amino	  
acids:	  motifs	  A	  and	  B	  (also	  known	  as	  Walker	  A	  and	  B	  boxes),	  motif	  B’	  (or	  the	  B’	  box),	  
and	  motif	  C	  (or	  the	  sensor	  1	  motif).	  These	  motifs	  form	  the	  core	  active	  site,	  and	  are	  
essential	   for	   nucleotide	   binding,	   metal	   coordination	   and	   for	   sensing	   of	   the	  
phosphorylation	  state	  of	  the	  bound	  nucleotide	  (Hanson	  and	  Whiteheart	  2005).	  The	  
B’	  motif,	   unique	   to	   SF3	   helicases,	   has	   been	   suggested	   to	   play	   a	   key	   role	   in	   DNA	  
binding	  and	  in	  the	  coupling	  of	  ssDNA	  binding	  to	  ATP	  hydrolysis	  (Yoon-­‐Robarts	  et	  al.	  
2004).	  	  
Structural	  studies	  of	  Rep40	  (equivalent	  to	  the	  minimal	  helicase	  domain)	  revealed	  
that	   it	   has	   a	   bi-­‐modular	   architecture	   (Figure	   7)	   (James	   et	   al.	   2003;	   James	   et	   al.	  
2004).	  The	  N-­‐terminus	  forms	  a	  small	  helical	  bundle	  of	  unknown	  function,	  while	  the	  
C-­‐terminal	  part	   is	   a	   larger	  α/β	  domain	   that	   contains	   the	   characteristic	   SF3	  motifs	  
(Figure	  7).	  This	  α/β	  fold	  consists	  of	  a	  central	  5-­‐stranded	  antiparallel	  β	  sheet	  flanked	  
on	  both	  sides	  by	  several	  α	  helices,	  and	  has	  the	  topology	  of	  AAA+	  proteins	  (ATPases	  
associated	  with	  diverse	  cellular	  activities)	  (James	  et	  al.	  2003).	  AAA+	  proteins	  are	  a	  
vast	  family	  of	  P-­‐loop	  ATPases	  that	  couple	  ATP	  hydrolysis	  to	  conformational	  changes	  
and	  support	  a	  wide	  array	  of	  biological	  functions,	  including	  helicase	  activities	  such	  as	  
that	  of	  AAV	  Rep	  (Iyer	  et	  al.	  2004;	  Hanson	  and	  Whiteheart	  2005).	  Rep,	  like	  other	  SF3	  
helicases,	  contains	  a	  modified	  version	  of	  the	  canonical	  AAA+	  structure	  (James	  et	  al.	  
2003).	   In	   addition,	   it	   has	   an	   incomplete	   nucleotide	   binding	   site	   that	   requires	   the	  
formation	  of	  an	  oligomeric	  interface	  to	  stabilise	  the	  binding	  of	  nucleotides	  through	  
an	  arginine	  finger	  provided	  by	  a	  neighbouring	  subunit	  (James	  et	  al.	  2004).	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Figure	  7:	  Crystal	  structure	  of	  Rep40.	  	  
The	   structure	   of	   Rep40,	   defined	   as	   the	   minimal	   helicase	   domain	   of	   AAV	   Rep,	   is	   bi-­‐modular	   and	  
contains	   an	   N-­‐terminal	   small	   helical	   bundle	   (bottom)	   and	   an	   AAA+-­‐like	   core	   characteristic	   of	   SF3	  
helicases.	  
	  
1.2.1.5 Zn	  finger	  domain	  
Of	   the	   three	  domains	  of	  Rep,	   the	  C-­‐terminal	  Zn	   finger	  domain,	  present	  only	   in	  
the	  unspliced	  variants	  Rep78	  and	  Rep52,	  is	  the	  least	  well	  characterised.	  While	  it	  has	  
been	  shown	  that	  the	  Zn	  finger	  can	  bind	  zinc	  ions	  (Horer	  et	  al.	  1995),	  its	  function	  and	  
importance	   during	   the	   AAV	   life	   cycle	   are	   not	   clear.	   To	   date,	   the	   only	   functional	  
differences	   identified	   between	  Rep78	   and	  Rep68	   and	   between	  Rep52	   and	  Rep40	  
concern	  the	  interaction	  with	  other	  proteins	  (Di	  Pasquale	  and	  Stacey	  1998)	  and	  the	  
transcriptional	   regulation	   of	   heterologous	   promoters	   (Horer	   et	   al.	   1995).	  
Furthermore,	   the	   Zn	   finger	   domain	   has	   been	   suggested	   to	   be	   necessary	   for	   the	  
AAV-­‐induced	  de-­‐regulation	  of	  the	  cell	  cycle	  by	  AAV	  (Berthet	  et	  al.	  2005).	  	  
1.2.2 HUH	  endonucleases	  
HUH	   endonucleases	   are	   specialised	   enzymes	   that	   process	   site-­‐specific	   ssDNA	  
and	   catalyse	   cleavage	   and	   re-­‐ligation	   reactions.	   They	   are	   widespread	   across	   the	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three	  domains	  of	  life,	  and	  include	  Rep	  proteins	  involved	  in	  bacterial	  and	  viral	  rolling	  
circle	   replication	   (RCR),	   relaxases	   that	   catalyse	   bacterial	   conjugation	   and	  
transposases	   (Ilyina	  and	  Koonin	  1992).	  This	   family	  of	  endonucleases	   is	  defined	  by	  
the	   presence	   of	   two	   conserved	   protein	  motifs:	   the	   HUH	  motif,	   consisting	   in	   two	  
histidines	   separated	   by	   a	   large	   hydrophobic	   residue,	   and	   the	   Y	  motif,	   containing	  
one	  or	  two	  tyrosine	  residues	  and	  a	  lysine	  residue	  separated	  by	  several	  amino	  acids	  
(Ilyina	   and	   Koonin	   1992).	   HUH	   endonucleases	   can	   be	   classified	   based	   on	   the	  
number	   of	   tyrosine	   residues:	   Y1	   HUH	   endonucleases	   contain	   a	   single	   tyrosine	  
residue	  in	  the	  Y	  motif,	  while	  Y2	  proteins,	  which	  include	  AAV	  Rep78/68,	  contain	  two	  
(Chandler	   et	   al.	   2013).	   Surprisingly,	   although	   Rep78/68	   contain	   two	   tyrosine	  
residues	  –	  Y152	  and	  Y156	  –	  only	  Y156	   is	  essential	   for	  catalysis	   (Davis	  et	  al.	  2000).	  
The	   ssDNA	   nicking	   mechanism	   involves	   the	   formation	   of	   a	   5’-­‐phosphotyrosine	  
intermediate	  using	  one	  tyrosine	  from	  the	  Y	  motif	  and	  frees	  a	  3’-­‐OH	  at	  the	  cleavage	  
site	   that	   can	   be	   used	   for	   various	   subsequent	   reactions,	   including	   the	   priming	   of	  
replication.	  The	  HUH	  motif	  is	  necessary	  for	  the	  coordination	  of	  a	  divalent	  metal	  ion	  
that	   facilitates	   the	   ssDNA	   cleavage	   reaction	   (Chandler	   et	   al.	   2013).	   The	   relative	  
position	  of	  the	  two	  motifs	  distinguishes	  the	  relaxases	  (or	  Mob)	  subgroup,	  in	  which	  
the	  Y	  motif	   is	   found	  upstream	  of	   the	  HUH	  motif,	  and	   the	  Rep	  group	   that	  has	   the	  
motifs	   arranged	   in	   the	   opposite	   order.	   Three-­‐dimensionally,	   however,	   the	  
arrangement	   of	   the	   two	  motifs	   relative	   to	   each	   other	   is	   identical	   (Figure	   8).	   The	  
HUH	  motif	   sits	   in	   the	   central	   β-­‐strand	   of	   a	   four-­‐	   or	   five-­‐stranded	   antiparallel	   β-­‐
sheet,	  while	  the	  active	  site	  tyrosine(s)	  is	  positioned	  in	  a	  α-­‐helix	  that	  faces	  the	  HUH	  
motif	   (Figure	   8)	   (Chandler	   et	   al.	   2013).	   In	   addition	   to	   ssDNA	   nicking,	   many	   HUH	  
endonucleases	   also	   recognise	   and	   bind	   DNA	   hairpin	   structures.	   Furthermore,	   in	  
view	   of	   the	   functional	   variety	   of	   these	   proteins,	   it	   is	   not	   surprising	   that	   HUH	  
domains	  are	  often	  combined	  with	  additional	  functional	  domains,	  notably	  helicase,	  
oligomerisation	   and	   Zn-­‐binding	   domains	   (Chandler	   et	   al.	   2013).	   Finally,	   a	   few	  
members	   of	   the	   HUH	   endonucleases	   family,	   including	   AAV	   Rep,	   the	   conjugative	  
relaxase	  TrwC	  of	   plasmid	  R388	   (Figure	  8)	   and	   the	  TnpA(REP)	   transposase	   from	  E.	  
coli	   K12,	  have	  been	   shown	   to	  possess	   the	  biotechnologically	   interesting	  ability	   to	  
mediate	  site-­‐specific	  recombination	  and	  integration	  into	  dsDNA	  (Gonzalez-­‐Prieto	  et	  
al.	  2013).	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Figure	  8:	  Structural	  conservation	  in	  HUH	  endonucleases.	  	  
(A)	  Topology	  diagram	  of	  the	  OBD	  of	  Rep	  (red,	  top)	  and	  TrwC	  (blue,	  bottom).	  The	  structures	  
that	  form	  the	  core	  active	  site	  typical	  of	  HUH	  endonucleases	  are	  in	  dark	  red	  and	  dark	  blue,	  
respectively.	   (B)	  Ribbon	  diagrams	  shown	  in	  the	  same	  orientation	  as	  in	  (A),	  with	  the	  active	  
site	   tyrosine	   highlighted	   in	   yellow	   and	   the	   consensus	   HUH	  motif	   in	   green.	   (C)	   Structural	  
alignment	  of	  Rep	  (red)	  and	  TrwC	  (blue)	  show	  a	  high	  degree	  of	  similarity	  between	  the	  two	  
proteins	  active	  sites.	  
	  
1.2.3 SF3	  helicases	  
Helicases	   are	   molecular	   motors	   that	   use	   the	   energy	   obtained	   from	   NTP	  
hydrolysis	   to	   translocate	  along	  DNA	  or	  RNA	  and	  unwind	  double-­‐stranded	  regions.	  
They	   are	   involved	   in	   every	   aspect	   of	   nucleic	   acid	   metabolism,	   including	   DNA	  
replication,	  repair,	  transcription,	  translation	  and	  RNA	  metabolism.	  They	  form	  a	  vast	  
class	  of	  enzymes	   that	  are	   identified	  and	  classified	  based	  on	  a	   series	  of	   conserved	  
primary	  and	  tertiary	  structure	  motifs	  (Gorbalenya	  and	  Koonin	  1993;	  Singleton	  et	  al.	  
2007).	   Helicase	   superfamilies	   1	   and	   2	   (SF1	   and	   SF2)	   are	   the	   largest	   and	   best	  
characterised;	   they	   contain	   seven	   conserved	   sequence	   motifs	   and	   include	  
monomeric	   helicases	   that	   perform	   a	   wide	   variety	   of	   functions	   (Singleton	   et	   al.	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2007).	   The	   oligomeric	   SF3	   helicases	   have	   3’-­‐5’	   translocation	   directionality	   and	  
group	  non-­‐structural	  proteins	  found	  in	  the	  genomes	  of	  small	  DNA	  and	  RNA	  viruses	  
(Gorbalenya	  and	  Koonin	  1993).	   They	  are	   identified	  by	  only	   four	   conserved	  motifs	  
(A,	   B,	   B’	   and	  C)	   and	   are	   topologically	   a	  modified	   version	  of	  AAA+	  motor	  proteins	  
(Hanson	  and	  Whiteheart	   2005;	  Hickman	  and	  Dyda	  2005).	  Motifs	  A	   and	  B	   are	   the	  
canonical	  Walker	  A	   and	  B	  motifs,	   involved	   in	  ATP	   binding	   and	   divalent	  metal	   ion	  
coordination,	  respectively.	  Motif	  C	  is	  the	  sensor	  1	  motif,	  which	  has	  been	  suggested	  
to	  “sense”	  the	  phosphorylation	  state	  of	  the	  bound	  nucleotide.	  Motif	  B’	  binds	  DNA	  
and	   is	   thought	   to	   be	   involved	   in	   the	   translation	   of	   ATP	   hydrolysis	   into	   the	  
conformational	  changes	  that	  lead	  to	  translocation	  along	  the	  DNA	  (Yoon-­‐Robarts	  et	  
al.	  2004).	   In	  addition,	  a	  conserved	  arginine	  finger	  in	  one	  subunit	  of	  the	  oligomeric	  
complexes	  formed	  by	  these	  helicases	  contributes	  to	  ATP	  binding	  and	  hydrolysis	   in	  
neighbouring	  subunits.	  	  
	  
	  
Figure	  9:	  Domain	  architecture	  of	  SF3	  helicases.	  	  
Schematic	  diagram	  representing	  the	  different	  domain	  organisations	  of	  three	  well-­‐characterised	  SF3	  
helicases.	   The	  key	   functional	  domains,	  described	   throughout	   the	   text,	   are	   the	  helicase	  domain	   (in	  
green)	  and	  the	  ori	  binding	  domain	  (in	  blue).	  Figure	  based	  on	  (Hickman	  and	  Dyda	  2005).	  
	  
The	   peculiarity	   of	   SF3	   helicases	   is	   the	   combination	   of	   multiple	   enzymatic	  
functions	   within	   a	   single	   protein.	   In	   particular,	   the	   highly	   conserved	   helicase	  
domain	   is	   preceded	   by	   a	   less	   well-­‐conserved	   origin-­‐binding	   domain	   (Figure	   9)	  
(Hickman	  and	  Dyda	  2005).	  This	   is	  especially	  relevant	  for	  small	  viruses	  that	  rely	  on	  
the	   complex	   replicative	   machinery	   of	   the	   cell	   but	   need	   to	   recruit	   it	   to	   the	   viral	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origin	  of	  replication.	  The	  best-­‐characterised	  members	  of	  the	  SF3	  helicases	  are	  the	  
E1	   protein	   of	   papilloma	   virus	   (PV),	   the	   large	   T	   antigen	   (LTag)	   of	   simian	   virus	   40	  
(SV40)	  and	  AAV	  Rep	  (Figure	  9);	  the	  crystal	  structures	  of	  both	  the	  origin	  binding	  and	  
the	  helicase	  domains	  are	  available	  for	  all	  three	  proteins	  (James	  et	  al.	  2003;	  Li	  et	  al.	  
2003a;	  Abbate	  et	  al.	  2004;	  James	  et	  al.	  2004).	  The	  core	  AAA+-­‐like	  α/β	  fold	  is	  highly	  
conserved	   amongst	   these	   three	   SF3	   helicases,	   and	   consists	   of	   a	   5-­‐stranded	   anti-­‐
parallel	  β	  sheet	  flanked	  by	  α	  helices	  on	  both	  sides.	  Surprisingly,	  the	  overall	  fold	  of	  
the	   origin	   binding	   domains	   is	   also	   conserved	   despite	   little	   sequence	   homology	  
(Hickman	  and	  Dyda	  2005).	  This	  is	  even	  more	  striking	  considering	  that	  the	  Rep	  OBD	  
has	  an	  additional	  endonuclease	  function	  and	  binds	  direct	  repeats,	  in	  contrast	  to	  the	  
palindromic	  sequences	  that	  are	  recognised	  by	  SV40-­‐LTag	  and	  PV-­‐E1.	  Furthermore,	  
the	   genome	   structure	   and	   the	   replication	   strategies	   of	   SV40	   and	   PV	   are	   very	  
different	   from	   those	   of	   AAV.	   SV40	   and	   PV	   genomes	   are	   covalently	   closed	   dsDNA	  
circles	  and	  contain	  specific	  binding	  sites	  within	  the	  ori	  that	  are	  recognised	  by	  LTag	  
and	  an	  E1/E2	  complex,	  respectively.	  Binding	  is	  followed	  by	  the	  assembly	  of	  double-­‐
hexameric	   rings	   that	   leads	   to	   the	  unwinding	  of	   the	  ori	   and	   initiates	  bi-­‐directional	  
replication	  (Fouts	  et	  al.	  1999;	  Gomez-­‐Lorenzo	  et	  al.	  2003;	  Li	  et	  al.	  2003a;	  Abbate	  et	  
al.	   2004;	   Enemark	   and	   Joshua-­‐Tor	   2006;	   Fanning	   and	   Zhao	   2009;	   Schuck	   and	  
Stenlund	   2011;	   Bergvall	   et	   al.	   2013).	   In	   contrast,	   the	   AAV	   genome	   is	   linear	   and	  
replication	   proceeds	   unidirectionally	   (Ward	   2006),	   and	   the	   oligomerisation	  
properties	   of	   Rep	   are	   still	   under	   debate	   (see	   section	   1.2.4).	   Finally,	   sandwiched	  
between	  the	  origin-­‐binding	  and	  core	  helicase	  domains,	  is	  a	  small	  all-­‐helical	  bundle	  
of	   unknown	   function	   that	   is	   much	   less	   conserved.	   Structural	   studies	   of	   the	  
hexameric	  rings	   formed	  by	  LTag	  and	  E1	  revealed	  that	   this	  small	  domain	   is	  part	  of	  
the	  oligomerisation	  interface	  (Li	  et	  al.	  2003a;	  Enemark	  and	  Joshua-­‐Tor	  2006).	  
1.2.4 AAV	  Rep	  oligomerisation	  
Based	  on	   the	   fundamental	   role	  of	  oligomerisation	   in	   the	  mechanisms	  of	  origin	  
melting	  and	  DNA	  unwinding	  described	   for	   the	  SV40-­‐LTag	  and	  PV-­‐E1	  proteins,	   it	   is	  
likely	  that	  oligomerisation	  also	  plays	  a	  critical	  role	  in	  the	  functions	  of	  the	  AAV	  Rep	  
proteins.	  However,	  limited	  information	  is	  available	  on	  the	  oligomeric	  properties	  of	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the	  AAV	  Rep	  proteins	  and	  the	  functional	  roles	  of	  the	  oligomeric	  complexes	  remain	  
poorly	  characterised.	  	  
The	  small	  Rep	  proteins,	  Rep52	  and	  Rep40,	  have	  been	  shown	  to	  be	  monomeric	  in	  
solution	  (Smith	  and	  Kotin	  1998;	  James	  et	  al.	  2003;	  James	  et	  al.	  2004;	  Dignam	  et	  al.	  
2007a;	   Mansilla-­‐Soto	   et	   al.	   2009).	   The	   fact	   that	   Rep52	   and	   Rep40	   are	   active	  
helicases	   (Smith	   and	   Kotin	   1998;	   Collaco	   et	   al.	   2003),	   however,	   implies	   that	   they	  
must	  exist	  at	   least	  as	   transient	  dimers	   to	   form	  an	  active	  ATPase	  site	   (James	  et	  al.	  
2004).	   The	   formation	  of	  dimers	  was	   indeed	  observed	   in	   the	  presence	  of	  ATP	  and	  
ssDNA	  (Dignam	  et	  al.	  2007a).	  In	  contrast	  to	  the	  monomeric	  behaviour	  of	  Rep40	  the	  
equivalent	   helicase	   domain	   of	   the	   SV40-­‐LTag	   and	   PV-­‐E1	   proteins	   readily	   form	  
hexamers	  (Sedman	  and	  Stenlund	  1998;	  Li	  et	  al.	  2003a).	  The	  structural	  determinants	  
of	  these	  differences,	  however,	  remain	  unknown.	  
The	   oligomerisation	   of	   the	   large	   Rep	   proteins,	  which	   has	  mainly	   been	   studied	  
using	  Rep68,	  is	  more	  complex,	  and	  contrasting	  results	  have	  been	  reported	  (Smith	  et	  
al.	   1997;	   Hickman	   et	   al.	   2004;	   Dignam	   et	   al.	   2007b;	   Mansilla-­‐Soto	   et	   al.	   2009).	  
Rep68	  has	  been	  suggested	  to	  form	  hexamers	  in	  the	  presence	  of	  the	  AAV	  ori	  in	  two	  
separate	  reports	  (Smith	  et	  al.	  1997;	  Dignam	  et	  al.	  2007b),	  while	  two	  other	  studies	  
have	   described	   five	   Rep68	   molecules	   bound	   to	   an	   RBS-­‐containing	   DNA	   and	  
suggested	  a	  possible	  intermediate	  stage	  of	  assembly	  of	  a	  larger	  Rep	  complex	  on	  the	  
AAV	   ori	   (Hickman	   et	   al.	   2004;	   Mansilla-­‐Soto	   et	   al.	   2009).	   Mansilla-­‐Soto	   and	  
colleagues	   also	   described	   a	   double-­‐octameric	   complex	   that	   is	   formed	   in	   the	  
presence	  of	  a	  ssDNA	  substrate	  and	  is	  able	  to	  unwind	  a	  heteroduplex	  DNA	  substrate	  
(Mansilla-­‐Soto	  et	  al.	  2009).	  In	  addition,	  the	  authors	  of	  this	  study	  provided	  evidence	  
of	   substrate-­‐dependent	   oligomerisation,	   by	   observing	   the	   formation	   of	   different	  
oligomeric	  complexes	  in	  the	  presence	  of	  different	  DNA	  substrates	  (Mansilla-­‐Soto	  et	  
al.	   2009).	   Taken	   together,	   these	   results	   suggest	   a	   complex	   and	   dynamic	  
oligomerisation	  that	  may	  be	  directed	  by	  the	  DNA	  substrate	  interacting	  with	  Rep68.	  
The	   functional	   importance	  of	  Rep78/68	  oligomerisation	  and	   the	  properties	   that	   it	  
confers	   to	   these	   multifunctional	   proteins	   remain	   to	   be	   addressed,	   and	   will	   be	  
discussed	  in	  more	  details	  in	  Chapters	  4	  and	  5.	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CHAPTER	  2: AIMS	  OF	  THIS	  STUDY	  
The	   aims	   of	   this	   study	   are	   A.	   to	   contribute	   to	   the	   understanding	   of	   the	  
mechanisms	   of	   action	   of	   AAV	   Rep	   proteins	   by	   identifying	   functionally	   relevant	  
structural	   determinants	   of	   AAV	   Rep68	   oligomerisation;	   and	  B.	   to	   investigate	   the	  
feasibility	  and	   the	   safety	  of	  Rep-­‐mediated	   integration	   into	   the	   safe	  harbour	   locus	  
AAVS1	  in	  a	  translationally	  relevant	  clinical	  model.	  
	  
Accordingly,	   the	   main	   hypotheses	   established	   at	   the	   beginning	   of	   this	   thesis	  
were:	  
• The	   substrate-­‐directed	   oligomerisation	   of	   the	   remarkably	   multifunctional	  
large	   Rep	   proteins	   of	   AAV	   contributes	   to	   the	   regulation	   of	   its	   enzymatic	  
activities	  and	  coordinates	  its	  functions	  
• Rep-­‐mediated	  integration	  into	  AAVS1	  is	  a	  naturally	  evolved	  strategy	  to	  site-­‐
specifically	   insert	  exogenous	  genetic	  material	   into	  the	  human	  genome	  that	  
can	  be	  exploited	  for	  targeted	  transgene	  addition	  
	  
All	  of	  the	  work	  presented	  in	  this	  thesis	  revolves	  around	  the	  multiple	  functions	  of	  
the	   large	   Rep	   proteins	   of	   AAV.	   Result	   chapters	   4	   and	   5	   focus	   on	   the	   oligomeric	  
properties	  of	  Rep68,	  and	  describe	  the	  identification	  of	  structural	  features	  that	  are	  
essential	   for	   its	  oligomerisation	  and	   function.	   The	  data	  presented	   in	   the	   first	   two	  
chapters	  are	  the	  product	  of	  a	  fruitful	  collaboration	  with	  the	  laboratory	  of	  Dr	  Carlos	  
Escalante	   at	   the	   Molecular	   biophysics	   research	   centre	   of	   the	   Virginia	  
Commonwealth	   University,	  which	   led	   to	   three	   publications	   (see	   annex	   2)	   and	   an	  
additional	  manuscript	  currently	  in	  preparation.	  The	  final	  results	  chapter	  presents	  a	  
project	   that	   was	   designed	   to	   investigate	   the	   feasibility	   of	   using	   Rep-­‐mediated	  
targeted	   gene	   addition	   to	   modify	   cells	   with	   proliferative	   potential	   in	   a	   clinically	  
relevant	   disease	   model,	   namely	   X-­‐linked	   Severe	   Combined	   Immunodeficiency	  
(SCID-­‐X1).	   This	   chapter	   describes	   the	   generation	   and	   characterisation	   of	   SCID-­‐X1	  
patient-­‐derived	  induced	  pluripotent	  stem	  cells	  (iPSCs)	  as	  well	  as	  the	  generation	  and	  
validation	  of	   the	   therapeutic	   targeting	  vector.	  Unfortunately,	   this	   study	  could	  not	  
be	  completed	  due	  to	  an	  untreatable	  mycoplasma	  infection	  of	  the	  iPSCs.	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CHAPTER	  3: MATERIALS	  AND	  METHODS	  
3.1 MOLECULAR	  CLONING	  
3.1.1 	  Standard	  Polymerase	  Chain	  Reaction	  (PCR)	  	  
This	  is	  the	  basic	  PCR	  reaction	  that	  was	  used	  for	  colony	  screening	  and	  other	  tests.	  
The	  polymerase	  kit	  used	  was	  the	  standard	  goTaq®	  DNA	  polymerase	  (Promega).	  PCR	  
reactions	   were	   carried	   out	   in	   a	   total	   volume	   of	   25µl	   containing	   (final	  
concentrations):	  200µM	  dNTPs	  (mix	  of	  dATP,	  dCTP,	  dGTP	  and	  dTTP,	  from	  NEB),	  1X	  
Colorless	  GoTaq	  Reaction	  Buffer,	  1.25U	  GoTaq	  DNA	  polymerase,	  1µM	  each	  of	   the	  
primers,	   ~50ng	  DNA,	   and	   ddH2O	   to	   a	   final	   25µl	   volume.	   0.01μmol	   of	   unmodified	  
oligonucleotide	  primers	   for	   PCR	   amplification	  were	  obtained	   from	  Eurofins	  MWG	  
Operon	  and	  re-­‐suspended	  with	  ddH2O	  to	  make	  stock	  solutions	  at	  100µM.	  Forward	  
(sense)	  and	  reverse	  (anti-­‐sense,	  reverse	  complement)	  oligonucleotide	  primers	  were	  
designed	  following	  the	  manufacturer’s	  directions:	  15-­‐30	  nucleotides	   in	   length,	  40-­‐
60%	  GC	  content,	  and	   terminating	   in	  at	   least	  one	  G/C	  base.	  PCRs	  were	  performed	  
using	  an	  Eppendorf	  Mastercycler	  ep	  gradient	  thermocycler.	  A	  typical	  PCR	  reaction	  
initiated	  with	  a	  2	  minute	  denaturing	  step	  at	  95˚C	  followed	  by	  25-­‐35	  cycles	  including	  
a	  denaturing	  step	  of	  20	  seconds	  at	  95˚C,	  an	  annealing	  step	  of	  45	  seconds	  at	  50°C	  
(depending	   on	   the	   primers’	   melting	   temperature)	   and	   an	   extension	   step	   of	  
1minute/kb	   at	   72°C.	   A	   final	   5	   minutes	   extension	   at	   72°C	   followed	   the	   cycles.	  
Reactions	  were	  kept	  at	  4°C	  until	  use.	  For	  information	  on	  all	  the	  PCR	  primers	  used	  in	  
this	  thesis	  please	  see	  Table	  2	  in	  Annex	  1,	  p.	  152.	  
3.1.2 High	  fidelity	  PCR	  
For	  all	  PCR	  reactions	  performed	  to	  amplify	  DNA	  fragments	  necessary	  for	  cloning,	  
sequencing,	   and	   to	   prepare	   radiolabelled	   probes,	   the	   Phusion	   High	   Fidelity	  
polymerase	  kit	  (Thermo	  Scientific)	  was	  used	  to	  ensure	  high	  fidelity	  amplification	  of	  
target	   sequences.	   PCR	   reactions	  were	   carried	   out	   in	   a	   total	   volume	   of	   25μl,	   in	   a	  
mixture	   containing	   (final	   concentrations)	   1-­‐5ng	   of	   DNA	   template	   (more	   template	  
was	  used	  for	  complex	  genomic	  DNA),	  0.5µM	  of	  forward	  and	  reverse	  primers,	  10mM	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of	   dNTPs	   (NEB),	   0.02u/μl	   Phusion®	   High-­‐Fidelity	   DNA	   polymerase	   (Thermo	  
Scientific),	   1X	   Phusion®	   HF	   or	   GC	   Buffer	   and	   brought	   to	   the	   final	   volume	   with	  
ddH2O.	   PCRs	   were	   performed	   using	   an	   Eppendorf	   Mastercycler	   ep	   gradient	  
thermocycler.	   Phusion	  GC	  buffer	  was	  used	   in	   reactions	   that	   initially	   did	  not	  work	  
with	  HF	  buffer,	   as	   it	   is	   indicated	   for	  GC-­‐rich	   templates	  or	   those	  prone	   to	   forming	  
secondary	   structures.	  Reaction	   conditions	  were	  varied	  depending	  on	   the	   size	  and	  
GC	  content	  of	  the	  fragment	  to	  be	  amplified.	  A	  typical	  PCR	  reaction	  initiated	  with	  a	  
30	  seconds	  denaturing	  step	  at	  98°C	  followed	  by	  25-­‐35	  cycles	  including	  a	  denaturing	  
step	   of	   10	   seconds	   at	   98°C,	   an	   annealing	   step	   of	   20	   seconds	   at	   60°C	   and	   an	  
extension	   step	   of	   30	   seconds/kb	   at	   72°C.	   A	   final	   5	   minutes	   extension	   at	   72°C	  
followed	   the	   cycles.	   Reactions	   were	   kept	   at	   4°C	   until	   use.	   The	   annealing	   step	  
temperature	  was	  adjusted	  to	  the	  melting	  temperature	  of	  the	  primers.	  Primers	  were	  
designed	  and	  obtained	  from	  Eurofins	  MWG	  Operon	  as	  explained	  above.	  For	  some	  
cloning	   strategies,	   primers	   were	   designed	   with	   external	   overhangs	   containing	  
restriction	  sites	  matching	  those	  in	  the	  destination	  construct.	  For	  information	  on	  all	  
the	  high	   fidelity	  PCR	  primers	  used	   in	   this	   thesis	  please	  see	  Table	  2	   in	  Annex	  1,	  p.	  
153.	  
3.1.3 Site-­‐directed	  mutagenesis	  	  
To	  generate	  Rep	  point	  mutants	  the	  Stratagene	  site-­‐directed	  mutagenesis	  kit	  was	  
used.	  Primers	  were	  designed	  to	  contain	  the	  desired	  point	  mutations	   in	  the	  centre	  
flanked	  by	  10-­‐15	  base	  pairs	  on	  either	  side	  matching	  the	  template	  sequence	  to	  allow	  
sufficient	   annealing	   to	   the	   template	  DNA.	   This	   technology	  was	   used	   to	   introduce	  
the	  following	  mutations	  in	  Rep:	  C151S,	  C405S,	  L193A-­‐V196A,	  Y224A,	  Y224F,	  I251A.	  
For	  information	  on	  all	  the	  mutagenesis	  primers	  used	  in	  this	  thesis	  please	  see	  Table	  
2	  in	  Annex	  1,	  p.	  152.	  
3.1.4 Agarose	  gel	  electrophoresis	  	  
Amplified	   DNA	   PCR	   products	   or	   DNA	   fragments	   from	   restriction	   enzyme	   (RE)	  
digestions	   from	   PCR	   were	   diluted	   with	   5X	   DNA	   loading	   dye	   (NEB).	   Agarose	   gels	  
were	   prepared	   by	   dissolving	   agarose	   powder	   (UltraPureTM	   Agarose,	   Life	  
Technologies)	   in	  1X	  TAE	  buffer	  (10X:	  Tris-­‐Base	  48.4g/L,	  Acetic	  acid	  11.4ml/L,	  EDTA	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3.7g/L)	  and	  heating	  until	  boiling.	  The	  agarose	  percentage	  varied	  between	  0.7%	  and	  
1.5%	  depending	  on	   the	   size	  of	   the	   fragment	   to	  be	  observed/isolated,	  with	  higher	  
percentages	  used	  to	  achieve	  better	  separation	  of	  smaller	  fragments.	  After	  allowing	  
the	  dissolved	  agarose	  to	  cool	  down,	  1μg/ml	  of	  Ethidium	  bromide	  solution	  (Sigma)	  
was	  added	  and	  the	  mixture	  was	  poured	  into	  an	  electrophoresis	  tank	  (BioRad).	  Once	  
solidified,	  the	  gel	  was	  immersed	  in	  1X	  TAE	  buffer	  and	  DNA	  samples	  were	  loaded	  in	  
the	  wells	  of	  the	  gel.	  Gels	  were	  run	  at	  80-­‐120V	  for	  about	  30-­‐90	  minutes,	  depending	  
on	   the	   separation	   required	   between	   bands.	   Band	   sizes	  were	  monitored	  with	   the	  
100bp	  or	  the	  1kb	  DNA	  ladder	  (NEB),	  which	  was	  run	  in	  parallel.	  Ethidium	  bromide-­‐
stained	  DNA	  fragments	  were	  visualized	  under	  a	  ultra-­‐violet	  trans-­‐illuminator	  using	  a	  
ChemiDocTM	  XRS+	  System	  (BioRad).	  	  
3.1.5 Extraction	  and	  purification	  of	  DNA	  fragments	  from	  agarose	  gels	  
DNA	  fragments	  of	   interest	  were	  excised	  from	  agarose	  gels	  and	  purified	  using	  a	  
QIAGEN	  Gel	  Extraction	  Kit.	  Three	  volumes	  of	   solubilisation	  and	  binding	  QG	  buffer	  
were	  added	  to	  the	  agarose	  gel	  slice,	  the	  mixture	  was	  heated	  to	  50°C	  for	  10	  minutes	  
and	   vortexed	   to	   dissolve	   the	   slice.	  One	   volume	   of	   isopropanol	  was	   added	   to	   the	  
mixture	  and	  subsequently	  added	  to	  a	  QIAquick	  spin-­‐column.	  DNA	  was	  bound	  to	  the	  
column	  by	  centrifugation	  at	  10000rpm	  for	  1	  minute,	  after	  which	  the	  flow-­‐through	  
was	  discarded	  and	  the	  column	  washed	  with	  750μl	  of	  ethanol-­‐containing	  PE	  buffer	  
and	   centrifuged	   twice	   to	   completely	   remove	   the	   ethanol.	   The	   DNA	   was	   finally	  
eluted	  into	  a	  sterile	  eppendorf	  tube	  with	  30μl	  of	  ddH2O.	  	  
A	  similar	  procedure	  was	  used	  to	  purify	  RE	  digestion	  products	  that	  were	  not	  run	  
on	  agarose	  gels.	  The	  same	  kit	  and	  protocol	  were	  used,	  with	  the	  exception	  that	  the	  
RE	  digestion	  mixture	  was	  directly	  mixed	  with	  the	  QG	  buffer	  and	  isopropanol	  before	  
proceeding	  with	  the	  column	  purification.	  
3.1.6 DNA	  digestion	  by	  restriction	  enzymes	  	  
For	   analytical	   RE	   digestions,	   0.5μl	   of	   RE	   (NEB)	   was	   used	   to	   digest	   500ng	   of	  
plasmid	  DNA	  in	  a	  1X	  solution	  of	  the	  buffer	  supplied	  by	  the	  manufacturer,	  and	  total	  
reaction	  volume	  was	  adjusted	   to	  20μl	  with	  ddH2O.	  For	  RE	  digestions	   to	  generate	  
fragments	  for	  cloning,	  1µl	  of	  RE	  was	  used	  to	  digest	  2-­‐5µg	  of	  DNA.	  All	  reactions	  were	  
performed	  at	   the	   indicated	   temperature	   for	   the	  used	  RE	   (generally	  at	  37˚C)	   for	  2	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hours.	   When	   digestions	   with	   two	   restriction	   enzymes	   were	   performed,	   a	  
compatible	   reaction	   buffer	   was	   used	   as	   indicated	   by	   manufacturer.	   After	   single-­‐
enzyme	   digestions	   to	   generate	   plasmid	   fragments	   for	   cloning,	   vector	   DNA	   was	  
treated	   with	   calf	   intestinal	   phosphatase	   (CIP,	   NEB)	   to	   remove	   the	   5’	   phosphate	  
group	   from	   the	   digested	   vector	   to	   prevent	   re-­‐circularisation	   between	   compatible	  
ends.	  0.5µl	  of	  CIP	  were	  added	  directly	  to	  the	  RE	  digestion	  mixture	  and	  incubated	  at	  
37˚C	  for	  30	  minutes	  and	  further	  purified	  as	  described	  above.	  
3.1.7 DNA	  ligations	  	  
The	  purified	  DNA	  insert	  and	  vector	  were	  mixed	  at	  a	  3:1	  ratio	  with	  1μl	  of	  10X	  T4	  
ligase	  buffer	  (NEB)	  and	  0.5μl	  of	  T4	  ligase	  enzyme	  (NEB),	  in	  a	  total	  reaction	  volume	  
adjusted	  to	  10μl	  with	  ddH2O.	  Reactions	  were	  incubated	  at	  room	  temperature	  for	  1	  
hour	  or	  overnight	  at	  16˚C.	  	  
3.1.8 Competent	  bacterial	  cells:	  media	  and	  maintenance	  	  
For	   DNA	   transformations	   and	   plasmid	   DNA	   amplification,	   two	   types	   of	  
chemically	   competent	   cells	  were	  used.	  The	  Escherichia	   coli	   SURE	  supercompetent	  
cells	   (Stratagene),	   that	   have	   reduced	   recombination	   potential,	   were	   used	   for	  
transformation	   and	   amplification	   of	   plasmids	   containing	   AAV	   ITRs	   and	   grown	   at	  
30˚C.	  The	  Escherichia	  coli	  TOP10	  competent	  cells	  (Life	  Technologies)	  were	  used	  for	  
all	   other	   plasmids	   and	   cultured	   at	   37˚C.	   Competent	   cells	   were	   stored	   at	   -­‐80˚.	  
Autoclaved	   LB	   (Fisher	   Scientific,	   20g/L	   ddH20)	   was	   used	   for	   liquid	   cultures.	  
Autoclaved	  LB	  agar	  (37g/L	  ddH20)	  set	  in	  Sterilin	  10cm	  Petri	  dishes	  was	  used	  for	  solid	  
phase	  growth	  cultures.	  Antibiotics	  were	  added	   to	  autoclaved	  broth	  or	  autoclaved	  
agar	   cooled	   to	   50°C.	   Ampicillin	   (Sigma,	   100μg/ml	   in	   dH2O)	   or	   Kanamycin	   sulfate	  
(Fisher	  Scientific,	  50μg/ml	  in	  ddH2O)	  were	  used	  for	  selection.	  Stock	  preparations	  of	  
transformed	  bacteria	  were	  kept	  as	  glycerol	  stocks	  (bacterial	  pellet	  resuspended	  in	  
LB	  +	  10-­‐15%	  glycerol)	  at	  -­‐80˚C.	  	  
3.1.9 Transformation	  of	  competent	  bacteria	  	  
5μl	   of	   the	  DNA	   insert-­‐vector	   ligation	   reaction	   or	   10-­‐50ng	   of	   plasmid	  DNA	  was	  
used	   for	   transformation	   into	   competent	   cells	   following	   the	   manufacturer’s	  
protocol.	   For	   SURE	   competent	   cells,	   50μl	   of	   competent	   bacteria	   were	   initially	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incubated	   with	   1µl	   of	   β-­‐mercaptoethanol	   for	   10	   minutes	   on	   ice.	   DNA	   was	   then	  
added	  and	  incubated	  for	  30	  minutes	  on	  ice,	  followed	  by	  a	  heat	  shock	  at	  42°C	  for	  45	  
seconds	  and	  further	  2	  minutes	  on	  ice.	  For	  Top10	  competent	  cells,	  50µl	  of	  cells	  were	  
mixed	  with	  DNA	  and	  incubated	  for	  30	  minutes	  on	  ice,	  followed	  by	  a	  30	  second	  heat	  
shock	  at	  42˚C	  and	  a	  final	  2	  minutes	  incubation	  on	  ice.	  In	  both	  cases,	  reactions	  were	  
then	   incubated	  with	  250μl	   of	   LB	   at	   30˚C	   for	   1	  hour	   and	  plated	  on	   LB	   agar	  plates	  
containing	   the	  appropriate	  antibiotic.	  Plates	  were	   incubated	  upside	  down	  at	  30˚C	  
or	  37°C	  overnight.	  
3.1.10 Plasmid	  DNA	  amplification	  and	  purification	  –	  mini	  preps	  	  
Single	   colonies	   from	   transformed	   or	   re-­‐streaked	   bacteria	   were	   picked	   and	  
inoculated	  in	  3ml	  of	  LB	  with	  antibiotic	  at	  the	  appropriate	  temperature	  overnight	  in	  
an	   incubator	  shaker.	  The	  following	  day,	  2ml	  of	  the	  culture	  were	  transferred	  to	  an	  
eppendorf	  tube	  and	  cells	  were	  pelleted	  in	  a	  bench-­‐top	  centrifuge	  at	  8000rpm	  for	  4	  
minutes.	  DNA	  was	  extracted	  using	  the	  QIAGEN	  mini	  prep	  kit.	  Briefly,	  cells	  were	  re-­‐
suspended	  in	  QIAGEN	  P1	  buffer	  and	  then	  lysed	  in	  100μl	  of	  P2	  lysis	  buffer	  and	  mixed	  
by	  inverting	  the	  tube.	  After	  a	  5-­‐minutes	  incubation	  at	  room	  temperature,	  chilled	  P3	  
neutralisation	   buffer	   was	   added	   to	   neutralise	   the	   mixture	   and	   samples	   were	  
incubated	   on	   ice	   for	   5	   minutes.	   DNA	   was	   separated	   from	   bacterial	   debris	   by	  
centrifugation	  at	  13000rpm	  for	  10	  minutes	  in	  a	  bench-­‐top	  centrifuge.	  Supernatant	  
containing	   DNA	   was	   then	   transferred	   to	   a	   QIAprep	   spin	   column	   to	   bind	   DNA	  
followed	   by	  washing	  with	   ethanol	   containing	   PE	   buffer	   and	   elution	   in	   40-­‐50µl	   of	  
ddH2O.	  DNA	  was	  kept	  at	  4˚C	  for	  short	  term	  storage	  or	  at	  -­‐20˚C	  for	  longer	  storage.	  
3.1.11 Plasmid	  DNA	  amplification	  and	  purification	  –	  midi/maxi	  preps	  	  
1ml	   of	   transformed	   bacteria	   culture	   or	   10µl	   from	   a	   glycerol	   stock	   were	  
inoculated	   overnight	   in	   100ml	   (300-­‐500ml	   for	   maxi	   preps)	   of	   LB	   with	   antibiotic	  
selection.	  Cells	  were	  harvested	  by	  centrifugation	  at	  6000rpm	  for	  10	  minutes	  at	  4°C	  
and	   DNA	   extraction	   was	   performed	   using	   the	   NucleoBond®	   Xtra	   Midi/Maxi	   kit	  
(Macherey-­‐Nagel),	   following	   the	   manufacturer’s	   protocol.	   The	   general	   principle	  
behind	   this	   plasmid	   purification	   protocol	   is	   based	   on	   a	   modified	   alkaline	   lysis	  
procedure,	   followed	   by	   plasmid	   DNA	   binding	   to	   a	   NucleoBond	   resin	   under	  
appropriate	   low	   salt	   and	   pH	   conditions.	   RNA,	   proteins,	   dyes	   and	   low	  molecular–
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weight	   impurities	   are	   removed	   by	   several	   wash	   steps,	   and	   the	   plasmid	   DNA	   is	  
finally	   eluted	   in	   a	   high-­‐salt	   buffer,	   concentrated	   and	   desalted	   by	   isopropanol	  
precipitation,	  and	  washed	  in	  ethanol.	  Finally,	  the	  clean	  DNA	  pellet	  was	  allowed	  to	  
air	   dry	   before	   re-­‐suspending	   in	   100-­‐1000μl	   ddH2O	   depending	   on	   the	   amount	   of	  
purified	   DNA	   and	   the	   desired	   final	   concentration.	   DNA	   concentration	   was	  
subsequently	  measured	   (see	   below).	   Preparations	   obtained	   by	   this	  method	  were	  
typically	  at	  a	  concentration	  of	  1μg/μl	  and	  stored	  short-­‐term	  at	  4˚C	  or	  long-­‐term	  at	  -­‐
20˚C.	  
3.1.12 Determination	  of	  DNA	  concentration	  and	  DNA	  sequencing	  	  
DNA	   concentration	   was	   determined	   using	   a	   Nanodrop	   ND-­‐100	  
Spectrophotometer	  (Labtech	  International).	  Following	  a	  blank	  measurement,	  1μl	  of	  
undiluted	  DNA	  preparation	  was	  loaded	  onto	  the	  measuring	  pedestal.	  The	  Nanodrop	  
calculates	   the	   DNA	   concentration	   measuring	   the	   sample	   absorbance	   at	   260nm	  
(OD260)	   and	   assuming	   that	   1	   OD260	   unit	   corresponds	   to	   50μg/ml	   of	   dsDNA.	   The	  
purity	  of	  the	  DNA	  sample	  can	  be	  assessed	  by	  the	  OD260/OD280	  ratio,	  which	  at	  ≈1.8	  is	  
considered	  ‘pure’	  for	  DNA	  (free	  from	  protein	  contamination).	  
	  DNA	   sequencing	   was	   performed	   at	   Eurofins	   MWG	   Operon	   from	   1.5µg	   of	  
plasmid	   DNA	   in	   15μl	   ddH2O	   pre-­‐mixed	   with	   2µl	   of	   the	   appropriate	   primer	   at	  
10pmol/μl.	  Sequencing	  was	  performed	  using	  the	  Value	  Read	  service	  in	  tube	  format,	  
results	   were	   returned	   on-­‐line	   and	   subsequently	   analysed	   using	   the	   APE	   DNA	  
analysis	   software	   and	   the	   NCBI	   Blast	   tool.	   Information	   on	   the	   primers	   used	   for	  
sequencing	  can	  be	  found	  in	  Table	  2,	  Annex	  1,	  p.	  152.	  
3.1.13 Plasmids	  
Here,	   I	  present	  the	  basic	  plasmids	  that	   I	  have	  used	  during	  my	  thesis	  and	  those	  
that	   have	   required	   cloning.	   When	   the	   cloning	   strategy	   is	   identical	   for	   several	  
plasmids,	  the	  general	  strategy	  is	  described.	  For	  a	  list	  of	  all	  the	  plasmids	  used,	  please	  
see	  Table	  1	  in	  annex	  1,	  p.	  150.	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3.1.13.1 WT	  AAV	  and	  Rep68	  plasmids	  
The	   pDG	  plasmid	   is	   a	   valuable	   tool	   for	   the	   production	   of	   recombinant	   and	  wt	  
AAV.	  It	  contains	  all	  the	  adenovirus	  helper	  factors	  necessary	  for	  AAV	  production,	  as	  
well	  as	  the	  AAV2	  Rep	  and	  Cap	  ORFs	  (Grimm	  et	  al.	  1998).	  
The	  mini-­‐pDG	  plasmid	  was	  derived	  by	  Dr	  Els	  Henckaerts	  from	  pDG	  and	  contains	  
only	  the	  AAV2	  Rep	  and	  Cap	  ORFs.	  All	  the	  mutagenesis	  to	  generate	  the	  Rep	  mutants	  
were	  performed	  on	  this	  plasmid.	  
The	  pAV2	  plasmid	   is	   infectious	  and	  contains	   the	   full	  WT	  AAV	  genome	   inserted	  
between	  two	  BglII	   linkers	   (Laughlin	  et	  al.	  1983).	  All	   the	  Rep	  mutants	  were	  cloned	  
into	   this	   plasmid	   using	   a	   SfiI	   and	   HindIII	   fragment	   generated	   from	   the	  mini-­‐pDG	  
variants.	  	  
pCMV(∆6)-­‐Rep68	  was	   derived	   from	   the	   pCMV(∆6)	   plasmid,	   kindly	   provided	   by	  
Prof	  Martin-­‐Serrano,	  part	  of	  a	   series	  of	  plasmids	  containing	   truncated	  versions	  of	  
the	   CMV	   promoter	   designed	   to	   fine-­‐tune	   the	   level	   of	   expression	   of	   a	   protein	   of	  
interest	  (Morita	  et	  al.	  2012).	  The	  pCMV(∆6)	  plasmid	  was	  selected	  for	  the	  low	  levels	  
of	  Rep68	  obtained	  upon	  293T	  cells	  transfection.	  The	  Rep68	  sequence	  was	  derived	  
from	  the	  pRep68-­‐M225G	  plasmid	  (cloned	  by	  Dr	  Nathalie	  Dutheil	  in	  the	  lab)	  by	  PCR	  
and	   cloned	   into	   the	  pCMV(∆6)	  multiple-­‐cloning	   site	  using	  PCR	  overhangs	   and	   the	  
REs	  XbaI	  and	  XhoI.	  All	  the	  Rep	  mutants	  were	  cloned	  into	  the	  WT	  pCMV(∆6)-­‐Rep68	  
using	  a	  SfiI	  and	  HindIII	  fragment	  generated	  from	  the	  mini-­‐pDG	  variants.	  
3.1.13.2 rAAV	  production	  plasmids	  
The	   pTRUF11	   plasmid	   carries	   the	   humanised	   green	   fluorescent	   protein	   (hGFP)	  
sequence	   under	   the	   control	   of	   the	   hybrid	   CMVie	   enhancer/chicken	   β-­‐actin	  
promoter	   (CAG)	   and	   the	   SV40	   early	   polyA	   signal,	   together	   with	   the	   neomycin	  
resistance	  gene	  driven	  by	  the	  HSV	  thymidine	  kinase	  promoter	  and	  the	  bGH	  polyA,	  
flanked	  by	  the	  AAV2	  ITRs.	  This	  plasmid	  is	  used	  to	  produce	  rAAV2-­‐GFP	  (Zolotukhin	  et	  
al.	  1996).	  	  
The	   pHGTI-­‐Adeno1	   plasmid	   contains	   all	   the	   adenovirus	   helper	   functions	  
necessary	   for	  AAV	  production	  and	   is	  used	  to	  produce	  WT	  or	   recombinant	  AAV	  by	  
double	  or	  triple	  transfection	  schemes,	  respectively	  (Streck	  et	  al.	  2006).	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The	   IL2RG-­‐containing	   plasmids	  were	   generated	  by	   cloning	   an	   IL2RG-­‐containing	  
cassette	   from	  the	  SINLV-­‐IL2RG	  vector	   (kindly	  provided	  by	  A.	  Thrasher,	   Institute	  of	  
Child	  Health,	   London,	  UK).	   This	   vector	   contains	   a	   short	   version	   of	   the	   Elongation	  
Factor	  1	  alpha	  promoter	  that	  drives	  the	  expression	  the	  IL2RG	  gene.	  This	  expression	  
cassette	  was	  cloned	  into	  the	  pTRUF11	  ITR-­‐containing	  plasmid	  using	  XhoI	  and	  SacI	  to	  
generate	  the	  pTRUF11-­‐GFP-­‐CG	  vector.	  To	  generate	  the	  pUTRF11-­‐CG	  construct,	  the	  
GFP	  expression	  cassette	   from	  pTRUF11-­‐GFP-­‐CG	  was	   removed	  using	  KpnI	  and	  ClaI.	  
The	   other	   IL2RG-­‐expressing	   plasmids	   were	   generated	   in	   the	   pSUB201	   backbone,	  
containing	   modified	   ITRs	   for	   reduced	   recombination	   and	   the	   WT	   AAV	   genome	  
flanked	  by	  XbaI	   sites	   (Samulski	  et	  al.	  1987).	  The	  AAV	  genes	  were	   replaced	  by	   the	  
IL2RG	   expression	   cassette	   using	   the	   XbaI	   sites	   to	   generate	   pMB13-­‐CG,	   and	  
additional	   restriction	   sites	  were	   added	  on	  both	   sides	   of	   the	   cassette	   to	   allow	   for	  
further	  modifications.	   pSUB201-­‐IL2RG	  was	   generated	   by	   adding	   a	  WPRE	   element	  
and	  a	  new	  polyA	  (SV40	  early)	  obtained	  by	  PCR	  to	  pMB13-­‐CG	  using	  XhoI	  and	  AvrII	  
sites.	   To	   generate	   the	   pSUB201-­‐IL2RG-­‐GFP	   construct,	   a	   CMV-­‐GFP-­‐bGHpolyA	  
expression	  cassette	  was	  cloned	  using	  XhoI	  and	  NotI	  sites	  into	  pSUB201-­‐IL2RG.	  
3.2 CELL	  CULTURE	  AND	  TRANSFECTIONS	  
3.2.1 Cell	  lines,	  media	  and	  maintenance	  	  
All	  cell	  culture	  work	  was	  performed	  in	  assigned	  mycoplasma-­‐free	  tissue	  culture	  
hoods.	   Adherent	   HeLa	   and	   293T	   cells	   were	   obtained	   from	   the	   American	   Tissue	  
Culture	   Collection	   (ATCC).	   HeLa	   cells	   derive	   from	   a	   human	   epithelial	   cervical	  
adenocarcinoma	  (initially	  from	  a	  patient,	  Henrietta	  Lacks),	  while	  HEK293T	  cells	  are	  
human	  embryonic	  kidney	  cells	  modified	  to	  contain	  the	  SV40	  large	  T	  antigen.	  These	  
cells	  were	  grown	   in	  Dulbecco’s	  Modified	  Eagle	  Medium	  (DMEM)	  +4.5g/L	  Glucose,	  
+L-­‐	   Glutamine,	   +Pyruvate	   (GIBCO	   41966,	   Invitrogen),	   and	   10%	   heat	   inactivated	  
(56°C	  for	  30	  minutes)	  foetal	  bovine	  serum	  (FBS,	  Invitrogen).	  Cells	  were	  cultured	  at	  
37°C	  and	  5%	  CO2	   in	  10cm	  dishes	   (Corning).	  Unless	  otherwise	   required,	   cells	  were	  
regularly	   passaged	   using	   1ml	   TrypLETM	   Express	   (GIBCO	   12605,	   Invitrogen).	   To	  
passage	   them,	   cells	   were	   incubated	   with	   trypsin	   for	   1-­‐3	   minutes	   at	   37°C,	   re-­‐
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suspended	  by	  repeated	  pipetting	  and	  the	  required	  proportion	  was	  transferred	  to	  a	  
10cm	  dish	  containing	  pre-­‐warmed	  fresh	  complete	  DMEM.	  
ED7R	   cells	   are	   a	   human	   T-­‐cell	   line	   that	   does	   not	   express	   the	   common	   γ-­‐chain	  
(Zhang	  et	  al.	  2007)	  and	  were	  kindly	  provided	  by	  Prof	  Adrian	  Thrasher.	  ED7R-­‐CG	  cells	  
are	  identical	  to	  ED7R	  cells	  but	  contain	  3	  integrated	  copies	  of	  the	  IL2RG	  gene.	  ED7R	  
and	   ED7R-­‐CG	   cells	   grow	   in	   suspension	   and	   were	   cultured	   in	   RPMI	   1640	   (GIBCO,	  
Invitrogen)	  medium	  at	  37°C	  and	  5%	  CO2	   in	  T25	   flasks	   (Corning).	  Unless	  otherwise	  
required,	  cells	  were	  regularly	  passaged	  by	  dilution.	  
3.2.2 Freezing	  and	  thawing	  of	  cell	  lines	  	  
Stocks	  of	  frozen	  cells	  were	  long-­‐term	  stored	  in	  liquid	  nitrogen.	  For	  freezing	  cells,	  
at	   least	   2-­‐3	   confluent	   10cm	   dishes	   of	   each	   cell	   line	   were	   prepared.	   Cells	   were	  
detached	  using	  1ml	  of	   trypsin	  and	  washed	   in	  5-­‐10ml	   fresh	  culture	  medium.	  After	  
harvesting	   the	   cells	   by	   centrifugation	   at	   1200rpm	   for	   5	   minutes,	   cells	   were	   re-­‐
suspended	   in	   1ml	   of	   freezing	   medium	   containing	   10%	   DMSO	   (Sigma),	   50%	   FBS	  
(Invitrogen)	   and	   40%	   culture	   medium	   and	   immediately	   transferred	   to	   a	   1.8ml	  
labelled	  cryovial.	  Cryovials	  were	   initially	  stored	  at	  -­‐80˚C	  and	  after	  24-­‐48	  hours	  the	  
cryovials	  were	  moved	  to	  a	  liquid	  nitrogen	  tank.	  To	  later	  recover	  the	  cryo-­‐preserved	  
cells,	   vials	   were	   thawed	   rapidly	   at	   37°C,	   cells	   were	   pelleted	   at	   1200rpm	   for	   5	  
minutes	   and	   rapidly	   re-­‐suspended	   in	   10ml	   of	   pre-­‐warmed	   DMEM	  with	   10%	   FBS.	  
Cells	  were	  left	  to	  recover	  in	  10cm	  dish	  for	  at	  least	  24-­‐48	  hours.	  
3.2.3 Mycoplasma	  testing	  
Standard	  mycoplasma	  testing	  was	  performed	  regularly	  on	  all	  cells	  cultured	  in	  the	  
mycoplasma-­‐free	  tissue	  culture	  room	  using	  the	  MycoAlertTM	  Mycoplasma	  Detection	  
Kit	   (Lonza)	   and	   the	   controls	   from	   the	   MycoAlertTM	   Assay	   Control	   Set	   (Lonza)	  
following	   the	   manufacturer’s	   protocol.	   This	   test	   is	   based	   on	   the	   activity	   of	  
mycoplasmal	  enzymes	  that	  are	  found	  in	  all	  six	  of	  the	  main	  mycoplasma	  cell	  culture	  
contaminants	  but	  are	  not	  present	  in	  eukaryotic	  cells,	  which	  convert	  ADP	  present	  in	  
the	  MycoAlert	  substrate	  to	  ATP.	  The	  ATP	   is	  then	  transferred	   into	  a	   light	  signal	  via	  
the	  luciferase	  enzyme	  in	  the	  MycoAlert	  Reagent.	  By	  measuring	  the	  level	  of	  ATP	  in	  a	  
sample	   both	   before	   (read	   A)	   and	   after	   the	   addition	   of	   the	   MycoAlert	   Substrate	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(read	  B),	  a	  ratio	  can	  be	  obtained	  which	  is	  indicative	  of	  the	  presence	  or	  absence	  of	  
mycoplasma.	  
3.2.4 Transient	  transfection	  of	  DNA	  plasmids	  	  
For	   regular	   plasmid	   DNA	   transfection,	   293T	   cells	   were	   seeded	   24	   hours	  
beforehand	   and	   transfected	   using	   polyethylinimine	   (PEI,	   Polysciences).	   For	   a	   24-­‐
well	   plate,	   1μg	  of	  plasmid	  DNA	  was	   combined	  with	  4μl	   of	   PEI	   in	   50μl	   serum-­‐free	  
DMEM	   for	   10	   minutes	   before	   drop-­‐wise	   addition	   to	   cells	   with	   fresh	   DMEM.	   For	  
transfections	  that	  required	  high	  efficiency,	  cells	  were	  seeded	  24	  hours	  beforehand	  
and	  transfected	  using	  Lipofectamine	  2000	  (Invitrogen)	  according	  to	  manufacturer’s	  
instructions.	  For	  a	  24-­‐well	  plate,	  1μl	  Lipofectamine	  was	  mixed	  with	  50μl	  Optimem	  
(GIBCO	  31985,	   Invitrogen)	  per	  sample,	  mixed	  and	  incubated	  at	  room	  temperature	  
for	  5	  minutes.	  In	  a	  separate	  eppendorf	  tube,	  50μl	  of	  Optimem	  were	  added	  to	  1μg	  
of	   plasmid	   DNA.	   The	   transfection	   reagent	  mix	  was	   then	   combined	  with	   the	   DNA	  
mixture	   and	   the	   samples	   were	   incubated	   at	   room	   temperature	   for	   20	   minutes	  
before	   drop-­‐wise	   application	   to	   the	   cells.	   In	   all	   cases,	   the	   culture	   media	   was	  
changed	  4-­‐8	  hours	  post	  transfection.	  For	  larger-­‐scale	  transfections,	  quantities	  were	  
scaled	  up	  accordingly.	  
3.3 AAV	  PRODUCTION,	  PURIFICATION	  AND	  QUANTIFICATION	  
3.3.1 AAV	  production	  
Virus	   productions	   carried	   out	   during	   this	   thesis	  were	   relatively	   small.	   2X	   T225	  
flasks	  were	  seeded	  with	  293T	  cells.	  The	  following	  day	  the	  cells	  were	  co-­‐transfected	  
using	   PEI:	   13.8µg	   of	   ITR-­‐containing	   plasmid,	   13.8µg	   of	   pDG	   and	   41.5µg	   of	   HGTI	  
(1:1:1	  molecular	  ratio)	  were	  mixed	  into	  5ml	  serum-­‐free	  DMEM,	  and	  combined	  with	  
5ml	  serum-­‐free	  DMEM	  containing	  242µl	  PEI	  (1mg/ml,	  pH	  7.0,	  use	  3.5ml	  PEI	  per	  mg	  
of	  DNA).	  The	  DNA/PEI/DMEM	  mixture	  was	  incubated	  20	  minutes	  and	  then	  added	  to	  
80ml	   pre-­‐warmed	   complete	   DMEM	   and	   added	   to	   the	   cells.	   For	   WT	   AAV	   (or	  
mutants)	  production,	  only	  the	  pAV2	  plasmid	  was	  transfected	  (without	  pDG).	  After	  
three	  days,	  the	  cells	  were	  detached	  by	  tapping/shaking	  the	  flasks,	  and	  transferred	  
to	  a	  50	  ml	  tube	  per	  flask.	  The	  cells	  were	  spun	  at	  1200rpm	  for	  10	  minutes,	  washed	  
with	  PBS	  and	  spun	  again	  before	  being	  lysed	  in	  150	  mM	  NaCl,	  50	  mM	  Tris	  at	  pH	  8,5,	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followed	   by	   three	   freeze	   (-­‐80˚C)	   -­‐	   thaw	   (37˚C	  water	   bath)	   cycles.	   The	   lysate	  was	  
then	   treated	   for	   30	   minutes	   at	   37˚C	   with	   150	   units/ml	   of	   benzonase	   (Sigma,	  
requires	  a	  working	  concentration	  of	  1mM	  MgCl2),	  to	  digest	  all	  DNA	  and/or	  RNA	  not	  
encapsidated,	   and	   subsequently	   cleared	   by	   centrifugation.	   The	   lysate	   was	   then	  
used	  to	  purify	  AAV	  by	  the	  iodixanol	  gradient	  method	  (see	  below).	  
3.3.2 AAV	  purification	  by	  iodixanol	  density	  gradient	  
The	   lysate	   was	   overlaid	   on	   top	   of	   an	   iodixanol	   (Optiprep®	   Density	   Gradient	  
medium,	  Sigma)	  gradient,	  and	  then	  spun	  at	  40000rpm	  for	  3h	  at	  18˚C	   (in	  a	  Sorvall	  
discovery	   90SE	   ultracentrifuge,	   TH641	   rotor),	   to	   separate	   the	   components	   of	   the	  
lysate.	   AAV	   particles	   are	   found	   at	   the	   40-­‐60%	   iodixanol	   interface	   after	   the	  
ultracentrifugation	  from	  were	  it	   is	  extracted	  using	  a	  syringe.	  The	  following	  density	  
fractions	   form	  the	  gradient	   (bottom-­‐to-­‐top):	  1.55ml	  60%	  (1.55ml	  Optiprep,	  3.88µl	  
phenol	  red),	  1.55ml	  40%	  (1.05ml	  Optiprep,	  0.31ml	  5X	  TD,	  0.186ml	  ddH2O),	  1.88ml	  
25%	   (0.78ml	   Optiprep,	   0.376ml	   5X	   TD,	   0.724ml	   ddH2O,	   4.7µl	   phenol	   red),	   2.8ml	  
15%	   (0.7ml	  Optiprep,	   0.56ml	   5M	  NaCl,	   0.56ml	   5X	   TD,	   0.98ml	   ddH2O).	   The	   5X	   TD	  
buffer	   contains	   5X	   PBS,	   5mM	   MgCl2	   and	   12.5mM	   KCl.	   To	   re-­‐buffer	   the	   virus,	  
samples	   (the	   iodixanol	   layer	   containing	   AAV	   particles)	   were	   diluted	   in	   Lactated	  
Ringer’s	   solution	   (Hartmann’s	   solution,	   Baxter),	   added	   to	   a	   sterile	   Vivaspin	   20	  
100KDa	  cut	  off	  concentrator	  (Sartorius	  Stedium	  Biotech),	  and	  spun	  down	  to	  a	  final	  
volume	  between	  500	  and	  800µl.	   The	  viral	  prep	  was	   finally	  aliquoted	  and	  aliquots	  
were	  stored	  at	  -­‐80˚C	  for	  long-­‐term	  storage	  or	  at	  4˚C	  for	  immediate	  use.	  
3.3.3 Quantification	  of	  viral	  particles	  
The	   quantification	   of	   AAV	   particles	   was	   performed	   as	   previously	   described	  
(Kohlbrenner	   et	   al.	   2012).	   A	   BSA	   standard	   curve	   and	   purified	   AAV	   samples	  were	  
loaded	  and	  ran	  on	  a	  polyacrylamide	  gel	  (see	  section	  3.4.1	  for	  details	  on	  SDS-­‐PAGE).	  
The	   BSA	   standard	   curve	   was	   prepared	   using	   at	   least	   5	   BSA	   dilutions,	   ranging	  
between	  2000ng	  to	  31.25ng,	  10µl	  of	  appropriate	  BSA	  dilution	  was	  mixed	  with	  5µl	  of	  
water	   and	   3µl	   of	   6X	   loading	   buffer	   (0.8g	   SDS,	   5ml	   Tris	   pH	   6.8,	   5ml	   glycerol,	   4mg	  
bromophenol	  blue,	   5%	  beta-­‐mercaptoethanol).	   For	   viral	   samples,	   15µl	  of	  purified	  
virus	  were	  mixed	  with	  3µl	  of	  6X	   loading	  buffer.	  The	  gel	  was	  migrated	  at	  80V	  until	  
the	   blue	   stain	   ran	   out	   of	   the	   gel.	   The	   gel	  was	   then	   fixed	  with	   a	   solution	   of	   50%	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ethanol	   and	   15%	   acetic	   acid	   in	   water,	   washed	   with	   water,	   and	   stained	   with	   the	  
KryptonTM	  Infrared	  Protein	  Stain.	  The	  destaining	  solution	  was	  made	  with	  5%	  acetic	  
acid	   and	   0.1%	   Tween®-­‐20	   in	  water.	   The	   gel	   was	   finally	   imaged	  with	   an	   Odyssey®	  
Infrared	   Imaging	   system	   (Li-­‐Cor),	   and	   quantified	   with	   the	   Odyssey	   software.	   The	  
protein	   content	   (in	   ng)	   of	   the	   band	   corresponding	   to	   the	   viral	   VP3	   protein	   was	  
deduced	   from	   the	   BSA	   standard	   curve,	   and	   the	   viral	   particle	   titre	  was	   calculated	  
from	  the	  known	  amount	  of	  VP3	  proteins	  per	  capsid	  (4.986868*10-­‐9ng/capsid)	  and	  
the	  volume	  of	  virus	  loaded.	  
3.3.4 Quantification	  of	  viral	  genomes	  
The	   viral	   genome	   titre	   (or	   genome-­‐containing	   particle	   titre)	  was	   quantified	   by	  
quantitative	   PCR	   (qPCR)	   using	   the	   absolute	   quantification	   method	   described	   in	  
section	  3.5.3.	  Primers	  were	  designed	  (see	  Table	  2,	  Annex	  1,	  p.	  152	  for	  details)	  for	  all	  
AAVs	   produced	   (WT	   or	   recombinant)	   to	   be	   used	   at	   the	   standard	   conditions	  
described	  in	  section	  3.5.3.	  	  
3.3.5 AAV	  infection	  and	  transduction	  
The	  same	  basic	  principle	  applies	  to	  all	  infections	  (using	  WT	  or	  mutant	  AAVs)	  and	  
transductions	   (using	   rAAVs)	   performed	   during	   this	   thesis.	   Briefly,	   cells	   were	  
infected/transduced	  at	  60/70%	  confluency	   in	   low	  volume	   (200µl	   for	  a	  well	  of	  24-­‐
well	   plate,	   volumes	   adjusted	   proportionally	   to	   the	   size	   of	   the	   culture	   vessel)	   and	  
incubated	  for	  1h	  at	  37˚C	  while	  gently	  shaking	  the	  plate/dish	  every	  15	  minutes.	  This	  
adsorption	   step	   ensures	   maximal	   infection/transduction	   efficiency.	   After	   1h,	   the	  
medium	  was	  replenished	  to	  the	  normal	  culture	  volume	  (i.e.	  500µl	  for	  a	  well	  of	  24-­‐
well	   plate).	  Medium	  was	   replaced	   after	   24	   hours.	   Cells	  were	   generally	   harvested	  
after	   48-­‐72	   hours	   for	   further	   analysis	   (Western	   blot,	   section	   3.6.2,	   or	   flow	  
cytometry,	  section	  3.6.4).	  
3.4 DNA,	  RNA	  AND	  PROTEIN	  EXTRACTION	  FROM	  EUKARYOTIC	  CELLS	  
For	   some	  of	   the	   results	  presented	   in	  Chapter	  4,	  DNA,	  mRNA	  and	  protein	  were	  
extracted	   from	  cells	  derived	   from	  a	  single	   transiently	   transfected	  and	  adenovirus-­‐
infected	  10cm	  dish	  split	  in	  4.	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3.4.1 Total	  DNA	  extraction	  
For	   total/genomic	  DNA	  extraction	   the	  QIAGEN	  DNeasy	   Blood	  &	   Tissue	   Kit	  was	  
used	   as	   per	   manufacturer’s	   instructions.	   Cells	   were	   first	   washed	   in	   PBS	   and	  
pelleted,	   followed	  by	   lysis	   and	  proteinase	  K	  digestion	   to	   remove	  all	   proteins.	   The	  
DNA	   isolation/purification	  was	  performed	  using	   a	   silica-­‐based	  DNA	  purification	   in	  
spin-­‐columns	  using	  the	  kit	  buffers.	  
3.4.2 Isolation	  of	  small	  molecular	  weight	  DNA	  (Hirt	  extracts)	  
For	   specific	   isolation	  of	   small	  molecular	  weight	  DNA	  a	  modified	   version	  of	   the	  
Hirt	  extraction	  protocol	  (Hirt	  1967)	  was	  used.	  The	  volumes	  presented	  here	  are	  for	  
extraction	  of	  DNA	   from	  293T	  cells	   from	  a	  ¼	  of	  a	  10cm	  dish.	  Cells	  were	  harvested	  
and	  pelleted	  in	  their	  medium,	  and	  subsequently	  washed	  in	  PBS.	  Cells	  were	  pelleted	  
by	   centrifugation	   for	   5	   minutes	   at	   1200rpm,	   then	   resuspended	   in	   50µl	   PBS	   and	  
transferred	  to	  a	  clean	  eppendorf	   tube.	  Cells	  were	   lysed	   in	  500µl	  Hirt	  buffer	   (0.6%	  
SDS,	   10mM	   Tris	   HCl	   pH	   7.4,	   10mM	   EDTA),	   followed	   by	   lysate	   digestion	   using	  
50µg/ml	  proteinase	  K	  (Sigma)	  for	  1	  hour	  at	  37˚C.	  120µl	  5M	  NaCl	  was	  added	  (final	  
concentration	   1M),	   the	   tube	   was	   gently	  mixed	   and	   stored	   overnight	   at	   4˚C.	   The	  
following	  day,	  the	  tubes	  were	  spun	  for	  45	  minutes	  at	  4˚C	  at	  maximum	  speed	  on	  a	  
bench-­‐top	   centrifuge	   (13000rpm)	   and	   the	   supernatant	   (approx.	   500µl)	   carefully	  
collected	   in	   a	   new	   tube.	   This	   was	   followed	   by	   addition	   of	   1	   volume	   (500µl)	   of	  
Phenol/Chloroform/Isoamylalcohol	   (25:24:1	   mixture,	   Sigma),	   gentle	   mixing,	   a	   10	  
minutes	   spin	   at	   4˚C	   at	   maximum	   speed	   on	   a	   bench-­‐top	   centrifuge	   (13000rpm),	  
transfer	   of	   the	   supernatant	   (approx.	   400µl)	   carefully	   collected	   in	   a	   new	   tube,	  
addition	  of	  40µl	  3M	  Na	  acetate	  (pH	  5.5,	  final	  concentration	  0.3M)	  and	  0.7	  volumes	  
(350µl)	   isopropanol	   and	  gentle	  mixing.	   The	   sample	  was	   stored	  at	   -­‐20˚C	  overnight	  
for	  DNA	  precipitation.	  On	  the	  final	  day,	  the	  mixture	  was	  spun	  20	  minutes	  at	  4˚C	  at	  
maximum	  speed	  in	  a	  bench-­‐top	  centrifuge	  (13000rpm),	  the	  supernatant	  discarded	  
and	  the	  pellet	  washed	   in	  70%	  ethanol	  before	  air	  drying	   in	  a	   laminar-­‐flow	  cabinet.	  
The	  DNA	  pellet	  was	  finally	  resuspended	  in	  50µl	  ddH2O	  containing	  100µg/ml	  RNAse	  
(Sigma),	  and	  stored	  at	  -­‐20˚C	  long-­‐term.	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3.4.3 Total	  RNA	  extraction	  
RNA	   extraction	  was	   performed	   using	   the	   RNeasy	  mini	   Kit	   (QIAGEN),	   following	  
the	   manufacturer’s	   instructions.	   Cells	   were	   first	   washed	   in	   PBS	   and	   pelleted,	  
followed	  by	  lysis	  in	  the	  supplied	  buffer,	  homogenisation	  using	  a	  syringe	  and	  a	  21G	  
needle,	   and	   column	   purification.	   RNA	   was	   eluted	   using	   50µl	   RNAse-­‐free	   water	  
(supplied)	   and	   the	   concentration	   determined	   using	   the	   Nanodrop	  
spectrophotometer	   in	   a	   procedure	   analogous	   to	   that	   used	   for	   DNA	   (see	   section	  
3.1.12).	  At	  this	  point,	  10µg	  of	  RNA	  were	  diluted	  in	  a	  final	  volume	  of	  87.5µl	  RNAse-­‐
free	   water	   and	   mixed	   with	   10μl	   Buffer	   RDD	   (Quiagen	   DNAseI	   kit)	   and	   2.5μl	   of	  
DNaseI	  stock	  solution	  (Quiagen	  DNAse	  I	  kit)	  and	  incubated	  for	  20	  minutes	  at	  room	  
temperature.	   The	  DNAse	   I-­‐treated	  RNA	  was	   then	   re-­‐cleaned	  using	   the	  RNeasy	  kit	  
(following	   the	   RNA	   clean-­‐up	   protocol,	   supplied).	   The	   DNaseI	   stock	   solution	   was	  
prepared	  by	  dissolving	  the	  lyophilized	  DNaseI	  (1500	  Kunitz	  units,	  QIAGEN)	  in	  550μl	  
of	  the	  RNase-­‐free	  water	  provided.	  RNA	  was	  stored	  at	  -­‐80˚C.	  
3.4.4 Total	  cellular	  protein	  extraction	  
Volumes	   indicated	   are	   for	   a	  well	   of	   a	   24	  well	   plate.	   Cells	  were	   harvested	   and	  
washed	  in	  PBS	  and	  pelleted.	  The	  cell	  pellet	  was	  then	  dissolved	  in	  50µl	  RIPA	  buffer	  
(25mM	   Tris	   HCl	   pH	   7.4,	   150mM	  NaCl,	   1%	  NP-­‐40,	   1%	   sodium	   deoxycholate,	   0.1%	  
SDS)	   containing	   2µl	   of	   25X	   protease	   inhibitor	   cocktail	   (Complete,	   Roche),	   and	  
incubated	   on	   ice	   for	   15	   minutes.	   The	   lysate	   was	   then	   spun	   at	   13000rpm	   for	   10	  
minutes	   at	   4˚C,	   and	   the	   supernatant	   transferred	   to	   a	   clean	   1.5ml	   tube.	   Proteins	  
were	  stored	  at	  -­‐80˚C.	  
3.5 DNA	  AND	  RNA	  DETECTION	  AND	  ANALYSIS	  
3.5.1 Preparation	  and	  detection	  of	  radiolabelled	  probes	  
For	   this	   study,	   two	   radiolabelled	   probes	  were	   used:	   one	   for	   AAV	   Rep	   and	   the	  
other	   for	   the	  ampicillin	  gene	  present	   in	  our	  plasmids.	  For	   the	  Rep	  probe,	  primers	  
ND44	  and	  ND45	  were	  used,	  while	   for	   the	  ampicillin	  probe	  primers	  MB5	  and	  MB6	  
were	  used	   (see	  Table	  2	   in	  Annex	  1,	  p.	  152,	   for	   sequences).	  Primers	  were	  used	   to	  
amplify	   the	   probe	   sequence	   from	   a	   plasmid,	   and	   the	   amplified	   PCR	   product	  was	  
cloned	   into	   the	   TOPO	   vector	   using	   the	   TOPO-­‐TA	   cloning	   system	   (Invitrogen).	   The	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TOPO-­‐probe	  vector	  was	  used	  from	  a	  second	  PCR	  to	  amplify	  the	  probe,	  which	  was	  
then	   cleaned	   and	   labelled	  with	   [32P]dCTPs	   (Perkin	   Elmer)	   using	   the	   Prime-­‐It	   RmT	  
random	  primer	  labeling	  kit	  (Stratagene),	  following	  the	  manufacturer’s	  instructions,	  
[32P]dCTPs.	  UV	  cross-­‐linked	  membranes	  from	  slot	  blot	  or	  Southern	  blot	  experiments	  
(see	  sections	  2.5.2	  and	  2.5.3,	  respectively)	  were	  prehybridised	  in	  0.75X	  nylon	  wash	  
solution	   (NW;	  40.6g	  Na2HPO4,	  18.65g	  EDTA,	  500g	  SDS	   in	  3.58	   litres	  of	  ddH2O,	  pH	  
7.2)	  buffer	  at	  65°C.	  The	  membranes	  were	  hybridised	  overnight	  in	  0.75X	  NW	  buffer	  
to	  either	  of	  the	  radiolabeled	  probe.	  The	  membranes	  were	  then	  washed	  twice	  with	  
0.5X	   NW	   buffer,	   followed	   by	   an	   additional	   wash	   in	   0.1X	   NW	   buffer.	   Finally,	   the	  
membranes	  were	  exposed	  to	  a	  phosphor	  screen	  (GE	  Healthcare	  Life	  Sciences)	  for	  2	  
hours	   up	   to	   overnight	   (depending	   on	   the	   strength	   of	   the	   signal).	   Images	   were	  
acquired	   using	   the	   Typhoon	   imaging	   system	   (GE	   Healthcare	   Life	   Sciences)	   and	  
analysed	  with	  the	  ImageQuant	  software	  (GE	  Healthcare	  Life	  Sciences).	  
3.5.2 Slot	  blot	  
293T	   cells	   were	   transfected	   with	   Lipofectamine	   2000	   (Invitrogen,	   see	   section	  
3.2.4)	  with	  the	  pAV2	  (or	  mutants)	  plasmid	  and	  after	  24h	  infected	  with	  adenovirus	  
at	  an	  MOI	  of	  10.	  After	  an	  additional	  48h,	  the	  cells	  were	  harvested,	  lysed	  in	  350µl	  of	  
0.2M	  NaOH–10mM	  EDTA,	   and	  boiled	   for	   15	  minutes.	   Each	   sample	  was	   loaded	   in	  
100µl	   triplicates	   onto	   a	   nylon	   hybridisation	   membrane	   (Amersham	   Biosciences)	  
using	  a	  Bio	  Dot	  apparatus	  (Biorad).	  The	  membranes	  were	  rinsed	  in	  2X	  SSC	  (1X	  SSC	  is	  
150mM	   NaCl	   plus	   15mM	   Na	   citrate,	   pH	   7),	   air-­‐dried,	   UV	   cross-­‐linked,	   and	  
radiolabelled	  as	  explained	  above.	  
3.5.3 Southern	  blot	  
The	  samples	  used	  for	  Southern	  blots	  presented	   in	  this	  thesis	  were	  obtained	  by	  
Hirt	   extracts	   (section	   3.4.2)	   and	   used	   to	   study	   AAV	   replication	   (section	   3.7.2).	   A	  
300ml	  0.8%	  agarose	  gel	  was	  prepared	  as	  described	  in	  section	  3.1.4.	  Samples	  were	  
migrated	   overnight	   at	   35V.	   Then,	   the	   gel	   was	   incubated	   30	   minutes	   rocking	   in	  
denaturing	   solution	   (1.5M	  NaCl,	   0.5M	  NaOH	   in	   ddH2O),	  washed	   shortly	   in	   ddH2O	  
twice,	   and	   incubated	   twice	   30	  minutes	   in	   neutralising	   solution	   (Tris	   0.5M	   pH7.4,	  
1.5M	  NaCl	  in	  ddH2O).	  The	  transfer	  system	  was	  then	  assembled:	  the	  gel	  was	  placed	  
face	  down	  on	  a	  Whatman	  paper	  soaking	  in	  20X	  SSC	  (175.3g	  NaCl,	  88.2g	  Na	  citrate	  in	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1l	  ddH2O),	  topped	  with	  a	  nitrocellulose	  membrane	  (GE	  Healthcare	  Life	  Sciences),	  2	  
layers	  of	  Whatman	  paper	   the	   same	   size	  of	   the	   gel,	   several	   tissues	   for	   adsorption	  
and	   finally	   2	  weights.	   The	   transfer	   of	   the	   DNA	   from	   the	   gel	   to	   the	   nitrocellulose	  
membrane	   occurs	   by	   capillarity,	   and	   is	   done	   overnight.	   The	   following	   day,	   the	  
membrane	  was	   soaked	   in	   2X	   SSC,	   air-­‐dried,	   UV	   cross-­‐linked	   and	   radiolabelled	   as	  
explained	  in	  section	  3.5.1.	  
3.5.4 qPCR:	  absolute	  quantification	  
Absolute	  quantification	  of	  AAV	  genomes	  was	  performed	  by	  qPCR	  using	  the	  SYBR	  
Green	   Jump	   Start	   Taq	   ready	   mix	   without	   MgCl2	   (Sigma)	   according	   to	   the	  
manufacturer’s	   instructions	   on	   an	   ABI	   Prism	   cycler	   (AB	   Applied	   Biosystems).	   The	  
MgCl2	  and	  primer	  concentrations	  were	  optimized	  previously	  (Zeltner	  et	  al.	  2010),	  to	  
4mM	  and	  0.25µM	  respectively.	   Linearised	  mini-­‐pDG	  plasmid	  was	  used	   to	  prepare	  
the	   standard	   curve	   for	   WT	   quantification,	   while	   pMB13	   was	   used	   for	   the	   IL2RG	  
standard	   curve.	   Standard	   curves	   had	   concentrations	   ranging	   from	   2ng	  
(corresponding	  to	  2.53	  x	  108	  molecules	  of	  dsDNA)	  to	  0.2ng	  (corresponding	  to	  2.53	  x	  
105	  molecules	  of	  dsDNA).	  1µl	  of	  purified	  and	  concentrated	  virus	  and	  three	  10-­‐fold	  
serial	  dilutions	  were	  used	  as	  viral	  samples.	  The	  primers	  used	  were	  Cap1	  and	  Cap2	  
for	  WT	  AAV	  quantification,	  CGfw	  and	  CGrv	  for	  quantification	  of	  the	   IL2RG	  vectors.	  
The	  cycling	  parameters	  were	  the	  following:	  2	  minutes	  at	  94˚C	  followed	  by	  40	  times	  
15	   seconds	   at	   94	  ̊C,	   15	   seconds	   at	   58	  ̊C	   and	   1	   minute	   at	   72	  ̊C.	   The	   amount	   of	  
genomes	   in	   the	   viral	   samples	  was	   calculated	   from	   the	   amount	   of	   DNA	   detected.	  
Each	   standard,	   control	   and	   sample	   was	   loaded	   in	   duplicate.	   For	   details	   on	   all	  
primers	  see	  Table	  2	  in	  Annex	  1,	  p.	  152.	  
3.5.5 Reverse	  transcription	  
For	   RNA	   analysis,	   RNA	   was	   reverse-­‐transcribed	   using	   the	   High-­‐Capacity	   cDNA	  
Reverse	   Transcription	   Kit	   (Applied	   Biosystems)	   following	   the	   manufacturer’s	  
instructions.	   First,	   a	   2X	   RT	  master	  mix	  was	   prepared	   by	  mixing	   (volumes	   for	   one	  
reaction)	   the	   following	   provided	   reagents:	   2µl	   10X	   RT	   buffer,	   0.8µl	   dNTP	   mix	  
(100mM),	   2µl	   10X	   RT	   random	   primers,	   1µl	   MultiScribeTM	   Reverse	   Transcriptase,	  
4.2µl	  nuclease-­‐free	  ddH2O.	  10µl	  of	  2X	  RT	  master	  mix	  was	  then	  mixed	  with	  10µl	  RNA	  
at	  the	  desired	  concentration.	  Reverse	  transcription	  was	  performed	  using	  a	  thermal	  
	   67	  
cycler	   with	   the	   following	   programme:	   10	   minutes	   at	   25˚C,	   2	   hours	   at	   37˚C,	   5	  
minutes	  at	  85˚C.	  The	  obtained	  cDNA	  was	  stored	  at	  4˚C	  for	  short-­‐term	  storage	  or	  at	  -­‐
20˚C	   for	   long-­‐term	  storage,	  and	  was	  used	   for	   relative	  quantification	  by	  qPCR	   (see	  
below).	  
3.5.6 qPCR:	  relative	  quantification	  
3’FAM-­‐5’TAMRA-­‐conjugated	   qPCR	   probes	   and	   qPCR	   primers	   designed	   to	   bind	  
into	   the	   Rep	   or	   the	   Cap	   genes	   were	   obtained	   from	  MWG	   Eurofins	   (see	   Table	   2,	  
Annex	   1,	   p.	   152,	   for	   details).	   qPCR	  was	   performed	   on	   50ng	   cDNA	   using	   TaqMan	  
Universal	  PCR	  master	  mix	  (Life	  Technologies)	  and	  the	  custom	  primer-­‐probe	  mix	  of	  
choice,	   primers	   were	   used	   at	   a	   final	   concentration	   of	   900nM,	   and	   probes	   at	  
250mM.	  Relative	  expression	  levels	  were	  determined	  by	  the	  comparative	  threshold	  
cycle	  (Ct)	  method	  (Schmittgen	  and	  Livak	  2008).	  	  
3.6 PROTEIN	  DETECTION	  AND	  ANALYSIS	  
3.6.1 Sodium	  dodecyl	  sulphate	  polyacrylamide	  gel	  electrophoresis	  (SDS-­‐PAGE)	  	  
4-­‐10µl	  of	  protein	  extracts	  in	  RIPA	  buffer	  (section2.4.4)	  were	  mixed	  with	  1-­‐2µl	  of	  
loading	  buffer	  (0.8g	  SDS,	  5ml	  Tris	  pH	  6.8,	  5ml	  glycerol,	  4mg	  bromophenol	  blue,	  5%	  
beta-­‐mercaptoethanol)	   and	   denatured	   by	   boiling	   for	   5	   minutes.	   Subsequently,	  
proteins	  were	  separated	   in	  10%	  or	  12%	  polyacrylamide	  mini-­‐gels.	  The	  percentage	  
was	  determined	  by	  altering	  the	  volume	  of	  40%	  Acrylamide	  solution	  (Acrylamide:Bis-­‐
Acrylamide	  29:1,	  Fisher	  Scientific)	  and	  ddH2O	  to	  a	  reaction	  mixture	  of	  1.5M	  Tris-­‐HCl	  
pH8.8,	  0.4%	  SDS,	  3.3μl/ml	  10%	  ammonium	  persulphate	  (APS,	  Sigma)	  and	  0.6μl/ml	  
of	  N,N,N’N’-­‐	  Tetramethylethylenediamine	   (TEMED,	  Sigma).	  The	  stacking	  gels	  were	  
made	   using	   0.5M	   Tris-­‐Cl	   pH6.8,	   0.4%	   SDS,	   5μl/ml	   10%	   APS,	   1μl/ml	   TEMED	   and	  
ddH2O.	   Polymerised	   gels	   were	   transferred	   to	   the	   running	   tank	   and	   immersed	   in	  
running	   buffer	   (100ml	   10X	   Tris-­‐glycine	   and	   10ml	   10%	   SDS	   and	   ddH2O	   to	   1l).	   10X	  
Tris-­‐glycine	  was	  prepared	  by	  mixing	  61g	  Tris	  base	  and	  288g	  glycine	  in	  2l	  ddH2O.	  Gels	  
were	  typically	  run	  at	  120V	  until	  the	  blue	  dye	  front	  had	  migrated	  to	  the	  bottom	  of	  
the	  gel,	  using	   the	  Protean	   II	  mini	  gel	  electrophoresis	  kit	   (BioRad).	  2µl	  of	  Precision	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Plus	   Protein	   Dual	   Color	   Standards	   (Bio-­‐Rad)	   was	   used	   as	   a	   guide	   for	   molecular	  
weights	  in	  all	  gels.	  	  
3.6.2 Western	  blot	  	  
Proteins	  resolved	  in	  SDS-­‐PAGE	  were	  transferred	  onto	  pure	  nitrocellulose	  0.45μm	  
membrane	   (VWR	   International).	   Gel	   to	  membrane	   transfer	  was	   achieved	   using	   a	  
BioRad	   Mini	   Trans-­‐Blot®	   transfer	   system	   with	   transfer	   buffer	   (100ml	   10X	   Tris-­‐
glycine,	  200ml	  methanol,	  700ml	  ddH2O)	  at	  16V	  overnight	  or	  at	  100V	  on	  ice	  for	  75	  
minutes.	  Membranes	  were	  then	  removed	  from	  the	  transfer	  tank	  and	  blocked	  with	  
5%	  (w/v)	  skimmed	  dried	  milk	  in	  PBS-­‐Tween	  (1X	  PBS,	  0.1%	  Tween	  20,	  Sigma)	  for	  30	  
minutes.	  Membranes	  were	  then	   incubated	  with	  the	   indicated	  primary	  antibody	   in	  
5%	  milk	   in	  PBS-­‐Tween	  for	  3	  hours	  at	  room	  temperature	  or	  overnight	  at	  4˚C.	  Next,	  
membranes	  were	  washed	  3	  times	  for	  15	  minutes	   in	  PBS-­‐Tween	  and	  consequently	  
incubated	   with	   the	   corresponding	   secondary	   antibody	   for	   1	   hour.	   Finally,	  
membranes	  were	  washed	  three	  times	  for	  15	  minutes	  in	  PBS-­‐Tween	  and	  developed	  
according	  to	  the	  antibody	  and	  technology	  used	  (see	  section	  below).	  	  
3.6.3 Protein	  detection	  methods	  	  
Infrared	   IRDye®-­‐conjugated	   680nm	   and	   800nm	   secondary	   antibodies	   were	  
detected	  using	  a	  LI-­‐COR	  Odyssey	  infrared	  scanner	  (LI-­‐COR	  Biosciences).	  Membranes	  
were	  placed	  on	  the	  scanner	  with	  a	   few	  drops	  of	  1X	  PBS	  to	  avoid	  them	  drying	  out	  
but	   making	   sure	   there	   were	   no	   air	   bubbles	   between	   the	   membrane	   and	   the	  
scanning	  surface.	  Laser	  intensities	  were	  adjusted	  according	  to	  the	  signal	  obtained.	  
Alternatively,	   the	   signal	   of	  membranes	   incubated	  with	   horseradish	   peroxidase	  
(HRP)-­‐conjugated	  secondary	  antibodies	  was	  detected	  with	  a	  SuperSignal	  West	  Pico	  
chemiluminescene	   system	   (Thermo	   Scientific),	   prepared	   according	   to	   the	  
manufacturers’	   instructions	   and	   applied	   on	   the	   membrane	   for	   5	   minutes.	   The	  
membrane	  was	   then	   sandwiched	  between	   two	   clear	  plastic	   sheets	   and	   visualised	  
using	   a	   Image	   Quant	   LAS4000	   (GE	   Healthcare)	   chemiluminescence	   imaging	  
technology.	  
Information	   on	   all	   the	   primary	   and	   secondary	   antibodies	   that	   were	   used	   to	  
generate	  the	  data	  presented	  in	  this	  thesis	  can	  be	  found	  in	  Table	  3,	  Annex	  1,	  p.	  154.	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3.6.4 Flow	  cytometry	  
GFP	  transfected	  or	  transduced	  cells	  were	  washed,	  passed	  through	  a	  cell	  strainer	  
to	   ensure	   single-­‐cell	   separation,	   and	   analysed	   for	   protein	   expression	   by	   flow	  
cytometry	  on	  a	  BD	  FACSCantoII	  flow	  cytometer	  using	  the	  BD	  FACSAriaII	  program.	  All	  
results	   obtained	   by	   flow	   cytometry	   were	   analysed	   using	   the	   FlowJo	   software.	  
Information	   on	   all	   the	   FACS	   antibodies	   that	   were	   used	   to	   generate	   the	   data	  
presented	  in	  this	  thesis	  can	  be	  found	  in	  Table	  3,	  Annex	  1,	  p.	  154.	  
3.6.5 Protein	  structure	  analysis	  
All	   the	   protein	   structures	   presented	   were	   generated	   using	   the	   Mac	   PyMOL	  
protein	  visualisation	  software.	  	  
3.7 IMAGING	  
3.7.1 Cell	  fixation	  and	  immunostaining	  	  
iPSCs	  were	  prepared	  in	  24-­‐well	  plates.	  Following	  aspiration	  of	  the	  medium,	  cells	  
were	   washed	   once	   with	   1X	   PBS	   and	   fixed	   (protein	   cross-­‐linking)	   in	   4%	  
paraformaldehyde	   (PFA,	   Thermo	   Scientific,	   diluted	   in	   PBS,	   pH	   7.4)	   for	   15-­‐20	  
minutes	   at	   room	   temperature.	   The	   cells	  were	   then	  washed	   twice	   in	   PBST	   (0.05%	  
Tween-­‐20	  in	  1X	  PBS),	  permeabilised	   in	  0.1%	  Triton	  X-­‐100	  (Sigma)	   in	  1X	  PBS	  for	  10	  
minutes,	  washed	   twice	   again	   in	   PBST,	   blocked	   in	   blocking	   solution	   (4%	   FBS	   in	   1X	  
PBS)	  for	  30	  minutes,	  stained	  for	  2	  hours	  with	  primary	  antibody	  (diluted	  to	  working	  
concentration	  in	  PBS),	  washed	  twice	  in	  PBST,	  stained	  with	  the	  secondary	  antibody	  
(diluted	   to	   working	   concentration	   in	   PBS	   containing	   1:10000	   diluted	   Hoechst	  
chromatin	  stain,	  Invitrogen)	  for	  45	  minutes,	  and	  washed	  a	  final	  three	  times	  in	  PBST.	  	  
	  293T	  cells	  were	  prepared	  on	  coverslips	  and	  handled	  in	  a	  24-­‐well	  plate.	  The	  cells	  
were	  fixed	  and	  permeabilised	  using	  cold	  (-­‐20˚C)	  methanol	  for	  at	   least	  20	  minutes.	  
Cells	  were	  then	  carefully	  washed	  three	  times	  in	  PBST,	  blocked	  in	  blocking	  solution	  
for	  45	  minutes	  before	  incubating	  with	  primary	  antibody	  for	  2h	  (diluted	  to	  working	  
concentration	   in	  PBS).	  Cells	  were	   then	  washed	   three	   times	   in	  1X	  PBS	  and	  stained	  
with	   the	   secondary	   antibody	   (diluted	   to	  working	   concentration	   in	   PBS	   containing	  
1:10000	   diluted	   Hoechst	   chromatin	   stain,	   Invitrogen)	   for	   1h.	   Samples	   were	   then	  
washed	   three	   times	   with	   1X	   PBS	   and	   mounted	   onto	   microscope	   slides	   (VWR	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International)	  in	  Mowiol	  (Calbiochem).	  The	  slides	  were	  then	  covered,	  left	  overnight	  
at	  room	  temperature	  to	  dry	  and	  stored	  at	  room	  temperature	  in	  the	  dark.	  	  
Images	   were	   acquired	   on	   a	   Nikon	   Ti-­‐Eclipse	   widefield	   inverted	   microscope	  
(Nikon,	  10X	  dry	  objective	  lens	  for	  iPSCs,	  60X	  oil	  objective	  lens	  for	  293Ts)	  equipped	  
with	  the	  NIS-­‐Elements	  software	  (Nikon).	  Excitation	  and	  emission	  filters	  specific	  for	  
the	  secondary	  antibody	  and	  DAPI	  were	  used.	  Multiple	  fields	  of	  view	  were	  selected	  
at	   various	  XY	  plate	   coordinates	  and	  at	   least	  6	   fields	  per	   condition	  were	  analysed.	  
Selected	   .TIF	   files	   generated	   directly	   using	   the	   NIS-­‐Elements	   software	   or	   the	   NIS	  
Elements	   viewer	   software	   (Nikon)	   were	   exported	   and	   assembled	   in	   Adobe	  
Photoshop	   to	   generate	   overlay	   images.	   Information	   on	   all	   the	   primary	   and	  
secondary	  antibodies	  that	  were	  used	  to	  generate	  the	  data	  presented	  in	  this	  thesis	  
can	  be	  found	  in	  Table	  3,	  Annex	  1,	  p.	  154.	  
3.7.2 Transmission	  electron	  microscopy	  
Transmission	  EM	  microscopy	  was	  performed	  in	  collaboration	  with	  the	  Centre	  for	  
Ultrastructural	   Imaging	   (CUI)	   of	   King’s	   College.	   Samples	   were	   prepared	   by	   a	  
technique	  called	  negative	  staining.	  The	  purified	  virus	  was	  applied	  on	  an	  EM	  grid	  and	  
exposed	  to	  a	  heavy	  metal	   (uranyl)	  stain.	  The	  grids	  were	  washed	  and	   imaged	  on	  a	  
transmission	  electron	  microscope	  FEI	  Tecnai	  T20	  and	  the	  associated	  software.	  
3.8 AAV	  LIFE	  CYCLE	  AND	  REP	  FUNCTIONAL	  ASSAYS	  
3.8.1 Infectious	  particles	  production	  assay	  
This	  assay	  was	  developed	  during	  this	  thesis	  and	  was	  designed	  to	  test	  rapidly	  and	  
simply	  the	  effects	  of	  Rep	  mutations	  on	  the	  overall	  AAV	  lifecycle.	  For	  the	  purpose	  of	  
the	   studies	   presented	   here	   it	   was	   only	   used	   to	   test	   Rep	  mutants,	   but	   the	   same	  
assay	   can	   be	   used	   to	   test	  mutations	   in	   any	   of	   the	  AAV	  proteins.	   293T	   cells	  were	  
triple-­‐transfected	  using	  PEI	  (see	  section	  3.2.4)	  with	  plasmids	  pTRUF11,	  mini-­‐pDG	  (or	  
Rep	  mutants	  variants	  of	  mini-­‐pDG)	  and	  pHGTI-­‐Adeno1	  to	  produce	  rAAV2-­‐GFP.	  After	  
72h,	   the	   cell	   supernatant	   was	   harvested	   and	   increasing	   volumes	   (1µl,	   10µl	   and	  
100µl)	   of	   supernatant	  were	  used	   to	   transduce	  HeLa	   cells	   (as	   explained	   in	   section	  
3.3.5).	  The	  percentage	  of	  GFP-­‐positive	  Hela	  cells	  was	  determined	  48h	  post-­‐infection	  
by	  flow	  cytometry	  (see	  section	  3.6.4).	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3.8.2 Replication	  assays	  
Three	  methods	  were	   used	   for	   the	   assessment	   of	   AAV	   replication.	   In	   all	   cases,	  
293T	  cells	  were	  first	  transfected	  using	  PEI	  (see	  section	  3.2.4),	  6h	  later	  infected	  with	  
adenovirus	   at	   MOI	   5	   to	   stimulate	   AAV	   replication	   or	   mock	   infected	   for	   no	  
replication	  controls,	  and	  harvested	  72h	  post-­‐transfection.	  
The	  first	  method	  used	  to	  detect	  AAV	  replication	  was	  slot	  blot	  (section	  3.5.2).	  The	  
total	  AAV	  DNA	  present	  in	  the	  cell	  was	  detected	  using	  the	  Rep-­‐specific	  radiolabelled	  
probe	   and	  normalised	   to	   the	   input	  plasmid	  DNA	  detected	  using	   the	  Amp-­‐specific	  
probe	  (probes	  prepared	  as	  described	  in	  section	  3.5.1).	  
The	  second	  method	  used	  was	  based	  on	  absolute	  quantification	  by	  qPCR	  (section	  
3.5.4).	  The	  total	  DNA	  was	  extracted	  from	  the	  cells	  (section	  3.4.1)	  and	  serial	  dilutions	  
were	  quantified	  by	  qPCR.	  Cap	  primers	  were	  used	  for	  quantification	  of	  the	  total	  AAV	  
DNA	  that	  was	  normalised	  to	  the	  housekeeping	  gene	  control	  cyclophillin.	  
For	  the	  third	  method,	  small-­‐molecular	  weight	  DNA	  was	  extracted	  using	  the	  Hirt	  
extraction	   method	   (described	   in	   section	   3.4.2).	   ~2µg	   of	   DNA	   per	   sample	   were	  
digested	   with	   the	   DpnI	   RE	   to	   degrade	   the	   input	   plasmid	   DNA.	   1µg	   of	   DNA	   was	  
loaded	   on	   a	   Southern	   blot	   gel,	   migrated	   and	   transferred	   to	   a	   nitrocellulose	  
membrane	   as	   described	   in	   section	   3.5.4.	   The	  membranes	   obtained	  were	   probed	  
and	   imaged	  using	   a	  Rep	  or	  Amp	   radiolabelled	  probe	   (see	   section	  3.5.1)	   to	   reveal	  
AAV	  DNA	  and	  input	  DNA,	  respectively.	  Success	  of	  the	  DpnI	  digestion	  is	  controlled	  by	  
the	  Amp-­‐probed	  membrane:	  no	  bands	  are	  visible	  if	  the	  DpnI	  digestion	  is	  successful,	  
while	  AAV	  replication	   is	  apparent	  by	  the	  appearance	  of	  bands	  on	  the	  Rep-­‐probed	  
membrane	   (because	  of	   the	  DpnI	  digestion	  only	  newly	   replicated	  AAV	  DNA	  will	  be	  
visible).	  In	  case	  of	  normal	  AAV	  replication,	  a	  band	  for	  the	  monomeric	  AAV	  genome	  
at	  4.7kb	  and	  a	  band	  for	   the	  dimeric	   replicative	   form	  of	   the	  AAV	  genome	  at	  9.4kb	  
are	  expected.	  Additional	   larger	  bands	  (larger	  concatamers)	  can	  also	  be	  visible.	  For	  
non-­‐digested	  DpnI	  samples,	   in	  addition	  to	   the	  replication	   intermediates	  described	  
above,	  plasmid	  DNA	  should	  be	  detected	   in	   the	   same	  way	   in	  both	  Amp-­‐	  and	  Rep-­‐
probed	  membranes.	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3.8.3 Supercoiled	  (sc)	  DNA	  nicking	  assay	  
scDNA	   nicking	   activity	   of	   purified	   Rep68*	   and	  mutants	   (kindly	   provided	   by	   Dr	  
Carlos	  Escalante)	  was	  assayed	  as	  described	  previously	  (Lamartina	  et	  al.	  2000a;	  Petri	  
et	   al.	   2015).	   Briefly,	   assays	   were	   performed	   in	   30μl	   reactions	   containing	   30mM	  
Hepes-­‐KOH	  (pH	  7.5),	  7mM	  MgCl2,	  0.5mM	  DTT,	  4mM	  ATP,	  40mM	  creatine	  phostate	  
(Sigma),	   1μg	   creatine	   phosphokinase	   (Sigma),	   in	   15mM	  NaCl	   final	   concentration.	  
100ng	  scDNA	  plasmid	  and	  200ng	  of	  purified	  Rep68*	  were	  added	  to	  the	  reactions.	  
To	   test	   Rep68*	   scDNA	   nicking	   activity,	   different	   amounts	   of	   purified	   protein	   and	  
100ng	  of	  scDNA	  plasmid	  were	   incubated	   in	  a	  buffer	  containing	  30mM	  Hepes-­‐KOH	  
(pH	  7.5),	  7mM	  MgCl2	  and	  0.5mM	  DTT,	   in	  50nM	  NaCl.	  All	   samples	  were	   incubated	  
for	  1h	  at	   37°C	  and	   terminated	  by	  adding	  10μl	  of	   stop	   reaction	   (proteinase	  K	   [1.2	  
μg/μl],	   0.5%	  SDS	  and	  30mM	  EDTA	  pH7.5)	  and	   incubating	   for	  1h	  at	  37°C.	   Samples	  
were	   resolved	   in	   1%	   agarose	   gel	   (1X	   TAE),	   which	  was	   subsequently	   stained	  with	  
ethidium	   bromide	   (0.3μg/ml)	   in	   1X	   TAE.	   scDNA	   plasmids	   used	   in	   this	   assay	  were	  
pRVK	  (contains	  AAVS1	  nucleotides	  1	  to	  3536	   including	  the	  RBS	  and	  TRS	  sites)	  and	  
pRVK-­‐mutTRS	  (contains	  a	  mutated	  TRS	  that	   is	  not	  recognised	  by	  Rep)	  amplified	   in	  
TOP10	  competent	  cells	  (Petri	  et	  al.	  2015).	  
3.9 IPSCS	  GENERATION	  AND	  CULTURE	  
3.9.1 Generation	  of	  iPSCs	  from	  dermal	  fibroblasts	  
Patient-­‐derived	  human	  dermal	  fibroblasts	  at	  passage	  6	  were	  plated	  in	  fibroblast	  
media	   (IMDM,	   GIBCO,	   with	   10%	   FBS)	   onto	   gelatin-­‐coated	   6-­‐well	   plates.	   For	  
mycoplasma	   prevention,	   PlasmocinTM	   (Invivogen)	   was	   used	   at	   a	   prophylactic	  
concentration	   of	   2.5µg/ml	   in	   all	   culture	   media.	   Cells	   were	   then	   transduced	   at	  
various	  MOIs	  with	   an	   excisable	   lentiviral	   vector	   carrying	   the	   four	   reprogramming	  
factors	  Oct4,	  Sox2,	  Klf4,	  and	  c-­‐Myc	  (Somers	  et	  al.	  2010).	  After	  24h,	  cell	  media	  was	  
replaced	  with	  fresh	  iPSC	  media.	  iPSC	  medium	  is	  IMDM	  containing	  10%	  FBS,	  1nM	  of	  
non-­‐animal	   L-­‐glutamine	   (Invitrogen),	   1X	   sodium	   pyruvate	   (Invitrogen),	   1X	   non-­‐
essential	   AA	   (NEAA,	   Invitrogen),	   1X	   antibiotics,	   0.1mM	   beta-­‐mercaptoethanol	  
(Invitrogen),	   4ng/bFGF	   (from	   a	   100ug/ml	   stock,	   Miltenyi	   Biotec)	   and	   50ng/ml	  
ascorbic	   acid	   (Sigma).	   At	   day	   5,	   the	   cells	   were	   passaged	   onto	   10cm	   dishes	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containing	   irradiated	   mouse	   embryonic	   fibroblasts	   (iMEFs),	   and	   at	   day	   10	   the	  
culture	  medium	  was	  switched	  to	  hESC	  medium	  containing	  DMEM-­‐F12	  (GIBCO),	  20%	  
Knockout	   serum	   replacement	   (GIBCO),	   1mM	   L-­‐glutamine,	   0.1mM	   beta-­‐
mercaptoethanol,	  1%	  NEAA,	  1X	  antibiotics,	  1X	  Na	  pyruvate,	  7.5%	  NA	  bicarbonate,	  
and	  10ng/ml	  of	  bFGF.	  At	   this	  point,	   the	  medium	  was	  changed	  every	  2-­‐3	  days	  and	  
cells	  were	   left	   in	  culture	   for	  at	   least	  28	  days.	  Subsequently,	   the	  colonies	  with	   the	  
most	  promising	  morphologies	  were	  hand	  picked	  and	  placed	  in	  single	  wells	  of	  a	  24-­‐
well	  plate.	  At	  this	  point,	  medium	  was	  changed	  daily	  and	  cells	  were	  passaged	  when	  
necessary	  using	  TrypLE	  (GIBCO).	  	  
3.9.2 High-­‐sensitivity	  mycoplasma	  detection	  
The	  LookOut	  Mycoplasma	  PCR	  Detection	  Kit	  (Sigma)	  was	  used	  for	  high-­‐sensitivity	  
mycoplasma	   detection	   as	   per	   manufacturer’s	   instructions,	   using	   the	   suggested	  
JumpStart	   Taq	   DNA	   polymerase	   (Sigma).	   Briefly,	   supernatants	   from	   cells	   pre-­‐
cultured	  in	  the	  absence	  of	  anti-­‐mycoplasma	  agents	  for	  several	  days	  were	  boiled	  for	  
5	  minutes	   and	   centrifuged	   to	  pellet	   cellular	   debris.	   PCRs	  were	  performed	   in	   25µl	  
combining	   2µl	   of	   cellular	   supernatant	   and	   23µl	   of	   DNA	   polymerase/Rehydration	  
Buffer	  mix	   (provided).	   Cycling	   conditions	   were	   as	   follows:	   2	  minutes	   at	   94˚C,	   40	  
cycles	  of	  30	  seconds	  at	  94˚C	  followed	  by	  30	  seconds	  at	  55˚C	  and	  40	  seconds	  at	  42˚C,	  
and	  a	  final	  cool	  down	  step	  to	  4˚C.	  8µl	  for	  each	  PCR	  sample	  were	  loaded	  on	  a	  1.2%	  
agarose	   gel	   and	   imaged	   as	   described	   in	   section	   3.1.4.	   Negative	   samples	   show	   a	  
single	  band	  at	  481bp,	  while	  positive	  samples	  show	  a	  band	  at	  260bp.	  
3.9.3 Mycoplasma	  treatment	  
In	   an	   attempt	   to	   eradicate	   mycoplasma	   contamination	   of	   iPSCs,	   PlasmocinTM	  
(Invivogen)	  was	  used	  at	   a	   curative	   concentration	  of	   25	  µg/ml	   in	   complete	  hES	  or	  
fibroblast	  medium	  for	  2	  to	  3	  weeks.	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CHAPTER	  4: STRUCTURAL	   DETERMINANTS	   OF	   REP68	  
OLIGOMERISATION	  
	  
The	  data	  presented	   in	   this	   chapter	   is	  part	  of	   two	  publications	   (Zarate-­‐Perez	  et	  al.	  
2012;	  Zarate-­‐Perez	  et	  al.	  2013)	   (see	  also	  Annex	  2,	  p.	  162)	   that	  were	  generated	   in	  
close	   collaboration	   with	   the	   laboratory	   of	   Dr	   Carlos	   Escalante	   at	   Virginia	  
Commonwealth	  University	  (Richmond,	  Virginia,	  USA).	  My	  role	  in	  these	  publications	  
was	   to	   investigate	   the	   functional	   consequences	   of	  mutations	   introduced	   into	   the	  
Rep78/68	  proteins.	  The	  structural	  findings	  presented	  in	  this	  chapter,	   including	  the	  
data	   on	   the	   oligomerisation	   of	   the	   large	   Rep	   proteins	   and	   the	   in	   vitro	   functional	  
assays	  were	  generated	   in	  Dr	   Escalante’s	   lab.	  Where	  necessary	   to	  ensure	   that	   the	  
implications	   of	   our	   findings	   are	   clear	   to	   the	   reader,	   contributions	   from	   Dr	  
Escalante’s	  lab	  are	  included	  and	  clearly	  indicated	  in	  the	  figure	  legends.	  
4.1 	  INTRODUCTION	  
The	  genomes	  of	  small	  DNA	  viruses	  encode	  for	  specialised	  initiator	  proteins	  that	  
are	  essential	  for	  viral	  DNA	  replication.	  The	  Rep	  proteins	  from	  AAV,	  the	  LTag	  protein	  
from	  SV40	  and	  E1	  protein	   from	  PV	  are	  amongst	   the	  best-­‐characterised	  examples.	  
These	  proteins	  belong	  to	  the	  SF3	  of	  helicases,	  structurally	  defined	  by	  the	  presence	  
of	  an	  AAA+	  motor	  domain	  (Hickman	  and	  Dyda	  2005).	  The	  combination	  of	  an	  AAA+	  
motor	  domain	  with	  an	  origin-­‐binding	  domain	  confers	  a	  striking	  versatility	  to	  these	  
proteins,	   allowing	   them	   to	  act	   as	   initiator	  proteins	   rather	   than	  mere	  helicases.	   In	  
the	  case	  of	  AAV,	  Rep78/68	  recognise	  the	  origin	  of	  replication	  (ori)	  through	  the	  RBS,	  
and	  then	  unwind	  and	  nick	  the	  TRS	  to	  start	  a	  new	  cycle	  of	  DNA	  replication	  (Im	  and	  
Muzyczka	   1990;	   Owens	   et	   al.	   1993;	   Brister	   and	  Muzyczka	   2000).	   Similarly,	   SV40-­‐
LTag	  and	  PV-­‐E1	  bind	  to	  their	  respective	  ori	  were	  they	  promote	  melting	  of	  the	  origin	  
sequences	   and	   initiation	   of	   replication	   (Fanning	   and	   Zhao	   2009;	   Bergvall	   et	   al.	  
2013).	  Unwinding	  by	  SF3	  helicases	  is	  ATP-­‐dependent	  and	  requires	  the	  formation	  of	  
an	  active	  helicase	  complex,	  which,	  in	  the	  case	  of	  SV40-­‐LTag	  and	  PV-­‐E1,	  is	  a	  double-­‐
hexameric	  ring	  (Fouts	  et	  al.	  1999;	  Valle	  et	  al.	  2000).	  Formation	  of	  this	  complex	  may	  
be	  induced	  by	  the	  presence	  of	  DNA	  and/or	  ATP.	  The	  oligomerisation	  behaviour	  of	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AAV	  Rep	  and	  its	  functional	  importance	  in	  the	  AAV	  life	  cycle,	  however,	  are	  less	  clear.	  
Importantly,	  there	  are	  relevant	  functional	  differences	  between	  Rep	  and	  SV40-­‐LTag	  
and	   PV-­‐E1.	   Notably,	   the	   OBD	   of	   Rep	   contains	   an	   endonuclease	   function	   that	   is	  
required	  for	  DNA	  replication	  and	  Rep-­‐mediated	  genomic	  integration.	  This	  function	  
is	  absent	   in	  SV40-­‐LTag	  and	  PV-­‐E1	  despite	  structural	  similarities,	  due	  to	  the	   loss	  of	  
the	  HUH	  and	  Y	  motifs	  that	  form	  the	  endonuclease	  active	  site.	  
The	   first	   indications	   that	   the	   large	   Rep	   proteins	   could	   oligomerise	   came	   from	  
several	  studies	  that	  reported	  the	  formation	  of	  multiple	  species	  in	  gel	  mobility	  shift	  
assay	  experiments	  used	  to	  study	  Rep78/68	  binding	  to	  RBS-­‐containing	  DNA	  (McCarty	  
et	   al.	   1994b;	   Kyostio	   et	   al.	   1995;	   Weitzman	   et	   al.	   1996;	   Smith	   et	   al.	   1997).	  
Investigations	   stemming	   from	   these	   observations	   described	   Rep-­‐Rep	   interactions	  
for	   Rep78	   and	   Rep68,	   and	   it	   was	   suggested	   that	   the	   presence	   of	   RBS-­‐containing	  
DNA	   and	   ATP	   could	   promote	   the	   formation	   of	  multimers	   (Hermonat	   and	   Batchu	  
1997;	  Di	  Pasquale	  and	  Stacey	  1998;	  Davis	  et	  al.	  1999).	  Moreover,	  using	  Rep68	  and	  
C-­‐terminally	   truncated	  Rep	  mutants	   that	   retained	  endonuclease	   activity	   and	  RBS-­‐
binding,	  Weitzman	  et	  al.	  showed	  that	  Rep	  proteins	  could	  form	  hetero-­‐oligomers	  on	  
AAV	  hairpin	  DNA	   (Weitzman	  et	   al.	   1996).	  Because	  of	   the	   structural	   similarities	  of	  
AAV	  Rep	  with	  SV40	  LTag	  and	  PV	  E1,	   it	   is	  reasonable	  to	  assume	  that	  the	   large	  Rep	  
proteins	  also	  form	  hexameric	  rings.	  In	  support	  of	  this	  hypothesis,	  two	  studies	  have	  
suggested	  that	  Rep	  forms	  hexamers	  in	  the	  presence	  of	  ori	  DNA	  (Smith	  et	  al.	  1997;	  
Dignam	   et	   al.	   2007b).	   Smith	   and	   colleagues	   were	   the	   first	   to	   investigate	   the	  
stoichiometry	   of	   Rep-­‐DNA	   complexes.	  Using	   gel	   chromatography	   and	   crosslinking	  
experiments,	  the	  authors	  showed	  that	  in	  the	  presence	  of	  a	  dsDNA	  substrate	  Rep78	  
formed	  a	  complex	   suggestive	  of	  a	  hexamer.	  The	   formation	  of	   the	  Rep78	  complex	  
was	  dependant	  on	  the	  presence	  of	  DNA	  but	  not	  ATP;	  in	  the	  absence	  of	  DNA	  Rep78	  
remained	   monomeric	   (Smith	   et	   al.	   1997).	   Dignam	   et	   al.	   later	   reported	   that	  
activation	   of	   the	   ATPase	   activity	   of	   Rep	   required	   the	   formation	   of	   Rep-­‐DNA	  
complexes	   and	  was	   stimulated	   by	   the	   presence	   of	  ori	   sequences	   and,	   to	   a	   lower	  
extent,	   non-­‐specific	   DNA.	   Rep78	   and	   Rep68	   showed	   a	   concentration-­‐dependent	  
oligomeric	  behaviour,	  both	  in	  the	  presence	  and	  absence	  of	  DNA,	  and	  the	  oligomeric	  
species	  observed	  by	  gel	  chromatography	  were	  consistent	  with	  a	  hexamer	  bound	  to	  
two	   copies	   of	   RBS-­‐containing	   DNA	   (Dignam	   et	   al.	   2007b).	   Li	   and	   colleagues	   had	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previously	   reported	   a	   similar	   concentration-­‐dependent	   effect	   on	   oligomerisation	  
that	  also	  suggested	  that	  more	  than	  one	  copy	  of	  DNA	  was	  bound	  per	  complex,	  but	  
the	  authors	  did	  not	  investigate	  the	  number	  of	  Rep68	  molecules	  bound	  to	  the	  DNA	  
(Li	  et	  al.	  2003b).	  The	  observation	  that	  Rep68	  complexes	  could	  bind	  more	  than	  one	  
copy	  of	  DNA	   is	   also	   consistent	  with	   the	   intriguing	   report	   that	  Rep	   complexes	   can	  
bind	  simultaneously	  to	  the	  ITR	  and	  AAVS1	  sequences	  (Weitzman	  et	  al.	  1994).	  	  
Other	  reports,	  however,	  have	  described	  the	  formation	  of	  complexes	  other	  than	  
hexamers.	  The	  crystal	  structure	  of	  the	  AAV5	  Rep	  OBD	  bound	  to	  RBS-­‐containing	  DNA	  
showed	   five	   OBDs	   bound	   to	   one	   DNA	  molecule	   (Hickman	   et	   al.	   2004).	   However,	  
when	   a	   longer	   DNA	   substrate	   and/or	   full-­‐length	   Rep68	   were	   used,	   formation	   of	  
larger	   complexes	   was	   observed	   (Hickman	   et	   al.	   2004).	   A	   more	   recent	   study	   by	  
Mansilla-­‐Soto	  and	  colleagues	  also	  described	  a	  pentameric	  complex	  in	  the	  presence	  
of	   a	   short	   RBS-­‐containing	   dsDNA,	   and	   the	   authors	   suggest	   that	   this	  might	   be	   an	  
intermediate	  assembly	  step	  towards	  a	   larger	  Rep68-­‐ITR	  complex	  (Mansilla-­‐Soto	  et	  
al.	   2009).	   This	   report	  went	   further	   to	   demonstrate	  how	  different	  DNA	   substrates	  
can	   modulate	   the	   formation	   of	   distinct	   oligomeric	   species	   (Mansilla-­‐Soto	   et	   al.	  
2009).	  Surprisingly,	  the	  authors	  found	  that	  in	  the	  presence	  of	  an	  unspecific	  ssDNA	  
or	   heteroduplex	   (ssDNA-­‐dsDNA)	   substrate	   Rep68	   forms	   a	   large	   double-­‐octameric	  
complex.	   This	   complex	   was	   purified	   and	   shown	   to	   unwind	   the	   heteroduplex	  
substrate	   in	   the	  presence	  of	  ATP	  and	  magnesium	   (Mansilla-­‐Soto	  et	  al.	  2009).	  The	  
two	   octameric	   rings	   in	   this	   complex	   are	   oriented	   head-­‐to-­‐head,	   suggestive	   of	   a	  
bidirectional	   activity.	   However,	   the	   current	   AAV	   replication	  model,	   unlike	   that	   of	  
SV40	  and	  PV,	  doesn’t	  predict	  a	  bidirectional	  mechanism.	  SV40	  and	  PV	  have	  a	  dsDNA	  
genome,	   and	   their	   respective	  ori	   contain	   inverted	   repeats	   that	   are	   recognised	  by	  
the	   initiator	   proteins	   and	   promote	   the	   formation	   of	   a	   head-­‐to-­‐head	   double	  
hexameric	  complex	  necessary	  for	  bi-­‐directional	  replication	  (Fanning	  and	  Zhao	  2009;	  
Bergvall	  et	  al.	  2013).	  The	  AAV	  ITRs,	  however,	  only	  contain	  a	  series	  of	  direct	  repeats.	  
Thus,	  it	  is	  not	  clear	  how	  a	  bidirectional	  Rep	  complex	  could	  function,	  although	  a	  few	  
plausible	   scenarios	   have	   been	   suggested	   (Mansilla-­‐Soto	   et	   al.	   2009).	   First,	   if	   we	  
assume	  that	  Rep	  complexes	  can	  bind	  more	  than	  one	  DNA	  molecule	  (Weitzman	  et	  
al.	   1994;	   Li	   et	   al.	   2003b;	   Dignam	   et	   al.	   2007b),	   a	   bidirectional	   complex	   could	  
mediate	   the	   synchronised	   resolution	   (step	   e	   in	   Figure	   3)	   of	   two	   separate	   ITRs.	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Alternatively,	   the	  double-­‐octameric	   complex	   could	   coordinate	   ITR	   refolding	   (after	  
terminal	   resolution	   and	   duplication,	   step	   g	   in	   Figure	   3,	   p.	   26)	   and	   unwinding	   of	  
double-­‐stranded	  AAV	  DNA	  to	  promote	  further	  rounds	  of	  replication.	  	  
The	   lack	  of	   full-­‐length	  Rep68	  or	  Rep78	  structures	  complicates	   the	   study	  of	   the	  
determinants	   of	   oligomerisation	   as	   well	   as	   the	   characterisation	   of	   functionally	  
relevant	   oligomeric	   complexes.	   Despite	   the	   fact	   that	   separate	   structures	   of	   the	  
AAV5	  Rep	  OBD	  and	  AAA+	  helicase	  domain	  have	  been	  solved,	   it	   is	  not	  known	  how	  
these	   two	   domains	   are	   oriented	   with	   respect	   to	   one	   another	   in	   the	   full-­‐length	  
Rep78/68.	   Because	   the	   large	   Rep	   proteins	   have	   a	   tendency	   to	   aggregate	   at	   high	  
concentrations	   and	   low	   ionic	   strength	   conditions,	   it	   is	   difficult	   to	   study	   their	  
oligomeric	  behaviour	  in	  the	  absence	  of	  DNA	  let	  alone	  the	  mechanisms	  of	  complex	  
assembly	   (Smith	   et	   al.	   1997;	   Dignam	   et	   al.	   2007b;	  Mansilla-­‐Soto	   et	   al.	   2009).	   In	  
addition,	   the	   tendency	   of	   the	   large	   Rep	   proteins	   to	   aggregate	   hinders	   structural	  
studies	   of	   full-­‐length	   Rep68	   and	   Rep78.	   In	   a	   systematic	   analysis	   of	   Rep68	  
aggregation,	  our	  collaborators	  determined	  that	  only	  reducing	  agents	  decreased	  the	  
aggregation	  significantly	  (Zarate-­‐Perez	  et	  al.	  2013).	  This	  implies	  that	  aggregation	  is	  
induced	   by	   oxidation,	   potentially	   through	   the	   formation	   of	   intermolecular	  
disulphide	  bonds,	  as	  was	  previously	  suggested	  by	  Smith	  and	  colleagues	  (Smith	  et	  al.	  
1997).	  This	  led	  us	  to	  investigating	  the	  roles	  of	  specific	  cysteine	  residues	  in	  Rep78/68	  
aggregation,	  and	  whether	  these	  residues	  are	  functionally	  important	  for	  the	  AAV	  life	  
cycle.	  
In	  the	  context	  of	  AAV	  Rep	  oligomerisation,	  it	  is	  important	  to	  note	  that	  Rep40	  and	  
Rep52	   remain	   monomeric	   in	   solution	   (Smith	   and	   Kotin	   1998;	   James	   et	   al.	   2003;	  
James	  et	  al.	  2004;	  Mansilla-­‐Soto	  et	  al.	  2009).	  This	  is	  in	  contrast	  to	  the	  behaviour	  of	  
the	  corresponding	  domains	  of	  LTag	  and	  E1,	  which	  readily	  form	  hexamers	  (Sedman	  
and	  Stenlund	  1998;	  Enemark	  and	  Joshua-­‐Tor	  2006).	  Importantly,	  it	  has	  been	  shown	  
that	   the	   Rep	   OBD	   is	   also	  monomeric	   in	   the	   absence	   of	   DNA,	   implying	   that	   both	  
domains	   cooperate	   in	   the	   formation	   of	   oligomers	   (Mansilla-­‐Soto	   et	   al.	   2009).	  
Interestingly,	  a	  previous	  study	  using	  small	  deletion	  mutants	  of	  Rep68	  in	  an	  attempt	  
to	  identify	  regions	  important	  for	  Rep68-­‐Rep68	  interactions	  indicated	  residues	  151-­‐
188	  (a	  putative	  coiled-­‐coiled	  region)	  and	  334-­‐347	  (part	  of	  the	  AAA+	  active	  site)	  as	  
important	  for	  multimerisation,	  supporting	  the	  notion	  that	  both	  domains	  participate	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to	   oligomeric	   interfaces	   (Smith	   et	   al.	   1997).	   A	   careful	   comparison	   of	   the	  
oligomerisation	  interfaces	  of	  SV40-­‐LTag	  and	  PV-­‐E1	  reveals	  an	   important	  similarity:	  
both	   the	   core	   AAA+	   and	   the	   α-­‐helical	   bundle	   that	   connects	   to	   the	   origin-­‐binding	  
domain,	   contribute	   to	   the	   formation	   of	   a	   large	   hydrophobic	   oligomerisation	  




Figure	  10:	  Structural	  comparison	  of	  SF3	  helicases.	  	  
(A)	  Ribbon	  representations	  of	  AAV2-­‐Rep40,	  PV-­‐E1	  and	  SV40-­‐LTag.	  The	  core	  AAA+-­‐like	  fold	  and	  the	  
small	   helical	   bundle	   defined	   as	   OD	   in	   PV-­‐E1	   and	   SV40-­‐LTag	   are	   represented	   in	   blue	   and	   salmon	  
colours,	   respectively.	   (B)	   Dimer	   of	   PV-­‐E1	  with	   residues	   participating	   in	   the	   hydrophobic	   interface	  
highlighted	  in	  blue	  and	  red.	  (C)	  Structural	  alignment	  of	  the	  helical	  bundles	  of	  AAV2-­‐Rep40	  (green),	  
PV-­‐E1	  (cyan)	  and	  SV40-­‐LTag	  (magenta).	  Figure	  adapted	  from	  (Zarate-­‐Perez	  et	  al.	  2012).	  Panels	  B	  and	  
C	  are	  courtesy	  of	  C.	  Escalante.	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Importantly,	   one	   side	   of	   the	   AAA+	   part	   of	   the	   large	   oligomerisation	   interface	  
includes	   all	   the	   catalytic	   residues	   of	   the	   AAA+	   domain.	   Residues	   in	   the	   small	   α-­‐
helical	  bundle,	   termed	  the	  oligomerisation	  domain	   (OD)	   in	  PV-­‐E1,	  are	  also	  part	  of	  
the	  interface.	  In	  particular,	  two	  α-­‐helices	  in	  the	  OD	  are	  involved	  in	  the	  formation	  of	  
the	   hydrophobic	   interface	   (Figure	   10B).	   In	   Rep40,	   this	   potential	   oligomerisation	  
domain	   is	   significantly	   shorter	   than	   in	   SV40-­‐LTag	   and	   PV-­‐E1,	   measuring	   only	   52	  
residues	   compared	   to	   89	   AAs	   and	   68	   AAs	   in	   SV40-­‐LTag	   and	   PV-­‐E1,	   respectively	  
(Figure	   10A	   and	   C).	   The	   consequent	   decrease	   in	   accessible	   surface	   could	   be	  
sufficient	  to	  explain	  the	  lack	  of	  oligomerisation	  of	  Rep52/40.	  
In	   this	   chapter,	   I	   will	   present	   our	   contribution	   to	   the	   advancement	   in	  
understanding	  of	  determinants	  Rep68	  oligomerisation.	  Following	  the	  identification	  
of	  cysteine	  disulphide	  bond	   formation	  as	   the	  main	  cause	  of	  Rep68	  aggregation	   in	  
vitro,	  we	  investigated	  the	  role	  of	  two	  exposed	  cysteine	  residues	  in	  the	  formation	  of	  
aggregates.	   We	   identified	   a	   Rep68	   cysteine	   mutant	   that	   prevents	   Rep68	  
aggregation	  even	  at	  high	  concentrations.	  In	  addition,	  our	  results	  demonstrate	  that	  
this	   mutant	   is	   fully	   able	   to	   support	   the	   AAV	   lifecycle,	   and	   thus	   is	   a	   biologically	  
relevant	   and	   valuable	   tool	   for	   structural	   studies	   of	   AAV	   Rep68.	   This	  mutant	   was	  
then	   used	   to	   characterise	   the	   concentration-­‐dependent	   dynamic	   oligomeric	  
behaviour	   of	   Rep68.	   Subsequently,	   we	   investigated	   whether	   the	   shorter	   OD	   in	  
Rep52/40	  compared	  to	  SV40-­‐LTag	  and	  PV-­‐E1	  could	  be	  the	  reason	  behind	  the	  lack	  of	  
oligomerisation	   displayed	   by	   the	   small	   Rep	   proteins.	   We	   demonstrate	   that	   the	  
interdomain	   linker	  of	  Rep78/68	  plays	  a	   crucial	   role	   in	  Rep68	  oligomerisation,	  and	  
that	   its	   presence	   is	   sufficient	   to	   initiate	  oligomerisation	  of	  both	   the	  OBD	  and	   the	  
helicase	  domains	  of	  Rep68.	  Furthermore,	  we	  identified	  an	  aromatic	  residue	  in	  the	  
linker	  that	  is	  conserved	  in	  SF3	  helicases	  and	  that	  is	  critical	  for	  Rep78/68	  functions	  in	  
support	  of	  the	  AAV	  life	  cycle.	  
4.2 RESULTS	  
4.2.1 Mutation	  of	  cysteine	  151	  to	  serine	  prevents	  aggregation.	  
To	   understand	   the	   role	   of	   cysteines	   in	   Rep68	   aggregation,	   we	   analysed	   the	  
crystal	  structure	  of	  Rep40	  (James	  et	  al.	  2003)	  and	  an	  AAV2	  OBD	  model	  based	  on	  the	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AAV5	  OBD	  crystal	  structure	  (Hickman	  et	  al.	  2002).	  There	  are	  six	  cysteine	  residues	  in	  
Rep68:	   four	  are	  buried	  and	  semi-­‐buried	   in	  the	  protein	  while	  two,	  C151	  and	  C405,	  
are	  exposed	  to	  the	  solvent	  (Figure	  11A).	  C151	  is	  part	  of	  the	  OBD	  and	  is	  positioned	  
right	  next	  to	  tyrosine	  152,	  which	  is	  part	  of	  the	  Y	  motif	  of	  Rep68	  (see	  section	  1.2.2).	  
Despite	  the	  fact	  that	  Y152	  is	  not	  the	  active	  site	  tyrosine	  that	  is	  directly	  involved	  in	  
the	  catalysis	  of	  ssDNA,	   it	  has	  nonetheless	  been	  suggested	  to	  be	   important	  for	  the	  
endonuclease	   activity	   of	   Rep68	   (Davis	   et	   al.	   2000).	   C405,	   on	   the	   other	   hand,	   is	  
located	  in	  the	  helicase	  domain,	  more	  specifically	  within	  the	  pre-­‐sensor	  1	  β-­‐hairpin	  
that	  is	  implicated	  in	  DNA	  translocation	  during	  DNA	  unwinding	  (Yoon-­‐Robarts	  et	  al.	  
2004).	   Consequences	   of	   mutation	   C405	   have	   never	   been	   studied,	   but	   mutants	  
K404A	  and	  K406A	  have	  been	   shown	   to	  disrupt	   the	  helicase	  activity	  of	  Rep40	  and	  
Rep68.	  Interestingly,	  C405	  is	  conserved	  in	  other	  AAV	  serotypes,	  while	  C151	  is	  not.	  
In	  the	  corresponding	  position	  in	  AAV5	  a	  serine	  residue	  can	  be	  found	  instead	  of	  the	  
cysteine	  (Figure	  11B).	  Analytical	  gel	  filtration	  profiles	  of	  Rep68	  containing	  the	  C151S	  
mutation	   or	   the	   C405S	   mutation	   were	   compared	   to	   the	   profile	   of	   Rep68	   WT.	  
Aggregates	  of	  Rep68	  elute	  with	  the	  void	  volume,	  suggesting	  their	  size	  is	  larger	  than	  
the	  exclusion	   limit	  of	   the	   column	  used	   for	   this	   study.	  Mutation	  of	  C151	   to	   serine	  
(C151S)	   prevents	   the	   formation	   of	   aggregates,	   while	   the	   C405S	   mutant	   only	  
reduces	   Rep68	   aggregation	   (Figure	   11C).	   Thus,	   cysteine	   151	   in	   the	   OBD	   but	   not	  
cysteine	   405	   in	   the	   helicase	   domain	   seems	   to	   be	   critical	   in	   the	   formation	   of	   the	  
intermolecular	  disulphide	  bonds	  that	  cause	  Rep68	  aggregation	  in	  solution.	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Figure	  11:	  Mutation	  of	  cysteine	  residue	  C151	  to	  serine	  prevents	  aggregation	  of	  Rep68.	  	  
(A)	  Sphere	  representation	  of	  a	  model	  of	  AAV2	  OBD	  and	  of	  Rep40.	  Cysteine	  residues	  are	  highlighted	  
in	  red.	  The	  two	  cysteine	  residues	  that	  appear	  to	  be	  fully	  exposed	  to	  the	  solvent,	  C151	  and	  C405,	  are	  
highlighted	  in	  red.	  The	  semi-­‐buried	  cysteine	  C355	  is	  also	  indicated.	  (B)	  Sequence	  alignment	  of	  AAV2	  
and	   AAV5.	   Identical	   residues	   are	   highlighted	   in	   red,	   cysteine	   residues	   are	   shown	   in	   purple.	   The	  
alignment	   was	   performed	   with	   the	   ClustalW2	   programme.	   (C)	   Analytical	   gel	   filtration	   profiles	   of	  
Rep68	  WT,	  Rep68-­‐C151S	  and	  Rep68-­‐C405S.	  The	  oligomerisation	  of	  WT	  Rep68	  was	  assessed	  at	  two	  
concentrations	  of	  the	  reducing	  agent	  TCEP.	  Panel	  C	  is	  courtesy	  of	  C.	  Escalante.	  
	  
4.2.2 Rep68-­‐C151S	  is	  functionally	  equivalent	  to	  Rep68	  WT.	  
To	  be	  able	  to	  use	  Rep68-­‐C151S	  for	  further	  structural	  and	  biochemical	  studies,	  we	  
first	  needed	  to	  determine	   if	   this	  mutant	  was	   functional.	  Although	  C151	  has	  never	  
been	  identified	  in	  mutagenesis	  screens	  aimed	  at	  identifying	  residues	  important	  for	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the	  catalytic	  activity	  of	  the	   large	  Rep	  proteins	  and	  serine	   is	  the	  most	  conservative	  
AA	  substitution	  for	  cysteine,	  the	  C151S	  mutation	  could	  have	  detrimental	  effects	  on	  
the	  functions	  of	  Rep68	  due	  to	  its	  vicinity	  to	  the	  Y	  motif.	  We	  initially	  compared	  the	  
biochemical	   activities	   of	   Rep68-­‐C151S	   to	   those	   of	   Rep68	   WT	   using	   in	   vitro	  
functional	   assays.	   ATPase	   activity	   was	   assessed	   by	   a	   colorimetric	   assay	   that	  
measures	  the	  amount	  of	  free	  phosphate	  in	  a	  reaction	  (Figure	  12A).	  Helicase	  activity	  
was	  determined	  by	  measuring	  DNA	  unwinding	  in	  a	  fluorescence	  resonance	  energy	  
transfer	   (FRET)-­‐based	   fluorimetric	   assay	   (Figure	   12B),	   while	   DNA	   binding	   was	  
assessed	  by	  fluorescence	  anisotropy	  (Figure	  12C).	  Rep68-­‐C151S	  performed	  as	  well	  
as	  WT	  Rep68	  in	  all	  these	  in	  vitro	  assays	  (Figure	  12A,	  B	  and	  C).	  Then,	  we	  tested	  the	  
ability	  of	  the	  mutant	  Rep	  to	  support	  the	  AAV	  life	  cycle.	  First	  we	  assessed	  if	  Rep68-­‐
C151S	  could	  efficiently	  replicate	  AAV	  DNA	  in	  293T	  cells	  transfected	  with	  the	  pAV2	  
plasmid	   (WT	   or	   containing	   the	   Rep78/68-­‐C151S	   mutant)	   and	   infected	   with	  
adenovirus	   to	   stimulate	  AAV	   replication.	   The	   amount	   of	   AAV	  DNA	  present	   in	   the	  
cells	  was	  quantified	  by	  slot	  blot	  using	  a	  Rep	  specific	  radiolabelled	  probe.	  Rep78/68	  
containing	   the	  C151S	  mutation	  proved	   to	   replicate	  AAV	  DNA	  as	   efficiently	   as	  WT	  
Rep78/68	   in	   the	   presence	   of	   adenovirus	   (Figure	   12D).	   To	   determine	   if	   the	  
Rep78/68-­‐C151S	  mutant	  was	  also	  able	  to	  support	  the	  production	  of	  infectious	  viral	  
particles,	  we	  infected	  HeLa	  cells	  using	  increasing	  volumes	  of	  supernatant	  from	  293T	  
cells	  producing	   recombinant	  AAV2-­‐GFP	   in	   the	  context	  of	   the	  mutant	  Rep	  protein.	  
Figure	  12E	  shows	  that	  infectious	  rAAV2-­‐GFP	  particles	  were	  efficiently	  formed	  in	  the	  
presence	  of	  Rep78/68-­‐C151S,	  albeit	  at	   slightly	   lower	   titres	   than	  WT	  Rep.	  Because	  
the	   Rep78/68	   supported	   AAV	   replication	   to	   WT	   levels,	   the	   cause	   of	   this	   small	  
difference	  in	  infectious	  particles	  production	  is	  likely	  to	  be	  downstream	  of	  the	  DNA	  
replication.	  To	  assess	  if	  defects	  in	  the	  efficiency	  of	  DNA	  packaging	  were	  the	  cause	  of	  
this	  difference,	  we	  produced	  and	  purified	  WT	  and	  Rep-­‐C151S	  AAV2	  and	  assessed	  
the	   fraction	   of	   full	   particles	   in	   our	   preparations	   by	   transmission	   electron	  
microscopy.	   A	   significantly	   lower	   percentage	   of	   full	   particles	   is	   an	   indication	   of	  
inefficient	   packaging	   of	   the	   viral	   DNA.	   The	   presence	   of	   the	  mutation	   in	   the	   Rep-­‐
C151S	   AAV	   virus	   was	   confirmed	   by	   sequencing	   (data	   not	   shown),	   but	   it	   did	   not	  
affect	  the	  ratio	  of	  empty	  to	  full	  particles	  (Figure	  12F).	  	  
	  
	   83	  
	  
	  
Figure	  12:	  Functional	  comparison	  of	  Rep68	  WT	  and	  Rep68-­‐C151S.	  	  
(A)	   ATPase	   activity,	   (B)	   helicase	   activity	   and	   (C)	   DNA	   binding	   activities	   showed	   no	   significant	  
difference	   between	   the	   WT	   and	   C151S	   proteins.	   (D)	   Determination	   of	   viral	   replication	   in	   the	  
presence	   of	  WT	   or	   C151S	  mutant	   Rep.	   The	   bar	   graph	   shows	   the	   quantification	   of	   three	   slot	   blot	  
experiments.	  The	  signal	  obtained	  with	  the	  Rep-­‐specific	  probe	  was	  normalized	  to	  that	  obtained	  with	  
the	   ampicillin-­‐specific	   probe,	   to	   normalise	   for	   input	   (transfected)	   DNA.	   The	   replication	   of	   the	  WT	  
AAV2	  genome	  in	  the	  presence	  of	  adenovirus	  was	  set	  as	  100%.	  Data	  are	  presented	  as	  mean	  ±	  s.e.m	  
from	  three	  experiments.	  (E)	  Comparison	  of	  the	  production	  of	  rAAV2-­‐GFP	  infectious	  particles	  in	  the	  
presence	  of	  WT	  or	  C151S	  Rep.	  rAAV2-­‐GFP	  particles	  were	  produced	  in	  293T	  cells	  in	  the	  presence	  of	  
WT	  or	  C151S	  Rep.	  Various	  volumes	  of	  crude	  lysate	  (in	  µl,	  x	  axis)	  were	  added	  to	  HeLa	  cells,	  and	  the	  
percentage	   of	   GFP-­‐positive	   infected	   cells	   was	   determined	   by	   FACS	   analysis.	   Data	   from	   four	  
experiments	  are	  presented	  as	  mean	  ±	  s.e.m.	  (F)	  Visualisation	  of	  WT	  AAV2	  and	  AAV2-­‐RepC151S	  viral	  
particles	  by	  transmission	  electron	  microscopy	  at	  50,000X	  magnification.	  Empty	  viral	  particles	  appear	  
as	  white	   rings.	   For	   each	   sample,	   6	   fields	   of	   approximately	   200	   particles	  were	   counted;	   the	  mean	  
percentage	   of	   full	   particles	   and	   the	   standard	   deviation	   are	   indicated.	   Panels	   (A),	   (B)	   and	   (C)	   are	  
courtesy	  of	  C.	  Escalante.	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Taken	  together,	   these	  results	  demonstrate	   that	  Rep78/68-­‐C151S	   is	   functionally	  
comparable	  to	  WT	  Rep78/68	  in	  supporting	  AAV	  replication	  and,	  more	  generally,	  the	  
AAV	   life	   cycle.	   Furthermore,	   the	   biochemical	   properties	   of	   Rep68,	   including	   RBS	  
binding,	  DNA	  unwinding	  and	  the	  ATPase	  activity,	  are	  recapitulated	  by	  Rep68-­‐C151S.	  
We	  conclude	  that	  Rep68-­‐C151S	  is	  sufficiently	  similar	  to	  Rep68	  WT	  and	  thus	  that	  this	  
mutant	   is	   biologically	   relevant	   and	   can	   be	   used	   for	   further	   structural	   and	  
biochemical	   studies.	   We	   have	   used	   this	   mutant	   as	   the	   new	   standard	   for	   the	  
characterisation	   of	   the	   oligomeric	   behaviour	   of	   Rep68,	   and	   I	  will	   refer	   to	   Rep68-­‐
C151S	  as	  Rep68*	  henceforth.	  
4.2.3 The	  interdomain	  linker	  is	  essential	  for	  Rep68	  oligomerisation.	  
Identifying	   the	   structural	   features	   that	   promote	   oligomerisation	   is	   pivotal	   to	  
understanding	  the	  mechanisms	  of	  assembly	  of	  functionally	  relevant	  Rep	  complexes.	  
The	  structural	  comparison	  of	  SF3	  helicases	  revealed	  that	  the	  monomeric	  small	  AAV	  
Rep	  proteins	  have	  a	  shorter	  OD	  compared	  to	  that	  of	  the	  hexameric	  SV40-­‐Tag	  and	  
PV-­‐E1	   proteins	   (see	   Figure	   10).	   In	   the	   large	   Rep	   proteins,	   Rep78	   and	   Rep68,	   this	  
shorter	  OD	   is	   connected	   to	   the	  OBD	   via	   a	   linker	   that	   spans	   residues	   200-­‐224.	   To	  
investigate	   whether	   this	   linker	   extends	   the	   OD	   in	   Rep68/78	   and	   contributes	   to	  
oligomerisation,	  we	   carried	  out	   secondary	   structure	   prediction	  on	   the	   linker.	   The	  
results	  suggest	  that	  while	  most	  of	  the	  linker	  is	  predicted	  to	  be	  disordered,	  residues	  
219	  to	  224	  have	  the	  potential	  to	  form	  an	  α-­‐helix,	  possibly	  extending	  the	  N-­‐terminal	  
α	  -­‐helix	  of	  the	  OD	  and	  increasing	  the	  surface	  accessible	  area	  (Figure	  13A).	  To	  test	  if	  
this	   part	   of	   the	   linker	   functionally	   belongs	   to	   the	   OD,	   we	   assessed	   the	  
oligomerisation	   properties	   of	   a	   truncated	   Rep	  missing	   the	  OBD	   but	   including	   the	  
linker	   (Rep68∆209)	   by	   sedimentation	   velocity	   experiments.	   These	   experiments,	  
performed	   by	   analytical	   ultracentrifugation,	   allow	   the	   determination	   of	   size	  
distribution	  functions,	  which	  provide	  information	  on	  the	  protein	  species	  present	  in	  
a	  sample.	  From	  the	  known	  mass	  of	  a	  protein	  or	  complex	  it	  is	  possible	  to	  calculate	  a	  
theoretical	  sedimentation	  coefficient,	  which	  can	  then	  be	  used	  to	  infer	  the	  identity	  
of	  the	  species	  (peaks)	  observed	  in	  the	  size	  distribution	  functions.	  In	  this	  case,	  Figure	  
13B	   shows	   that	   in	   contrast	   to	   Rep40,	  which	   is	  monomeric,	   Rep68∆209	   can	   form	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oligomers.	   Surprisingly,	   addition	   of	   the	   linker	   to	   the	   OBD	   also	   induced	  
oligomerisation	  (Figure	  13C).	  Thus,	  the	  linker	  is	  sufficient	  to	  induce	  oligomerisation	  
of	  both	  domains	  of	  Rep68,	  which	  are	  otherwise	  monomeric.	  Taken	  together,	  these	  
results	   provide	   evidence	   that	   the	   interdomain	   linker	   of	   Rep68	   is	   a	   functional	  
component	  of	  the	  OD	  and	  establish	  its	  critical	  role	  in	  Rep68	  oligomerisation.	  	  
	  
	  
Figure	  13:	  The	  interdomain	  linker	  of	  Rep68	  is	  essential	  for	  oligomerisation.	  	  
(A)	   Schematic	   diagram	   of	   the	   domain	   architecture	   of	   Rep78,	   including	   the	   OBD	   (green),	   the	   OD	  
(pink),	   the	  helicase	  domain	   (blue)	   and	   the	  ZnF	  domain	   (red).	   The	   sequence	  of	   the	   linker	   is	   shown	  
below	   together	   with	   the	   predicted	   helical	   regions	   indicated	   by	   H.	   Sedimentation	   profiles	   of	   (B)	  
Rep40	  and	  Rep68∆209	  and	  of	  the	  OBD	  and	  the	  OBD-­‐linker	  (C).	  Panels	  (B)	  and	  (C)	  are	  courtesy	  of	  C.	  
Escalante.	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4.2.4 Linker	  residue	  Y224	  is	  critical	  for	  Rep68	  oligomerisation	  and	  function	  and	  
represents	  a	  conserved	  feature	  in	  SF3	  helicases	  
A	  structural	  model	  of	  the	  helicase	  domain	  of	  Rep68	  with	  the	  addition	  of	  the	  last	  
7	   residues	   from	   the	   linker	   (Rep68∆217)	  was	   generated	  using	   the	   available	  Rep40	  
structure	  and	  the	  linker	  residues	  added	  as	  a	  helical	  extension.	  This	  model	  was	  then	  
used	   for	   structural	   alignment	  with	   the	  OD	  domains	   of	   SV40-­‐LTag	   and	   PV-­‐E1.	   The	  
alignment	  reveals	  that	  the	  modelled	  α-­‐helix	  superimposes	  with	  helix	  1	  of	  SV40-­‐LTag	  
and	  PV-­‐E1	  helicase	  domains.	  Furthermore,	  Rep	  residue	  Y224	  (the	  last	  residue	  of	  the	  
linker)	  corresponds	  to	  aromatic	  residues	  W270	  and	  F313	  of	  SV40-­‐LTag	  and	  PV-­‐E1,	  
respectively	  (Figure	  14	  A	  and	  B).	  These	  aromatic	  residues	  appear	  to	  be	  an	  integral	  
part	   of	   the	   oligomerisation	   interface	   in	   LTag	   and	   E1	   hexameric	   rings.	   Thus,	   we	  
tested	   the	  hypothesis	   that	  Y224	  plays	  an	  equivalent	   role	   in	  Rep	  by	  mutating	   it	   to	  
alanine	   and	   assessing	   the	   consequences	   on	   Rep68*	   oligomerisation	   and	   more	  
generally	   on	   the	   AAV	   life	   cycle.	   Rep68*-­‐Y224A	   showed	   severe	   oligomerisation	  
(Figure	  14C).	  Moreover,	  to	  assess	  if	  this	  oligomerisation	  defect	  caused	  by	  the	  Y224A	  
mutation	  has	  any	  consequences	  on	  Rep	   functions	  and	   thus	  on	   the	  AAV	   life	   cycle,	  
supernatant	  collected	  from	  cells	  producing	  rAAV2-­‐GFP	  in	  cells	  transfected	  with	  WT	  
or	  mutated	  Rep78/68	  was	  then	  used	  to	  infect	  HeLa	  cells.	  Figure	  14D	  shows	  that	  the	  
supernatant	  collected	   from	  cells	   transfected	  with	   the	  mutant	  helper	  virus	  did	  not	  
contain	  any	   infectious	  rAAV2-­‐GFP,	  as	  determined	  by	  FACS	  analysis	  of	  GFP	  positive	  
cells.	   Thus,	   Rep68*-­‐Y224	   was	   completely	   unable	   to	   support	   the	   production	   of	  
infectious	   AAV	   particles.	   Taken	   together,	   these	   results	   suggest	   that	   AAV	   Rep	  
residue	   Y224	   and	   the	   oligomerisation	   properties	   it	   confers	   to	   Rep78/68	   play	   a	  
crucial	  role	  in	  supporting	  the	  AAV	  life	  cycle.	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Figure	  14:	  The	  conserved	  residue	  Y224	  is	  essential	  for	  Rep68	  oligomerisation	  and	  function.	  	  
(A)	  Structural	  alignment	  of	  the	  OD	  domains	  of	  AAV2-­‐Rep,	  PV-­‐E1,	  SV40-­‐LTag	  and	  the	  bacterial	  RepB,	  
and	   of	   two	   non-­‐structural	   parvoviral	   proteins	   from	   snake	   parvovirus	   1	   and	   point-­‐tailed	  macaque	  
parvovirus	  NS1.	  A	  conserved	  aromatic	  residue	   is	  highlighted	   in	  blue.	  (B)	  Structure	  superposition	  of	  
the	   conserved	   aromatic	   residue	   for	   AAV2-­‐Rep	   (green),	   SV40-­‐Tag	   (magenta)	   and	   PV-­‐E1	   (cyan).	   (C)	  
Comparative	  analysis	  of	  the	  sedimentation	  profiles	  of	  Rep68	  and	  Rep68-­‐Y224A.	  (D)	  Consequences	  of	  
the	  Y224A	  mutation	  on	  the	  production	  of	  rAAV2-­‐GFP	   infectious	  particles	   in	  the	  presence	  of	  WT	  or	  
Y224A	   Rep.	   Data	   from	   three	   experiments	   presented	   as	  mean	   ±	   s.e.m.	   Panels	   (A),	   (B)	   and	   (C)	   are	  
courtesy	  of	  C.	  Escalante.	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4.3 DISCUSSION	  
The	   role	   of	   SF3	   helicases	   such	   as	   SV40-­‐LTag	   or	   PV-­‐E1	   as	   initiators	   of	   DNA	  
replication	   relies	   on	   their	   ability	   to	   oligomerise	   upon	   binding	   to	   the	   ori	   DNA.	  
Similarly,	  it	  is	  thought	  that	  AAV	  Rep	  oligomerisation	  is	  also	  required	  for	  its	  functions	  
during	  the	  AAV	  life	  cycle.	  However,	  while	  it	  is	  well	  established	  that	  SV40-­‐LTag	  and	  
PV-­‐E1	   form	  hexameric	   rings,	   the	   oligomeric	   behaviour	   of	   AAV	  Rep	   appears	   to	   be	  
more	  flexible	  (Li	  et	  al.	  2003b;	  Mansilla-­‐Soto	  et	  al.	  2009;	  Zarate-­‐Perez	  et	  al.	  2013).	  In	  
particular,	  the	  small	  Rep	  proteins	  are	  monomeric,	  while	  the	  large	  Rep	  proteins	  form	  
larger	   complexes.	   Pentameric,	   hexameric	   and	   octameric	   complexes	   have	   been	  
suggested	   for	   Rep78/68	   (Smith	   et	   al.	   1997;	   Li	   et	   al.	   2003b;	   Dignam	   et	   al.	   2007b;	  
Mansilla-­‐Soto	  et	  al.	  2009).	  However,	  studies	  of	  Rep	  oligomerisation	  and	  its	  further	  
structural	  characterisation	  have	  been	  hindered	  by	  its	  tendency	  to	  aggregate	  (Smith	  
et	   al.	   1997;	   Dignam	   et	   al.	   2007b;	  Mansilla-­‐Soto	   et	   al.	   2009).	  We	   have	   identified	  
oxidation	  and	  the	  formation	  of	  intermolecular	  disulphide	  bonds	  as	  the	  cause	  of	  this	  
aggregation.	  In	  particular,	  cysteine	  151	  seems	  to	  be	  involved	  in	  this	  process,	  and	  its	  
mutation	   to	   serine	   prevents	   Rep68	   aggregation.	   Intriguingly,	   while	   it	   has	   never	  
been	   possible	   to	   obtain	   a	   crystal	   structure	   for	   Rep68	   or	   the	   OBD	   of	   AAV2,	   the	  
crystal	   structure	   of	   the	   Rep	   OBD	   from	   AAV5,	   which	   contains	   a	   serine	   in	   the	  
corresponding	   position,	   was	   solved.	   Importantly,	   we	   have	   shown	   that	   Rep68	  
containing	   this	   conservative	   mutation	   is	   functional,	   rendering	   Rep68*	   (Rep68-­‐
C151S)	   a	   biologically	   relevant	   tool	   for	   the	   study	   of	   AAV2	   Rep	   structure	   and	  
oligomerisation.	   Rep68*	   was	   used	   for	   further	   characterisation	   of	   Rep	  
oligomerisation	   in	   the	   absence	   of	   DNA,	   and	   revealed	   a	   complex	   and	   dynamic	  
picture	   (Zarate-­‐Perez	   et	   al.	   2013).	   In	   particular,	   Rep68*	   showed	   a	   concentration	  
and	  nucleotide	  dependent	  oligomerisation,	  forming	  a	  monomer-­‐dimer	  equilibrium	  
at	   low	  concentrations	  and	  heptameric	  and	  octameric	   rings	  at	  high	  concentrations	  
(Figure	   15).	   More	   recently,	   Rep68*	   proved	   useful	   in	   determining	   the	   crystal	  
structure	   of	   the	   OBD	   and	   OBD-­‐linker	   of	   AAV2	   Rep,	   the	   first	   structural	  
characterisation	   of	   the	   full-­‐length	   Rep68,	   and	   the	   X-­‐ray	   structure	   of	   the	   OBD	   of	  
Rep68	   bound	   to	   the	   AAVS1	   RBS-­‐TRS	   site	   (Musayev	   et	   al.	   2015a;	   Musayev	   et	   al.	  
2015b).	  The	  structure	  of	   the	  AAV2	  OBD	   is	  very	  similar	   to	   the	  AAV5	  structure	   that	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was	   reported	   previously	   (Hickman	   et	   al.	   2002),	   with	   the	   exception	   of	   the	   DNA	  
binding	   loop	   and	   the	   C-­‐terminal	   long	   α-­‐helix	   (helix	   F),	   which	   are	   positioned	   at	  
different	   angles.	   The	   linker	  was	   found	   to	   be	   partially	   structured,	   a	   property	   that	  
was	  supported	  by	  small-­‐angle	  X-­‐ray	  scattering	  (SAXS)	  data	  of	  Rep68*	  that	  showed	  a	  
compact	  molecule	  with	   all	   the	   functionally	   important	   residues	   positioned	  on	  one	  
face	   of	   the	   protein	   (Musayev	   et	   al.	   2015a).	   The	   study	   of	   Rep68*	  OBD	  binding	   to	  
AAVS1	   identified	   a	   heptameric	   ring	   as	   the	   oligomer	   that	   binds	   AAVS1	   and	   the	  
assembly	   of	   this	   complex	   required	   the	   OBD,	   the	   linker	   and	   the	   helicase	   domain.	  
Furthermore,	   the	   X-­‐ray	   structure	   of	   Rep68	   bound	   to	   the	   AAVS1	   RBS-­‐TRS	   site	  
provides	   insights	   into	   the	   mechanism	   of	   AAVS1	   DNA	   recognition	   by	   Rep68*	  
(Musayev	  et	  al.	  2015b).	  
	  
Figure	  15:	  A	  model	  of	  the	  dynamic	  oligomerisation	  of	  Rep68.	  	  
A	  model	  of	   the	  dynamic	  oligomeric	  properties	  of	  Rep68*.	  A	  model	   for	   full-­‐length	  Rep68	  was	  built	  
from	  available	  structures	  of	  the	  OBD	  (dark	  blue)	  and	  helicase	  domain	  (blue)	  and	  a	  modelled	  flexible	  
C-­‐terminal	  tail.	  The	  model	  is	  based	  on	  a	  systematic	  analysis	  of	  the	  oligomeric	  behaviour	  of	  Rep68*	  
by	  analytical	  ultracentrifugation.	  Rep68*	  was	  shown	  to	  shift	  from	  a	  monomer-­‐dimer	  equilibrium	  at	  
low	   concentrations	   to	   the	   formation	   of	   large	   oligomeric	   rings,	   through	   intermediate	   trimeric	   and	  
tetrameric	  complexes.	  Adapted	  from	  (Zarate-­‐Perez	  et	  al.	  2013).	  
	  
	   90	  
Identifying	  the	  determinants	  of	  Rep	  oligomerisation	  is	  key	  to	  our	  understanding	  
of	   the	   assembly	   of	   Rep	   complexes	   on	   the	   relevant	   DNA	   substrates	   and	   their	  
mechanism	  of	  action.	  The	  analysis	  of	  the	  oligomeric	  interface	  formed	  by	  SV40-­‐LTag	  
and	   PV-­‐E1	   revealed	   a	   crucial	   role	   of	   the	   OD	   in	   stabilising	   the	   hexamers	   that	   are	  
formed	  by	  these	  proteins	  (Titolo	  et	  al.	  2000;	  Gai	  et	  al.	  2004;	  Weisshart	  et	  al.	  2004).	  
In	  Rep40,	  the	  OD	  is	  significantly	  shorter	  and	  the	  available	  surface	  is	  not	  sufficient	  to	  
stably	  oligomerise.	  We	  have	  shown	  that	  part	  of	  the	  interdomain	  linker	  of	  Rep	  is	  in	  
fact	  an	  extension	  of	  the	  OD	  and	  promotes	  oligomerisation	  even	  in	  the	  absence	  of	  
DNA.	   Secondary	   structure	   prediction	   shows	   that	   the	   C-­‐terminal	   residues	   of	   the	  
linker	  have	  the	  potential	  to	  extend	  the	  first	  helix	  of	  the	  SF3	  helicase	  domain	  of	  Rep.	  
Furthermore,	   substitution	   of	   the	   Rep	   linker	   with	   an	   unrelated	   and	   unstructured	  
linker	   disrupts	   oligomerisation	   (Zarate-­‐Perez	   et	   al.	   2012).	   In	   agreement	   with	   our	  
results,	  a	  recent	  report	  also	  highlighted	  the	  role	  of	  the	  linker	  in	  the	  oligomerisation	  
of	  AAV5	  Rep68	   (Maggin	  et	  al.	  2012).	  These	   results	  confirm	  the	  critical	   role	  of	   the	  
OD	   in	  promoting	  and	  stabilising	   the	  oligomerisation	  of	  SF3	  helicases.	   Importantly,	  
constructs	   of	   SV40-­‐LTag	   and	   PV-­‐E1	   helicase	   domains	   lacking	   the	   OD	   fail	   to	  
oligomerise	  (Titolo	  et	  al.	  2000;	  Gai	  et	  al.	  2004;	  Weisshart	  et	  al.	  2004).	  An	  OD	  that	  
promotes	  dimerisation	  has	  also	  been	  mapped	  to	  the	  region	  that	  connects	  the	  OBD	  
and	   the	   helicase	   domain	   of	   the	   non-­‐structural	   protein	   (NS1)	   of	   MVM,	   another	  
parvovirus.	  Perhaps	  not	  surprisingly,	  some	  proteins	  that	  belong	  to	  the	  HUH	  family	  
of	   endonucleases,	   and	   thus	   are	   evolutionarily	   related	   to	  AAV	  Rep78/68	   and	  NS1,	  
also	  contain	  a	  functional	  oligomerisation	  domain.	  For	  example,	  the	  Rep	  proteins	  of	  
plant	   geminiviruses,	   such	   as	   the	   tomato	   yellow	   leaf	   curl	   virus	   (TYLCV),	   share	   a	  
domain	  architecture	  with	  AAV	  Rep,	  with	  an	  N-­‐terminal	  HUH	  origin-­‐binding	  domain,	  
a	  central	  oligomerisation	  domain	  and	  a	  C-­‐terminal	  SF3	  helicase	  function	  (Fondong	  
2013).	   Another	   example	   is	   the	   RCR	   initiator	   RepB	   protein	   from	   the	   streptococcal	  
plasmid	  pMV158,	  which	  assembles	  as	  a	  hexameric	  complex	  to	  initiate	  plasmid	  DNA	  
replication	  (Boer	  et	  al.	  2009).	  This	  protein	  lacks	  the	  C-­‐terminal	  AAA+	  motor	  domain,	  
but	   contains	   a	   four-­‐helical	   bundle	   OD	   similar	   to	   that	   of	   SF3	   helicases	   located	   C-­‐
terminally	  to	  a	  HUH	  endonuclease	  domain.	  
AAV	   Rep	   residue	   Y224,	   the	   last	   AA	   before	   the	   start	   codon	   of	   the	  monomeric	  
Rep52/40,	  plays	  a	  critical	   role	   in	  Rep68	  oligomerisation.	  Strikingly,	  Rep	  containing	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the	  Y224A	  mutation	  is	  unable	  to	  support	  the	  production	  of	  infectious	  AAV	  vectors.	  
While	   this	  phenotype	  can	  be	  attributed	   to	  a	  defective	  oligomerisation	  of	   the	  Rep	  
proteins,	   it	   is	   at	   present	   unclear	  which	   enzymatic	   activities	   are	   actually	   affected.	  
Importantly,	   a	   more	   conservative	   mutation,	   Y224F,	   was	   previously	   identified	   as	  
defective	  in	  ITR	  DNA	  binding	  as	  well	  as	  endonuclease,	  ATPase	  and	  helicase	  activities	  
(Walker	  et	  al.	  1997a).	  Because	  Y224	  is	  not	  part	  of	  any	  of	  the	  enzymatic	  sites	  of	  Rep,	  
these	  results	  suggest	  that	  Rep	  oligomerisation	  is	  important	  in	  all	  of	  these	  functions.	  
The	   importance	   of	   this	   residue	   is	   also	   highlighted	   by	   the	   fact	   that	   its	   aromatic	  
character	  appears	  to	  be	  conserved	  in	  non-­‐structural	  proteins	  of	  other	  parvoviruses,	  
in	  SF3	  helicases,	  as	  well	  as	  in	  the	  prokaryotic	  RepB	  protein	  (Figure	  14A).	  	  
It	  is	  remarkable	  that	  AAV	  appears	  to	  have	  evolved	  two	  sets	  of	  Rep	  proteins	  that	  
are	   functional	   helicases	   by	   virtue	   of	   a	   shared	   helicase	   domain	   but	   differ	   in	   their	  
ability	  to	  oligomerise.	  The	  small	  Rep	  proteins	  Rep52	  and	  Rep40,	  generated	  from	  the	  
p19	  promoter,	  are	  monomeric	  due	  to	  their	  truncated	  OD,	  and	  only	  transiently	  form	  
a	  dimer	  required	  for	  ATP	  hydrolysis	  (Dignam	  et	  al.	  2007b;	  Zarate-­‐Perez	  et	  al.	  2012).	  
Intriguingly,	   the	   last	   base	   pair	   before	   the	   start	   codon	  of	   Rep52/40	   encodes	   for	   a	  
conserved	   tyrosine	   residue	   that	   plays	   a	   crucial	   role	   in	   the	   oligomerisation	   of	  
Rep78/68	   and	  more	   generally	   in	   the	  AAV	   life	   cycle.	   Based	   on	   the	   oligomeric	   and	  
functional	  differences	  between	  the	  large	  and	  the	  small	  Rep	  proteins,	  we	  speculate	  
that	  AAV	  may	  utilise	  a	  single	  AAA+	  helicase	  domain	  for	  two	  distinct	  mechanisms	  of	  
unwinding.	   The	  mechanism	   of	   translocation	   by	   the	   transiently	   dimeric	   small	   Rep	  
proteins	   could	   be	   more	   similar	   to	   that	   of	   dimeric	   helicases,	   implying	   either	   an	  
inchworm	   mechanism	   or	   rolling	   mechanism	   of	   translocation	   (Patel	   and	   Donmez	  
2006).	   The	   large	   Rep	   proteins,	   on	   the	   other	   hand,	   may	   function	   as	   classic	  
multimeric	  helicases	   like	  other	  SF3	  helicases	   (Enemark	  and	   Joshua-­‐Tor	  2006).	  The	  
process	  of	  DNA	  packaging	  mediated	  by	   the	  small	  Rep	  proteins,	  however,	   remains	  
elusive,	   and	   it	   is	   plausible	   that	   multimerisation	   of	   these	   proteins	   is	   induced	   by	  
interaction	  with	  the	  capsid	  proteins.	  
The	   results	   presented	   in	   this	   chapter	   describe	   how	   we	   have	   identified	   and	  
addressed	   the	   causes	   of	   Rep68	   aggregation	   that	  was	   hindering	   further	   structural	  
studies	   of	   this	   remarkably	   multi-­‐functional	   protein.	   Cysteine	   residue	   C151	   was	  
found	  to	  be	  critical	  for	  the	  formation	  of	  intermolecular	  disulphide	  bonds	  that	  cause	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Rep68	   aggregation,	   and	   its	   mutation	   to	   serine	   prevents	   the	   formation	   of	  
aggregates.	   In	   addition,	   we	   demonstrated	   that	   the	   C151S	   mutant	   of	   Rep68	   (or	  
Rep68*)	  is	  functionally	  equivalent	  to	  Rep68	  WT.	  Rep68*	  is	  proving	  a	  useful	  tool	  that	  
can	  be	  used	  to	  improve	  our	  understanding	  of	  Rep68	  structural	  biology.	  Apo-­‐Rep68*	  
was	   shown	   to	   have	   a	   dynamic	   and	   concentration-­‐dependent	   oligomerisation,	  
supporting	  previous	  reports	  that	  showed	  that	  Rep68	  can	  form	  different	  oligomeric	  
complexes	   in	   the	  presence	  of	   different	  DNA	   substrates	   (Li	   et	   al.	   2003b;	  Mansilla-­‐
Soto	  et	  al.	  2009).	  Furthermore,	  in	  our	  investigations	  of	  the	  structural	  determinants	  
of	  Rep68	  oligomerisation	  we	  identified	  a	  functional	  OD	  in	  Rep68	  that	  includes	  part	  
of	  the	  interdomain	  linker	  and	  is	  sufficient	  to	  initiate	  oligomerisation	  of	  the	  OBD	  and	  
the	  helicase	  domain,	  which	  are	  otherwise	  monomeric.	  We	  described	  how	  the	  linker	  
residue	   Y224,	   conserved	   in	   parvoviral	   non-­‐structural	   proteins	   and	   SF3	   helicases,	  
plays	   a	   critical	   role	   in	   oligomerisation	   and,	  more	   generally,	   in	   the	   AAV	   life	   cycle.	  
Further	   investigations	   of	   the	   oligomeric	   behaviour	   of	   Rep	   could	   thus	   provide	  
insightful	   information	   into	   the	   mechanisms	   underlying	   the	   multiple	   functions	   of	  
Rep	   during	   the	  AAV	   life	   cycle.	   The	   next	   step	  will	   be	   to	   investigate	   the	   functional	  
importance	  of	  the	  oligomeric	  interfaces	  formed	  between	  Rep68	  molecules	  and	  how	  
these	  interfaces	  contribute	  to	  the	  dynamic	  oligomerisation	  of	  Rep68.	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CHAPTER	  5: IDENTIFICATION	  OF	  AN	  OLIGOMERIC	   INTERFACE	  
ESSENTIAL	  FOR	  AAV	  REP	  FUNCTIONS	  
	  
A	   manuscript	   based	   on	   the	   findings	   presented	   in	   this	   chapter	   is	   currently	   in	  
preparation	  (see	  Annex	  2,	  p.	  162).	  This	  work	  combines	  structural	  findings	  from	  the	  
laboratory	   of	   Dr	   Carlos	   Escalante	   with	   our	   thorough	   functional	   study	   on	   the	  
consequences	   of	   disrupting	   potential	   oligomeric	   interfaces.	   Where	   necessary	   to	  
ensure	   that	   the	   implications	  of	  our	   findings	  are	  clear	   to	   the	   reader,	   contributions	  
from	  Dr	  Escalante’s	  lab	  are	  included	  and	  clearly	  indicated	  in	  the	  figure	  legends.	  
5.1 INTRODUCTION	  
In	  the	  previous	  chapter,	  I	  have	  described	  how	  we	  addressed	  the	  problem	  of	  AAV	  
Rep	   aggregation	   that	   was	   hindering	   further	   structural	   studies	   of	   these	   intriguing	  
viral	  proteins.	  The	  discovery	  of	  a	  Rep	  mutant	  (Rep68*)	  that	  did	  not	  aggregate	  even	  
at	   high	   concentrations	   and	   was	   fully	   functional	   allowed	   a	   meticulous	  
characterisation	   of	   the	   oligomeric	   behaviour	   of	   apo-­‐Rep68	   (Zarate-­‐Perez	   et	   al.	  
2013).	   The	   result	   is	   a	   complex	   and	   dynamic	   model	   of	   Rep68	   oligomerisation,	  
supporting	   the	   idea,	   initially	   introduced	   by	   Muzyczka	   and	   colleagues	   (Li	   et	   al.	  
2003b),	  that	  Rep78/68	  can	  adopt	  different	  oligomeric	  states	  depending	  on	  the	  DNA	  
substrate	   encountered,	   the	   presence	   of	   nucleotides,	   and	   the	   concentration	   of	  
Rep78/68.	  The	  discovery	  that	  the	  interdomain	  linker	  of	  AAV	  Rep	  plays	  a	  crucial	  role	  
in	  oligomerisation	  by	  providing	  part	  of	  the	  OD	  is	  an	  initial	  insight	  into	  the	  structural	  
requirements	   for	   the	   functional	   oligomerisation	   of	   Rep	   proteins	   and	   provides	   a	  
structural	   explanation	   for	   the	   observed	   lack	   of	   oligomerisation	   of	   the	   small	   Rep	  
proteins.	  Moreover,	   it	   suggests	   important	   similarities	   between	   AAV	   Rep	   proteins	  
and	   related	   SF3	   helicases	   or	   HUH	   endonucleases	   proteins	   in	   terms	   of	  
oligomerisation.	  	  
Identifying	   the	   protein-­‐protein	   interfaces	   formed	   in	   specific	   oligomeric	  
complexes	  would	   allow	   a	   better	   structural	   and	  mechanistic	   understanding	   of	   the	  
enzymatic	   properties	   of	   the	   AAV	   Rep	   proteins.	   For	   example,	   SV40-­‐LTag	   mutants	  
that	   form	  hexamers	  but	   fail	   to	   form	  stable	  double	  hexamers	  have	  been	  shown	  to	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perform	  well	   in	  a	   series	  of	   in	  vitro	  assays	  measuring	  DNA	  binding	  and	  unwinding,	  
but	   fail	   to	   support	   viral	   replication,	   and	   have	   proved	   valuable	   in	   defining	   the	  
bidirectional	   steps	   of	   SV40	   replication	   (Weisshart	   et	   al.	   1999).	   However	   very	   few	  
studies	  have	  addressed	  the	  consequences	  of	  mutations	  in	  AAV	  Rep	  in	  the	  context	  of	  
oligomerisation.	   These	   studies	   identified	   the	   C-­‐terminal	   region	   of	   Rep,	   as	  well	   as	  
short	  internal	  deletions	  of	  residues	  151-­‐188	  and	  residues	  334-­‐347,	  as	  important	  for	  
oligomerisation	   (Weitzman	   et	   al.	   1996;	   Hermonat	   and	   Batchu	   1997;	   Smith	   et	   al.	  
1997).	  The	  picture	  is	  complicated	  by	  the	  difficulty	  of	  distinguishing	  between	  defects	  
in	  specific	  enzymatic	  functions	  and	  defects	  in	  oligomerisation	  that	  indirectly	  affect	  
those	  functions.	  For	  this	  reason,	   it	   is	  possible	  that	  some	  studies	  on	  the	  functional	  
consequences	   of	   Rep	  mutations	   have	   identified	  non-­‐functional	  mutants	   defective	  
for	  oligomerisation	  without	  knowing	  it.	  Mutants	  that	  fall	   in	  this	  category	  are	  likely	  
to	  be	  Rep78/68	  mutants	  that	  are	  defective	  in	  RBS	  binding,	  TRS	  nicking	  and	  helicase	  
activity,	   such	   as	   the	   Y224F	   mutant	   (Walker	   et	   al.	   1997b)	   or	   the	   P415H	   mutant	  
(McCarty	  et	  al.	  1992).	  Misfolded	  or	  degraded	  proteins,	  however,	  could	  also	  explain	  
a	   completely	   inactive	   Rep78/68	  mutant.	   Furthermore,	  mutations	   that	   affect	  DNA	  
binding	   interfaces,	   such	   as	   the	   K136A	   and	   R138A	   Rep78	   mutants	   identified	   by	  
Urabe	  et	  al.	  (Urabe	  et	  al.	  1999),	  could	  also	  affect	  oligomerisation,	  despite	  not	  being	  
directly	   involved	   in	   the	   formation	   of	   oligomeric	   interfaces.	   Confirming	   this	  
possibility,	  mutation	  of	  residue	  R107,	  which	  was	   initially	   identified	  as	  essential	  for	  
DNA	  binding	   (Urabe	  et	   al.	   1999),	  was	   later	   shown	   to	   also	  disrupt	  oligomerisation	  
(Mansilla-­‐Soto	  et	  al.	  2009).	  	  
In	  this	  chapter,	  we	  take	  advantage	  of	  the	  possibility	  to	  use	  Rep68*	  to	  study	  the	  
oligomeric	  properties	  of	  Rep	  in	  the	  absence	  of	  DNA	  to	  identify	  Rep	  oligomerisation	  
mutants	   independently	   of	   DNA	   binding.	   Nevertheless,	   we	   anticipate	   that	  
oligomerisation-­‐deficient	   mutants	   will	   also	   fail	   to	   bind	   DNA.	   Furthermore,	   an	  
additional	  goal	  of	  this	  study	  was	  to	  begin	  defining	  the	  oligomerisation	  requirements	  
for	   specific	   enzymatic	   functions	   of	   Rep	   by	   discovering	   residues	   that	   are	   part	   of	  
oligomeric	  interfaces	  but	  that	  do	  not	  affect	  the	  catalytic	  folds	  of	  the	  proteins.	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5.2 RESULTS	  
5.2.1 Identification	  of	  potential	  oligomeric	  interfaces	  formed	  by	  AAV	  Rep	  
To	   identify	   potential	   functionally	   relevant	   Rep-­‐Rep	   interfaces,	   we	   used	   two	  
approaches.	  The	  first	   interface	  we	  decided	  to	   investigate	   is	  based	  on	  a	  Rep	  dimer	  
modelled	  using	  the	  available	  structure	  of	  the	  C-­‐terminal	  helicase	  domain	  extended	  
as	  an	  α-­‐helix	  to	  nucleotide	  217	  to	  mimic	  the	  PV-­‐E1	  dimer	  interface	  (Figure	  16A).	  A	  
closer	   analysis	   of	   this	   Rep-­‐Rep	   interface	   reveals	   that	   the	   conserved	   aromatic	  
residue	  Y224,	  which	  is	  part	  of	  the	  OD	  and	  plays	  a	  crucial	  role	  in	  oligomerisation	  (see	  
Chapter	  4),	  is	  an	  important	  component	  of	  this	  interface.	  Y224	  is	  participating	  in	  the	  
oligomeric	   interface	   by	   forming	   hydrophobic	   interactions	   with	   the	   isoleucine	  
residue	  I251	  and	  an	  hydrogen	  bond	  with	  the	  main	  chain	  carbonyl	  oxygen	  of	  Asn254	  
in	  the	  neighbouring	  Rep	  molecule	  (Figure	  16B).	  	  
	  
	  
Figure	  16:	  Identification	  of	  Rep-­‐Rep	  interfaces.	  	  
(A)	   A	   Rep-­‐Rep	   dimer	   was	   modelled	   based	   on	   the	   described	   PV-­‐E1	   dimer.	   One	   Rep	   monomer	   is	  
depicted	  in	  green,	  the	  other	  in	  cyan.	  Residues	  that	  participate	  to	  the	  interface	  are	  highlighted	  in	  red	  
and	   magenta,	   respectively.	   (B)	   Close-­‐up	   on	   the	   interactions	   formed	   by	   the	   conserved	   aromatic	  
residue	  Y224	  within	  the	  modelled	  oligomeric	  interface.	  These	  interactions	  include	  the	  formation	  of	  a	  
hydrogen	   bond	  with	   the	  main	   chain	   carbonyl	   oxygen	   of	   N254	   and	   hydrophobic	   interactions	  with	  
I251A.	  (C)	  The	  formation	  of	  an	  OBD-­‐OBD	  dimer	  was	  reported	  in	  the	  crystallisation	  studies	  of	  AAV5	  
and	  AAV2	  Rep	  OBD.	  (D)	  Close-­‐up	  on	  the	  interface	  observed	  in	  crystallography	  studies.	  Residues	  L193	  
and	  V196	  contribute	  to	  both	  sides	  of	  the	  hydrophobic	  interface.	  Figure	  courtesy	  of	  C.	  Escalante.	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The	  second	  interface	  is	  the	  result	  of	  the	  crystallography	  studies	  of	  the	  Rep	  OBD	  
from	  AAV2	  (Musayev	  et	  al.	  2015a).	  Two	  of	  three	  OBD	  molecules	  in	  the	  asymmetric	  
unit	  consistently	  form	  a	  dimer	  through	  interactions	  between	  the	  long	  C-­‐terminal	  α-­‐
helix	   (α-­‐helix	  F),	   resembling	  a	  pseudo-­‐coiled	  coil	   interaction	  (Figure	  16C	  and	  D).	  A	  
similar	   interface	  was	   also	   observed	   in	   structural	   studies	   of	   the	  AAV5	  Rep	  OBD	   in	  
complex	  with	  RBS	  DNA	  (Hickman	  et	  al.	  2004).	  In	  AAV2,	  the	  residues	  involved	  in	  the	  
formation	   of	   this	   interface	   include	   residues	   L193	   and	   V196	   making	   hydrophobic	  
interactions	  and	  residues	  H192	  and	  S197	  forming	  a	  hydrogen	  bond	  (Figure	  16D).	  	  
Based	   on	   these	   observations,	   we	   designed	   a	   series	   of	   mutants	   to	   test	   the	  
relevance	  of	  these	  two	  interfaces	  for	  Rep	  functions	  during	  the	  AAV	  life	  cycle.	  While	  
we	  have	  shown	  previously	  that	  the	  mutant	  Rep68-­‐Y224A	  fails	  to	  oligomerise	  in	  vitro	  
and	  that	  it	  cannot	  support	  the	  production	  of	  infectious	  AAV	  particles	  (see	  Chapter	  
3),	  we	   have	   not	   determined	  what	   the	   consequences	   of	   this	  mutation	   are	   on	   the	  
diverse	   functions	  of	  Rep.	   In	  addition	  to	  Y224A,	  we	  have	  also	  tested	  the	   impact	  of	  
the	  more	  conservative	  Y224F	  mutation.	  This	  mutation	  maintains	  the	  evolutionarily	  
conserved	   aromatic	   character	   of	   this	   amino	   acid,	   but	   was	   shown	   previously	   to	  
affect	  Rep	   functions,	   including	  DNA	  binding,	  nicking	  and	  unwinding	   (Walker	  et	  al.	  
1997a).	   We	   have	   also	   assessed	   the	   consequences	   of	   mutating	   the	   residue	   I251	  
(alone	  or	  in	  combination	  with	  Y224)	  to	  alanine.	  Finally,	  we	  have	  tested	  the	  double	  
mutant	   L193A-­‐V196A,	   which	   is	   part	   of	   the	   interface	   observed	   in	   crystallographic	  
studies	  of	  Rep	  OBD.	  Importantly,	  all	  the	  mutants	  that	  we	  have	  selected	  are	  not	  part	  
of	  the	  known	  enzymatic	  folds	  of	  Rep.	  
5.2.2 Consequences	  of	  mutations	  on	  the	  oligomerisation	  of	  Rep68*	  
We	   first	   studied	   the	   oligomeric	   behaviour	   of	   Rep68*-­‐Y224A,	   Rep68*-­‐Y224F,	  
Rep68*-­‐I251A,	   Rep68*-­‐YI	   (Y224A-­‐I251A)	   and	   Rep68*-­‐LV	   (L193A-­‐V196A)	   by	  
analytical	   ultracentrifugation.	   Figure	   17	   shows	   the	   sedimentation	   profiles	   of	  
Rep68*	   and	   the	   oligomerisation	   interface	   mutants.	   Confirming	   our	   previous	  
observations	   (see	   Chapter	   3),	   Rep68*-­‐Y224A	   does	   not	   form	   the	   large	   complexes	  
described	  for	  Rep68*	  (Zarate-­‐Perez	  et	  al.	  2013)	  and	  only	  forms	  small	  intermediate	  
complexes.	   Rep68*-­‐Y224F,	   on	   the	   other	   hand,	   seems	   to	   be	   able	   to	   form	   larger	  
oligomeric	  complexes,	  although	  not	  to	  the	  same	  extent	  as	  Rep68*.	  Both	  the	  single	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mutant	  Rep68*-­‐I251A	  and	  the	  double	  mutant	  Rep68*-­‐YI	  are	  mostly	  monomeric	  and	  
fail	   to	   oligomerise	   under	   our	   experimental	   conditions.	   Finally,	   the	   oligomeric	  
properties	   of	   the	   Rep68*-­‐LV	   mutant,	   containing	   mutations	   in	   the	   interface	  
observed	  in	  crystallography	  studies,	  are	  comparable	  to	  Rep68*.	  	  
	  
	  
Figure	  17:	  Sedimentation	  velocity	  analysis	  of	  the	  oligomeric	  properties	  of	  interface	  mutants.	  	  
The	   interface	   mutants	   identified	   in	   Figure	   16	   were	   assessed	   for	   their	   ability	   to	   oligomerise	   by	  
analytical	  ultracentrifugation.	  Courtesy	  of	  C.	  Escalante.	  
	  
5.2.3 Oligomerisation-­‐deficient	  mutants	  fail	  to	  support	  the	  AAV	  life	  cycle	  
In	  view	  of	  their	  oligomerisation	  properties,	  we	  then	  sought	  to	  assess	  the	  ability	  
of	  these	  mutants	  to	  support	  the	  AAV	  life	  cycle.	  First,	  we	  tested	  the	  performance	  of	  
the	  oligomerisation	  mutants	   in	  producing	   infectious	  AAV-­‐GFP	  particles.	  This	  assay	  
allows	   for	   a	   very	   general	   assessment	   of	   the	   ability	   of	   Rep	   (and	   potentially	   Cap)	  
mutants	   to	   support	   the	   production	   of	   AAV	   vectors	   (AAV2-­‐GFP	   in	   this	   case	   as	   it	  
provides	   an	   easy	   readout)	   and	   thus	   to	   support	   the	   viral	   life	   cycle.	  Defects	   in	   any	  
step	   of	   the	   AAV	   life	   cycle,	   including	   viral	   DNA	   replication,	   packaging,	   and	   virus	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release	   will	   be	   detected	   by	   a	   reduction	   in	   the	   amounts	   of	   infectious	   particles	  
produced.	   However,	   the	   readout	   of	   this	   assay	   does	   not	   provide	   information	   on	  
which	  stage	  of	  the	  life	  cycle	  is	  not	  supported	  by	  the	  mutants.	  As	  a	  negative	  control,	  
we	  used	  the	  NTP-­‐binding	  mutant	  K340H,	  which	  has	  been	  shown	  to	  be	  deficient	  for	  
ATPase	  and	  helicase	  activities	  and	  does	  not	  support	  AAV	  replication,	  but	  is	  still	  able	  
to	   oligomerise	   (Chejanovsky	   and	   Carter	   1990;	   Owens	   et	   al.	   1991;	   Kyostio	   and	  
Owens	  1996;	  Smith	  et	  al.	  1997).	   Figure	  18A	  shows	   that,	  not	   surprisingly,	  mutants	  
defective	  in	  oligomerisation	  are	  also	  unable	  to	  produce	  infectious	  AAV	  particles.	  As	  
described	  in	  Chapter	  3,	  the	  Y224A	  Rep	  mutant	  does	  not	  support	  the	  production	  of	  
infectious	  AAV-­‐GFP	  particles.	  The	  monomeric	  I251A	  and	  Y224A-­‐I251A	  mutants	  also	  
fail	  to	  produce	  viral	  particles.	  The	  more	  conservative	  mutation	  Y224F,	  which	  retains	  
some	   potential	   to	   oligomerise,	   is	   severely	   impaired	   but	   not	   entirely	   deficient	   in	  
producing	   infectious	   AAV.	   The	   double	   mutant	   L193A-­‐V196A,	   on	   the	   other	   hand,	  
supports	  the	  production	  of	  infectious	  AAV-­‐GFP	  to	  levels	  comparable	  to	  WT	  Rep	  and	  
Rep68*	  (Figure	  18A).	  
We	   then	   assessed	   the	   ability	   of	   the	  mutants	   to	   support	   AAV	   replication	   using	  
two	  different	  assays.	  First,	  we	  quantified	  the	  total	  viral	  DNA	  present	  in	  the	  cells	  by	  
qPCR	  (Figure	  18B).	  The	  readout	  of	  this	  assay	  is	  the	  extent	  of	  AAV	  DNA	  amplification	  
from	   the	   input	   plasmid	  DNA	  by	  Rep-­‐mediated	   replication.	  We	   also	   isolated	   small	  
molecular	  weight	  DNA	  by	  a	  modified	  Hirt	  extract	  procedure	  to	  study	  the	  replicative	  
intermediates	   formed	   during	  AAV	   replication	   (Figure	   18C).	   The	   interface	  mutants	  
Y224A,	   I251A	  and	   the	  double	  mutant	   Y224A-­‐I251A	  all	   failed	   to	   support	  AAV	  DNA	  
replication	   in	  both	  assays.	  Similarly	  to	  what	  we	  observed	  in	  the	   infectious	  particle	  
production	   assay,	   the	   Y224F	   mutant	   supported	   limited	   AAV	   replication	   in	   the	  
presence	  of	  the	  helper	  adenovirus,	  while	  the	  L193A-­‐V196A	  double	  mutant	  appears	  
to	  efficiently	   replicate	  AAV	  DNA.	   In	  all	   cases	  where	  we	  observed	  DNA	  replication,	  
the	   relative	   levels	   of	   monomeric	   and	   dimeric	   replicative	   intermediates	   were	  
comparable	   (Figure	   18C).	   The	   low	   level	   replication	   observed	   in	   the	   absence	   of	  
adenovirus	  is	  due	  to	  the	  presence	  of	  the	  adenoviral	  E1A	  and	  E1B	  proteins	  in	  293T	  
cells	   (Graham	   et	   al.	   1977).	   Thus,	   it	   appears	   that	   the	   defects	   we	   observed	   in	   the	  
production	   of	   infectious	   viral	   particles	   (Figure	   18A)	   are	   caused	   by	   the	   lack	   of	  
replication	  of	  viral	  DNA.	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Figure	  18:	  Oligomerisation-­‐deficient	  mutants	  do	  not	  support	  the	  viral	  life	  cycle.	  	  
(A)	   The	   ability	   of	   the	   Rep68	   interface	   mutants	   to	   support	   the	   AAV	   life	   cycle	   was	   assessed	   by	  
producing	   rAAV2-­‐GFP	   in	   presence	   of	   WT	   or	   mutant	   Rep68.	   Increasing	   volumes	   of	   supernatant	  
collected	  from	  the	  producers	  cells	  was	  used	  to	  infect	  Hela	  cells.	  Data	  is	  presented	  as	  mean	  ±	  s.e.m.	  
from	   three	   independent	   experiments.	   (B)	   AAV	   replication	   in	   presence	   of	   either	   Rep	   WT	   or	   the	  
interface	   mutants	   was	   assessed	   by	   quantification	   of	   the	   amount	   of	   AAV	   DNA	   in	   293T	   cells	   in	  
presence	   of	   helper	   virus.	   (C)	   AAV	   replication	   was	   also	   assessed	   by	   analysing	   the	   formation	   of	  
replicative	  intermediates	  in	  293T	  cells	  in	  presence	  of	  helper	  virus.	  Left:	  Southern	  blot	  probed	  with	  a	  
radiolabelled	  ampicillin	  probe	   to	   control	   for	   the	  digestion	  of	   input	  AAV	  DNA.	  Right,	   Southern	  blot	  
probed	  with	  a	  radiolabelled	  Rep	  probe	  that	  detects	  replicated	  AAV	  DNA.	  
	  
Taken	   together,	   these	   results	   suggest	   that	   oligomerisation	   of	   Rep	   proteins	   is	  
essential	   for	   the	   efficient	   replication	   of	   AAV	   DNA	   and	   thus	   the	   production	   of	  
infectious	   virus.	   This	   data,	   however,	   does	   not	   exclude	   the	   possibility	   that	   Rep	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oligomerisation	  may	  be	   important	   for	   the	   packaging	   of	   viral	  DNA	   into	   preformed	  
capsids.	  
5.2.4 The	  mutant	  Rep	  proteins	  are	  stable	  and	  localise	  to	  the	  nucleus	  
To	  exclude	  that	  the	  observed	  failure	  of	  the	  oligomerisation	  interface	  mutants	  to	  
support	   AAV	   replication	   is	   due	   to	   a	  misfolded	   or	   unstable	   protein	   that	   is	   rapidly	  
degraded,	  we	  analysed	  all	  mutants	  by	  western	  blot.	   In	  addition,	  we	  verified	   if	   the	  
mutant	  proteins	  were	  able	  to	  translocate	  to	  the	  nucleus.	  Figure	  19A	  shows	  that	  all	  
mutants	   are	   expressed	   to	   similar	   levels	   48h	   after	   transfection	   in	   293T	   cells,	  
suggesting	  that	  instability	  of	  the	  mutant	  proteins	  is	  not	  the	  cause	  of	  the	  observed	  
lack	   of	   AAV	   replication.	   Similarly,	   all	   mutants	   show	   the	   expected	   nuclear	  




Figure	  19:	  The	  interface	  mutants	  are	  stable	  and	  localise	  to	  the	  nucleus.	  	  
(A)	  Rep68	  WT	  or	  mutant	  was	  transfected	  in	  293T	  cells	  and	  was	  tested	  for	  protein	  expression	  levels	  
by	  western	  blot	  36h	  post-­‐transfection.	   (B)	  293T	  cells	   transfected	  with	  Rep68	  WT	  or	  mutants	  were	  
transfected	   and	   the	   Rep68	   protein	   localisation	   was	   assessed	   48h	   post-­‐transfection	   by	  
immunostaining	  (green).	  The	  nuclei	  are	  stained	  in	  blue.	  
	   101	  
5.2.5 Oligomerisation	  is	  required	  for	  DNA	  binding	  and	  nicking	  
In	   order	   to	   establish	   the	   cause	   of	   the	   observed	   phenotype	   of	   the	  
oligomerisation-­‐deficient	  mutants,	  we	  assessed	  their	  biochemical	  activities	  in	  vitro.	  
Rep	  has	   three	  well-­‐characterised	  enzymatic	   functions	  –	  RBS-­‐specific	  DNA	  binding,	  
TRS	   nicking	   and	   ATP-­‐dependent	   DNA	   unwinding	   –	   all	   of	   which	   are	   necessary	   for	  
AAV	  DNA	  replication.	  Table	  1	  shows	  the	  binding	  constants	  of	  Rep68*	  and	  mutant	  
Rep	  proteins	  on	  p5	  and	  AAVS1	  RBS-­‐containing	  dsDNA	  substrates	  as	  determined	  by	  
fluorescence	  anisotropy	  DNA	  binding	  assay.	  Rep68*,	  Rep68*-­‐Y224F	  and	  the	  control	  
Rep68*-­‐K340H	  all	  appear	  to	  bind	  both	  DNA	  substrates	  efficiently.	  Rep68*-­‐LV	  binds	  
the	   RBS-­‐containing	   DNA	   slightly	   less	   efficiently	   than	  WT,	   perhaps	   explaining	   the	  
slightly	   lower	  levels	  of	  DNA	  replication	  observed	  (Figure	  18B	  and	  C).	  We	  were	  not	  
able	  to	  detect	  any	  binding	  for	  the	  other	  mutant	  Rep	  proteins,	  with	  the	  exception	  of	  
Rep68*-­‐I251A,	   which	   binds	   AAVS1	   DNA	   with	   10-­‐fold	   lower	   affinity	   than	   its	   WT	  
counterpart.	  
	  
Protein	   AAVS1-­‐41	  [nM]	   p5-­‐41	  [nM]	  
Rep68*	   128	   203	  
Rep68*-­‐K340H	   123	   136	  
Rep68*-­‐Y224A	   nd*	   nd*	  
Rep68*-­‐Y224F	   221	   311	  
Rep68*-­‐I251A	   1438	   nd*	  
Rep68*-­‐YI	   nd*	   nd*	  
Rep68*-­‐LV	   281.3	   795.5	  
Table	  1:	  Oligomerisation-­‐deficient	  mutants	  do	  not	  bind	  RBS-­‐containing	  DNA	  substrates.	  	  
Two	  RBS-­‐containing	  DNA	  substrates,	  one	  derived	  from	  AAVS1	  and	  the	  other	  from	  the	  p5	  promoter,	  
were	   used	   to	   calculate	   the	   DNA	   binding	   constants	   of	   Rep68*	   and	   interface	   mutants.	   Nd*:	   not	  
determined.	  Courtesy	  of	  C.	  Escalante.	  
	  
We	  then	  analysed	  the	  helicase	  activity	  of	  Rep68*	  and	  mutants	  on	  a	  fluorophore-­‐
labelled	   heteroduplex	   DNA	   substrate,	   which	   allows	   the	   monitoring	   of	   DNA	  
unwinding.	  Surprisingly,	  all	  Rep68	  mutants	  tested	  exhibited	  similar	  helicase	  activity,	  
suggesting	  that	  Rep68	  can	  unwind	  DNA	  under	  our	  experimental	  conditions	  even	  in	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the	   absence	   of	   oligomerisation	   (Figure	   20A).	   Alternatively,	   it	   is	   possible	   that	   a	  
completely	   different	   oligomerisation	   interface	   is	   necessary	   for	   the	   helicase	  
function.	  
Finally,	  we	  assessed	  the	  ability	  of	  the	  mutants	  to	  nick	  a	  supercoiled	  plasmid	  DNA	  
containing	  RBS	  and	  TRS	  sequences	   (Figure	  20B).	  A	  supercoiled	  plasmid	  containing	  
the	  RBS	  and	  TRS	  region	  of	  AAVS1	  was	  previously	  shown	  to	  be	  efficiently	  nicked	  by	  
Rep68	   in	   an	   ATP-­‐dependent	   manner	   (Lamartina	   et	   al.	   2000a),	   in	   a	   reaction	   that	  
closely	  mimics	  the	  terminal	  resolution	  step	  of	  AAV	  replication.	  Nicking	  by	  Rep68	  at	  
the	   TRS	   changes	   the	   plasmid	   conformation	   from	   supercoiled	   to	   open	   circular	  
(Figure	  20B),	   and	   the	   two	  plasmid	   species	   are	   easily	   distinguished	  by	   agarose	   gel	  
electrophoresis.	  Because	  the	  nicking	  reaction	  follows	  the	  binding	  to	  the	  RBS	  site,	  it	  
was	  no	  surprise	  that	  the	  mutants	  that	  failed	  to	  bind	  RBS-­‐containing	  DNA	  also	  failed	  
to	   nick	   the	   plasmid	   DNA	   (Figure	   20C	   and	   D).	   Both	   the	   Rep68*-­‐Y224F	   and	   the	  
Rep68*-­‐LV	   mutants	   were	   able	   to	   bind	   DNA,	   but	   while	   the	   Rep68*-­‐LV	   mutant	  
efficiently	   nicks	   the	   substrate	   Rep68*-­‐Y224F	   showed	   significantly	   lower	   nicking	  
activity	  compared	  to	  Rep68*	  (Figure	  20C	  and	  D).	  This	  reduced	  nicking	  activity	  could	  
explain	   the	   lower	   levels	  of	  AAV	  DNA	   replication	  observed	   for	   this	  mutant	  despite	  
efficient	  RBS-­‐containing	  DNA	  binding.	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Figure	  20:	  Biochemical	  characterisation	  of	  the	  interface	  mutants.	  	  
(A)	  The	  ability	  of	  the	  interface	  mutants	  to	  unwind	  DNA	  was	  assessed	  on	  a	  heteroduplex	  substrate.	  
Courtesy	  of	  C.	  Escalante.	  (B)	  Schematic	  diagram	  of	  the	  mechanism	  behind	  the	  in	  vitro	  nicking	  assay.	  
SC	  plasmid	  is	  mixed	  with	  the	  protein	  of	  interest;	  if	  the	  endonuclease	  activity	  is	  intact	  it	  will	  insert	  a	  
nick	  and	   relax	   the	  plasmid	  conformation	   to	  an	  OC	   form.	  The	  SC	  and	  OC	  plasmid	   forms	  are	   readily	  
separated	   by	   agarose	   gel	   electrophoresis.	   Figure	   courtesy	   of	   Leticia	   Agundez.	   (C)	   Representative	  
example	   of	   the	   readout	   of	   this	   nicking	   assay.	   pUC18-­‐TRSwt:	   pUC18-­‐based	   plasmid	   containing	   the	  
AAVS1	  sequences,	  including	  the	  RBS	  and	  TRS	  sites,	  that	  is	  readily	  nicked	  by	  Rep68.	  pUC18-­‐TRSmut:	  
this	  plasmid	  is	  identical	  to	  the	  nicking	  substrate	  pUC18-­‐TRSwt	  except	  for	  a	  mutation	  in	  the	  TRS	  site	  
that	   prevents	   nicking	   by	   Rep68.	   (D)	   Quantification	   of	   three	   independent	   experiments.	   Data	  
presented	  as	  mean	  ±	  s.e.m.	  
	  
5.2.6 Rep	  oligomerisation	  is	  important	  for	  transcriptional	  regulation	  
The	  dominant-­‐negative	  mutant	  Rep-­‐K340H,	  used	  here	  as	  a	  negative	  control	   for	  
AAV	  replication,	  has	  been	  shown	  to	  fail	  to	  auto-­‐regulate	  the	  levels	  of	  Rep	  proteins	  
and	   to	   overproduce	   Rep	   proteins	   under	   permissive	   conditions	   (Chejanovsky	   and	  
Carter	  1990).	  To	  test	  whether	  oligomerisation	  also	  plays	  a	  role	  in	  the	  regulation	  of	  
the	   levels	   of	   Rep	   proteins,	  we	   extracted	   the	   proteins	   from	   the	   cells	   used	   for	   the	  
replication	  assay	  and	  assessed	  Rep	  proteins	  levels	  by	  immunoblotting.	  We	  observed	  
a	   striking	   increase	   in	   the	   levels	   of	   all	   Rep	   isoforms	   in	   the	   presence	   of	   all	   the	  
oligomerisation-­‐defective	   mutant	   Rep	   proteins,	   as	   well	   as	   the	   control	   K340H	  
mutant	   (Figure	   21A,	  middle	   panel,	   Rep*-­‐Y224A,	   Rep*-­‐I251A,	   Rep*-­‐YI).	   The	   Y224F	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mutant,	  which	  partially	  oligomerises,	  showed	  a	  very	  modest	  increase	  in	  expression,	  
while	   the	   LV	  double	  mutant	   showed	  Rep	   levels	   similar	   to	   the	  WT	  protein	   (Figure	  
21A,	  middle	  panel,	  Rep*-­‐Y224F	  and	  Rep*-­‐LV).	  Interestingly,	  Cap	  protein	  levels	  were	  
the	  exact	  opposite:	  only	  in	  the	  presence	  of	  Rep	  proteins	  that	  support	  the	  AAV	  life	  
cycle	  we	  detected	  high	  Cap	  levels,	  with	  the	  sole	  exception	  being	  the	  K340H	  mutant	  
(Figure	   21A,	   top	   panel).	   The	   same	   trend	  was	   observed	   both	   in	   the	   presence	   and	  
absence	  of	  adenovirus	  infection,	  although	  the	  Cap	  levels	  were	  significantly	  lower	  in	  
the	  absence	  of	  helper	  virus	  (Figure	  21A,	  top	  panel).	  These	  results	  suggest	  that	  the	  
oligomerisation	   mutants	   fail	   to	   regulate	   the	   levels	   of	   expression	   of	   the	   AAV	  
proteins.	  	  
To	  better	  understand	  the	  important	  differences	  in	  protein	  amounts	  we	  assessed	  
the	   levels	  of	   the	  AAV	   transcripts	  by	  RT-­‐PCR	   (Figure	  21B).	  Because	  all	  AAV	  mRNAs	  
use	   the	   same	   polyadenylation	   signal,	   we	   could	   not	   quantify	   the	   p19	   and	   p40	  
transcripts	   separately	   from	   the	   p5	   transcripts	   using	   this	   technique.	   As	   expected,	  
with	  all	  sets	  of	  primers	  used	  (one	  specific	  for	  p5	  transcripts,	  one	  detects	  p5	  and	  p19	  
transcripts	   and	   the	   last	   one	   detects	   all	   known	   AAV	   mRNAs),	   we	   observed	   an	  
increase	  in	  mRNA	  levels	  in	  response	  to	  adenovirus	  in	  the	  presence	  of	  Rep	  proteins	  
that	  support	  AAV	  replication	  (Figure	  21B).	  In	  the	  presence	  of	  the	  Y224F	  mutant,	  the	  
response	  to	  adenovirus	  is	  still	  present,	  but	  is	  nevertheless	  reduced	  compared	  to	  WT	  
Rep.	  The	  oligomerisation-­‐deficient	  mutants	  Y224A,	  I251A,	  and	  Y224A-­‐I251A,	  which	  
are	  also	  unable	   to	  bind	   the	  RBS	  at	   the	  p5	  promoter	   (Table	  1),	  have	  higher	  mRNA	  
levels,	  varying	  between	  2-­‐	  and	  10-­‐fold,	  and	  do	  not	  respond	  to	  adenovirus	  infection.	  
In	  the	  context	  of	  adenovirus	  co-­‐infection,	  however,	  the	  differences	  in	  mRNA	  levels	  
do	  not	   correlate	  with	   those	  of	  protein	   levels,	   suggesting	   that	   some	   level	   of	   post-­‐
transcriptional	  regulation	  is	  complicating	  the	  picture.	  In	  the	  presence	  of	  the	  K340H	  
mutant,	   which	   oligomerises	   but	   fails	   to	   support	   AAV	   replication,	   we	   observed	  
considerably	  higher	  basal	  mRNA	  levels	  compared	  to	  WT	  Rep	  and	  a	  lack	  of	  response	  
to	  adenovirus,	  possibly	  explaining	  the	  high	  Cap	  protein	  amounts	  observed.	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Figure	  21:	  Rep	  oligomerisation	  is	  important	  for	  transcriptional	  regulation.	  	  
(A)	   Protein	   expression	   levels	   during	   permissive	   and	   non	   permissive	   conditions	   were	   assessed	   by	  
transfecting	   an	   infectious	   plasmid	   containing	   the	   full	   AAV	   genome	   in	   293T	   cells.	   The	   expression	  
levels	   of	   the	   viral	   Rep	   and	   Cap	   proteins	  were	   detected	   by	  western	   blot.	   The	   first	   lane	   of	   the	   left	  
panel	   is	  equivalent	  to	  the	  third	   lane	  of	   the	  right	  panel.	  (B)	  Transcription	   levels	  of	  AAV	  genes	  were	  
investigated	   under	   the	   same	   experimental	   conditions.	   P5	   (left	   panel)	   indicates	   that	   the	   data	   is	  
specific	   for	  p5	  transcripts;	  primers	  that	  bind	  after	  p19	  but	  before	  40	  (middle	  panel)	  detect	  mRNAs	  
generated	   from	   both	   p5	   and	   p19	   promoters;	   p40	   primers	   detect	   mRNAs	   from	   all	   three	   viral	  
promoters.	  The	  fold	  change	  was	  calculated	  relative	  to	  the	  mRNA	  levels	  in	  presence	  of	  WT	  Rep	  but	  in	  
absence	  of	  adenovirus.	  Data	  is	  presented	  as	  mean	  ±	  s.e.m,	  N=3.	  
	  
Taken	   together,	   our	   data	   supports	   a	   model	   in	   which	   Rep	   oligomerisation	   is	  
involved	  in	  the	  regulation	  of	  the	  AAV	  promoters,	  potentially	  through	  binding	  at	  the	  
RBS	  in	  the	  p5	  promoter,	  and	  is	  necessary	  to	  achieve	  a	  correct	  transcription	  profile.	  
5.3 DISCUSSION	  
The	  limited	  genome	  capacity	  of	  small	  viruses	  has	  driven	  the	  evolution	  of	  highly	  
multifunctional	   non-­‐structural	   proteins	   that	   combine	   several	   enzymatic	   functions	  
necessary	  to	  support	  the	  viral	  life	  cycle.	  In	  AAV,	  the	  Rep	  proteins	  are	  responsible	  for	  
orchestrating	   the	   whole	   viral	   life	   cycle,	   including	   transcriptional	   regulation,	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replication,	   packaging	   of	   the	   viral	   DNA	   and	   Rep-­‐mediated	   integration.	   The	  
combination	   of	   several	   enzymatic	   functions,	   including	   DNA	   binding,	   nicking	   and	  
unwinding,	   and	   the	   ability	   to	   interact	   with	   a	   multitude	   of	   DNA	   substrates	   and	  
proteins,	  allows	  the	  Rep	  proteins	  to	  support	  the	  productive	  replication	  of	  AAV.	  The	  
coordination	   of	   all	   these	   functions,	   thus,	   needs	   to	   be	   tightly	   controlled.	   We	  
hypothesised	  that	  the	  substrate-­‐dependent	  dynamic	  oligomerisation	  properties	  of	  
AAV	  Rep	   contribute	   to	   the	   regulation	  of	   Rep	   functions.	  While	   it	   is	   clear	   that	   Rep	  
oligomerisation	  is	  functionally	  relevant,	  little	  data	  is	  available	  on	  the	  regions	  of	  Rep	  
that	  contribute	  to	  oligomerisation	  and	  data	  on	  possible	  oligomerisation	   interfaces	  
are	   scarce.	   Initial	   studies	   that	   investigated	   the	   oligomerisation	   determinants	  
identified	  the	  C-­‐terminal	  region	  of	  Rep	  as	  important	  for	  multimerisation	  (Weitzman	  
et	  al.	  1996;	  Hermonat	  and	  Batchu	  1997;	  Smith	  et	  al.	  1997).	   Smith	  and	  colleagues	  
used	   co-­‐immunoprecipitation	   experiments	   to	   identify	   two	   regions	   that,	   when	  
deleted,	  disrupted	  Rep	  oligomerisation:	  residues	  151-­‐188	  forming	  a	  putative	  coiled-­‐
coil	  interaction,	  and	  residues	  334-­‐347	  that	  include	  the	  ATP	  binding	  site	  (Smith	  et	  al.	  
1997).	  Importantly,	  in	  the	  hexamers	  of	  PV-­‐E1	  and	  SV40-­‐LTag	  the	  corresponding	  ATP	  
binding	  pocket	   is	  part	  of	   the	  oligomeric	   interface.	  The	  authors	  of	   this	   study	  went	  
further	  and	  investigated	  how	  the	  point	  mutations	  L156G,	  L180T	  and	  K340H	  affected	  
Rep	  oligomerisation.	   L156G	  showed	  a	  decrease	  but	  not	  a	   complete	  abrogation	  of	  
Rep78-­‐Rep78	  binding,	  while	  the	  other	  mutants	  oligomerised	  normally	  (Smith	  et	  al.	  
1997).	   However,	   Smith	   and	   colleagues	   did	   not	   investigate	   the	   functional	  
consequences	  of	   the	  oligomerisation-­‐disrupting	  deletions	   and	  point	  mutations	  on	  
Rep68.	   Davis	   et	   al.,	   in	   a	   study	   that	   investigated	   the	   effects	   of	   charge	   cluster	  
mutations	   on	   Rep68	   functions,	   described	   several	   mutants	   that	   showed	   reduced	  
oligomerisation	   as	   well	   as	   reduced	   functional	   activities	   (Davis	   et	   al.	   1999).	   The	  
authors	  placed	  particular	  emphasis	  on	  a	  putative	  coiled-­‐coil	  domain	  located	  at	  the	  
C-­‐terminus	  of	  Rep68	  and	  spanning	  residues	  441	  to	  481,	  which	  included	  most	  of	  the	  
mutations	   that	   affected	   oligomerisation.	  More	   recently,	   one	   report	   showed	   that	  
residue	   R107,	   which	   is	   essential	   for	   RBS	   binding	   and	   nicking	   as	   well	   as	   for	   Rep-­‐
mediated	  plasmid	  integration	  (Urabe	  et	  al.	  1999;	  Hickman	  et	  al.	  2004),	  completely	  
eliminates	   Rep68	   oligomerisation	   in	   the	   presence	   of	   ssDNA	   (Mansilla-­‐Soto	   et	   al.	  
2009).	  In	  this	  chapter	  I	  have	  described	  how,	  building	  on	  the	  most	  recent	  advances	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in	  AAV2	  Rep	  structural	  biology,	  we	  have	  designed	  new	  Rep	  mutants	  that	  are	  part	  of	  
oligomeric	  interfaces	  in	  (potentially)	  functionally	  relevant	  Rep	  complexes.	  Contrary	  
to	  previous	  studies,	  we	  have	  designed	  our	  mutants	   in	  regions	  that	  are	  not	  part	  of	  
the	  well-­‐characterised	   enzymatic	   folds	   of	   the	   Rep	   proteins,	   but	   rather	   fall	   in	   the	  
recently	  described	  OD	  of	  Rep	  (Zarate-­‐Perez	  et	  al.	  2012).	  
The	  first	  oligomerisation	  interface	  was	  identified	  in	  a	  dimer	  model	  created	  using	  
the	  available	  Rep40	   structure	  with	  an	  extended	  N-­‐terminal	  α-­‐helix	   (up	   to	   residue	  
217)	  to	  complete	  the	  OD.	  In	  this	  model,	  a	  hydrophobic	  interface	  is	  formed	  through	  
interactions	  of	  the	  OD	  of	  two	  Rep	  molecules	  that	  involve	  residues	  Y224	  on	  one	  Rep	  
molecule	   and	   I251	   on	   the	   other	   (Figure	   16A).	   I	   have	   described	   in	   the	   previous	  
chapter	   that	   Y224	   is	   important	   for	   Rep68	   oligomerisation	   and	   its	   mutation	   to	  
alanine	  disrupts	  the	  AAV	  life	  cycle.	  At	  that	  stage,	  however,	  the	  consequences	  of	  the	  
Y224A	  mutation	  on	  specific	  Rep	  functions	  were	  not	  addressed.	  A	  similar	  but	  more	  
conservative	  mutation,	  Y224F,	  was	  studied	   in	  an	  earlier	   report	  and	  was	  shown	  to	  
completely	  disrupt	  DNA	  binding,	  endonuclease	  and	  helicase	  activities	  of	  a	  Rep68-­‐
MBP	   (maltose-­‐binding	   protein)	   fusion	   in	   vitro	   (Walker	   et	   al.	   1997a).	   To	   our	  
knowledge,	   point	   mutations	   of	   residue	   I251	   have	   not	   been	   studied	   before.	   The	  
results	  presented	  here	  show	  that	  mutations	  Y224A,	  I251A	  and	  the	  combination	  of	  
the	   two	   (Y224A-­‐I251A)	   disrupt	   the	   oligomeric	   interface	   and	   that	   this	   interface	   is	  
functionally	   relevant.	   While	   Rep68*-­‐Y224A	   can	   still	   form	   some	   small	   multimers,	  
Rep68*-­‐I251	   and	   Rep68*-­‐YI	   are	   completely	   monomeric	   under	   our	   experimental	  
conditions	   (Figure	   17).	   These	   three	   oligomerisation-­‐disrupting	   mutations	  
completely	   abrogated	   the	   ability	   of	   Rep	   to	   support	   the	   production	   of	   infectious	  
AAV-­‐GFP	  particles	  (Figure	  18A).	  Our	  data	  suggest	  that	  defects	  in	  DNA	  binding,	  and	  
thus	   also	   in	   the	   endonuclease	   activity	   of	   Rep	   (Figure	   20),	   are	   responsible	   for	   the	  
absence	  of	  AAV	  DNA	  replication	  in	  the	  presence	  of	  these	  mutants	  and	  thus	  also	  for	  
the	  lack	  of	  AAV-­‐GFP	  particles	  production	  (Figure	  18).	  Our	  data	  does	  not	  rule	  out	  the	  
possibility	  that	  these	  mutants	  are	  also	  defective	  in	  viral	  DNA	  packaging.	  In	  addition,	  
these	  mutants	  are	  also	  severely	  impaired	  in	  the	  regulation	  of	  the	  expression	  of	  the	  
viral	  genes,	  and	  show	  increased	  protein	  levels	  of	  all	  Rep	  isoforms	  and	  lower	  levels	  
of	   capsid	   proteins	   (Figure	   21).	   The	   disruption	   of	   the	   gene-­‐regulatory	   functions	   of	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the	   Rep	   proteins,	   and	   their	   deregulated	   expression,	   could	   also	   contribute	   to	   the	  
functional	  phenotypes	  observed.	  
The	   more	   conservative	   Rep-­‐Y224F	   mutant	   had	   an	   intriguing	   intermediate	  
phenotype.	   Analytical	   ultracentrifugation	   experiments	   suggest	   that	   Rep68*-­‐Y224F	  
retain	  the	  potential	  to	  form	  some	  of	  the	  oligomeric	  complexes	  formed	  by	  Rep68*	  in	  
vitro	   (Figure	   18).	   Our	   results	   indicate	   that	   this	   is	   not	   sufficient,	   however,	   to	   fully	  
support	  the	  viral	  life	  cycle.	  The	  production	  of	  AAV-­‐GFP	  particles	  and	  AAV	  replication	  
in	   the	   presence	   of	   this	   mutant	   were	   severely	   affected,	   but	   not	   completely	  
abolished,	   as	   was	   seen	   for	   the	   oligomerisation-­‐deficient	   mutants	   (Figure	   18).	  
Surprisingly,	  and	  in	  disagreement	  with	  a	  previous	  report	  (Walker	  et	  al.	  1997a),	  the	  
binding	  of	  RBS-­‐containing	  DNA	  does	  not	  appear	  to	  be	  compromised	  for	  this	  mutant	  
(Figure	  20A).	  A	  possible	  explanation	   for	   the	  observed	  defect	   in	  AAV	   replication	   is	  
that	  the	  nicking	  activity	  of	  Rep68*-­‐Y224F	  is	  severely	  impaired,	  although	  not	  entirely	  
abolished	   (Figure	   20B	   and	   C).	   Thus,	   this	   mutant	   retains	   the	   ability	   to	   bind	   RBS-­‐
containing	   DNA	   and	   to	   unwind	   DNA,	   but	   fails	   to	   promote	   the	   subsequent	   DNA	  
nicking	   step.	   How	   this	   transition	   is	   affected,	   however,	   is	   not	   clear.	   An	   intriguing	  
possibility	  would	  be	  that	   the	   initial	  Rep	  binding	  to	   the	  RBS	  and	  the	  origin	  melting	  
promotes	   the	   assembly	   of	   a	   second	   Rep-­‐DNA	   complex	   that	   is	   necessary	   for	   the	  
nicking	  reaction,	  and	  that	  the	  Y224	  residue	  plays	  a	  role	  in	  regulating	  this	  process.	  In	  
contrast	  to	  our	  findings,	  the	  report	  by	  Walker	  and	  colleagues	  describes	  the	  Y224F	  
mutants	   as	   completely	   defective	   in	   ITR	   binding,	   TRS	   endonuclease,	   DNA	   helicase	  
and	  ATPase	  activities	  (Walker	  et	  al.	  1997a).	  The	  differences	  between	  these	  studies	  
are	  probably	  due	  to	  the	  different	  experimental	  strategies.	  
Surprisingly,	   all	   the	   mutants	   described	   here	   were	   still	   able	   to	   unwind	   a	  
heteroduplex	   DNA	   substrate	   (Figure	   20D).	   This	   suggests	   that	   interaction	   and	  
unwinding	   of	   this	   DNA	   substrate	   do	   not	   require	   the	   formation	   of	   large	   Rep	  
oligomers,	   or	   alternatively	   that	   the	   presence	   of	   heteroduplex	   DNA	   and	   ATP	  
stabilises	   the	   formation	  of	   an	  oligomeric	   complex.	  Because	  Rep40	  and	  Rep52	  are	  
monomeric	  in	  solution	  and	  only	  transiently	  form	  smaller	  oligomers	  in	  the	  presence	  
of	  DNA	  and	  ATP	  but	  retain	  helicase	  activity	  (Dignam	  et	  al.	  2007a;	  Zarate-­‐Perez	  et	  al.	  
2012),	   it	   is	  plausible	  that	  the	  mutants	  described	  here	  are	  still	  able	  to	  unwind	  DNA	  
by	  a	  mechanism	  equivalent	  to	  that	  of	  Rep52/40.	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The	  regulation	  of	  protein	  levels	  appeared	  to	  be	  impaired	  in	  the	  presence	  of	  Rep	  
mutants	  that	  do	  not	  bind	  p5	  or	  AAVS1	  DNA.	  The	  levels	  of	  Rep	  proteins	  are	  tightly	  
regulated	   to	  be	  optimal	   for	  efficient	  AAV	  replication,	  and	  our	   results	   suggest	   that	  
oligomerisation	  of	  the	  large	  Rep	  proteins	  is	  necessary	  for	  the	  correct	  regulation	  of	  
the	   transcription	   of	   all	   AAV	   promoters	   (Figure	   21).	   The	   oligomerisation-­‐deficient	  
mutants	  fail	  to	  induce	  transcription	  of	  the	  viral	  promoters	  upon	  infection	  with	  the	  
helper	  virus	  adenovirus,	  and	  are	  also	   impaired	   in	  controlling	  the	   levels	  of	  both	  p5	  
and	  p19	  transcripts.	  While	  the	  presence	  of	  the	  Y224A	  mutation	  creates	  a	  stronger	  
Kozak	  sequence	  at	  the	  p19	  promoter,	  this	  is	  not	  sufficient	  to	  explain	  the	  differences	  
observed,	   in	   particular	   for	   the	   observed	   levels	   of	   Rep78.	   The	   increase	   in	   Rep52	  
expression	   in	   the	   presence	   of	   the	   Y224A-­‐I251A	   mutations,	   in	   addition,	   is	   not	   as	  
striking	   as	   that	   observed	   for	   the	   Y224A	   alone.	   We	   hypothesise	   that	   the	   defects	  
observed	   are	   due	   to	   the	   lack	   of	   RBS	   binding	   by	   the	   oligomerisation-­‐deficient	  
mutants,	  rather	  than	  differences	  in	  the	  p19	  promoter	  sequences.	  
The	   second	   interface	   we	   have	   characterised	   was	   directly	   observed	   in	  
crystallography	  studies	  of	   the	  Rep	  OBD	  from	  AAV2	   (Musayev	  et	  al.	  2015a).	   In	   the	  
AAV2	   Rep*-­‐OBD	   crystals,	   two	   OBD	   molecules	   are	   closely	   packed	   and	   interact	  
through	  their	  C-­‐terminal	  α-­‐helix	  (α-­‐helix	  F),	  forming	  a	  pseudo	  coiled-­‐coil	  interaction	  
(Figure	   16C).	   The	   residues	   involved	   in	   the	   formation	   of	   this	   interface	   include	  
residues	   L193	   and	  V196	  making	   hydrophobic	   interactions	   and	   residues	  H192	   and	  
S197	   forming	  a	  hydrogen	  bond	   (Figure	  16D).	  Because	   this	  OBD-­‐OBD	  arrangement	  
was	  also	  observed	  in	  studies	  of	  the	  AAV5	  OBD	  (Hickman	  et	  al.	  2004),	  we	  decided	  to	  
investigate	   whether	   this	   interface	   was	   functionally	   relevant.	   The	   double	   mutant	  
Rep*-­‐L193A-­‐V196A	   was	   found	   to	   be	   functional	   in	   all	   the	   assays	   used,	   and	   thus	  
suggests	   that	   this	   pseudo	   coiled-­‐coil	   interaction	  may	   be	   a	   crystallisation	   artefact	  
that	   is	   not	   relevant	   for	   the	   AAV	   life	   cycle.	   Similarly,	  mutating	   residues	  H192	   and	  
S197	  to	  alanine	  did	  not	  affect	  Rep	  oligomerisation	  and	  DNA	  binding	  (Musayev	  et	  al.	  
2015a).	  	  
In	  conclusion,	  our	  study	  identifies	  and	  describes	  two	  Rep-­‐Rep	  protein	  interfaces.	  
The	  results	  presented	  in	  this	  chapter	  suggest	  that	  one	  of	  these	  interfaces,	  stabilised	  
by	   interactions	   that	   include	   the	   OD	   of	   Rep,	   is	   involved	   in	   the	   formation	   of	   Rep	  
complexes	  and	  is	  functionally	  important	  throughout	  the	  AAV	  life	  cycle.	  Although	  we	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have	  not	  tested	  the	  ability	  of	  interface	  mutants	  to	  mediate	  genomic	  integration,	  we	  
anticipate	  that	  our	  oligomerisation-­‐deficient	  mutants	  will	  not	  support	  this	  function.	  
The	   identification	   of	   oligomeric	   interfaces,	   and	   further	   structural	   and	   functional	  
characterisation	   of	   Rep	   oligomeric	   complexes,	   particularly	   in	   the	   presence	   of	  
different	   DNA	   substrates,	   will	   provide	   additional	   insights	   into	   the	   molecular	  
mechanisms	  behind	  the	  remarkable	  multifunctionality	  of	  AAV	  Rep	  proteins.	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CHAPTER	  6: REP-­‐MEDIATED	   TARGETED	   GENE	   ADDITION	   IN	  
CELLS	  WITH	  PROLIFERATIVE	  POTENTIAL	  
6.1 INTRODUCTION	  
To	   date,	   AAV	   remains	   the	   only	   known	   eukaryotic	   virus	   that	   has	   evolved	   a	  
mechanism	  to	  site-­‐specifically	   integrate	   in	   its	  host	  genome.	  This	  unique	  process	   is	  
mediated	   by	   the	   large	   Rep	   proteins	   Rep78	   and	   Rep68,	   which	   are	   versatile	  
regulatory	   proteins	   that	   orchestrate	   the	   AAV	   life	   cycle.	   To	   improve	   our	  
understanding	  of	  AAV	  Rep-­‐mediated	  integration	  and	  its	  biotechnological	  potential,	  
one	  approach	  is	  to	  characterise	  the	  mechanism	  of	  action	  of	  the	  Rep	  proteins	  on	  the	  
AAVS1	   integration	   site	   and	   how	   the	   biochemical	   and	   structural	   properties	   of	  
Rep78/68	  mediate	  the	  integration	  event.	  In	  this	  context,	  the	  data	  presented	  in	  the	  
first	   two	   chapters	   present	   an	   important	   platform	   that	   can	   be	   used	   for	   the	  
characterisation	  of	  the	  complex	  formed	  by	  Rep78/68	  on	  AAVS1.	  A	  second	  approach	  
is	   to	   characterise	   the	   consequences	   of	   AAV	   integration	   on	   the	   host	   genome,	  
including	  potential	  genotoxicity	  caused	  by	   the	   integration	  event.	   In	   this	  chapter,	   I	  
present	  a	  project	  that	  was	  aimed	  at	  studying	  the	  consequences	  and	  the	  potential	  of	  
Rep-­‐mediated	  targeted	  gene	  addition	  in	  a	  clinically	  relevant	  disease	  model.	  	  
6.1.1 Gene	  therapy	  for	  monogenic	  immunodeficiency	  diseases	  
Primary	   immunodeficiencies	   (PIDs)	   are	   a	   heterogeneous	   group	   of	   genetic	  
disorders	   that	   primarily	   affect	   the	   development	   and/or	   the	   functionality	   of	   the	  
immune	   system	   (Fischer	   2015).	   Common	   symptoms	   include	   an	   increased	  
susceptibility	   to	   infections,	   autoimmunity	   and	   autoinflammatory	   diseases,	   as	  well	  
as	   some	   malignancies.	   If	   left	   untreated,	   the	   most	   severe	   of	   these	   conditions,	  
including	   X-­‐linked	   severe	   combined	   immunodeficiency	   (SCID-­‐X1),	   adenosine	  
deaminase	   SCID	   (ADA-­‐SCID),	   chronic	   granulomatous	   disease	   (CGD)	   and	   Wiskott-­‐
Aldrich	  syndrome	  (WAS),	   lead	  to	  early	  mortality	  in	  patients.	  The	  therapy	  of	  choice	  
for	   severe	   PIDs	   is	   allogeneic	   transplantation	   of	   hematopoietic	   stem	   cells	   (HSCs)	  
(Fischer	   2015).	   The	   recent	   developments	   in	   transplantation	   protocols	   and	   in	  
purification	  of	  HSCs	  have	  improved	  safety	  and	  efficacy	  of	  this	  treatment.	  However,	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HLA-­‐matched	   donors	   are	   still	   unavailable	   for	   a	   significant	   number	   of	   patients,	  
making	  procedures	  based	  on	  ex	  vivo	  genetic	  correction	  of	  autologous	  HSCs	  clinically	  
relevant	   (Rivat	   et	   al.	   2012;	   Fischer	   et	   al.	   2013).	  While	   AAV	   has	   been	   extensively	  
developed	   as	   a	   gene	   therapy	   vector	   to	   treat	   non-­‐dividing	   and	   differentiated	   cell	  
populations,	   the	   episomal	  mode	  of	   rAAV	  persistence	   cannot	   be	   exploited	   for	   the	  
treatment	  of	  PIDs,	  which	   require	   the	  genetic	  modification	  of	   stem	  cells	   and	   their	  
proliferation	   to	   re-­‐establish	   a	   functional	   immune	   system.	  More	   specifically,	   gene	  
transfer	   to	   cells	   with	   proliferative	   potential	   such	   as	   HSCs	   requires	   transgene	  
integration	   into	  the	  host	  genome	  to	  achieve	   lifelong	  expression.	  Thus,	  the	  vectors	  
of	   choice	   for	   gene	   therapy	   treatment	   of	   PIDs	   have	   been	   based	   on	   retroviruses,	  
which	  stably	  integrate	  their	  genome	  into	  the	  host	  genome.	  In	  particular,	  γ-­‐retroviral	  
vectors	  have	  been	  used	  in	  clinical	  trials	  for	  SCID-­‐X1,	  ADA-­‐SCID,	  CGD	  and	  WAS	  (Rivat	  
et	   al.	   2012;	   Fischer	   et	   al.	   2013).	   Around	   100	   patients	   have	   now	   entered	   gene	  
therapy	  clinical	  trials	  for	  the	  treatment	  of	  these	  PIDs,	  and	  the	  results	  have	  generally	  
been	   encouraging,	   providing	   proof	   of	   principle	   that	   gene	   therapy	   can	   have	   long	  
lasting	  curative	  effects	  and	  significantly	   improve	  the	  patient’s	   life	  quality	   (Rivat	  et	  
al.	   2012;	   Fischer	   et	   al.	   2013).	   Nonetheless,	   severe	   adverse	   events	   such	   as	   the	  
development	  of	  T-­‐cell	  leukaemia	  have	  been	  reported,	  highlighting	  the	  potential	  for	  
insertional	   mutagenesis	   of	   retrovirus-­‐mediated	   integration	   and	   clonal	   expansion	  
(Williams	   and	   Thrasher	   2014).	   In	   all	   cases,	   the	   development	   of	   leukaemia	   was	  
associated	  with	  proviral	  integration	  events	  near	  proto-­‐oncogenes	  such	  as	  the	  LMO2	  
gene	  and	  caused	  a	  deregulation	  of	  gene	  expression	  at	  the	  integration	  site,	  possibly	  
due	   to	   the	   strong	   enhancer	   activity	   of	   the	   retroviral	   long	   terminal	   repeats	   (LTRs)	  
(Williams	   and	   Thrasher	   2014).	   More	   recent	   trials	   use	   newly	   designed	   retroviral	  
vectors	   that	   have	   shown	   increased	   safety	   in	   pre-­‐clinical	   and	   clinical	   studies,	  
however	   the	   patient’s	   haematopoietic	   clonal	   cell	   repertoires	   remain	   carefully	  
monitored	  (Rivat	  et	  al.	  2012;	  Fischer	  et	  al.	  2013;	  Williams	  and	  Thrasher	  2014).	  
6.1.2 AAV	  Rep-­‐mediated	  targeted	  integration:	  an	  opportunity	  for	  targeted	  gene	  
addition	  to	  the	  human	  genome?	  
Because	   of	   the	   intrinsically	   semi-­‐random	   integration	   of	   retroviruses	   into	   the	  
human	   genome,	   it	   is	   very	   difficult	   to	   predict	   the	   safety	   and	   efficacy	   of	   gene	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therapies	   that	  use	   this	   approach	   to	   genetically	  manipulate	   cells	  with	  proliferative	  
potential	   (Sadelain	   et	   al.	   2012).	   In	   addition	   to	   the	   mentioned	   risk	   of	   insertional	  
mutagenesis,	  the	  levels	  of	  expression	  of	  the	  transgene	  and	  its	  potential	  epigenetic	  
silencing	   will	   vary	   depending	   on	   the	   chromosomal	   context	   surrounding	   the	  
integration	  site	  (Sadelain	  et	  al.	  2012).	  To	  overcome	  these	  issues,	  efforts	  have	  been	  
made	   in	   recent	   years	   to	   develop	   strategies	   for	   the	   targeted	  modification	   of	   cells	  
with	   proliferative	   potential,	   such	   as	   embryonic	   stem	   cells	   (ESCs),	   induced	  
pluripotent	  stem	  cells	  (iPSCs)	  and	  HSCs.	  Examples	  include	  the	  use	  of	  bacteriophage	  
integrases,	  homing	  nucleases,	  zinc-­‐finger	  nucleases	   (ZFNs),	   transcription	  activator-­‐
like	   effector	   nucleases	   (TALENs)	   and	   most	   recently	   RNA-­‐guided	   engineered	  
nucleases	   (RGENs),	   based	   on	   the	   CRISPR-­‐Cas	   system	   (Kim	   and	   Kim	   2014).	   These	  
strategies	   rely	   on	   the	   ability	   of	   the	   cellular	   machinery	   to	   repair	   double	   strand	  
breaks	   (DSBs)	   in	   the	  DNA	   through	  homologous	   recombination.	   The	  nucleases	   can	  
be	   engineered	   to	   introduce	   a	   DSB	   at	   a	   specific	   target	   in	   the	   genome,	   while	  
exogenous	   donor	   DNA	   containing	   regions	   of	   homology	   to	   the	   targeted	   genomic	  
locus	   provides	   the	   template	   for	   the	   repair	   of	   the	   double	   strand	   break	   by	  
homologous	  recombination	  (Kim	  and	  Kim	  2014).	  This	  mechanism	  can	  be	  exploited	  
in	   several	   ways,	   including	   for	   repairing	   a	   mutated	   gene	   directly	   or	   for	   targeted	  
transgene	  addition	  at	  a	  defined	  genomic	  locus.	  The	  efficiency	  and	  the	  specificity	  of	  
this	   approach	   for	   targeted	   gene	   addition	   depend	   on	   the	   target	   locus,	   on	   the	  
template	   DNA,	   and	   on	   the	   designer	   nuclease	   of	   choice	   (Kim	   and	   Kim	   2014).	   In	  
particular,	  genotoxicity	  due	  to	  off-­‐target	  DSB	  induction	  and	  imperfect	  DSB	  repair	  is	  
a	  significant	  risk	  that	  needs	  to	  be	  considered	  when	  using	  any	  of	  these	  approaches	  
(Gabriel	  et	  al.	  2011).	  
The	   preference	   of	   AAV	   for	   integration	   into	   AAVS1	   has	   prompted	   the	  
investigation	   of	   AAV	   Rep-­‐mediated	   integration	   as	   an	   alternative	   strategy	   for	  
targeted	   gene	   addition.	   However,	   because	  AAVS1	   is	   located	  within	   a	   gene-­‐dense	  
region,	   assessing	   the	   genotoxicity	   of	  AAV	   integration	   is	   critical.	   Although	   this	   site	  
has	  been	  designated	  as	  safe	  harbour	  site	  for	  transgene	   integration,	  the	  functional	  
consequences	  of	  AAVS1	  disruption	  was	  initially	  only	  assessed	  in	  the	  context	  of	  AAV-­‐
mediated	   targeted	   integration	   (Henckaerts	   et	   al.	   2009).	   Rep-­‐mediated	   targeted	  
insertion	   of	   a	   recombinant	   AAV	   vector	   encoding	   a	   marker	   gene	   into	   the	   AAVS1	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ortholog	   in	   mouse	   embryonic	   stem	   cells	   (mESCs)	   resulted	   in	   strong	   transgene	  
expression	   throughout	   in	   vitro	   differentiation	   into	   multiple	   lineages,	   without	  
causing	  any	  apparent	  defects	   in	  differentiation	  (Dutheil	  et	  al.	  2009;	  Henckaerts	  et	  
al.	   2009).	   Furthermore,	   these	   cells	   were	   able	   to	   successfully	   contribute	   to	   the	  
development	   of	   all	   tissues	   when	   injected	   into	   blastocysts,	   without	   visible	  
phenotypic	   defects	   throughout	   the	   life	   of	   the	   chimeric	   mice	   (Henckaerts	   et	   al.	  
2009).	   Similarly,	   Rep-­‐mediated	   integration	   into	   AAVS1	   in	   human	   ESCs	   showed	  
strong	   and	   stable	   marker	   gene	   expression,	   and	   did	   not	   affect	   the	   in	   vitro	  
differentiation	   of	   the	   cells	   (Yang	   et	   al.	   2008).	   In	   addition,	   these	   cells	   functionally	  
integrated	   into	  a	  mouse	  heart	  when	  differentiated	   into	  human	  cardiac	  progenitor	  
cells	   (Yang	   et	   al.	   2008).	   Together,	   these	   experiments	   showed	   that	   Rep-­‐mediated	  
integration	   into	   AAVS1	   could	   result	   in	   safe	   and	   robust	   transgene	   addition	   in	   a	  
translationally	   relevant	   context,	   and	   warranted	   further	   investigations	   of	   the	  
feasibility	  of	  targeted	  gene	  addition	  by	  Rep-­‐mediated	  integration.	  	  
Intriguingly,	   the	  AAV2	   integration	  hotspot	  AAVS1	  has	  become	  one	  of	   the	  most	  
used	   loci	   for	   targeted	   gene	   addition	   using	   designer	   nucleases	   and	   has	   proven	   to	  
support	   robust	   transgene	   expression,	   including	   throughout	   ESC	   and	   iPSC	  
differentiation	   (DeKelver	   et	   al.	   2010;	   Lombardo	   et	   al.	   2011;	   Sadelain	   et	   al.	   2012;	  
Tiyaboonchai	  et	  al.	  2014).	  
6.1.3 Project	  outline	  and	  strategy	  
The	   aim	   of	   this	   project	   was	   to	   study	   the	   feasibility	   and	   safety	   profile	   of	   Rep-­‐
mediated	  targeted	  gene	  addition	  into	  AAVS1	  in	  a	  clinically	  relevant	  context.	  For	  this	  
purpose,	  we	  decided	  to	  use	  SCID-­‐X1	  as	  a	  disease	  model.	  As	  described	  earlier	  in	  this	  
chapter,	   proof	   of	   principle	   of	   the	   curative	   effects	   of	   gene	   therapy	   in	   SCID-­‐X1	  
patients	   has	   been	   demonstrated	   using	   lentiviral	   vectors.	   SCID-­‐X1	   is	   the	   most	  
common	  variant	  of	  SCID	  and	  results	  from	  loss	  of	  function	  mutations	  of	  the	  common	  
cytokine	  receptor	  γ-­‐chain,	  a	  shared	  component	  of	  the	  receptors	  for	  interleukin	  (IL)-­‐
2,	   IL-­‐4,	   IL-­‐7,	   IL-­‐9,	   IL-­‐15,	   and	   IL-­‐21,	   encoded	   by	   the	   IL2RG	   gene	   (Fischer	   2000).	  
Because	   the	   IL2RG	   gene	   is	   located	  on	   the	   X-­‐chromosome,	   the	   inheritance	   of	   this	  
disease	  is	  sex-­‐linked.	  Patients	  display	  a	  lack	  of	  T	  and	  NK	  cells,	  as	  well	  as	  abnormal	  B	  
cell	  development;	  the	  disease	  is	  associated	  with	  early	  mortality	  if	  left	  untreated	  and	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survival	  depends	  on	  the	  reconstitution	  of	  immunity	  by	  allogeneic	  transplantation	  or	  
gene	  therapy	  (Fischer	  2000).	   In	  the	  latter	  case,	  HSCs	  are	  isolated	  from	  the	  patient	  
and	   transduced	   ex	   vivo	   with	   a	   retroviral	   vector	   carrying	   the	   IL2RG	   gene	   before	  
being	  returned	  to	  the	  patient	   (Rivat	  et	  al.	  2012;	  Fischer	  et	  al.	  2013).	  AAV	  vectors,	  
however,	   do	   not	   readily	   transduce	   HSCs.	   To	   overcome	   this	   problem,	   we	   took	  
advantage	  of	  induced	  pluripotent	  stem	  cell	  technology	  to	  generate	  patient-­‐specific	  
iPSCs.	   Through	   our	   collaboration	  with	   Prof	   Adrian	   Thrasher	   of	   University	   College	  
London,	  we	  were	  able	  to	  obtain	  SCID-­‐X1	  patient-­‐derived	  dermal	  fibroblasts,	  which	  
we	   reprogrammed	   to	   iPSCs	   to	   generate	  an	  unlimited	   source	  of	   SCID-­‐X1	   cells	   that	  
could	  be	  transduced	  with	  AAV	  vectors	  and	  used	  for	  further	  studies.	  IPSCs	  are	  ESC-­‐
like	   pluripotent	   stem	   cells	   that	   are	   derived	   from	   somatic	   cells	   through	   forced	  
expression	  of	   transcription	   factors	   such	  as	  Oct4,	  Klf4,	   Sox2	  and	  c-­‐Myc	   (Yamanaka	  
2007;	  Buganim	  et	  al.	  2013).	  They	  were	  initially	  described	  as	  reprogramming	  factors	  
by	   Takahashi	   and	   Yamanaka	   in	   2006	   (Takahashi	   and	   Yamanaka	   2006),	   for	   which	  
they	   received	   the	   Nobel	   Prize	   in	   2012.	   In	   recent	   years	   the	   iPSC	   technology	   has	  
greatly	   improved;	   iPSCs	   have	   been	   derived	   from	   a	   multitude	   of	   cell	   types,	   and	  
several	  methods	  to	  deliver	  the	  reprogramming	  factors	  are	  now	  available	  (Gonzalez	  
et	  al.	   2011).	   These	  developments	  open	   the	  door	   to	   the	  production	  of	  autologous	  
cells	  with	  proliferative	  potential	  for	  both	  cell	  therapy	  and	  drug	  screening	  (Inoue	  et	  
al.	   2014).	   In	   theory,	   it	   is	   now	  possible	   to	   obtain	   patient-­‐specific	   cell	   lines	   for	   any	  
disease	  and	   to	   subsequently	  use	   them	  to	  generate	  differentiated	  cell	  populations	  
and	  to	  recapitulate	  the	  disease	  phenotype	  in	  vitro,	  allowing	  to	  screen	  for	  pathways	  
that	   are	   involved	   in	   disease	   progression	   and/or	   therapies	   that	   can	   reverse	   the	  
disease	  phenotype	  (Inoue	  et	  al.	  2014).	  	  
As	   summarised	   in	   Figure	   22,	   the	   first	   steps	   in	   this	   project	  were	   to	   obtain	   and	  
characterise	  SCID-­‐X1	  iPSCs	  from	  the	  patient	  fibroblasts,	  and	  to	  design	  a	  rAAV-­‐IL2RG	  
vector	  to	  be	  used	  for	  targeted	  Rep-­‐mediated	  gene	  addition	  into	  AAVS1.	  This	  would	  
have	   been	   followed	   by	   a	   careful	   characterisation	   of	   the	   integration	   site(s)	   and	  
surrounding	   regions,	   and,	   finally,	   by	   differentiation	   of	   the	   iPSCs	   into	   the	  
hematopoietic	   lineage	   to	   compare	   the	   developmental	   potential	   of	   the	   isogenic	  
SCID-­‐X1	   and	   corrected	   iPSCs.	   Unfortunately,	   this	   ambitious	   project	   was	   never	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completed	  for	  the	  reasons	  explained	  below.	  In	  this	  chapter,	  I	  will	  present	  the	  initial	  
developments	  of	  the	  project.	  
	  
	  
Figure	  22:	  Project	  outline.	  	  
The	   first	   step	   of	   this	   project	   was	   the	   generation	   of	   patient-­‐specific	   SCID-­‐X1	   iPSCs.	   The	  
reprogramming	   factors	   would	   have	   been	   excised	   before	   infecting	   the	   iPSCs	   with	   a	   rAAV	   vector	  
expressing	  the	  IL2RG	  gene	  and	  WT	  AAV2	  to	  promote	  Rep-­‐mediated	  integration	  in	  AAVS1.iPSC	  clones	  
containing	  IL2RG	  integrated	  in	  AAVS1	  would	  then	  be	  selected	  and	  used	  to	  assess	  the	  consequences	  
of	  integration	  throughout	  hematopoietic	  differentiation.	  
	  
6.2 RESULTS	  
6.2.1 Vector	  design	  and	  plasmid	  validation	  
To	  produce	  our	  rAAV	  vector	  it	  was	  first	  necessary	  to	  clone	  the	  common	  γ-­‐chain	  
gene	   IL2RG	   into	  an	   ITR-­‐containing	  plasmid.	  The	   initial	  vector	  design	  was	  based	  on	  
the	  pTRUF11	  construct	  (Zolotukhin	  et	  al.	  1996).	  This	  plasmid	  contains	  the	  GFP	  gene	  
under	  the	  control	  of	  the	  CAG	  promoter	  (a	  hybrid	  CMVie	  enhancer/chicken	  β-­‐actin	  
promoter)	   and	   neomycin	   resistance	   gene	   driven	   by	   the	   HSV	   thymidine	   kinase	  
promoter,	   flanked	   by	   the	   AAV2	   ITRs.	   The	   neomycin	   resistance	   cassette	   was	  
replaced	  by	  a	  common	  γ-­‐chain	  expression	  cassette	  containing	  a	  short	  version	  of	  the	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EF-­‐1	   alpha	   promoter	   and	   the	   IL2RG	   cDNA,	   which	   was	   cloned	   from	   a	   lentiviral	  
plasmid	   (kindly	   provided	   by	   Adrian	   Thrasher,	   Institute	   of	   Child	   Health,	   London,	  
United	  Kingdom).	  Additionally,	  we	  designed	  a	  second	  construct	  that	  did	  not	  contain	  
the	  GFP	  expression	  cassette.	  Before	  producing	  the	  AAV	  vectors,	  we	  assessed	  the	  γ-­‐
chain	  expression	  levels	  in	  transfected	  293T	  cells	  by	  western	  blot	  and	  FACS	  (CD132)	  
(Figure	   23B	   and	   C,	   pTRUF11-­‐GFP-­‐IL2RG	   and	   pTRUF11-­‐IL2RG).	   Compared	   to	   the	  
original	   lentiviral	   plasmid	   (Figure	   23B	   and	   C,	   SINLV-­‐IL2RG)	   the	   γ-­‐chain	   expression	  
levels	  were	  very	  low,	  and	  thus	  we	  decided	  to	  design	  new	  IL2RG	  constructs.	  The	  new	  
constructs	  were	  generated	  with	   the	  pSub201	  plasmid,	   to	   take	  advantage	  of	  more	  
suitable	   cloning	   sites	   and	   the	   reduced	   frequency	   of	   recombination	   of	   the	   ITRs	  
(Samulski	  et	  al.	  1987).	  We	  obtained	  and	  tested	  three	  new	  vectors.	  The	  first	  vector,	  
pMB13,	  contained	  the	  same	  γ-­‐chain	  expression	  cassette	  as	  described	  above	  but	  in	  
the	  pSub201	  backbone.	  To	  create	  the	  second	  construct,	  pSub201-­‐IL2RG,	  we	  added	  
the	  Woodchuck	  Hepatitis	  Virus	  Posttranscriptional	  Regulatory	  Element	  (WPRE)	  (Lee	  
et	  al.	  2005)	  behind	  the	  IL2RG	  gene	  to	  increase	  its	  expression	  (Figure	  23A).	  The	  third	  
plasmid	   was	   generated	   by	   adding	   a	   CMV-­‐driven	   GFP	   expression	   cassette	   to	  
pSub201-­‐IL2RG	   (Figure	   23A).	   Of	   the	   three	   new	   plasmids	   produced,	   pMB13	   still	  
showed	  low	  levels	  of	  γ-­‐chain	  expression,	  while	  the	  two	  constructs	  that	  contained	  a	  
WPRE	   element	   into	   the	   design	   (Figure	   23A)	   expressed	   the	   γ-­‐chain	   to	   levels	  
comparable	  to	  those	  observed	  with	  the	  SINLV-­‐IL2RG	  vector	   (Figure	  23B	  and	  Table	  
2).	  
	  
	   %	  GFP	   %	  CD132	   %	  dpos	  
-­‐ve	  ctrl	   0.97	   0.85	   0.11	  
pTRUF11	  (GFP	  ctrl)	   65.1	   0.73	   14.1	  
pSINLV-­‐IL2RG	  (CG	  ctrl)	   0	   82.2	   0.42	  
pSUB201-­‐IL2RG	   0.07	   68	   0.38	  
pSUB201-­‐IL2RG-­‐GFP	   11.9	   7.45	   71.7	  
Table	  2:	  CD132	  surface	  expression	  and	  GFP	  expression	  in	  293Ts	  transfected	  with	  IL2RG-­‐expressing	  
plasmids.	  	  
The	  expression	  levels	  of	  the	  cell	  surface	  marker	  CD132	  (γ-­‐chain)	  and	  of	  GFP	  were	  assessed	  48h	  after	  
293T	  transfection	  by	  FACS	  analysis.	  Values	  represent	  the	  mean	  of	  three	  experiments.	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Figure	  23:	  Vector	  design	  and	  validation	  of	  the	  plasmid	  constructs.	  	  
(A)	   Schematic	   design	   of	   the	   last	   two	   versions	   of	   IL2RG-­‐expressing	   vectors	   used	   in	   this	   study.	  
pSUB201-­‐IL2RG	  contains	  the	  IL2RG	  expression	  cassette,	  controlled	  by	  the	  EF1α	  and	  WPRE	  regulatory	  
elements.	   A	   second	   vector	   containing	   an	   excisable	   GFP	   expression	   cassette,	   pSUB201-­‐IL2RG-­‐GFP	  
was	  designed	  to	  allow	  a	  simpler	  selection	  of	   transduced	  cells.	   (B)	  Western	  blot	  analysis	  of	  γ-­‐chain	  
and	  GFP	  expression	  levels	  from	  all	  the	  vector	  constructs	  built	  during	  this	  study	  48h	  after	  transfection	  
of	  293T	  cells.	  	  
	  
6.2.2 Vector	  production	  and	  viral	  vector	  testing	  
Based	  on	  our	  preliminary	  tests	  on	  the	  transgene-­‐containing	  plasmids	  (Figure	  23),	  
we	  generated	  AAV2	  vectors	  using	  the	  pSub201-­‐IL2RG	  and	  the	  pSub201-­‐IL2RG-­‐GFP	  
plasmids.	   The	   resulting	   AAV2-­‐IL2RG	   and	   AAV2-­‐IL2RG-­‐GFP	   vectors	   were	   carefully	  
titred:	   the	   viral	   particle	   titre	   was	   determined	   by	   quantifying	   the	   amount	   VP3	   in	  
each	  viral	  preparation	  by	  SDS-­‐PAGE	  (Kohlbrenner	  et	  al.	  2012)	  and	  the	  viral	  genome	  
titre	  was	  measured	  by	  absolute	  qPCR	  quantification	  of	   IL2RG	  (Zeltner	  et	  al.	  2010).	  
The	  vectors	  were	  initially	  tested	  by	  transduction	  of	  293T	  cells.	  Figure	  24A	  shows	  the	  
levels	  of	  γ-­‐chain	  expression	  as	  determined	  by	  western	  blot	  and	  by	  CD132	  surface	  
staining	  (Table	  3).	  While	  both	  vectors	  expressed	  the	  γ-­‐chain,	  transduction	  with	  the	  
vector	   co-­‐expressing	  GFP	   resulted	   in	   significantly	   lower	   γ-­‐chain	   expression	   levels.	  
The	   GFP	   expression	   level	   was	   very	   high,	   suggesting	   some	   level	   of	   promoter	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interference	   between	   the	   two	   expressions	   cassettes	   in	   our	   bicistronic	   vector	   (de	  
Felipe	  2002;	  Eszterhas	  et	  al.	  2002).	  We	  used	  a	  cell	  line	  (ED7R-­‐CG)	  that	  carries	  three	  
integrated	   copies	   of	   the	   IL2RG	   gene	   (ED7R-­‐CG,	   kindly	   provided	   by	   Prof	   Adrian	  
Thrasher)	  as	  control	  for	  γ-­‐chain	  expression.	  
	  
	  
Figure	  24:	  Western	  blot	  analysis	  of	  γ-­‐chain	  and	  GFP	  expression	  levels.	  
293T	   cells	   were	   transduced	   with	   AAV2-­‐IL2RG	   and	   AAV2-­‐IL2RG-­‐GFP	   AAV	   vectors	   and	   protein	  
expression	  was	  assessed	  48h	  after	  transduction.	  	  
	  
condition	   %	  GFP	   %	  CD132	   %	  dpos	  
-­‐ve	  ctrl	   0.9	   0.8	   0.07	  
ED7R-­‐CG	   0.7	   44	   2.3	  
AAV2-­‐GFP	   91.5	   0.9	   1.16	  
AAV2-­‐IL2RG	   0.07	   10.7	   0.38	  
AAV2-­‐IL2RG-­‐GFP	   11.9	   3.7	   1.6	  
Table	  3:	  CD132	  surface	  expression	  and	  GFP	  expression	  in	  293Ts	  transduced	  with	  IL2RG-­‐expressing	  
rAAVs.	  	  
The	  expression	  levels	  of	  the	  cell	  surface	  marker	  CD132	  (γ-­‐chain)	  and	  of	  GFP	  were	  assessed	  48	  hours	  
after	  293T	  transduction	  by	  FACS	  analysis.	  Values	  represent	  the	  mean	  of	  three	  experiments.	  ED7R-­‐CG	  
were	  used	  as	  positive	  control	  for	  the	  staining.	  	  
	  
To	   further	  validate	  our	  vectors,	  we	   tested	   their	  ability	   to	  correct	   the	  ED7R	  cell	  
line	   (kindly	   provided	   by	   Prof	   Adrian	   Thrasher),	   a	   human	   T-­‐cell	   line	   that	   does	   not	  
express	   the	   common	   γ-­‐chain	   (Zhang	   et	   al.	   2007).	   In	   addition	   to	   assessing	   the	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expression	   levels	   of	   the	   CD132	   surface	   marker,	   this	   cell	   line	   also	   allows	   for	   the	  
study	   of	   the	   restoration	   of	   the	   IL2	   receptor	   pathway	   by	   intracellular	   staining	   of	  
phosphorylated	   STAT5,	   a	   downstream	   component	   of	   the	   IL2	   signalling	   pathway.	  
This	   pathway	   is	   functional	   in	   the	   ED7R-­‐CG	   control	   cell	   line.	   Because	   AAV	  
transduction	  of	  hematopoietic	  cells	  is	  generally	  poor,	  we	  first	  tested	  whether	  ED7R	  
cells	   could	  be	   transduced	  with	   rAAV-­‐GFP	  vectors,	   and	   found	   that	  AAV	  serotype	  2	  
gave	   the	   highest	   transduction	   efficiency	   (data	   not	   shown).	   As	   shown	   in	   Table	   4,	  
transduction	   of	   ED7R	   cells	   with	   our	   IL2RG	   vectors	   did	   not	   result	   strong	   γ-­‐chain	  
expression	  and	   led	   to	  minimal	   functional	   activation	  of	   the	   IL2	   signalling	  pathway.	  
Transduction	   with	   AAV2-­‐IL2RG-­‐GFP	   and	   control	   AAV2-­‐GFP	   vector,	   however,	  
showed	   high	   GFP	   expression,	   indicating	   that	   transduction	   was	   not	   a	   limitation.	  
Overall,	  these	  results	  suggest	  that	  expression	  of	  the	  IL2RG	  transgene	  in	  the	  context	  
of	  the	  recombinant	  vector	  is	  sub-­‐optimal	  in	  the	  ED7R	  cell	  line.	  	  
	  
condition	   %	  GFP	   %	  CD132	   %	  dpos	   %	  P-­‐STAT5	  
-­‐ve	  ctrl	   0.87	   0.6	   0.12	   0.7	  
ED7R-­‐CG	   0.7	   66	   2.3	   84.1	  
AAV2-­‐GFP	   90.9	   0.71	   0.42	   1.38	  
AAV2-­‐IL2RG	   0.07	   3.8	   0.38	   2.54	  
AAV2-­‐IL2RG-­‐GFP	   80.9	   1.39	   1.5	   2.29	  
Table	  4:	  CD132	  surface	  expression	  and	   IL2	  pathway	  reconstitution	   in	  ED7R	  cells	   transduced	  with	  
IL2RG-­‐expressing	  rAAVs.	  	  
The	  expression	  levels	  of	  the	  cell	  surface	  marker	  CD132	  (γ-­‐chain),	  of	  GFP,	  and	  the	  level	  of	  ℗-­‐STAT5	  
activation	  were	  assessed	  48h	  after	  ED7R	  cells	   transduction	  by	  FACS	  analysis.	  Values	   represent	   the	  
mean	  of	  two	  experiments.	  ED7R-­‐CG	  were	  used	  as	  positive	  control	  for	  the	  staining.	  
	  
6.2.3 Generation	  and	  characterisation	  of	  SCID-­‐X1	  iPSCs	  
While	  we	  were	  developing	  the	  AAV-­‐IL2RG	  vectors,	  we	  started	  the	  generation	  of	  
iPSCs	   from	   the	   SCID-­‐X1	   patient-­‐derived	   dermal	   fibroblasts.	   For	   the	   generation	   of	  
iPSCs,	   we	   used	   an	   excisable	   lentiviral	   vector	   containing	   the	   four	   reprogramming	  
factors	   Oct4,	   Klf4,	   Sox2	   and	   c-­‐Myc	   (Somers	   et	   al.	   2010)	   and	   a	   fibroblast	  
reprogramming	  protocol	   kindly	  provided	  by	  Dr	  Paul	  Gadue	   (Children's	  Hospital	  of	  
Philadelphia	   human	   ES/iPS	   cell	   core	   facility,	   Philadelphia,	   USA).	   Patient-­‐derived	  
dermal	   fibroblasts	   were	   transduced	   at	   passage	   6	   with	   varying	   MOIs	   of	   the	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reprogramming	   retroviral	   vector.	   The	   day	   after	   transduction	   the	   culture	  medium	  
was	  switched	  to	  a	  different	  formulation	  to	  improve	  the	  reprogramming	  efficiency.	  
Five	   days	   post-­‐transduction	   the	   cells	  were	   passaged	   and	   seeded	   on	   larger	   plates	  
containing	  a	  feeder	  layer	  of	  irradiated	  mouse	  embryonic	  fibroblasts.	  The	  cells	  were	  
left	   to	   grow	  without	   passaging	   for	   at	   least	   3	  weeks,	   after	  which	   the	   best-­‐looking	  
colonies	  were	  manually	  picked.	  Using	   this	   strategy	  we	  successfully	  generated	  and	  
selected	   several	   iPSC	   clones	  and	  after	  6	   to	  8	  passages	  we	  proceeded	   to	  an	   initial	  
assessment	  of	  pluripotency	  markers	  expression.	  Figure	  25	  shows	  a	   representative	  
staining	  for	  the	  pluripotency	  markers	  nanog,	  Tra1-­‐60	  and	  SSEA4	  of	  SCID-­‐iPSCs	  clone	  
1.	   The	   SCID-­‐X1	   iPSCs	   showed	  pluripotency	  marker	   staining	   comparable	   to	   that	   of	  
control	   hESCs.	   In	   addition,	   we	   tested	   the	   ability	   of	   different	   AAV	   serotypes	   to	  
transduce	   the	  SCID-­‐iPSCs	  using	  GFP	  expressing	  vectors.	  Table	  5	  shows	   that	  AAV2-­‐




Figure	  25:	  SCID-­‐X1	  iPSCs	  express	  pluripotency	  markers.	  	  
The	   expression	   of	   pluripotency	   markers	   Tra1-­‐60,	   nanog,	   SSEA-­‐4	   was	   assessed	   by	  
immunofluorescence.	  The	  hES2	  ESC	  line	  was	  used	  as	  control.	  Scale	  bar	  is	  100µl.	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   AAV	  MOI	  
105	  vg	  (%GFP)	  
neg	  ctrl	   0.22	  
AAV1	   5	  
AAV2	   64.6	  
AAV5	   0.5	  
AAV6	   42.1	  
AAV8	   14.4	  
AAV9	   29.9	  
Table	  5:	  Different	  AAV	  serotypes	  show	  different	  transduction	  efficiency	  of	  SCID-­‐iPSCs.	  	  
The	  same	  GFP	  expression	  cassette	  was	  packaged	  in	  different	  AAV	  serotype	  capsids	  and	  was	  used	  to	  
transduce	  SCID-­‐iPSCs.	  Data	  from	  two	  experiments.	  	  
6.2.4 Problems	  and	  project	  termination	  
After	  the	  initial	  characterisation	  of	  the	  iPSCs	  obtained	  from	  SCID-­‐X1	  patient	  cells,	  
the	  plan	  was	  to	  proceed	  with	  the	  excision	  of	  the	  reprogramming	  factors	  using	  the	  
Cre-­‐loxP	  system	  before	  transducing	  the	  cells	  with	  AAV.	  However,	  cultures	  that	  were	  
initially	   looking	   healthy	   and	   displayed	   normal	   growth	   characteristics	   started	   to	  
show	   changed	   morphology	   and	   drastically	   decreased	   cell	   viability.	   Cells	   tested	  
negative	   for	  mycoplasma	   infection,	   a	   common	   cell	   culture	   contaminant	   that	   can	  
have	  deleterious	  effects	  on	  stem	  cells	  (Young	  et	  al.	  2010),	  and	  thus	  the	  reason	  for	  
the	   sudden	  deterioration	  of	   the	   iPSCs	   cultures	   remained	  unknown.	  Control	  hESCs	  
cultured	   in	   parallel	   in	   the	   same	  medium	   did	   not	   show	   signs	   of	   declining	   health.	  
Finally,	   iPSCs	   that	  were	   left	  without	  media	   changes	   for	   3	  days	   tested	  positive	   for	  
mycoplasma.	   After	  multiple	   attempts	   to	   establish	   the	   origin	   of	   the	   infection	   and	  
rigorous	   testing	  of	  all	   the	   reagents,	  we	   identified	   the	   initial	   source	  of	   infection	   in	  
the	   patient-­‐derived	   fibroblasts,	   which	   presented	   a	   low-­‐level	   mycoplasma	  
contamination	   that	   remained	   undetectable	   with	   our	   luminescence-­‐based	  
mycoplasma	  testing	  method	  when	  the	  cell	  medium	  was	  changed	  daily.	  Mycoplasma	  
infection,	   however,	   could	   be	   detected	   by	   using	   a	   more	   sensitive	   PCR-­‐based	  
detection	  technique	  or	  after	  prolonged	  culture	  without	  media	  changes	  (Young	  et	  al.	  
2010).	   Despite	   our	   efforts,	   all	   attempts	   to	   eradicate	   the	   infection	   either	   in	   the	  
patient	   fibroblast	   or	   in	   the	   iPSCs	   using	   a	   curative	   regimen	   of	   anti-­‐mycoplasma	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antibiotics	  failed.	  Given	  that	  vector	  design	  would	  require	  further	  optimisation	  and	  
that	   the	   process	   to	   receive	   ethical	   approval	   to	   obtain	   additional	   patient	   samples	  
would	  take	  too	  long,	  we	  decided	  to	  abandon	  this	  project	  and	  focus	  our	  efforts	  on	  
the	  Rep	  oligomerisation	  studies.	  
6.3 DISCUSSION	  
The	  aim	  of	  this	  project	  was	  to	  study	  the	  consequences	  and	  the	  potential	  of	  Rep-­‐
mediated	  targeted	  gene	  addition	   into	  AAVS1	   in	  a	  clinically	  relevant	  disease	  model	  
such	  as	  SCID-­‐X1.	  Our	  hope	  was	  to	  provide	  further	  insights	  into	  the	  development	  of	  
an	  AAV-­‐mediated	  technology	  for	  gene	  addition	   in	  cells	  with	  proliferative	  potential	  
through	   site-­‐specific	   integration.	   AAV	   is	   the	   only	   eukaryotic	   virus	   known	   to	   have	  
evolved	   a	   mode	   of	   integration	   into	   the	   human	   genome	   that	   has	   a	   very	   strong	  
preference	  for	  a	  single	  locus	  (AAVS1).	  As	  several	  aspects	  of	  the	  unique	  mechanism	  
of	   integration	   of	   AAV	   are	   beginning	   to	   be	   understood	   (Henckaerts	   and	   Linden	  
2010),	  it	  is	  becoming	  increasingly	  tempting	  to	  suggest	  that	  this	  virus	  has	  evolved	  a	  
strategy	   for	  minimal	  disruption	  of	   the	  host	  cell	  upon	   integration.	   Importantly,	   the	  
observed	  duplication	  of	  the	  target	  gene,	  PPP1R12C,	  which	  is	  a	  consequence	  of	  the	  
replication-­‐based	  integration	  mechanism,	  could	  potentially	  allow	  for	  the	  ‘removal’	  
of	   the	   viral	   and	   duplicated	   cellular	   DNA,	   thereby	   restoring	   normal	   PPP1R12C	  
expression.	  (Henckaerts	  et	  al.	  2009).	  	  
Several	  questions,	  however,	   remain	  to	  be	  addressed.	  First	  of	  all,	   the	  frequency	  
of	   Rep-­‐mediated	   integration	   remains	   unclear.	   Studies	   that	   investigated	   the	  
frequency	  of	  Rep-­‐mediated	  integration	  describe	  different	  results,	  with	  frequencies	  
that	  range	  from	  0.1%	  to	  over	  10%	  (Huser	  et	  al.	  2002;	  Philpott	  et	  al.	  2002;	  McCarty	  
et	   al.	   2004;	  Guilbaud	   et	   al.	   2008;	  Henckaerts	   and	   Linden	   2010).	   A	   comparison	   of	  
these	   studies,	   however,	   is	   difficult	   due	   to	   the	   differences	   in	   the	   assays	   used	   to	  
detect	  integration,	  the	  viral	  MOI,	  and	  the	  cell	  type	  used.	  In	  addition,	  several	  reports	  
have	  recently	  challenged	  the	  actual	  specificity	  of	  Rep	  integration	  (Huser	  et	  al.	  2010;	  
Janovitz	  et	   al.	   2013;	  Huser	  et	   al.	   2014;	  Petri	   et	   al.	   2015).	   In	   these	   studies,	  AAVS1	  
was	   the	  most	   frequent	   hotspot	   for	   integration,	   but	   several	   other	   hotspots	   were	  
found.	  Most	  likely	  due	  to	  the	  differences	  in	  experimental	  strategies,	  the	  identity	  of	  
these	   additional	   integration	   sites	   was	   only	   partially	   overlapping	   amongst	   these	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studies.	  AAV	  integration	  was	  shown	  to	  be	  enhanced	  by	  the	  presence	  of	  an	  RBS-­‐like	  
site	   and	   an	   appropriately	   spaced	   TRS	   homologue,	   suggesting	   that	   integration	   at	  
non-­‐AAVS1	   sites	   may	   also	   happen	   via	   a	   Rep-­‐mediated	   mechanism	   (Huser	   et	   al.	  
2010;	  Janovitz	  et	  al.	  2013;	  Huser	  et	  al.	  2014;	  Petri	  et	  al.	  2015).	  Achieving	  reasonably	  
high	   frequency	  and	  high	  specificity	  of	   integration	   is	  a	   critical	  element	   to	   render	  a	  
gene	  targeting	  technology	  safe	  and	  effective.	  Furthermore,	  the	  requirement	  for	  the	  
presence	  of	   Rep78/68	   for	   the	  mediation	   of	   integration	   into	  AAVS1	   represents	   an	  
important	   technical	   challenge	   due	   to	   the	   pleiotropic	   effects	   of	   the	   Rep	   proteins.	  
Safe	  and	  controlled	  Rep	  delivery	   strategies	   that	   induce	  a	   temporary	  and	  carefully	  
balanced	   Rep	   expression	   to	   ensure	   efficient	   targeted	   integration	   combined	   with	  
low	  cytotoxicity	  have	  yet	  to	  be	  fully	  developed	  (Recchia	  and	  Mavilio	  2011).	  For	  the	  
purpose	   of	   this	   project,	   we	   planned	   to	   use	   WT	   AAV	   alongside	   the	   rAAV-­‐IL2RG	  
vectors	  to	  provide	  Rep	  to	  mediate	  targeted	  integration,	  and	  to	  subsequently	  isolate	  
cells	   that	   only	   contained	   integrated	   recombinant	   vector.	   If	   successful,	   our	   study	  
could	  have	  served	  as	  proof-­‐of-­‐principle	  for	  the	  use	  of	  Rep-­‐mediated	  targeted	  gene	  
addition	   in	   cells	   with	   proliferative	   potential	   and	   would	   have	   warranted	   further	  
efforts	   to	   develop	   this	   strategy	   for	   biotechnological	   purposes.	   For	   example,	   Rep	  
could	  be	  provided	   in	  trans	  via	  vectors	  that	  do	  not	  have	  the	  ability	  to	   integrate,	   in	  
which	  expression	   is	  controlled	  by	  a	  promoter	  that	  results	   in	  Rep	  expression	   levels	  
similar	  to	  those	  observed	  in	  latent	  infection.	  	  
The	   most	   used	   strategies	   for	   genomic	   engineering	   include	   ZFNs,	   TALENs	   and	  
RGENs,	   collectively	   referred	   to	   as	   programmable	   or	   designer	   nucleases	   (Kim	   and	  
Kim	  2014).	  The	  basic	  mechanism	  behind	  these	  three	  technologies	  is	  the	  same:	  the	  
nuclease	   introduces	   a	   DSB	   into	   chromosomal	   DNA	   in	   a	   site-­‐specific	   manner,	  
thereby	   triggering	   endogenous	   DNA	   repair	   pathways,	   which	   ultimately	   result	   in	  
genome	  modifications.	  While	   designer	   nucleases	   present	   several	   advantages	   and	  
have	   been	  used	   efficiently	   in	   recent	   years,	   their	   reliance	   on	  DSB	   induction	   is	   not	  
ideal	  and	  can	  result	  in	  significant	  genotoxicity	  (Kim	  and	  Kim	  2014).	  While	  most	  DSBs	  
will	   be	   repaired	   precisely	   by	   homologous	   recombination	   in	   the	   presence	   of	  
homologous	   sequences,	   DSBs	   can	   also	   be	   repaired	   through	   the	   non-­‐homologous	  
end-­‐joining	   (NHEJ)	   pathway,	  which	  will	   cause	   small	   deletions	   or	   insertions	   at	   the	  
target	   site	   and	   lead	   to	   significant	   off	   target	   events	   (Gabriel	   et	   al.	   2011).	   Rep,	   in	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contrast,	  recognises	  a	  specific	  sequence	  in	  the	  human	  genome	  and	  induces	  a	  single-­‐
stranded	   nick	   at	   the	   cellular	   TRS	   site,	   avoiding	   the	   potentially	   deleterious	   effects	  
caused	   by	   the	   induction	   of	   DSBs	   (Dutheil	   and	   Linden	   2006).	   In	   addition,	   Rep-­‐
mediated	   integration	   has	   been	   suggested	   to	   lead	   to	   a	   partial	   duplication	   of	   the	  
AAVS1	   target	   site,	   potentially	   minimising	   the	   consequences	   of	   disruption	   of	   the	  
PPP1R12C	   gene	   (Henckaerts	   et	   al.	   2009).	   Interestingly,	   programmable	   nickases	  
engineered	  from	  designer	  nucleases	  to	  only	  induce	  a	  ss	  nick	  instead	  of	  a	  DSB	  at	  the	  
target	  site,	  have	  been	  shown	  to	  significantly	   lower	  genotoxicity	  and	  to	  promote	  a	  
more	   precise	   genome	   editing,	   albeit	   at	   lower	   frequencies	   (Kim	   and	   Kim	   2014).	  
Ideally,	   a	   thorough	   study	   of	   the	   consequences	   of	   integration	   should	   take	   into	  
account	  not	  only	  possible	  interferences	  with	  the	  expression	  of	  PPP1R12C,	  but	  also	  
potential	   long-­‐range	   effects	   on	  other	   genes,	   as	  well	   as	   consider	   the	  possibility	   of	  
aberrant	  splicing	  events	  through	  cryptic	  splicing	  sites	  present	  in	  the	  vector	  genome	  
as	  reported	  for	  lentiviral	  vector	  integrations	  (Cesana	  et	  al.	  2012).	  
Zooming	  in	  on	  the	  results	  presented	  in	  this	  chapter,	  we	  were	  surprised	  to	  see	  a	  
difference	  in	  transgene	  expression	  between	  our	  transfection	  and	  our	  transduction	  
experiments.	  The	  reasons	  for	  this	  difference	  are	  not	  clear,	  but	  are	  likely	  to	  include	  
differences	   in	   the	   number	   of	   gene	   copies	   available	   for	   transcription.	   This	   could	  
possibly	  be	  caused	  by	  limited	  second-­‐strand	  synthesis	  of	  our	  viral	  vectors,	  a	  known	  
rate-­‐limiting	  step	  for	  efficient	  rAAV	  transduction	  (Ferrari	  et	  al.	  1996).	  This	  could	  be	  
assessed	   by	   analysing	   the	   mRNA	   levels	   of	   our	   transgenes	   in	   transfected	   and	  
transduced	  cells.	  In	  addition,	  the	  observation	  that	  GFP	  expression	  was	  much	  more	  
robust	   than	   γ-­‐chain	   expression	  points	   at	   significant	   differences	   in	   the	   strength	  of	  
the	  expression	  cassettes	  used	  in	  our	  study,	  and	  possibly	  to	  some	  level	  of	  promoter	  
interference	   (Eszterhas	  et	  al.	  2002).	  Taken	   together,	  our	   results	  warrant	  a	   careful	  
validation	  of	  vector	  design	  in	  studies	  that	  use	  AAV	  as	  their	  viral	  vector	  of	  choice.	  
This	   study	  was	  aimed	   to	   serve	  as	  proof-­‐of-­‐principle	   for	  Rep-­‐mediated	   targeted	  
gene	   addition	   in	   cells	  with	   proliferative	   potential	   in	   a	   clinically	   relevant	  model.	   If	  
successful,	   it	   would	   have	   justified	   further	   efforts	   to	   develop	   this	   strategy	   for	  
biotechnological	   purposes.	   At	   this	   time,	   however,	   the	   real	   potential	   of	   this	  
technology	   remains	   unclear,	   and	   while	   Rep-­‐mediated	   integration	   remains	   an	  
important	   aspect	   of	   AAV	   biology	   worth	   investigating,	   the	   rapid	   developments	   of	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more	  efficient	  and	  versatile	  technologies	  question	  the	  relevance	  of	  further	  studies	  
of	  Rep-­‐mediated	  gene	  addition	  as	  a	  technology.	   In	  particular,	  the	  discovery	  of	  the	  
mechanism	   of	   action	   of	   the	   CRISPR-­‐Cas9	   system	   (Jinek	   et	   al.	   2012)	   and	   its	  
biotechnological	   development	   as	   highly	   efficient	   and	   highly	   specific	   RGENs	  
(Sternberg	   and	   Doudna	   2015),	   make	   it	   more	   and	   more	   challenging	   to	   invest	   in	  
genome-­‐modifying	  technologies	  that	  are	  significantly	  less	  efficient.	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CHAPTER	  7: GENERAL	  DISCUSSION	  AND	  PERSPECTIVES	  
	  
AAV	   is	   a	   small,	   non-­‐enveloped,	   ssDNA	   virus	   that	   is	   intrinsically	   replication	  
incompetent	  and	  requires	  co-­‐infection	  by	  a	  helper	  virus	  to	  replicate.	  It	  was	  initially	  
discovered	  50	  years	  ago	  as	  a	  contaminant	  of	  adenoviral	  stocks.	  Despite	  50	  years	  of	  
research	  and	  widespread	  infection	  throughout	  the	  human	  population,	  AAV	  has	  not	  
been	  conclusively	  associated	  with	  any	  human	  pathology.	  Despite	  its	  small	  genome	  
size,	  AAV	  has	  a	  tightly	  regulated	  life	  cycle	  that	  reflects	  its	  reliance	  on	  helper	  viruses	  
for	  productive	  replication.	  In	  the	  presence	  of	  a	  helper	  virus,	  AAV	  DNA	  is	  efficiently	  
replicated	   and	   packaged	   to	   form	  new	   infectious	   AAV	  particles.	   In	   the	   absence	   of	  
helper	  virus,	  however,	  AAV	  can	  establish	  latency	  to	  persist	  in	  the	  infected	  cell.	  Two	  
mechanisms	   have	   been	   described	   for	   latency:	   episomal	   persistence	   and	  
chromosomal	   integration.	  These	  peculiar	   features	  of	   the	  AAV	   life	   style,	   combined	  
with	  the	  lack	  of	  disease	  association	  and	  a	  certain	  ease	  of	  manipulation,	  have	  fuelled	  
the	  development	  of	  AAV	  vectors	  for	  gene	  therapy	  and,	  today,	  most	  of	  the	  research	  
on	   AAV	   revolves	   around	   its	   potential	   as	   a	   gene	   therapy	   vector.	   After	   pre-­‐clinical	  
trials	   showed	   encouraging	   safety	   and	   efficacy	   results	   in	   several	   disease	   models,	  
numerous	  AAV	  vectors	  have	  now	  entered	  clinical	  trials,	  and	  several	  more	  are	  being	  
developed	  towards	  clinical	  application.	   In	  particular,	   the	  AAV	  capsid	  has	  been	  the	  
focus	  of	  detailed	   studies,	   and	  as	   capsid	  variants	  with	  defined	   tissue	   tropisms	  and	  
specificities	  are	  becoming	  available,	  we	  are	  now	  closer	  to	  an	  AAV	  capsid	  toolkit	  that	  
could	  allow	  tailoring	  of	  the	  capsid	  to	  the	  desired	  clinical	  target.	  Much	  remains	  to	  be	  
learned	  from	  the	  basic	  AAV	  biology,	  however,	  and	  important	  contributions	  to	  AAV	  
gene	  therapy	  are	  likely	  to	  come	  from	  basic	  research.	  
The	  biology	  of	  AAV	  presents	  several	   intriguing	  aspects	  that	  have	  yet	  to	  be	  fully	  
uncovered.	  For	  example,	  AAV	  has	  evolved	  a	  single	  gene,	  called	  Rep,	  which	  encodes	  
for	   the	   non-­‐structural	   proteins	   that	   orchestrate	   the	   entire	   AAV	   life	   cycle.	   The	  
products	   of	   the	   Rep	   gene,	   the	   proteins	   Rep78,	   Rep68,	   Rep52	   and	   Rep40,	   are	  
essential	   for	   virtually	   all	   stages	   of	   the	   AAV	   life	   cycle,	   including	   replication,	  
packaging,	  transcriptional	  regulation,	  and	  chromosomal	   integration.	  The	   large	  Rep	  
proteins,	   Rep78	   and	   Rep68,	   are	   remarkable	   examples	   of	   viral	   multifunctional	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proteins,	   which	   concentrate	   several	   enzymatic	   activities	   within	   a	   single	  
polypeptide.	   Rep78/68	   have	  DNA	  binding,	   nicking,	   helicase	   and	  ATPase	   activities,	  
which	  are	  necessary	  to	  mediate	  several	  DNA	  transactions	  during	  the	  AAV	  life	  cycle,	  
including	  the	  critical	  terminal	  resolution	  step	  of	  AAV	  replication	  and	  the	  integration	  
of	   AAV	   into	   its	   chromosomal	   target	   site	   AAVS1.	   Rep78/68	   have	   a	   multi-­‐domain	  
organisation:	  the	  N-­‐terminal	  domain	  contains	  RBS-­‐specific	  DNA	  binding	  and	  nicking	  
activities,	  while	   the	  C-­‐terminal	  domain	   is	   an	  ATP-­‐dependent	  helicase.	  Despite	   the	  
fact	   that	   the	   enzymatic	   functions	   of	   Rep78/68	   have	   been	   well	   defined,	   less	   is	  
known	  about	  the	  molecular	  mechanisms	  behind	  these	  functions.	  In	  particular,	  how	  
the	   variety	   of	   enzymatic	   activities	   are	   regulated	   and	   coordinated	   remain	   elusive.	  
The	  first	  objective	  of	  the	  research	  presented	  in	  this	  thesis	  was	  to	  contribute	  to	  the	  
understanding	  of	   the	   structural	   requirements	  behind	   the	  biochemical	   activities	  of	  
the	  large	  Rep	  proteins.	  More	  specifically,	  we	  aimed	  at	  defining	  functionally	  relevant	  
determinants	  of	  Rep68	  oligomerisation,	  which,	  we	  hypothesised,	  contribute	  to	  the	  
coordination	  of	  Rep68	  activities.	  Our	  investigations,	  presented	  in	  chapters	  4	  and	  5,	  
allowed	   us	   to	   identify	   a	   novel	   Rep68	  mutant	   that	   prevented	   aggregation	   of	   this	  
protein,	  which	  was	  hindering	   further	  structural	   studies	  of	  Rep68.	  This	  mutant	  has	  
already	  proven	   its	  potential	   allowing	  a	   systematic	   study	  of	  Rep68	  oligomerisation	  
(Zarate-­‐Perez	   et	   al.	   2013),	   the	   first	   structural	   characterisation	   of	   the	   full-­‐length	  
Rep68	   (Musayev	   et	   al.	   2015a)	   and	   the	   crystallisation	   of	   the	   OBD	   of	   Rep68	   in	  
complex	   with	   the	   RBS	   at	   the	   AAVS1	   integration	   site	   (Musayev	   et	   al.	   2015b).	  
Furthermore,	   we	   defined	   a	   new	   oligomerisation	   domain	   (OD)	   in	   Rep68	   that	  
includes	  part	  of	  the	  interdomain	  linker	  and	  provides	  an	  elegant	  explanation	  of	  the	  
differences	   in	   oligomerisation	   of	   the	   small	   and	   large	   Rep	   proteins.	   One	   linker	  
residue,	  Y224,	   is	  conserved	  amongst	  SF3	  helicases,	  and	  we	  showed	  that	   it	  plays	  a	  
critical	   role	   in	   Rep	   oligomerisation	   and	   function.	   Finally,	   the	   results	   presented	   in	  
chapter	  5	  describe	  the	  identification	  of	  an	  oligomeric	  interface	  that	  is	  essential	  for	  
the	   correct	   functioning	   of	   Rep68.	   Disruption	   of	   this	   hydrophobic	   interface	   had	  
drastic	   consequences	   on	   the	  biochemical	   activities	   of	   the	  Rep	  proteins	   and	  more	  
generally	  on	  the	  AAV	  life	  cycle,	  supporting	  the	  hypothesis	  that	  Rep	  oligomerisation	  
plays	  a	   critical	   role	   in	   the	  AAV	   life	   cycle.	  Determining	  how	  the	   large	  Rep	  proteins	  
oligomerise	   could	   provide	   significant	   insights	   into	   the	   enzymatic	   mechanisms	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behind	   Rep78/68	   functions,	   including	   Rep-­‐mediated	   chromosomal	   integration.	  
Further	   studies	   on	   the	   postulated	   role	   of	   substrate-­‐dependent	   oligomerisation	   in	  
coordinating	  Rep78/68	  enzymatic	  activities,	  in	  particular,	  will	  be	  important.	  	  
Identifying	   similarities	   and	   differences	   in	   the	   oligomeric	   properties	   of	   proteins	  
related	   to	   Rep78/68,	   such	   as	   parvoviral	   NS1	   proteins,	   SF3	   helicases	   or	   HUH	  
endonucleases,	   could	   also	   foster	   interesting	   developments.	   For	   instance,	   the	  
functional	   conservation	   of	   structural	   motifs	   within	   the	   HUH	   family	   of	  
endonucleases	  or	  within	  the	  SF3	  helicases,	  could	  be	  explored	  by	  swapping	  catalytic	  
motifs.	  This	  approach	  has	  been	  used	  previously	  to	  demonstrate	  that	  the	  ori-­‐specific	  
DNA	  binding	  activity	  of	  Rep78/68	  was	  fully	  contained	  within	  its	  OBD	  (Cathomen	  et	  
al.	   2000;	   Yoon	   et	   al.	   2001).	   Yoon	   and	   colleagues,	   however,	   were	   also	   able	   to	  
demonstrate	   that	   a	   chimeric	   protein	   made	   by	   combining	   the	   OBD	   of	   the	   goose	  
parvovirus	   (GPV)	   Rep1	   protein	   and	   the	   helicase	   domain	   of	   AAV2	   Rep78	   fully	  
supported	  the	  in	  vitro	  replication	  of	  a	  substrate	  that	  contained	  the	  GPV	  ori.	  It	  would	  
be	  interesting	  to	  test	  whether	  this	  chimeric	  protein	  supports	  GPV	  replication	  in	  cells	  
that	  are	  normally	  infected	  by	  GPV	  and	  in	  cells	  that	  are	  specific	  for	  AAV2	  replication.	  
It	   would	   be	   even	   more	   intriguing	   to	   assess	   the	   ability	   of	   less	   related	   HUH	  
endonucleases,	   such	   as	   plant	   viruses	   or	   even	   bacterial	   relaxases,	   to	   functionally	  
combine	  with	  the	  helicase	  domain	  of	  Rep.	  Potentially,	  this	  would	  allow	  to	  redirect	  
protein	   functions	   from	  one	   species	   to	   another,	   and	   could	   expand	   the	   number	   of	  
available	   substrates	   for	   enzymes	   that	   have	   biotechnological	   applications.	  
Understanding	   the	   precise	   domain	   boundaries,	   as	  well	   as	   defining	   the	   oligomeric	  
properties	   that	   support	   the	   functions	   investigated,	   is	   critical	   for	   the	   informed	  
design	   of	   such	   studies.	   For	   example,	   it	   is	   likely	   that	   functionally	   combining	   the	  
functions	   of	   two	   proteins	   that	   form	   the	   same	   oligomeric	   complex	   will	   be	   easier	  
than	   combining	   domains	   from	   proteins	   that	   have	   distinct	   oligomeric	   behaviours.	  
Importantly,	   the	   apparent	   conservation	   of	   an	   OD	   in	   the	   region	   that	   connects	  
catalytically	  active	  domains,	  such	  as	  the	  OBD	  and	  helicase	  domains	  of	  Rep68,	  needs	  
to	   be	   carefully	   considered	   in	   designing	   chimeric	   proteins	   whose	   oligomeric	  
properties	   are	   assumed	   to	   be	   functionally	   relevant.	   In	   the	   context	   of	   Rep68	  
functions	  in	  the	  AAV	  life	  cycle,	  it	  would	  be	  intriguing	  to	  investigate	  the	  possibility	  to	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redirect	   the	   specificity	   of	   Rep-­‐mediated	   integration	   into	   the	   human	   genome	   to	  
different	  target	  sites	  by	  combining	  it	  with	  the	  OBD	  of	  a	  related	  protein.	  
Rep-­‐mediated	   integration	   into	   the	   integration	   site	  AAVS1	  was	   the	   focus	  of	   the	  
last	  chapter	  of	  this	  thesis.	  Our	  aim	  was	  to	  study	  the	  safety	  and	  the	  feasibility	  of	  a	  
Rep-­‐mediated	   strategy	   to	   site-­‐specifically	   add	   a	   transgene	   into	   the	   safe-­‐harbour	  
locus	  AAVS1	  in	  a	  translationally	  relevant	  disease	  model,	  namely	  SCID-­‐X1	  iPSCs.	  The	  
standard	   cure	   for	   SCID-­‐X1,	   a	   devastating	   immunodeficiency,	   is	   allogeneic	   bone	  
marrow	   transplantation,	   but	   when	   a	   patient	   lacks	   an	   HLA-­‐matched	   donor,	   gene	  
therapy	   is	   a	   valuable	   option.	   Clinical	   trials	   that	   used	   autologous	  HSCs	   transduced	  
with	  a	  retroviral	  vector	  harbouring	  the	  corrective	  gene	  to	  reconstitute	  immunity	  in	  
SCID-­‐X1	   patients	   have	   shown	   great	   promise.	   A	   small	   percentage	   of	   the	   patients	  
treated	  with	  this	  approach,	  however,	  developed	  significant	  side	  effects	  in	  the	  form	  
of	  leukaemia	  due	  to	  the	  activation	  of	  proto-­‐oncogenes	  by	  the	  integrated	  provirus.	  
These	   results	   warranted	   the	   investigation	   of	   alternative	   strategies	   to	  modify	   the	  
genome	   in	  a	  controlled	  way.	   It	   is	   in	   this	   context	   that	  we	  decided	   to	  assess	   if	  Rep	  
mediated	   integration	  would	  be	  a	   viable	  alternative	  approach	   to	  modify	   cells	  with	  
proliferative	   potential.	   Our	   hypothesis	   was	   that	   Rep-­‐mediated	   integration	   into	  
AAVS1	   is	   a	   naturally	   evolved	   strategy	   to	   site-­‐specifically	   insert	   exogenous	   genetic	  
material	  into	  the	  human	  genome	  without	  major	  consequences	  for	  the	  host	  cell.	  Our	  
hypothesis	  was	  based	  on	  reports	  that	  showed	  that	  human	  and	  mouse	  ESCs	  carrying	  
a	   transgene	   integrated	   into	   AAVS1	   by	   Rep-­‐mediated	   integration	   showed	   normal	  
differentiation	   in	   vitro	   and	   in	   vivo	   and	   robust	   transgene	   expression	   throughout	  
differentiation.	   After	   successfully	   generating	   iPSCs	   from	   SCID-­‐X1	   fibroblasts	   and	  
validating	   a	   potential	   therapeutic	   targeting	   rAAV	   vector,	   unfortunately,	   an	  
untreatable	  mycoplasma	  infection	  of	  the	  iPSCs	  forced	  us	  to	  terminate	  this	  project.	  
If	  successful,	  this	  project	  would	  have	  supported	  the	  development	  of	  Rep-­‐mediated	  
integration	   as	   a	   viable	   approach	   to	   achieve	   targeted	   gene	   addition	   in	   clinically	  
relevant	   cell	   populations.	   However,	   during	   the	   time	   of	   this	   thesis,	   important	  
technological	   advancements,	   such	   as	   the	   development	   of	   RGENs	   as	   well	   as	  
significant	  contributions	  to	  our	  understanding	  of	  AAV	   integration,	  and	  particularly	  
of	   its	   specificity,	  argue	  against	   the	  development	  of	  Rep-­‐mediated	   integration	  as	  a	  
biotechnological	  tool.	  The	  low	  efficiency	  and	  the	  newly	  described	  limited	  specificity	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of	   AAV	   integration	   are	   significant	   limitations	   that	   cannot	   be	   overlooked.	   Only	  
developments	   that	  will	   overcome	   these	   important	   limitations	  would	   permit	   Rep-­‐
mediated	  integration	  to	  become	  an	  attractive	  option	  for	  gene	  therapy.	  The	  study	  of	  
the	   importance	   of	   AAV	   integration	   into	   the	   human	   genome,	   however,	   is	   still	  
relevant	   in	   the	   context	   of	   the	   biology	   of	   the	   AAV	   life	   cycle.	   Investigating	   the	  
existence	  of	   integrated	  AAV	   sequences	   in	   vivo	  will	   be	  particularly	   relevant	   to	   the	  
establishment	  of	  the	  role	  of	  Rep-­‐mediated	  integration	  in	  the	  AAV	  life	  cycle.	  
Finally,	   in	   addition	   to	   the	   research	   questions	   highlighted	   here	   and	   discussed	  
throughout	   the	   rest	   of	   this	   thesis,	   two	   facets	   of	   the	   basic	   AAV	   biology	   may	   see	  
significant	   developments	   in	   the	   coming	   years.	   The	   first	   is	   the	   study	   of	   AAV	  
interactions	  with	   the	  host	  cell	  and	   the	  consequences	  of	   these	   interactions	  on	   the	  
AAV	  life	  cycle.	  Most	  of	  the	  information	  available	  to	  date	  is	  extremely	  fragmented,	  
with	  multiple	  individual	  reports	  that	  identify	  a	  role	  for	  cellular	  factors	  but	  that	  have	  
not	  been	  followed	  up.	  Defining	  a	  coherent	  picture	  of	  the	  role	  of	  pathways	  of	  innate	  
immunity	  or	  of	  DDR,	   for	  example	  will	  provide	   intriguing	   insights	   into	  AAV	  biology	  
and	   the	   reasons	   for	   AAV’s	   inability	   to	   replicate	   autonomously.	   Furthermore,	  
investigating	   potential	   restriction	   factors	   for	   AAV	   replication,	   gene	   expression	   or	  
packaging,	   could	   also	   improve	   the	   current	   protocols	   for	   the	   production	   of	   AAV	  
vectors.	  As	  these	  host-­‐virus	   interactions	  become	  better	  defined	  and	  a	  role	  for	  the	  
Rep	   proteins	   in	   these	   interactions	   is	   established,	   structure-­‐function	   studies	   and	  
biophysical	   analyses	   as	   those	   presented	   here	   will	   further	   this	   field.	   The	   second	  
aspect	   of	   AAV	   biology	   that	   is	   particularly	   intriguing	   and	   warrant	   further	  
investigations	   is	   the	  dependence	  of	  AAV	  on	  helper	  virus	   functions.	   It	   is	  becoming	  
increasingly	  clear	   that	  viruses	   interact	  not	  only	  with	   their	  host	  but	  also	  with	  each	  
other.	   Improving	  our	  understanding	  of	  AAV-­‐adenovirus	   and	  AAV-­‐HSV	   interactions	  
may	   reveal	   important	   features	   of	   interviral	   interactions	   that	   could	   be	   applied	   to	  
other	  viral	  systems,	  including	  clinically	  relevant	  ones.	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ANNEX	  1:	  SUPPLEMENTARY	  INFORMATION	  
TABLE	  1:	  PLASMIDS	  	  
Plasmid	   Content	   Cloning	  strategy	   Resistance	  
	   	  	   	  	   	  	  AAV	  	  
pAV2	   Infectious	  AAV	  plasmids	   	   Amp	  
pSub201	   Infectious	  AAV	  plasmids	   	   Amp	  
pMB2	   pAV2	  based,	  C151S	  Rep	  mutation	   SfiI+HindIII	  from	  pMB1	   Amp	  
pMB7	   pMB2	  based,	  Y224A	  Rep	  mutation	   SfiI+HindIII	  from	  pET15b-­‐Rep68-­‐C151S-­‐Y224A	   Amp	  
pMB8	   pMB2	  based,	  Y224P	  Rep	  mutation	   SfiI+HindIII	  from	  pET15b-­‐Rep68-­‐C151S-­‐Y224P	   Amp	  
pMB9	   pMB2	  based,	  Y224F	  Rep	  mutation	   SfiI+HindIII	  from	  pET15b-­‐Rep68-­‐C151S-­‐Y224F	   Amp	  
pMB11	   pMB2	  based,	  Rep	  mutations	  L193A	  and	  V196A	   SfiI+HindIII	  from	  pMB10	   Amp	  
pMB27	   pMB2	  based,	  Rep	  mutations	  Y224A	  and	  I251A	   SfiI+HindIII	  from	  pMB28	   Amp	  
pMB31	   pMB2	  based,	  Rep	  mutations	  I251A	   SfiI+HindIII	  from	  pMB29	   Amp	  
pMB32	   pMB2	  based,	  Rep	  mutations	  K340H	   SfiI+HindIII	  from	  pMB30	   Amp	  
	   	  	   	  	   	  	  
Helpers	  
mini-­‐pDG	   Rep	  and	  CAP	  only	   	   Amp	  
HGTI	   Adeno	  helper	  functions	   	   Amp	  
pXX6	   Adeno	  helper	  functions	   	   Amp	  
pAAVDJ	   AAV2	  Rep	  and	  DJ	  Cap	   	   Amp	  
pMB1	   mini-­‐pDG	  based,	  C151	  Rep	  mutation	   mutagenesis	  on	  mini-­‐pDG	   Amp	  
pMB4	   pMB1	  based,	  Y224A	  Rep	  mutation	   SfiI+HindIII	  from	  pET15b-­‐Rep68-­‐C151S-­‐Y224A	   Amp	  
pMB5	   pMB1	  based,	  Y224P	  Rep	  mutation	   SfiI+HindIII	  from	  pET15b-­‐Rep68-­‐C151S-­‐Y224P	   Amp	  
pMB6	   pMB1	  based,	  Y224F	  Rep	  mutation	   SfiI+HindIII	  from	  pET15b-­‐Rep68-­‐C151S-­‐Y224F	   Amp	  
pMB10	   pMB1	  based,	  Rep	  mutations	  L193A	  and	  V196A	   mutagenesis	  on	  pMB1	   Amp	  
pMB28	   pMB1	  based,	  Rep	  mutations	  Y224A	  and	  I251A	   mutagenesis	  on	  pMB1	   Amp	  
pMB29	   pMB1	  based,	  Rep	  mutation	  I251A	   mutagenesis	  on	  pMB1	   Amp	  
pMB30	   pMB1	  based,	  Rep	  mutation	  340H	   BamHI+BstEII	  from	  pND232	   Amp	  
	   	  	   	  	   	  	  
rAAV	  
pTRUF11	   CAG-­‐GFP-­‐pk-­‐NEO	  between	  ITRs	   	   Amp	  
pMB12	   pSUB201-­‐EF1a-­‐CG	  (no	  WPRE,	  no	  polyA	  tail)	  
EF1a-­‐CG	  from	  SINLV-­‐CG	  with	  XbaI,	  SbfI	  (upstream)	  
and	  AvrII,	  XhoI,	  NotI,	  NheI	  (downstream)overhangs	  
by	  PCR	  cloned	  into	  pSUB201	  XbaI	  sites	  inside	  the	  
ITRs.	  The	  second	  XbaI	  site	  was	  lost	  because	  it	  was	  
ligated	  with	  the	  compatible	  NheI	  site	  in	  the	  insert.	  
Amp	  
pMB13	   pSUB201-­‐EF1a-­‐CG	  
WPRE	  and	  SV40	  (late)	  polyA	  	  from	  pLA100	  (LA/AA)	  
with	  AvrII	  (upstream)	  andLoxP,	  XhoI,	  NotI	  	  
(downstream)	  overhangs	  by	  PCR,	  cloned	  into	  
pMB12	  using	  AvrII	  and	  NotI.	  
Amp	  
pMB14	   pSUB201-­‐EF1a-­‐CG-­‐loxP-­‐CMV-­‐GFP-­‐loxP	  
CMV-­‐GFP-­‐pA(bGH)	  from	  CMV-­‐GFP	  plasmid	  with	  
XhoI	  (upstream)	  and	  LoxP-­‐NotI	  overhangs	  
(downstream),	  cloned	  into	  pMB13	  using	  XhoI	  and	  
NotI.	  
Amp	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Plasmid	   Content	   Cloning	  strategy	   Resistance	  
	   	   	   	  
Rep	   	  	   	  	   	  	  
pND226	   CMV-­‐Rep68	  Y156F	  M225G	   	   Kana	  
pMB21	   CMV-­‐Rep68	  M225G	   From	  pND226	  after	  mutagenesis	  to	  revert	  F156	  to	  Y	   Kana	  
pMB22	   CMV-­‐Rep68	  C151S	  M225G	   From	  pMB21	  after	  mutagenesis	  C151S	   Kana	  
pMB23	   CMV-­‐Rep68	  C151S	  M225G	  Y224A	   mutagenesis	  on	  pMB22	   Kana	  
pMB24	   CMV-­‐Rep68	  C151S	  M225G	  Y224F	   mutagenesis	  on	  pMB22	   Kana	  
pMB25	   CMV-­‐Rep68	  C151S	  L193A	  V196A	  M225G	   mutagenesis	  on	  pMB22	   Kana	  
pMB26	   CMV-­‐Rep68	  C151S	  M225G	  Y224A	  I251A	   BamHI+BstEII	  from	  pMB28,	  into	  pMB23	   Kana	  
pMB33	   CMV-­‐Rep68	  C151S	  M225G	  I251A	   BamHI+BstEII	  from	  pND29	   Kana	  
pMB34	   CMV-­‐Rep68	  C151S	  M225G	  K340H	   BamHI+BstEII	  from	  pND232	   Kana	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TABLE	  2:	  PRIMERS	  
	  
Name	   	  	   Sequence	  (5'-­‐>3')	   Target	  
	  	   	   	   	  
Primers	  for	  mutagenesis	   	   	   	  
MB1	   fw	   CAAGGTGGTGGATGAGTCTTACATCCCCAATTAC	   mutagenesis	  of	  Rep	  C151	  to	  S151	  
MB2	   rv	   GTAATTGGGGATGTAAGACTCATCCACCACCTTG	   mutagenesis	  of	  Rep	  C151	  to	  S152	  
MB18	   fw	   CGGTTGGTGGCGCAGCATGCCACGCACGCTTCGCAGACGCAGGAGC	   Rep	  mutagenesis:	  L193A	  +	  V196A	  
MB19	   rv	   GCTCCTGCGTCTGCGAAGCGTGCGTGGCATGCTGCGCCACCAACCG	   Rep	  mutagenesis:	  L193A	  +	  V196A	  
MB65_Y224A_fw	   fw	   CAAAAACTTCAGCCAGGgcCATGGAGCTGGTCGGG	   mutagenesis	  Y224A	  (wt)	  in	  Rep	  wt	  
MB66_Y224A_rv	   rv	   CCCGACCAGCTCCATGgcCCTGGCTGAAGTTTTTG	   mutagenesis	  Y224A	  (wt)	  in	  Rep	  wt	  
MB67_Y224F_fw	   fw	   CAAAAACTTCAGCCAGGTtCATGGAGCTGGTCGGG	   mutagenesis	  Y224F	  (wt)	  in	  Rep	  wt	  
MB68_Y224F_rv	   rv	   CCCGACCAGCTCCATGaACCTGGCTGAAGTTTTTG	   mutagenesis	  Y224F	  (wt)	  in	  Rep	  wt	  
MB69_Y224A_fw_M225G	   fw	   CAAAAACTTCAGCCAGGgcCggaGAGCTGGTCGGG	   mutagenesis	  Y224A	  (wt)	  in	  Rep	  M225G	  
MB70_Y224A_rv_M225G	   rv	   CCCGACCAGCTCtccGgcCCTGGCTGAAGTTTTTG	   mutagenesis	  Y224A	  (wt)	  in	  Rep	  M225G	  
MB71_Y224F_fw_M225G	   fw	   CAAAAACTTCAGCCAGGTtCggaGAGCTGGTCGGG	   mutagenesis	  Y224F	  (wt)	  in	  Rep	  M225G	  
MB72_Y224F_rv_M225G	   rv	   CCCGACCAGCTCtccGaACCTGGCTGAAGTTTTTG	   mutagenesis	  Y224F	  (wt)	  in	  Rep	  M225G	  
MB77_251fw	   rv	   GACCAGGCCTCATACGCCTCCTTCAATGCGGC	   mutagenesis	  I251A	  in	  Rep	  wt	  
MB78_251rv	   fw	   GCCGCATTGAAGGAGGCGTATGAGGCCTGGTC	   mutagenesis	  I251A	  in	  Rep	  wt	  
	   	   	   	  
Primers	  for	  cloning	   	   	   	  
MB12_Step1fw	   fw	   ccaaTCTAGACGTTGTCCCTGCAGGttatcgattggctccggtgcccgt	  
primer	  for	  1st	  step	  (EF1a-­‐CG)	  of	  cloning	  of	  
AAV-­‐CG-­‐GFP	  vector	  	  
MB13_Step1rv	   rv	   ccaaGCTAGCGGGCCGCcaacCTCGAGcaacCCTAGGtaggtttcaggctttagggtgtaacatgggg	  
primer	  for	  1st	  step	  (EF1a-­‐CG)	  of	  cloning	  of	  
AAV-­‐CG-­‐GFP	  vector	  	  
MB14_Step2fw	   fw	   ccaaCCTAGGCGCCgatccgtcgataatcaacctctggattacaa	  
primer	  for	  2nd	  step	  (WPRE-­‐pA)	  of	  cloning	  of	  
AAV-­‐CG-­‐GFP	  vector	  
MB15_Step2rv	   rv	   ccaaCTCGAGataacttcgtatagcatacattatacgaagttatGGTACCctgggggatcttcgatgctagacgat	  
primer	  for	  2nd	  step	  (WPRE-­‐pA)	  of	  cloning	  of	  
AAV-­‐CG-­‐GFP	  vector	  
MB16_Step3fw	   fw	   ccaaCTCGAGcgatgtacgggccagatatacgcgttgaca	   primer	  for	  3rd	  step	  (CMV-­‐GFP)	  of	  cloning	  of	  AAV-­‐CG-­‐GFP	  vector	  	  
MB17_Step3rv	   rv	   ccaaGCGGCCGCataacttcgtatagcatacattatacgaagttatATGCATagaagccatagagcccaccgcatcccc	  
primer	  for	  3rd	  step	  (CMV-­‐GFP)	  of	  cloning	  of	  
AAV-­‐CG-­‐GFP	  vector	  	  
MB81_Rep68_fw	   fw	   CCAAtctagaATGCCGGGGTTTTACGAGATTGTG	   amplification	  of	  Rep68	  from	  CMV-­‐Rep68,	  XbaI	  and	  NotI	  overhangs	  
MB82_Rep68_rv	   rv	   CCAAgcggccgcTCAGAGAGAGTGTCCTCGAGCCAATC	  
amplification	  of	  Rep68	  from	  CMV-­‐Rep68,	  
XbaI	  and	  NotI	  overhangs	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Name	   	  	   Sequence	  (5'-­‐>3')	   Target	  
	   	   	   	  
Primers	  for	  sequencing	   	   	   	  
MB3	   rv	   GTCAGGCTCATAATCTTTCCCGCA	   sequencing	  of	  Rep	  
MB20	   fw	   cttcacaaactgagtgaatcccagctag	   sequencing	  of	  IL2RG	  in	  AAV	  vectors	  
MB21	   rv	   tgctccaaacagtggttcaagaatctg	   sequencing	  of	  IL2RG	  in	  AAV	  vectors	  
MB22	   fw	   TCCTGGTTGCTGTCTCTTTATG	   sequencing	  of	  pMB14	  (WPRE)	  
MB23	   fw	   CGATGTACGGGCCAGATATAC	   sequencing	  of	  pMB14	  	  
MB24	   fw	   GTAAACGGCCACAAGTTCAG	   sequencing	  of	  pMB14	  (GFP)	  
MB25	   rv	   AGTTCCCGTGGTATTCAGTAAC	   sequencing	  of	  pMB14	  (IL2RG)	  
ND140	   fw	   GTTTCCTGAGTCAGATTCGCG	   sequencing	  of	  Rep	  
	   	   	   	  
qPCR	  primers	   	   	  
Cap1	   fw	   TTCTCAGATGCTGCGTACCGGAAA	   wt	  AAV	  quantification	  
Cap2	   rv	   TCTGCCATTGAGGTGGTACTTGGT	   wt	  AAV	  quantification	  
CycloFW	   fw	   TGCTGGACCCAACACAAATG	   wt	  AAV	  quantification	  
CycloRV	   rv	   TGCCATCCAACCACTCAGTCT	   wt	  AAV	  quantification	  
MB85_p5fw	   rv	   AACAAGGTGGTGGATGAGT	   taqman	  qPCR	  on	  AAV	  cDNA	  
MB86_p5rv	   fw	   CGTTTACGCTCCGTGAGATT	   taqman	  qPCR	  on	  AAV	  cDNA	  
MB87_p19fw	   fw	   TCACCAAGCAGGAAGTCAAAG	   taqman	  qPCR	  on	  AAV	  cDNA	  
MB88_p19rv	   rv	   CCCGTTTGGGCTCACTTATATC	   taqman	  qPCR	  on	  AAV	  cDNA	  
MB89_p40fw	   fw	   GGAAGCAAGGCTCAGAGAAA	   taqman	  qPCR	  on	  AAV	  cDNA	  
MB90_p40rv	   rv	   CCTCTCTGGAGGTTGGTAGATA	   taqman	  qPCR	  on	  AAV	  cDNA	  
CGfw	   fw	   CGCCACCATGTTGAAGCCATCATT	   titration	  of	  CG	  vectors	  
CGrv	   rv	   TCAGCTGTGGTGTCTTCATTCCCA	   titration	  of	  CG	  vectors	  
	  	  
qPCR	  probes	  
	   	   	  
	   	   	  
probe	  p5	   fw	   FAM-­‐ACTGTTCCATATTAGTCCACGCCCAC-­‐TAM	   FAM-­‐TAMRA	  probe	  to	  be	  used	  with	  primers	  MB85	  and	  MB86	  
probe	  p19	   fw	   FAM_ACGTGGTTGAGGTGGAGCATGAAT-­‐TAM	   FAM-­‐TAMRA	  probe	  to	  be	  used	  with	  primers	  MB87	  and	  MB88	  
probe	  p40	   fw	   FAM-­‐AGGAAATCAGGACAACCAATCCCGT-­‐TAM	   FAM-­‐TAMRA	  probe	  to	  be	  used	  with	  primers	  MB89	  and	  MB90	  
	  	  
Primers	  for	  SB	  probes	  
	   	   	  
	   	   	  
Rep1	   fw	   AACTGGACCAATGAGAACTTTCC	   amplification	  of	  Rep	  probe	  
Rep2	   rv	   AAAAAGTCTTTGACTTCCTGCTT	   amplification	  of	  Rep	  probe	  
MB4-­‐ampfw	   fw	   AATCAGTGAGGCACCTATCTCAGC	   amplification	  of	  ampicillin	  probe	  
MB5-­‐amprv	   rv	   AACTCGGTCGCCGCATACACTATT	   amplification	  of	  ampicillin	  probe	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TABLE	  3:	  ANTIBODIES	  	  	  
Primary	  antibodies	   	  	   	  	   	  	   	  	  
Antibody	   Species	   Source	  (Clone)	   Dilution	   Application	  
α-­‐HSP90	   rabbit,	  polyclonal	   Santa	  Cruz	  Biotechnology	  (H114)	   1:10000	   WB	  
α-­‐Rep	   mouse,	  monoclonal	   Progen	  (303.9)	   1:200	  /	  1:100	   WB,	  IF	  
α-­‐VP1,2,3	   mouse,	  monoclonal	   ARP	  (B1)	   1:200	   WB	  
α-­‐GFP	   mouse,	  monoclonal	   Roche	  (7.1/13.1)	   1:5000	   WB	  
α-­‐γChain	   mouse,	  monoclonal	   Santa	  Cruz	  Biotechnology	  (E7)	   1:500	   WB	  
α-­‐γChain-­‐BV650	   rat,	  monoclonal	   BD	  Biosciences	  (TUGh4)	   1:500	   FACS	  
α-­‐PSTAT5-­‐Alexa647	   mouse,	  polyclonal	   BD	  Biosciences	  (PY694)	   1:500	   FACS	  
α-­‐nanog	   rabbit,	  polyclonal	   Abcam	   1:100	   IF	  
α-­‐SSEA-­‐4	   mouse,	  monoclonal	   Millipore	  (MC-­‐813-­‐70)	   1:100	   IF	  
α-­‐Tra1-­‐60	   mouse,	  monoclonal	   Millipore	  (TRA-­‐1-­‐60)	   1:100	   IF	  
 
     
 	  	   	  	   	   	   
Secondary	  antibodies	  
Antibody	   Conjugation	   Source	   Dilution	   Application	  
α-­‐mouse	  IgG	   Dylight	  680	   Cell	  Signalling	  Technology	   1:5000	   WB,	  LI-­‐COR	  Odyssey	  
α-­‐rabbit	  IgG	   Dylight	  800	   Cell	  Signalling	  Technology	   1:5000	   WB,	  LI-­‐COR	  Odyssey	  
Goat	  α-­‐mouse	  IgG	   HRP	   Biorad	   1:10000	   WB,	  ImageQuant	  
Goat	  α-­‐rabbit	  IgG	   HRP	   Biorad	   1:10000	   WB,	  ImageQuant	  
Goat	  α-­‐rabbit	  IgG	   Alexa	  Fluor®	  488	  	   Invitrogen	  Life	  Technologies	   1:5000	   IF	  
Donkey	  α-­‐mouse	  IgG	   Alexa	  Fluor®	  594	   Invitrogen	  Life	  Technologies	   1:5000	   IF	  
Donkey	  α-­‐mouse	  IgG	  &	  IgM	   Alexa	  Fluor®	  488	  	   Invitrogen	  Life	  Technologies	   1:5000	   IF	  	  	  	  	  	  
TABLE	  4:	  REP	  MUTANTS	  REPORTED	  IN	  THE	  LITERATURE	  
	  
Table	  legend:	  
Mutant	  performs	  similarly	  to	  wt	  in	  this	  assay	  
Mutant	  has	  an	  intermediate	  phenotype	  
Mutant	  is	  completely	  non-­‐functional	  
	  
Different	  papers	  often	  use	  different	  assays	  to	  test	  for	  the	  same	  function,	  so	  caution	  
should	  be	  used	  when	  comparing	   results	   from	  different	  papers.	  This	   is	  particularly	  
the	   case	   for	   papers	   that	   studied	   Rep-­‐mediated	   integration	   and	   transcriptional	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ANNEX	  2:	  PUBLICATIONS	  DURING	  THE	  PHD	  
Structural	  Studies	  of	  AAV2	  Rep68	  Reveal	  a	  Partially	  Structured	  Linker	  and	  
Compact	  Domain	  Conformation.	  
Musayev	  FN,	  Zarate-­‐Perez	  F,	  Bardelli	  M,	  Bishop	  C,	  Saniev	  EF,	  Linden	  RM,	  Henckaerts	  
E,	  Escalante	  CR.	  
Biochemistry.	  2015	  Sep	  29;54(38):5907-­‐19.	  doi:	  10.1021/acs.biochem.5b00610.	  
Epub	  2015	  Sep	  14	  
	  
Oligomeric	  properties	  of	  adeno-­‐associated	  virus	  Rep68	  reflect	  its	  
multifunctionality.	  
Zarate-­‐Perez	  F,	  Mansilla-­‐Soto	  J,	  Bardelli	  M,	  Burgner	  JW	  2nd,	  Villamil-­‐Jarauta	  M,	  
Kekilli	  D,	  Samso	  M,	  Linden	  RM,	  Escalante	  CR.	  
J	  Virol.	  2013	  Jan;87(2):1232-­‐41.	  doi:	  10.1128/JVI.02441-­‐12.	  Epub	  2012	  Nov	  14.	  
	  
The	  interdomain	  linker	  of	  AAV-­‐2	  Rep68	  is	  an	  integral	  part	  of	  its	  oligomerization	  
domain:	  role	  of	  a	  conserved	  SF3	  helicase	  residue	  in	  oligomerization.	  
Zarate-­‐Perez	  F,	  Bardelli	  M,	  Burgner	  JW	  2nd,	  Villamil-­‐Jarauta	  M,	  Das	  K,	  Kekilli	  D,	  
Mansilla-­‐Soto	  J,	  Linden	  RM,	  Escalante	  CR.	  




Identification	  of	  a	  functionally	  relevant	  AAV	  Rep	  oligomerisation	  interface.	  
Bardelli	  M,	  Zarate-­‐Perez	  F,	  Linden	  RM,	  Escalante	  CR,	  Henckaerts	  E	  	  
Structural Studies of AAV2 Rep68 Reveal a Partially Structured Linker
and Compact Domain Conformation
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*S Supporting Information
ABSTRACT: Adeno-associated virus (AAV) nonstructural proteins Rep78 and
Rep68 carry out all DNA transactions that regulate the AAV life cycle. They
share two multifunctional domains: an N-terminal origin binding/nicking domain
(OBD) from the HUH superfamily and a SF3 helicase domain. A short linker of
∼20 amino acids that is critical for oligomerization and function connects the two
domains. Although X-ray structures of the AAV5 OBD and AAV2 helicase
domains have been determined, information about the full-length protein and
linker conformation is not known. This article presents the solution structure of
AAV2 Rep68 using small-angle X-ray scattering (SAXS). We ﬁrst determined the
X-ray structures of the minimal AAV2 Rep68 OBD and of the OBD with the
linker region. These X-ray structures reveal novel features that include a long C-
terminal α-helix that protrudes from the core of the protein at a 45° angle and a
partially structured linker. SAXS studies corroborate that the linker is not
extended, and we show that a proline residue in the linker is critical for Rep68 oligomerization and function. SAXS-based rigid-body
modeling of Rep68 conﬁrms these observations, showing a compact arrangement of the two domains in which they acquire a
conformation that positions key residues in all domains on one face of the protein, poised to interact with DNA.
The nonstructural Rep proteins from adeno-associated virus(AAV) are multifunctional proteins with specialized
domains equipped to handle the complex interactions with
DNA during the AAV life cycle.1,2 AAV has a single-stranded
DNA genome of ∼4.7 kb containing two major open reading
frames (ORFs) ﬂanked by inverted terminal repeats (ITRs).
The ITRs form T-shaped hairpin structures and contain the cis-
regulatory functions required for replication, transcriptional
regulation, and possibly site-speciﬁc integration.3−9 The stem of
the hairpin forms a double-stranded region containing a Rep
binding site (RBS) made up of several 5′-GCTC-3′ repeats.10
A terminal resolution site (trs) located upstream of the RBS is
the site of a strand- and site-speciﬁc endonuclease reaction
required to complete the replication of the AAV genome.3,11,12
Despite its limited genome size, AAV generates eight diﬀerent
polypeptide chains. The right ORF regulated by the P40
promoter produces three capsid proteins (VP1−3) and an
assembly activating protein (AAP).13−18 The left ORF uses two
diﬀerent promoters, and alternative splicing, to generate four
nonstructural proteins: two large Rep proteins (Rep78 and Rep68)
transcribed from the p5 promoter and two small Rep proteins
(Rep52 and Rep40) regulated through the p19 promoter.14,19−21
Thus, Rep40 is equivalent to the helicase domain of Rep68. Most
of the biochemical activities required for transcriptional regu-
lation,22,23 DNA replication24,25 and site-speciﬁc integration26−28
are carried out by the large Rep78/Rep68 proteins, whereas the
small Reps are thought to be important for DNA packaging into
preformed capsids.29,30
The wide spectrum of functions performed by Rep78/Rep68
is a direct reﬂection of the multifunctionality of their domains.
The N-terminal origin binding domain (OBD) displays site-
and strand-speciﬁc endonuclease activity and recognizes the
GCTC repeats.24,31−34 Structurally, the OBD is a member of
the HUH endonuclease family specialized in the cleavage and
rejoining of single-stranded DNA substrates (ssDNA), which
occurs during transposition, bacterial conjugation, rolling-circle
replication of bacterial DNA and bacteriophages, and in the
replication of small eukaryotic viruses.35 This family is
characterized by two signature motifs that participate in the
nuclease reaction: the HUH motif, which consists of two
histidine (H) residues separated by a large hydrophobic residue
(U), and the Y motif, with either one or two tyrosine (Y)
residues. Structurally, the common feature of HUH endonu-
cleases is a ﬁve-stranded antiparallel β-sheet surrounded by
α-helices, where the HUH motif is found in one of the strands.
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The position of the Y motif can vary: in the relaxase subgroup,
it is located N-terminally, whereas it is found at the C-terminus
in the Rep subclass.36−38
The helicase domain found in all Rep proteins is a
representative of the SF3 family helicase with 3′ to 5′
unwinding activity.38−43 The ATPase core is a modiﬁed version
of the AAA+ domain with additional features that include an
N-terminal helical bundle and a β-hairpin that is involved in
DNA binding during translocation.38 Consequently, the large
Rep proteins can interact with DNA in two diﬀerent modes:
one is mediated by the OBD and recognizes DNA in a
sequence-speciﬁc manner, whereas the SF3 helicase domain
interacts with DNA nonspeciﬁcally.44 Furthermore, the large
Rep proteins show a complex and dynamic oligomerization
behavior, which may add an additional level of regulation to
Rep interactions with DNA.45 How the two domains cooperate
with each other in order to interact with DNA and how they are
arranged in the context of Rep78/Rep68 is not known.
Moreover, studies have established that the linker region plays a
critical role in the oligomerization and function of AAV Rep
Figure 1. Structure of AAV2 OBD. (A) Domain structure of AAV2 Rep68 protein: OBD is shown in green, Rep40 (SF3 helicase domain), in blue,
and linker and C-terminal tail, in gray. The Rep40 protein spans residues 225−536 of Rep68. (B) Topology diagram of AAV2 OBD. (C) Ribbon
diagram of the OBD structure. The α-helices are light green, and β-strands are dark green. Secondary structure elements are labeled with α-helices
A−F, and β-sheets are numbered 1−5. The DNA binding loop LDB with missing residues in the structure is shown as a dotted line. (D) A view of the
structure rotated by 90° clockwise. α-Helix F is shown protruding from the core of the structure at an angle of almost 45°.
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proteins; therefore, it is likely that this region acquires a particular
secondary structure and may not simply be extended.46,47 To
answer these questions, we performed X-ray crystallography and
small angle X-ray scattering (SAXS) studies on the AAV2 Rep68
functional domains and full-length protein. Our results show that
the OBD has a long extended helix that includes part of the
linker, which is not extended, but is tilted in a way that brings the
two domains into a compact conﬁguration. SAXS studies on a
monomeric version of full-length Rep68 conﬁrm this observation
and show for the ﬁrst time the overall domain architecture of a
full-length AAV Rep protein.
■ MATERIALS AND METHODS
Protein Expression and Puriﬁcation. The DNA region
encoding amino acids 1−208 (OBD) and 1−224 (OBD plus
linker) from adeno-associated virus type 2 (AAV2) (GeneBank
protein_id = AF043303.1) was cloned into pET15b (Novagen)
using restriction sites NdeI and XhoI. The residue C151 was
mutated to serine, as it was found to produce disulﬁde bonds
and inhibit crystallization, and Rep-C151S was shown to be
fully functional in supporting the AAV life cycle.45 The OBD
constructs were overexpressed in Escherichia coli strain BL21
pLysS at 37 °C in Luria−Bertani (LB) broth. IPTG (isopropyl-
β-D-thiogalactopyranoside) was added to a ﬁnal concentration
of 1 mM when an OD of 0.6 was reached. Cells were harvested
after 5 h and stored at −80 °C. The cell pellets were
resuspended in binding buﬀer (20 mM Tris-HCl, 500 mM
NaCl, 10 mM imidazole, 10% glycerol, 1 mM TCEP, pH 7.9)
and lysed by sonication. The OBD was puriﬁed with a Ni-NTA
column (Qiagen) using step gradients of 10 and 30 mM
imidazole to wash nonspeciﬁc proteins binding to the column
and then eluted with 100 mM imidazole. Protein was loaded
onto a HiLoad desalting column (GE) to change into thrombin
buﬀer (25 mM Tris-HCl, 200 mM NaCl, 10% glycerol pH 8.0).
His-tag was cut by addition of thrombin (1 unit/mg) and
removed by passing through a Ni-NTA column. The untagged
OBD was collected from the ﬂow through, concentrated, and
further puriﬁed by gel ﬁltration on a HiLoad 16/60 Superdex
75 column (GE Healthcare) previously equilibrated with gel
ﬁltration (GF) buﬀer (25 mM Tris-HCl, 200 mM NaCl, 1 mM
TCEP, pH 7.5). The protein was concentrated to ∼40 mg/mL
using Millipore Centricon (10 kDa cutoﬀ). AAV2 Rep40 was
puriﬁed as described elsewhere.38 AAV-2 Rep68wt (1−536) and
Rep68Y224Δ were expressed in E. coli strain BL21 pLysS at
18 °C as described in earlier reports.46 In brief, histidine-tagged
Rep68 was puriﬁed in a Ni-NTA column, and after PreScission
protease cleavage of the His-tag, the protein was puriﬁed on a
HiLoad Superdex 200 16/60 column (GE Healthcare). OBDL
was puriﬁed using the same procedure.
Crystallization, X-ray Data Collection, and Structure
Determination. Crystallization was carried out using the
hanging-drop method with commercially available screening
kits at 4 °C. Crystals grew after 2 to 3 days in 50 mM
cacodylate, pH 6.5, 80 mM sodium acetate, 15 mM magnesium
acetate, and 8−10% isopropanol. Crystals were cryoprotected
in reservoir buﬀer and supplemented with 20% MPD before
ﬂash freezing them in liquid nitrogen. The crystals diﬀracted to
2.3 Å and belonged to space group P21212 with unit cell
dimensions a = 186.4 Å, b = 154.4 Å, c = 38.8 Å. Diﬀraction
data was collected at the National Synchrotron Light Source
(NSLS) at Brookhaven National Laboratory beamline X6a.
The data were processed with the program HKL2000,48 and
the structure was solved by molecular replacement using the
program PHENIX. We used the structure of the AAV5 OBD as
a search model (PDB ID: 1M55). Model building was carried
out using PHENIX,49 and manual building, using the program
COOT.50 OBDL data was collected using our X-ray home
source that consists of a Rigaku Micromax 007 X-ray generator
and a Raxis IV+2 area detector.
Sedimentation Velocity. Sedimentation velocity experiments
were carried out using a Beckman Optima XL-I analytical ultra-
centrifuge (Beckman Coulter Inc.) equipped with an eight-position
AN-60Ti rotor. Rep protein samples were loaded in the cells, using,
in all cases, the GF buﬀer. Samples in double sector cells were
centrifuged at 25 000 rpm. In all experiments, temperature was kept
at 20 °C. Sedimentation proﬁles were recorded using UV absorp-
tion (280 nm) and interference scanning optics. For analysis of the
data, the program Sedﬁt was used to calculate sedimentation
coeﬃcient distribution proﬁles using the Lamm equation.51
Small-Angle X-ray Scattering (SAXS). Data were
collected at three diﬀerent concentrations that produce a single
homogeneous population, as determined by sedimentation velocity
studies. Synchrotron SAXS measurements were performed at
Table 1. Data Collection and Reﬁnement Statistics
OBD (1−208) OBDL (1−224)
space group P21212 P21
Cell Dimensions
a, b, c (Å) 186.4, 154.4, 38.8 75.6, 178.7, 130.4
α, β, γ (deg) 90, 90, 90 90, 91.7, 90
wavelength (Å) 0.9792 1.54
resolution (Å) 30−2.30 (2.34−2.30) 30−2.6 (2.69−2.6)
no. of measured 566 473 426 030
no. of unique 50 960 105 074
data coverage (%)a 99.8 (100) 99.1 (98.9)
Rmerge(%)
a,b 0.099 (0.402) 0.075 (0.311)
I/σa 17.7 (8.6) 12.4 (4.1)
reﬁnement statistics
resolution range 30.0−2.3 29.8−2.6














bonds (Å) 0.02 0.003
angles (Å) 1.4 1.53
Ramachandran Plot Quality
most favored (%) 99.0 97.0
additional allowed (%) 1.0 3.0
generously allowed (%) 0 0.0
disallowed (%) 0 0
aValues for the outermost shells are given in parentheses. bRmerge =
∑|I − ⟨I⟩|/∑ I, where I is the integrated intensity of a given reﬂection.




Biochemistry 2015, 54, 5907−5919
5909
Brookhaven National Laboratories at beamline X9 and at the
Advanced Light Source at the Lawrence Berkeley National
Laboratory at the SYBILS beamline. Three diﬀerent concen-
trations of each sample were prepared and measured (1, 2, and
3 mg/mL). All data were processed with the package ATSAS.52
Buﬀer subtraction was carried out using beamline-speciﬁc
software. Radii of gyration (Rg) were evaluated using the Guinier
approximation, sRg < 1.3. Distance distribution functions and
maximum diameters Dmax were calculated using the program
GNOM.53 SAXS molecular envelopes were calculated using
the programs DAMMIN and GASBOR.54,55 Conformational
ﬂexibility of the linker and C-terminal tail was analyzed with
the program EOM.56 We used the structures of Rep40 (PDB
ID: 1s9h) and of OBDL and connect the two domains with a
ﬂexible linker (residues 215−224) to generate an atomic model
of AAV2 Rep68. Using this initial model, we performed rigid-
body and molecular dynamics using BILBOMD to generate the
best Rep68 model that ﬁts the SAXS data.57
Figure 2. Superposition of OBD molecules in the asymmetric unit. (A) Ribbon diagram of the superposition of the three molecules in the
asymmetric unit. Molecule A is shown in green; molecule B, blue; and molecule C, red. The three loops LDB have diﬀerent conformations and are
shown as dotted connections. (B) Ribbon diagram of the dimer in the asymmetric unit formed by molecules A and B. The small dimer interface
occurs through residues in α-helix F. (C) Details of the residues involved in the oligomeric interaction with Ser197, Val196, and Leu193 from
molecule A interacting with His192, Leu193, and Val196 from molecule B. (D) Sedimentation velocity proﬁles of Rep68wt, Rep68-L193AV196A,
Rep68-H192A, and Rep68-S197A. Experiments were carried out at 20 °C and 25 000 rpm on a Beckman XL-I analytical ultracentrifuge. Scans were
collected every 2 min using absorbance at 280 nm. Data was analyzed using the program Sedﬁt.51 (E) Helicase assay of Rep68 mutants. Fluorescent-
labeled DNA molecule has a 3′ single-stranded tail and an 18 bp region (ﬁrst lane). Upon ATP addition, helicase activity is shown as the
18 nucleotide ﬂuorescein-labeled ssDNA is displaced (second lane). Rep68, L193AV196A, H192A, and S197 proteins all unwind DNA. K340H
mutant is ATPase-negative and does not unwind DNA. Last lane shows the DNA substrate after heating at 100 °C for 5 min. (F) Comparison of the
production of rAAV2-GFP infectious particles in the presence of wt or LV mutant. Various volumes of supernatant (in (μ), x axis) from 293T cells
producing rAAV2-GFP were added to HeLa cells, and the percentage of GFP-positive infected cells was determined by FACS analysis, as described
in Materials and Methods. Data is presented as average ± standard deviation from three independent experiments.
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DNA Helicase Assay. The helicase assay was based on a
modiﬁcation of the strand-displacement assay described
elsewhere.58 The DNA substrate (28:18) consists of 3′ tail of
10 nucleotides adjacent to 18 bp. The top strand has been
labeled with ﬂuorescein (F) at the 5′ end. All reactions were
performed in a ﬁnal volume of 50 μL in a buﬀer containing
25 mM HEPES, 50 mM NaCl, pH. 7.0. For the reaction, 1 μM
protein was mixed with 0.5 μM ds F-DNA (28:18). The
reaction was started by addition of 5 mM ATP-MgCl2 and
2.5 μM trap ssDNA. Reaction was incubated at 25 °C for 1 h.
EDTA was used to stop the reaction at a ﬁnal concentration of
20 mM. Aliquots of 10 μL were loaded in a 12% bis-acrylamide
gel (30%) (19:1) using 6× loading dye (0.25 xylene cyanol FF,
30% glycerol). For densitometry and analysis of the bands, a
Gel Doc EZ Imager was used, using the automatic lane and
band detection tool. Lane background subtraction, white
illumination, and an activation time of 300 s were used for
the analysis.
Fluorescent Anisotropy Binding Assays. Binding assays
were performed using 5 nM ﬂuorescein labeled 41-mer DNA
containing the Rep binding site (TGGCGGCGGTTGGG-
GCTCGGCGCTCGCTCGCTCGCTGGGCG). Rep68 at dif-
ferent concentrations was mixed with DNA at a ﬁnal volume of
300 μL using the following buﬀer: 25 mM HEPES (pH 7.0),
200 mM NaCl, 1 mM TCEP. Fluorescence readings were taken
on a PC1 ﬂuorimeter (ISS, Inc.) with excitation and emission
ﬁlters at 492 and 528 respectively. Tubes were equilibrated at
20 °C for 20 min before measurement. Each anisotropy point is
the average of 10 measurements. Anisotropy is calculated as the
ratio of the diﬀerence between vertical and horizontal emission
intensities over the total normalized intensity. The fraction of
DNA bound (B) was calculated using eq 1
= − −B A A A A([ ] [ ] )/([ ] [ ] )x DNA FINAL DNA (1)
where [A]x represents the anisotropy measured at protein
concentration x, [A]DNA is the anisotropy of free ﬂuorescence
DNA, and [A]FINAL is the anisotropy at saturation. Data was ﬁt
to a single binding site model using the program PRISM6
(GraphPad). Each experiment was done in triplicate.
AAV Infectious Particles Assay. 293T cells were trans-
fected with three plasmids using polyethylenimine (PEI): an
AAV2 ITR-containing plasmid encoding a CAG-controlled
GFP gene (pTRUF11), a helper plasmid expressing AAV2 Rep
(wt or L193A-V196A cloned from the pHisRep68LV/15b) and
Cap derived from pDG, and a third construct containing
the adenovirus helper functions (HGTI plasmid).59,60 The
presence of the L193A−V196A double mutation was conﬁrmed
by sequencing (Euroﬁns). After 72 h, the cell supernatant was
harvested and increasing volumes of supernatant were used to
infect HeLa cells. The percentage of GFP-positive HeLa cells
was determined 48 h postinfection by FACS (FACSCanto, BD
Biosciences).
■ RESULTS
We opted to structurally characterize full-length AAV2 Rep68
using small-angle X-ray scattering and rigid-body modeling. A
diagram of the diﬀerent domains and protein constructs used in
this study is shown in Figure 1A. We ﬁrst determine the crystal
structure of its OBD including the region spanning the linker,
followed by SAXS studies of Rep40 (SF3 helicase domain) to
study the dynamic behavior of the C-terminal tail. Finally, to
determine the relative orientation of its two functional domains,
we determined the SAXS solution structure of Rep68.
Structure of AAV-2 Rep OBD. The OBD construct
(residues 1−208) was initially obtained from limited proteolysis
experiments.61 The structure was solved by molecular
replacement and reﬁned to 2.3 Å resolution (Table 1). There
are three molecules in the asymmetric unit: molecule A,
spanning residues 1−138 and 143−206, molecule B, spanning
residues 1−139 and 143−201, and molecule C, covering
residues 1−131 and 141−191. The missing residues are all part
of the DNA binding loop (LDB). Molecules A and B form a
dimer interacting through their C-terminal helix F, whereas
molecule C does not make any close contacts. The OBD
structure is characterized by a central ﬁve-stranded antiparallel
β-sheet ﬂanked by six α-helices, three at each side of the
sheet (Figure 1B). The topology of the β-sheet follows a 4−1−
3−2−5 order, with helices E and F on one side of the sheet and
helices B−D positioned on the opposite side (Figure 1C,D).
There are two long loops: the DNA binding loop LDB connects
β-strand 4 to α-helix E and loop LBC connects α-helices B
and C and protrudes underneath α-helix F (Figure 1C). LDB
was identiﬁed as being important in making speciﬁc contacts
with the major groove of GCTC repeats and shows the highest
degree of variation among all AAV Rep isoforms.31,62 This is a
dynamic region, as shown by the lack of electron density in all
three molecules found in the asymmetric unit. The C-terminal
helix αF is long, spanning residues 182−206, and protrudes
at an approximately 45° angle from the plane of the β-sheet
Figure 3. Comparison of AAV2 and AAV5 OBD structures.
(A) Ribbon diagram of the superposition of the AAV2 (green) and
AAV5 (blue) OBD structures. The N and C termini are marked.
Regions that have the largest rmsd are indicated by arrows. (B) Plot of
rmsd diﬀerences against residue number between AAV2 and AAV5
OBD. (C) Solvent-accessible electrostatic surface comparison of AAV2
and AAV5 OBDs showing three views of 90° counterclockwise
rotations. Positive regions are shown in blue, and negative, in red.
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(Figure 1D). The residues at the end of helix F appear to be
dynamic, as we could see only up to residue 201 in molecule B
and to residue 191 in molecule C. Helix F is loosely packed
against helix E and the loop connecting β5 to αF. The
interactions that keep these three elements together are sparse,
suggesting that helix F is ﬂexible. Several dynamic regions in the
AAV2 OBD can be observed by the superposition of the three
molecules in the asymmetric unit (Figure 2A). The three
molecules superimpose with an overall rmsd over 197 Cα of
0.62 Å. Two regions can be identiﬁed with larger than average
values: region 1 includes resides 15−34 spanning helices A and
B, and region 2 includes residues from LDB. Not surprisingly,
based on the AAV5 OBD−RBS structure, both of these regions
are involved in DNA interactions: region 1 is involved in
recognition of the ITR hairpin stem 2, and LDB recognizes part
of the GCTC repeat.31 Thus, folding and stabilization of these
elements must occur upon DNA binding. Two of the OBD
molecules in the asymmetric unit form a dimer through
interactions with residues present in α-helix F, resembling a
pseudocoiled coil (Figure 2B). These include L193, V196,
H192, and S197 making hydrophobic and hydrogen-bond
interactions (Figure 2C). This type of interface was also
observed in the AAV5 OBD−RBS complex, which may suggest
a functional role for this interface in the context of full-length
Rep78/Rep68 proteins.31 To determine if these interactions are
functionally relevant in Rep68 function and their eﬀect on the
AAV life cycle, we examined the ability of several Rep68
mutants to oligomerize, to unwind dsDNA, and to support the
production of infectious particles. Figure 2D shows that Rep68
mutants H192A, S197A, and L193AV196A have similar
sedimentation velocity proﬁles as that of Rep68wt, forming
the 13S peak that corresponds to heptameric/octameric ring
species.45 In addition, the mutants have similar unwinding
activity as that of the wild-type protein (Figure 2E). Thus,
the diﬀerent mutants are functionally equivalent to Rep68wt.
This conclusion is supported by the ability of the Rep68-
L193AV196A double mutant to produce infectious viral
particles as eﬃciently as wild-type Rep68 (Figure 2F). These
results show that the dimer interactions are generated during
crystal packing and are not involved in Rep68 oligomerization
and function.
Structural comparison of the AAV2 and AAV5 OBD.
The Rep proteins from the majority of AAV serotypes show an
overall homology with the AAV2 OBD of 95% (Figure S1). In
contrast, AAV5 Rep has only 59% identity over the N-terminal
224 residues. However, the AAV2 and AAV5 OBD struc-
tures superimposed well, with an overall rmsd of 0.94 Å for
191 aligned Cα carbons. As shown in Figure 3A,B, there are,
nonetheless, three regions that show diﬀerences: region A
(residues 12−15) includes the linker connecting β1 to αA,
region B (74−77) spans the turn connecting β3 to αD, and
region C (139−147) consists of LDB. Among all AAV serotypes,
Figure 4. Structure of OBDL. (A) Ribbon diagram of the structure spanning residues 1−214. (B) Electron density of region 206−214 contoured at
0.9σ. The density ﬁts most of the residues, but it suggests that the region is dynamic. (C) Superposition of OBD and OBDL structures illustrating
the ﬂexibility of helix F. (D) Comparison of the sedimentation velocity proﬁles between Rep68wt (top) and Rep68-P214A (bottom).
(E) Comparison of binding isotherms of Rep68wt and Rep68-P214A. Fluorescent anisotropy binding assays were carried out with a 41-mer AAVS1
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AAV5 and AAV8 have the largest sequence variations. For
instance, AAV5 has a shorter LDB loop than AAV2, whereas in
AAV8, the loop is longer by 2 residues. In addition, the AAV5
protein has four additional residues after position 198.
Moreover, sequence conservation in the αF region is low in
AAV5, suggesting that this structure may indeed be shorter
than in AAV2 (Figure S1). The overall electrostatic surface
representations of the two proteins look similar, but subtle
diﬀerences are visible. In both structures, one side of the surface
is highly positively charged; however, in AAV2 OBD, the
positive patch is wider and more intense. This is seen more
explicitly if we compare the positive surface potential values
between the two OBDs, with 2130.6 kcal/molq for AAV2 and
1720.4 kcal/molq for AAV5.63 This area includes LDB, helix D,
and the N-terminal half of α-helix C. The former two interact
with the GCTC repeats, whereas the latter is involved in the
recognition of the RBE′ hairpin in the ITRs.31 Helix F is mostly
negatively charged, but in AAV2, there is a slightly positive
patch located in the ﬁrst three turns that is not visible in AAV5
(Figure 3C). Because the structure of the AAV5 construct
includes up to residue 197 and the sequence homology around
this region is less than 80%, it is not apparent whether helix F in
AAV5 will be as extended as in AAV2. Whether these structural
and sequence variations found in LDB and the linker region
account for the diﬀerences in nicking speciﬁcity observed for
AAV2 and AAV5 Rep proteins remains to be determined and
will require structures with DNA substrates along the nicking
reaction pathway.64,65
Crystal Structure of OBD-Linker. We and others have
described previously that the linker region connecting the OBD
and the SF3 helicase domain of the large Rep proteins is pivotal
for the assembly of multimeric Rep protein complexes.46,47
To better characterize this region, we expressed, puriﬁed, and
crystallized a construct containing the OBD and the linker that
we termed OBDL, spanning residues 1−224. OBDL crystals
diﬀracted to 2.6 Å and belong to space group P21, with 11
molecules in the asymmetric unit. The electron density
corresponding to the C-terminus of helix F and the linker
region varies among the diﬀerent molecules in the asymmetric
unit; nevertheless, we were able to build a model of OBDL up
to residue 214 (Figure 4). We did not detect any electron
density from residues 215−224. The structure shows that helix
F spans to residue 205 and is followed by a loop that makes a
downward turn toward the core of the protein at proline 209
(Figure 4B). Superposition of OBD with OBDL shows that
helix F is ﬂexible and moves as a rigid body with respect to the
core of the protein, pivoting around the loop that connects it
with strand β5. While the two OBD structures superimpose
with an overall rmsd of ∼0.8 Å, the two αF helices superimpose
with an rmsd of only 1.3 Å and appear at a diﬀerent angle with
respect to the core of the protein, with a diﬀerence between
them of ∼2.4° (Figure 4C). The OBDL structure also implies
that the linker is not in an extended conformation but, instead,
has a particular structure that is constrained by the two prolines
in the linker. This particular conformation may bring the two
domains together in the context of full-length Rep68. To test
the importance of the proline residues, we mutated proline
214 to alanine and measured the eﬀect of this on Rep68’s
properties. Figure 4D shows that this mutation drastically alters
the oligomeric behavior of Rep68 and aﬀects its ability to form
the 13S oligomer species (Figure 4D). Moreover, the mutation
aﬀects the ability of Rep68 to bind double-stranded DNA
containing a Rep binding site (RBS). Figure 4E shows that the
Rep68-P214A mutant binds DNA ∼ 7 times less than wild-type
protein. Taken together, our results show that the con-
formation of the linker is critical for the function of Rep68.
SAXS Studies of OBDL Validate the Conformation of
the Linker. To gain further structural information about the
linker domain and to validate the OBDL X-ray structure, we
performed solution studies on OBD and OBDL. The
concentration of NaCl in the buﬀer was kept at 0.5−1 M to
prevent formation of oligomers induced by the presence of the
linker.46 The calculated sedimentation coeﬃcient for both
constructs is ∼2.0 S (Figure S2). The small diﬀerence in S value
suggests that the linker region is not in an extended confor-
mation. However, the smaller sedimentation velocity coeﬃcient
of OBDL implies a slightly more elongated shape. We subjected
both constructs to SAXS studies under conditions that
generated single species, as determined by sedimentation
velocity. Scattering proﬁles from three diﬀerent concentrations
were collected, and a ﬁnal scattering curve was obtained
by merging the best curves using the program Almerge.66
The scattering proﬁles for OBD and OBDL are shown in
Figure 5A. The merged data was used to calculate both the
radius of gyration (Rg) and the P(r) distribution function as
described in the Material and Methods (Figure 5B). Ab initio
models were produced using the programs DAMMIN and
GASBOR. For each protein, 10 independent models were
generated and averaged with Damaver. The ﬁnal models from
the two independent reconstructions were aligned using the
program Supcomb, resulting in an overall normalized spatial
discrepancy (NSD) value of 0.54, suggesting an excellent
correlation between the two independent reconstructions.67
The resulting GASBOR models for OBD and OBDL are shown
Figure 5. SAXS analysis for OBD and OBDL. (A) SAXS scattering data
from OBD (blue) and OBDL (red) in solution. Superimposed is the
scattering calculated from the atomic models for OBD (■) and OBDL
(△). (B) Normalized pair distribution functions P(r) for OBD (black)
and OBDL (red) calculated from the experimental scattering curves using
the program PRIMUS. (C) Low-resolution envelopes of DAMMIN and
GASBOR models for OBD (left) and OBDL (right) are superimposed
with the X-ray structure of OBD and OBDL, respectively.
Biochemistry Article
DOI: 10.1021/acs.biochem.5b00610
Biochemistry 2015, 54, 5907−5919
5913
in Figure 5C with the superimposed X-ray structures of the
corresponding constructs. The calculated Rg and Dmax values are
similar for both models (Table 2). The OBDL GASBOR
ab initio model shows an envelope that resembles a round
cylinder, suggesting that, under our experimental conditions,
the region between 208 and 224 is not extended but may
resemble the overall conformation seen in the OBDL crystal
structure (Figure 5C, right panel). To further corroborate the
hypothesis that the linker is neither extended nor highly
ﬂexible, we carried out molecular dynamics using BILBOMD to
determine if an ensemble with multiple conformations of
the linker described the SAXS scattering proﬁle of OBDL.57
The results show that inclusion of more than one conformation
does not improve the ﬁt to the experimental data signiﬁcantly
(data not shown).
Modeling Flexibility of C-Terminal Tail of Rep68. AAV
Rep proteins Rep40 and Rep68 have a C-terminal tail of 46
residues that extends from the core of the helicase domain, as
determined by limited proteolysis experiments.38 To determine
the overall ﬂexibility of the C-terminal tail, we carried out SAXS
experiments of Rep40wt at diﬀerent concentrations, and data
were analyzed as described previously. A GASBOR model of
Rep40 clearly resembles the overall shape of the helicase
domain and has a characteristic ﬂat disk shape with an
additional elongated density that is not represented in the X-ray
structure, which should correspond to the C-terminal tail
(Figure 6A). However, the dimensions are smaller than those
expected from a fully extended C-terminal tail. To analyze the
ﬂexibility of the tail, we used EOM software to search for an
optimal ensemble of conformations that will best ﬁt the
scattering data. This method generates a large pool of models
(10 000) with random conformations and uses a genetic
algorithm to select an optimized ensemble of conﬁgurations
that best describes the SAXS scattering data (Figure 6B).56,68
The best ensemble consisted of four models that ﬁt the
experimental curve with a χ of 0.5 (Figure 6C). However, the
Table 2. Hydrodynamic Parameters
parameter OBD (1−208) OBDL (1−224) Rep40wt (225−536) Rep68Y224AΔ (1−490)
S (s)a 2.1 1.97 ndd nd
Rg (nm)
b 21.5 ± 0.3 23.2 ± 2.3 27.6 ± 3.8 38.9 ± 0.1
Dmax (nm)
c 68.2 74.4 (104.96) 98.8 123.8
χ 1.0e 1.9e 0.5f 0.8g
aDetermined from sedimentation velocity data. bDetermined from Guinier analysis. cDetermined from P(r) analysis. dnd, not determined.
eExperimental/model data ﬁt using FoXS.74 fExperimental/model data ﬁt using EOM. gExperimental/model data ﬁt using CORAL.
Figure 6. SAXS analysis of Rep40/Rep68 C-terminal tail. (A) Shape reconstruction of Rep40wt and the docked X-ray structure of Rep40.
(B) Comparison of the Rg distribution of the initial EOM generated pool (black line) and the selected model ensemble (red line). (C) Scattering
curve of Rep40wt (black) and ﬁt of the optimal EOM model ensemble (red). (D) Superposition of the ensemble generated model showing the
preferred conformations of the C-terminal tails.
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narrowness of the ensemble Rg distribution suggests that a
limited number of conformations are preferred, with one
conﬁguration in particular accounting for about 50% of the
population. Interestingly, all of the selected models have the
C-terminal oriented toward the opposite site of the presensor 1
β-hairpin (PS1βH), a motif that is involved in DNA interactions
during DNA translocation and unwinding (Figure 6D).30,69
Thus, our study shows that the C-terminal tail, although ﬂexible,
has a preferred set of dominant conformations.
SAXS-Based Structural Modeling of Rep68 Shows a
Compact Conformation in Solution.We previously showed
that Rep68 has complex dynamic oligomeric behavior in
solution and is present as a mixture of multiple oligomers,
including heptameric and octameric rings.45 To obtain a homo-
geneous population of Rep68 monomers, we took advantage of
the Y224A mutation that aﬀects its tendency to form multiple
oligomeric species.46 The Rep68Y224A protein is present as a
monomer at concentrations less than 5 mg/mL and under high
salt conditions. Moreover, we have determined that this
mutation has helicase activity comparable to that of the wild-
type protein and does not cause any signiﬁcant structural
change.70 To facilitate model building and data interpreta-
tion, we used a truncated Rep68 (1−490) to eliminate the
C-terminal tail residues.38 SAXS data was collected at 2, 3, and
4 mg/mL and processed as described in the previous sections
(Figure 7A). The GASBOR generated model produces an
elongated prolate ellipsoid that is slightly curved with
dimensions 140 × 73 × 37 Å3 (Figure 7B). Individual atomic
structures of OBDL and Rep40 can be easily docked into the
envelope; in particular, one end of the particle has the shape of
a ﬂat disk that resembles the GASBOR Rep40 ab initio model
(Figure 7C). We performed rigid-body modeling using the
X-ray structures of OBDL (1−214) and Rep40 (225−490)
with CORAL.71 The domain boundaries deﬁne an unstructured
linker spanning residues 215−224. However, secondary
structure prediction suggests that the region between 220 and
Figure 7. SAXS modeling of Rep68. (A) Fit of the experimental SAXS data (black circles) with the theoretical scattering proﬁle obtained from
CORAL model (red line) with a χ value of 0.8. (B) Two views of the GASBOR averaged molecular envelope for Rep68Δ showing the approximate
dimensions in angstroms. (C) Docking of OBDL and Rep40 atomic structures to the GASBOR ab initio envelope. (D) Porod−Debye plot of
Rep68Y224AΔ SAXS data (black squares) supporting a compact protein with little ﬂexibility. Red line represents the linear plateau. (E) Three views
of the CORAL rigid-body ﬁnal model of Rep68Y224AΔ.
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224 could form a α-helix extending into the ﬁrst helix of the
helicase domain.46 Consequently, we generated multiple
models that extended this helix at diﬀerent positions. The
Rep68 models ﬁt the experimental data very well, with χ values
in the range of 1.1−0.8. All models show that the two domains
are positioned such that the long axis of the helicase domain is
almost perpendicular to the OBD, as shown in Figure 7E. The
best model was obtained by extending the N-terminal helicase
helix to residue 223. Two main observations can be drawn from
this model. First, the orientation of the two domains results in a
Rep68 structure where the motifs that interact with DNA
in both the OBD (LDB and helix C) and helicase domain
(β-hairpin 1) are on the same face of the protein. Second, the
two domains are closely positioned, making an extended linker
structure unlikely. To further support this conclusion, we
assessed interdomain ﬂexibility of Rep68 using two method-
ologies. First, a Porod−Debye plot of the scattering data shows
a plateau that is a signature for a compact molecule.72 The data
ﬁts the linear region with a Porod coeﬃcient of 4, again
consistent with a compact molecule (Figure 7D). In addition,
we carried out BILBOMD and determined that a single model
ﬁts the data equally as well as with multiple conformations
(Figure 7A).
■ DISCUSSION
Our results show new structural features that increase our
knowledge of the architecture of AAV Rep proteins. The
combined X-ray and SAXS studies show that the AAV2 Rep68
linker region is partially structured, with helix F of the OBD
extending until residue 209 and protruding from the main core
at a 45° angle. The presence of two proline residues (209 and
214) seems to impart a certain rigidity to the loop region,
making a small turn before continuing toward the helicase
domain (Figure 4). This conformation is important for Rep68
function, as mutation of one of the proline residues in the linker
(P214) is suﬃcient to prevent proper oligomerization and
DNA binding. In addition, part of the remaining linker may
extend the ﬁrst helix of the helical domain of Rep52/40.46 Both
Figure 8. Rep68 DNA interacting face. (A) Comparison of Rep68 model (left) and SV40-LTag (right). Colored equivalently are the OBD domain
(green) and the helicase domain (blue). (B) (left) Rep68 structure showing the regions that interact with DNA colored in pink. Orientation of
Rep68 is 90° counterclockwise from that in panel A. (right) Surface representation of Rep68 showing electropositive regions in blue and negative
regions in red. View is in the same orientation as that on the left.
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of these structural features bring the OBD and helicase domain
closer to each other. However, although the linker is not
extended, it allows for a certain degree of ﬂexibility. Our rigid-
body modeling generated diﬀerent models with slightly
diﬀerent conformations of the two domains that ﬁt the
scattering data equally well (Figure S3). This suggests a certain
degree of conformational ﬂexibility between the two domains.
Structurally, this ﬂexibility originates from the linker, the OBD
helix F, and the helical bundle of the helicase domain.
Alignment of the OBD and OBDL structures shows that
helix F can pivot and move relative to the main core of the
domain (Figure 4C). Likewise, alignment of the three Rep40
molecules found in the asymmetric unit of the X-ray structure
(PDB ID: 1s9h) shows the helical bundle at diﬀerent positions
relative to the AAA+ domain (data not shown). This ﬂexibility
is important to accommodate changes occurring upon DNA
binding and oligomerization. Moreover, analysis of the
ﬂexibility of the C-terminal tail in Rep68 suggest that there is
a preference in the conformations acquired by the C-terminal
tail that positions it at the opposite end of the β-hairpin. This is
important in the context of formation of Rep68 oligomeric
rings because other conformations may produce steric clashes
and inhibit their formation.
Finally, our Rep68 model closely resembles the conﬁguration
of the helicase and OBD in one of the molecules seen in the
X-ray structure of the SV40 large T antigen (SV40-LTag) in
complex with DNA.73 This arrangement results in critical
residues that interact with DNA being located on one face of
the protein (Figure 8B). In our Rep68 model, these regions
include loop LDB and helix αD in the OBD, the helicase domain
(PS1β residues K404 and K406), and linker residues R217 and
K219 that have been shown to play a role in complex formation
and DNA binding in AAV5.47 In addition, the SV40-LTag
structure shows that the helical bundle (Zn domain in SV40-
LTag) interacts with DNA, docking into the major groove.73
Our model shows that the position of the helical bundle is
similar, and it is intriguing to postulate that the conformation of
Rep68 is prealigned to interact with DNA in way similar to that
of SV40-LTag (Figure 8A).
In conclusion, we have completed the ﬁrst structural
description of full-length AAV2 Rep68 protein, revealing the
orientation and relative position of its functional domains.
These observations provide new clues to explain its DNA
binding mode; however, our model does not discard possible
changes that should occur upon DNA binding and/or
oligomerization. These questions require future structural
studies of high-resolution structures of Rep68 oligomers
alone and in complex with DNA.
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Oligomeric Properties of Adeno-Associated Virus Rep68 Reflect Its
Multifunctionality
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Monserrat Samso,a R. Michael Linden,c,e Carlos R. Escalantea
Department of Physiology and Biophysics, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USAa; Department of Human Genetics, Memorial
Sloan-Kettering Cancer Center, New York, New York, USAb; Department of Infectious Diseases, King’s College London School of Medicine at Guy’s, King’s and St. Thomas
Hospital, London, United Kingdomc; Department of Applied Sciences, University of the West of England, Bristol, United Kingdomd; UCL Gene Therapy Consortium, UCL
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The adeno-associated virus (AAV) encodes four regulatory proteins called Rep. The large AAV Rep proteins Rep68 and Rep78 are
essential factors required in almost every step of the viral life cycle. Structurally, they share two domains: a modified version of
the AAA domain that characterizes the SF3 family of helicases and an N-terminal domain that binds DNA specifically. The
combination of these two domains imparts extraordinary multifunctionality to work as initiators of DNA replication and regu-
lators of transcription, in addition to their essential role during site-specific integration. Althoughmost members of the SF3
family form hexameric rings in vitro, the oligomeric nature of Rep68 is unclear due to its propensity to aggregate in solution. We
report here a comprehensive study to determine the oligomeric character of Rep68 using a combination of methods that includes
sedimentation velocity ultracentrifugation, electronmicroscopy, and hydrodynamic modeling. We have determined that residue
Cys151 induces Rep68 to aggregate in vitro. We show that Rep68 displays a concentration-dependent dynamic oligomeric behav-
ior characterized by the presence of two populations: one with monomers and dimers in slow equilibrium and a second one con-
sisting of a mixture of multiple-ring structures of seven and eight members. The presence of either ATP or ADP induces forma-
tion of larger complexes formed by the stacking of multiple rings. Taken together, our results support the idea of a Rep68
molecule that exhibits the flexible oligomeric behavior needed to perform the wide range of functions occurring during the AAV
life cycle.
The adeno-associated virus (AAV) nonstructural protein Rep68belongs to the superfamily 3 of helicases (SF3), whose main
characteristic is their multifunctionality (1). Whereas the role of
most helicases is to unwind DNA ahead of the replication fork,
SF3 helicases also work as initiators of DNA replication, transcrip-
tional regulators, and motor pumps to pack DNA into empty cap-
sids (2). This multifunctionality is due in part to the presence of a
specialized AAA domain that is at the core of all DNA transac-
tions performed by these proteins. Their catalytic activities are
dependent on the formation of oligomeric complexes, where the
ATP binding and hydrolysis occurring at the interface of neigh-
boring subunits drive conformational changes that promote
translocation or remodeling of target substrates (3). Functional
diversity is achieved through formation of different number of
oligomers and the presence of specialized associated domains (4).
For instance, the AAA core of AAV Rep proteins contains a
-hairpin insertion that is involved in the coupling of ATP hydro-
lysis to DNA translocation/unwinding, and Rep68 and Rep78
have an origin binding domain (OBD) at the N terminus (5–7).
Combination of these structural features allows AAV Rep proteins
to play a central role in virtually every step of the viral life cycle,
such as DNA replication, transcription regulation of the p5 pro-
moter, and site-specific integration (8–11). The AAV Rep proteins
have distinct characteristics that position them apart from other
SF3 family members, such as simian virus 40 large T antigen
(SV40-LTag) and papillomavirus E1 protein (PV-E1). A case in
point is the OBD that contains an endonuclease activity that is
required for DNA replication and site-specific integration and is
similar to domains from other nonstructural proteins from gemi-
niviruses and bacteriophages that use rolling-circle replication
(RCR) to replicate their genome (12). Moreover, the minimal
AAA helicase domain of Rep proteins is monomeric, in contrast
to the equivalent domains of SV40-LTag and PV-E1, which form
hexameric rings (13–15). This important structural difference
may be a reflection of the diversity of DNA binding sites that Rep
proteins recognize and the special mechanisms used to replicate
the AAV genome. The AAV single-stranded genome contains pal-
indromic sequences at both ends that fold into three-way junction
structures called inverted terminal repeats (ITRs). The start of
replication initiates at the 3= end, which is used as a primer for
leading strand synthesis. This initial cycle of replication, which
requires unwinding of the 5=-end ITR, leaves a DNA molecule
with an ITR hairpin end that needs to be replicated to generate a
double-stranded DNA (dsDNA) molecule (16, 17). To complete
replication, Rep68/Rep78 bind to a specific site called the Rep
binding site (RBS) within the ITR and in a reaction that is ATP
dependent unwind and nick DNA, generating a new 3= end (18).
The nature of the Rep-DNA complex formed during this process
remains unknown, but because of the variety of DNA substrates
generated—from double-stranded DNA during the initial bind-
ing to single-stranded DNA after the melting reaction—it may
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require the assembly and disassembly of Rep-DNA complexes
with different stoichiometries (19). For instance, binding to both
AAV ori and AAV S1 sites may be a stepwise process where initial
binding to the RBS site is followed by additional recruitment of
more Rep molecules, as has been reported for similar initiator
proteins such as SV40-Tag and PV-E1. Therein lies the impor-
tance of determining the peculiar oligomeric nature of the apo-
Rep68/Rep78 proteins in order to understand their DNA-directed
assembly. Recently, we and others have determined that the linker
that connects the OBD to the AAA domain is critical for the
oligomerization of Rep proteins and may be important for DNA
complex formation (20, 21). Our current knowledge of Rep68/
Rep68 oligomerization derives mostly from studies of these pro-
teins bound to the AAV ori or other DNA targets showing a variety
of oligomers from hexameric to double octameric (19, 22). In this
study, we have used a multifaceted approach involving size-exclu-
sion chromatography, analytical ultracentrifugation, modeling,
plus electron microscopy, and we show below that Rep68 has a
dynamic behavior in solution and forms a mixture of monomer,
dimers, tetramers, and multiple-ring structures.
MATERIALS AND METHODS
Protein expression and purification. Rep68 wild type (wt), as well as the
other mutants proteins used here, was expressed and purified as described
before (19). Briefly, the His6-PreScission protease (PP) cleavage site-
Rep68 fusion protein was expressed in Escherichia coli BL21(DE3)/pLysS
bacteria at 37°C for 3 h in LB medium containing 1 mM IPTG (isopropyl-
-D-thiogalactopyranoside). Cell pellets were lysed in Ni-buffer A (20
mM Tris-HCl [pH 7.9 at 4°C], 500 mM NaCl, 5 mM imidazole, 10%
glycerol, 0.2% CHAPS {3-[(3-cholamidopropyl)-dimethylammonio]-1-
propanesulfonate}, 1 mM TCEP [Tris(2-carboxyethyl)phosphine]). After
five 10-s cycles of sonication, the fusion protein was purified using an Ni
column preequilibrated in Ni-buffer A. The protein that eluted was de-
salted using buffer A and a HiPrep 26/10 desalting column (GE Health-
care). The His-PP tag was removed by PreScission protease treatment
using 150 g PP/mg His-PP-Rep68. After overnight incubation at 4°C,
buffer was exchanged using the same desalting column and Ni-buffer A.
Subsequent Ni column chromatography using buffer B (the same as buf-
fer A but with 1 M imidazole) was performed to remove the uncleaved
fusion protein, and untagged Rep68 was eluted with 30 mM imidazole.
Rep68 was finally purified by gel filtration chromatography using a
HiLoad Superdex 200 16/60 column (GE Healthcare) and size-exclusion
buffer (25 mM Tris-HCl [pH 8.0], 200 mM NaCl, 2 mM TCEP). Rep68 wt
and mutant proteins were concentrated (1.0 mg/ml for wt and the Cys
mutants and 10 mg/ml for the double mutant of Cys). All proteins were
flash-frozen in liquid N2 and stored at80°C.
Analytical gel filtration chromatography. Samples of the different
versions of Rep68 (200 l) at 4-mg/ml concentrations were chromato-
graphed on a Superose 6 10/300 GL column (GE Healthcare) with a flow
rate of 0.5 ml/min. Size-exclusion buffer was used for all chromatographic
analyses. Protein elution was detected from its absorbance at 280 nm. A
standard curve for protein molecular masses was generated using the pro-
teins carbonic anhydrase (29 kDa), bovine serum albumin (66 kDa), al-
cohol dehydrogenase (ADH; 150 kDa), -amylase (210 kDa), apoferritin
(443 kDa), and thyroglobulin (669 kDa) (Sigma-Aldrich).
Cross-linking of Rep68*. The cross-linking reactions for the Rep68
Cys151Ser mutant (Rep68*) were done according to a protocol adapted
from that of Packman and Perham (23). The protein concentration was 82
M (5 mg/ml) in 20 mM phosphate buffer, added with 300 mM NaCl, pH
8.0. A 30-fold molar excess of 100 mM dimethyl pimelimidate dihydro-
chloride (DMP; MP Biomedicals, LLC) was added to the reaction mix-
ture, and the mixture was incubated at room temperature. The reaction
was quenched by addition of Tris (pH 7.5) to a final concentration of 50
mM after 1 h.
Analytical ultracentrifugation. Sedimentation velocity experiments
were carried out using a Beckman Optima XL-I analytical ultracentrifuge
(Beckman Coulter Inc.) equipped with both four- and eight-hole rotors.
Samples were loaded in the cells, using in all cases size-exclusion buffer.
Samples were centrifuged in 2-sector carbon-filled Epon centerpieces typ-
ically at 25,000 rpm and 20°C. Sectors were loaded with a 420-l sample
volume. Typically, 200 or more scans were collected at 5-min intervals at
25,000 rpm. Concentration profiles were collected using both UV absorp-
tion (280 nm) and Rayleigh interference optical systems. Results were
analyzed using both the SEDFIT and SEDPHAT programs (24, 25).
DNA binding. Fluorescence anisotropy experiments were performed
on an ISS PC1 fluorimeter (ISS, Champaign, IL). The DNA substrate used
was a single-stranded oligo(dT)38 oligonucleotide modified with a 5=
6-carboxyfluorescein molecule (Integrated DNA Technologies). Reac-
tions were performed in a volume of 500 l with a buffer containing 25
mM HEPES (pH 7.0), 100 mM NaCl, and a final concentration of 5 nM
DNA. Protein concentrations were in the range of 0 to 2.0 M. Samples
were incubated at 20°C for 30 min prior to measurement. Binding activity
was followed at an excitation of 492 nm and an emission of 520 nm. Data
analysis was performed as described by Yoon-Robarts et al. (7).
Helicase assay. DNA unwinding was measured using a fluorescence
resonance energy transfer (FRET)-based fluorometric assay based on the
protocol of Bjornson et al., with some modifications (26). The assay uses
a DNA molecule labeled at each strand with a FRET pair. The DNA site
consists of an 18-bp duplex region and a 10-nucleotide 3= tail in the bot-
tom strand. The top strand has been labeled with Iowa-Black Dark
quencher (IB) at the 3= end, and the bottom strand has been labeled with
cyanine 5 (Cy5) at the 5= end. IB quenches the fluorescent intensity of Cy5,
and upon DNA unwinding, the increase in fluorescent intensity of Cy5 is
measured. Fluorescent stopped-flow kinetics studies were carried out us-
ing an ISS PC1 fluorimeter (ISS, Champaign, IL) equipped with a Hi-Tech
SFA-20 rapid kinetics stopped-flow mixer (TgK Scientific Limited, United
Kingdom). The Rep68 protein and the ATP were mixed in a buffer con-
taining 25 mM HEPES, 50 mM NaCl, pH 7.0. A reaction mix of protein,
fluorescent DNA (IB/Cy5-dsDNA), and MgCl2 was placed in one syringe
of the device, and the ATP mix was placed in a second. Samples were
equilibrated at 20°C for 5 min before mixing. Helicase activities were
followed using 30 nM fluorescent DNA and 1M protein in each case for
900 s. ATP was kept at a 1 mM final concentration. An excitation of 645
nm (Cy5) and an emission of 670 nm (IB) were used for these experiments
with a slit of 1 mm. Data results were fit by nonlinear least-squares, using
the Origin (version 5.0) program, to Ft F0[1 exp(a · k)], where a is
the amplitude of the fluorescence, k is the first order rate constant, and Ft
and F0 are the total and initial fluorescent signals, respectively.
ATPase assay. The ATPase assay was performed using a protocol
modified from that of Baginski et al. (27). The conditions of the reactions
were as follows: 1 mM ATP and 1 M protein in the presence of 1 mM
MgCl2 were mixed in a final volume of 125l in reaction buffer A (25 mM
Tris-HCl, pH 8.0, 200 mM NaCl, 2 mM TCEP). The reaction mixture was
incubated at 25°C, and aliquots were removed every 15 s. This reaction
mixture was stopped with 250 l of solution MA (0.5% ammonium mo-
lybdate, 3% ascorbic acid– 0.5 N HCl). After 20 min of incubation in ice
water, solution CA (2% sodium citrate tribasic dihydrate, 2% sodium
arsenite, 2% acetic acid) was added to the samples. After 20 min of incu-
bation at room temperature, samples were read at 840 nm in a spectro-
photometer (Agilent Technologies) with a multiple-cell thermoregulated
compartment. The formation of inorganic phosphate was calculated from
phosphate standard curves.
Virus production and purification. HEK293T cells maintained in
Dulbecco’s modified Eagle medium (DMEM; Invitrogen, United King-
dom) supplemented with 10% fetal calf serum (FCS; Invitrogen, United
Kingdom) at 37°C and in 5% CO2 were transfected using polyethyleni-
mine (PEI) with 45 g of pAV2 plasmid (containing the AAV type 2
[AAV2] genome) or its C151S-mutated version, pMB2, and 135 g of
helper plasmid pXX6 (University of North Carolina Vector Core Facility;
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see http://genetherapy.unc.edu/mta.htm or a map and the sequence).
Cells were incubated in DMEM containing 2% fetal bovine serum, 100
units/ml of penicillin, 100g/ml streptomycin, and 25 mM HEPES. After
72 h, the cells were harvested and lysed in 150 mM NaCl, 50 mM Tris at pH
8.5, followed by three freeze (80°C)-thaw (37°C water bath) cycles. The
crude lysate was treated for 30 min at 37°C with 150 units/ml of Benzonase
(Sigma) and cleared by centrifugation. The virus was purified on an
iodixanol step gradient as previously described (28). The gradient was
formed in clear ultracentrifugation tubes (Beckman) by first adding 2.8 ml
of 15% iodixanol (Optiprep density gradient medium; Sigma) in 1 M
sodium chloride, 1 TD buffer (1 phosphate-buffered saline, 1 mM
MgCl2, 2.5 mM KCl) and then underlying, in succession, 1.88 ml 25%
iodixanol in 1 TD buffer containing 12.5 g/ml phenol red (Gibco,
Grand Island, NY), 1.55 ml 40% iodixanol in 1 TD buffer, and 1.55 ml
60% iodixanol containing 12.5g/ml phenol red. The cell lysate was then
applied on top of the gradient, which was centrifuged at 40,000 rpm for 3
h at 18°C in a Sorvall Discovery 90SE ultracentrifuge using a TH641 rotor.
The virus was extracted with an 18-gauge needle from the 40%-60%
iodixanol interphase as well as the majority of the 40% iodixanol phase. A
Vivaspin20, 100-kDa-cutoff concentrator (Sartorius Stedim, Goettingen,
Germany) was used to concentrate the virus in a final volume of 700l as
well as to exchange the buffer to lactated Ringer’s solution (Baxter, Deer-
field, IL).
Slot blot. HEK293T cells were transfected with pAV2 or pMB2 with
Lipofectamine 2000 (Sigma) and after 24 h infected with adenovirus at a
multiplicity of infection of 10. After an additional 48 h, the cells were
harvested, lysed in 350 l of 0.2 M NaOH–10 mM EDTA, and boiled for
15 min. Each sample was loaded in triplicate onto a nylon hybridization
membrane (Amersham Biosciences). The membranes were rinsed in 2
SSC (1 SSC is 0.15 M NaCl plus 0.015 M sodium citrate), dried, UV
cross-linked, and prehybridized in 0.75 nylon wash solution (NW; 40.6
g Na2HPO4, 18.65 g EDTA, 500 g SDS in 3.58 liters of H2O, pH 7.2) buffer
at 65°C. The membranes were hybridized overnight in 0.75NW buffer
to a radiolabeled probe (labeled using a Prime-It RmT random primer
labeling kit from Stratagene, [32P]dCTPs from PerkinElmer) consisting of
either a rep sequence or an ampicillin sequence. Primers used to amplify
the rep probe were 5=-AACTGGACCAATGAGAACTTTCC-3= and 5=-A
AAAAGTCTTTGACTTCCTGCTT-3=. To generate the ampicillin probe,
a 587-bp fragment of the mini-pDG plasmid was amplified by PCR, using
the primers ND44 5=-AATCAGTGAGGCACCTATCTCAGC-3= and 5=-
AACTCGGTCGCCGCATACACTATT-3=. The membranes were washed
twice with 0.5NW buffer, followed by an additional wash in 0.1NW
buffer. Finally, the membranes were exposed to a phosphorimager screen
for 2 h, and the image was analyzed with ImageQuant software (GE
Healthcare Life Sciences).
Determination of infectious particle production. HEK293T cells
(105) were seeded and triple transfected 2 days later with plasmids encod-
ing the recombinant AAV2 (rAAV2)-green fluorescent protein (GFP)
(pTRUF11), AAV Rep (wt or C151S mutant), and Cap (pDG or pMB1)
constructs and adenovirus helper functions (pXX6). Cells were harvested
3 days after transfection and treated as described above for virus produc-
tion. Increasing volumes of crude lysate were used to infect HeLa cells. At
3 days postinfection, HeLa cells were harvested and the percentage of
GFP-positive cells was determined by fluorescence-activated cell sorter
(FACS) analysis (FACSCalibur; BD).
Sequencing of viral preparations. PCR was used to prepare a frag-
ment of rep containing the C151S mutation. The primers used were
ND140 (forward, 5=-GTTTCCTGAGTCAGATTCGCG-3=) and ND45
(reverse, 5=-AAAAAGTCTTTGACTTCCTGCTT-3=), both at 0.5pmol/
l. Deoxynucleoside triphosphates (0.2 mM; NEB) and Go Taq polymer-
ase enzyme (0.05 U/l; Promega) were added to the reaction mixture. The
cycling parameters were 2 min at 94°C, followed by 35 cycles of 30 s at
94°C, 40 s at 64°C, and 1 min at 72°C, with a final 10 min of incubation at
72°C. The resulting fragment was cloned into the pCR2.1 TOPO vector
(Invitrogen) and sequenced using primers 5=-AAAAAGTCTTTGACTTC
CTGCTT-3= and MB3 5=-GTCAGGCTCATAATCTTTCCCGCA-3= at
Eurofins MWG Operon. The results were analyzed using the BLAST
(NCBI website) program to confirm the expected viral sequence.
Transmission electronmicroscopy (TEM) analysis. Protein samples
at 0.1 mg/ml were adsorbed directly onto carbon-coated copper grids.
Following negative staining with 0.75% (wt/vol) uranyl formate, samples
were visualized in an electron microscope (Tecnai F20) operated at 200
kV, and images were collected at a magnification of50,000 under low-
dose conditions on a Gatan 4k 4k charge-coupled-device camera. Par-
ticle windowing, two-dimensional (2D) alignment, and classification re-
construction were carried out with EMAN2 software. During the entire
process, the default settings of this image-processing software were fol-
lowed for eight iterative alignments. The 2D averages were obtained from
a final set of 560 particles.
Generation of Rep68 models. An initial model of AAV2 OBD was
built using the crystal structure of AAV5 OBD (Protein Data Bank [PDB]
accession number 1RZ9) encompassing residues 1 to 98. The structure of
AAV2 Rep40 (PDB accession number 1S9H) contains residues 225 to 490.
Using the program MODELLER, we generated the last 46 residues known
to be unstructured as an extended polypeptide chain (29). We generated
two linker models; the first was modeled as an extended polypeptide. The
second model was generated using the Robetta server with the sequence
from residues 205 to 230 (30). The three regions (OBD, linker, and heli-
case domain) were put together using the program COOT (31).
RESULTS
AAV2Rep68 formsmultiple oligomeric species in solutionwith
a tendency to aggregate. An initial characterization of Rep68 in
solution was carried out using gel filtration chromatography and
sedimentation velocity. Gel filtration profiles on a Superose 6 col-
umn clearly showed the presence of three major distributions. A
fraction of the protein, P1, eluted at the void volume (V0), thus
indicating the presence of aggregates with molecular masses larger
than the exclusion limit of the column, i.e., 40 MDa (Fig. 1A).
The two other species, P2 and P3, eluted at 13.3 and 15.9 ml, which
correspond to molecular masses of 550 kDa and 110 kDa,
respectively. These molecular masses should be considered ap-
proximations due to the elongated nature of the Rep68 molecule.
At higher concentrations (1 mg/ml), the fraction of total protein
in the aggregate peak increased substantially and constituted the
majority of the protein population. This behavior was also ob-
served in sedimentation velocity studies using concentrations
ranging from 2 M to 16 M (0.125 to 1 mg/ml), indicating that
even at the lowest concentration, significant formation of aggre-
gates with an apparent s20,w value of 40S occurs (Fig. 1B). The
two other major species have apparent sedimentation coefficients
of 4S and 13S. The width of the peaks suggests that each of
these species may be composed of more than one component. In
order to assess this possibility, we analyzed the data using the van
Holde-Weischet (VHW) method implemented by the program
UltraScan-SOMO (32). This method removes any effect from dif-
fusion on the calculation of s20,w, and any spread of these values
reflects the presence of multiple species. Figure 1C shows the
VHW analysis of the same data, showing significant drifts in both
4S and 13S peaks, indicative of a heterogeneous mixture of mul-
tiple oligomeric species.
Oxidation of Rep68 cysteine residues is the major contribu-
tor to Rep68 aggregation in vitro. Aggregation of Rep68 hinders
not only the further characterization of its oligomeric properties
but also future functional and structural work. To determine the
cause of Rep68 aggregation, we pursued a systematic study on the
influence of conditions such as pH, salt, detergents, as well as
Zarate-Perez et al.















chaotropic agents and reducing agents. We determined that only
reducing agents and specifically TCEP significantly reduced the
fraction of Rep68 aggregates present (Fig. 2). Protein samples at a
concentration of 2 mg/ml were analyzed on a Superose 6 column
equilibrated with buffer A containing different TCEP concentra-
tions ranging from 3 to 5 mM. These data clearly show that the
aggregate peak eluting at the void volume of the column is reduced
as the concentration of the reducing agent TCEP is increased. This
indicates that aggregation is caused by oxidation, which is perhaps
caused by the formation of intermolecular disulfide bonds.
Mutation of Cys151 prevents Rep68 aggregation. To identify
cysteine resides with the potential to form intermolecular disul-
fide bonds, we analyzed the crystal structure of AAV2 Rep40 and
an AAV2 OBD model based on the crystal structure of the AAV5
OBD AB (33). The structures show that of the six cysteine resi-
dues, four are buried or semiburied in the protein and only two,
Cys151 and Cys405, are fully exposed to the solvent. Cys151 re-
sides in the OBD and Cys405 is located in  hairpin 1 of the
helicase domain. Interestingly, Cys405 is conserved in other AAV
serotypes, while Cys151 is not. We thus proceeded to make single
Cys mutants and an additional mutant in which both residues
were replaced by serine/alanine. The mutant proteins were pu-
rified and analyzed on a Superose 6 column. Figure 3 shows
that mutation of Cys151 to alanine or serine abolished the
formation of aggregates at all concentrations tested. In con-
trast, the Cys405Ser mutant protein still showed significant
formation of aggregate eluting at the void volume (Fig. 3B). As
expected, the double mutant behaved like the single Cys151Ser
mutant (Fig. 3C).
TheRep68C151Smutant is functionally equivalent toRep68
wt. In order to determine if the Cys151Ser mutation affects any of
the biochemical activities of Rep68, we compared the biochemical
activities of the C151S mutant with those of Rep68 wt. We per-
formed ATPase (Fig. 4A), helicase (Fig. 4B), and DNA binding
functional (Fig. 4C) assays in vitro. Results show that the C151S
mutant protein performed as well as the wild-type protein in all
these functional assays. In addition, we assessed the performance
of the C151S mutant in a simple replication assay in HEK293T
cells. Figure 4D shows comparable replication efficiencies by both
the wt and mutant Rep68 proteins. To determine if the Rep C151S
mutant was also able to support the production of infectious viral
particles, we produced recombinant AAV2-GFP in the context of
the mutant Rep protein and infected HeLa cells with increasing
amounts of virus. Figure 4E shows that infectious rAAV2-GFP
particles were efficiently formed in the presence of the C151S Rep,
albeit at slightly lower titers than wt Rep. To investigate this small
difference, we then purified both AAV2 wt and AAV2 containing
the C151S mutation and assessed the fraction of empty particles in
our preparations by transmission electron microscopy (Fig. 4F).
The presence of the mutation in the purified viruses, confirmed by
sequencing part of the viral DNA containing the mutation, did not
affect the ratio of empty versus full particles.
Rep68* forms multiple species in solution. Similar to the re-
sults obtained for Rep68 wt (Fig. 1), Rep68* forms multiple oli-
gomers at moderate protein concentrations. To further character-
FIG 1 Rep68 wt oligomerization profile. (A) Rep68 wt (2 mg/ml) was injected
in a Superose 6 10/300 GL column with a flow rate of 0.5 ml/min. Protein
elution was followed by UV detection at 280 nm. The x axis represents the
elution volume. Molecular mass standards are shown above the plot. (B) Sed-
imentation velocity profiles of Rep68 wt at a concentration of a 0.5 optical
density (0.33 mg/ml). The experiment was run at 40,000 rpm and 20°C, as
described in Materials and Methods. (C) van Holde-Weischet analysis of the
sedimentation velocity data shown in panel B. The spread from the vertical at
both 4S and 13S indicates the presence of more than one species in each pop-
ulation.
FIG 2 Effect of TCEP on aggregation of Rep68 wt. Rep68 wt (2 mg/ml) was
injected with different concentrations of TCEP (3 and 5 mM). A Superose 6
10/300 GL column was used with a flow rate of 0.5 ml/min. Protein elution was
followed by UV detection at 280 nm. The aggregation peak of the protein at an
elution volume of7 ml decreases as the TCEP concentration increases.
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ize the oligomeric behavior of Rep68*, an extensive sedimentation
velocity study was undertaken at various Rep68* concentrations
and in the presence and absence of either ATP or ADP. The results
for apo-Rep68* show that the continuous sedimentation [c(S)]
distributions change significantly as the total concentration of
Rep68* is increased (Fig. 5A). At the lowest concentration (1M),
two species are present, sedimenting at 4S and 13S. The number of
species increases at higher concentrations, with as many as six
species present at 18M and the appearance of a faster-sediment-
ing species at 27S. Figure 5B shows the effect of the Rep68*
concentration on the weight (actually, the signal) average sedi-
mentation coefficient (swt) for the overall reaction and the mono-
mer-dimer equilibrium. These plots are considered a sensitive and
powerful proof of species at equilibrium (34). The fact that swt
increases significantly over the 18-fold concentration range indi-
cates that dynamic protein-protein interactions are occurring. For
the monomer-dimer reaction, swt was estimated by integrating
over a somewhat variable range from 2.5S to 6.5S, which is neces-
sary because at high Rep68* concentrations the larger particles
(13S and 27S) interfere with the sedimentation of the monomer
and dimer. The pattern exhibited is consistent with a strong
monomer interaction that forms dimers (positive slope) and the
well-known effect of an increasing concentration of a larger, more
rapidly sedimenting species that interferes hydrodynamically.
These results, although complex, are consistent with a kinetic pro-
cess that seems to be near or at the boundary between a slow and
an intermediate kinetic process (104 to 103/s and	105/s, re-
spectively). This is illustrated in the behavior of the 4S peak pres-
ent at low concentrations but at higher concentrations resolution
into two peaks of monomer and dimers as a result of a better
signal-to-noise ratio (Fig. 5A). In addition, calculation of the av-
erage molecular mass of the 4S species at the lowest concentration
gives a molecular mass of 81 kDa, a value between that of a
monomer and that of a dimer. Calculation of the molecular mass
of the 13S species gives a range of values from 360 to 450 kDa at the
lower concentrations. Together, these results indicate that in so-
lution, Rep68 forms two major populations: a monomer-dimer
population that is in slow equilibrium and sediments over the
range of 3S to 5S and a 13S population consisting of a mixture of
multiple oligomers of six or more Rep68* molecules. Interchange
between the two populations occurs as the concentration in-
creases and is mediated by an intermediate species that sediments
with an s20,w value of between 5S and 9S, suggesting Rep68* trim-
ers or tetramers. Sedimentation velocity data were also collected in
the presence of both 1 mM ATP and ADP, and a representative set
of these data at a 18 M concentration is shown in Fig. 5C. These
curves suggest that the presence of either ATP or ADP shifts the
equilibrium in favor of higher-order oligomers. This effect can
clearly be seen in Fig. 5D, which shows the amount of the 27S peak
formed as a function of protein concentration in the presence or
absence of nucleotides. The major difference with the apo-Rep68*
is the formation of a species sedimenting at27S, especially at the
lowest concentrations. At the highest concentration (18M), two
things are occurring: first, we have exceeded the Kd (dissociation
constant) for the formation of the 27S species in the absence of
nucleotides, and this explains the sudden increase in its formation
after 10M. Second, the amount of the 27S peak is the same in the
absence and presence of nucleotides because we have reached the
maximum amount of 27S that can be formed at this concentra-
tion. To estimate a value for the dissociation constants of these
oligomerizations, each peak was identified by comparing its esti-
mated S value from the peak integrations with S values calculated
by hydrodynamic modeling of the structure (see below). Table 1
shows the results of these dissociation constant calculations for
the oligomerization stepsK2¡1,K4¡2,K8¡4, andK16¡8, where the
subscripts represent our best estimation as to the minimum oli-
gomerization state described by the peak under investigation. The
one peak that is difficult to assess is that assigned to the tetramer,
since the signal from both the trimer and the hexamer might over-
lap the tetramer peak. The values in Table 1 show a degree of
consistency both between values determined for the same step in
the presence and absence of nucleotides and between those values
calculated for what we presume are linear molecules with the same
reactive interface (monomer-dimer and dimer-tetramer). There
is a larger 0.1-fold change in K8¡4 than in K4¡2, which might
indicate an entropic effect caused by ring closure. There seems to
be a small decrease in the values of the dissociation constants when
either ATP or ADP is added; although the effect is not large, the
trend seems to be there. The 27S peak must represent a higher-
order oligomer, and based on the electron microscopy results pre-
FIG 3 Effect of Cys mutations on Rep68 wt aggregation. Three Rep68 Cys
mutants were evaluated by gel filtration chromatography: Rep68 C151S,
Rep68 C405S, and a double Cys mutant, Rep68 C151A and C405S. A Superose
6 10/300 GL column was used with a flow rate of 0.5 ml/min. Protein elution
was followed by UV detection at 280 nm. When the protein contains the
Cys151S mutation (A), no aggregation was observed. In contrast, the C405S
mutation still shows an aggregation peak eluting at the void volume of the
column (B). (C) The double mutant behaves like the single C151S mutant. The
concentration of the proteins was 32.65 M (2 mg/ml).
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sented below, we tend to identify it as a stack set of rings consisting
of two either seven- or eight-member rings or a mixture of both.
TEM shows that the 13S population is a mixture of heptam-
eric and octameric rings. In order to determine the exact nature
of the 13S species identified in the sedimentation velocity experi-
ments, we carried out negative-stain TEM. We cross-linked all our
samples using DMP to stabilize the protein complexes prior to
purification on a Superose 6 gel filtration column. All samples
were first analyzed by sedimentation velocity to confirm the for-
mation of the 13S complexes. Figure 6A shows a representative
electron microscopic image of a negatively stained Rep68*-13S
peak where many ring-shaped particles can be seen. A reference-
free 2D alignment without imposing symmetry was carried out,
and Fig. 6B and C show a selection of several classes, clearly indi-
cating the presence of seven- and eight-ring structures. The hep-
tameric ring has an external diameter of 140.25 Å and an internal
diameter of 63.11 Å; the octameric ring has an external diameter of
144 Å and an internal diameter of 67.65 Å. We also analyzed by
TEM the effect of ATP on Rep68*. We observed the same seven-
and eight-ring structures seen in apo-Rep68*, and in addition, we
observed the formation of large filament-like structures. These
higher-order structures may represent a series of stacked rings or a
helical arrangement of Rep68 molecules, as has been observed in
several other AAA proteins and RecA-like proteins (Fig. 6D and
E) (35). In addition, we observed the same seven- and eight-ring
structures seen in apo-Rep68*.
Hydrodynamic modeling of Rep68 indicates the presence of
multiple oligomers. Taking advantage of the X-ray structures of
FIG 4 Functional comparison of Rep68 wt and the Rep68 C151S mutant. (A) ATPase activity showed no significant difference for the wt and C151S mutant
proteins. (B) Helicase activity for WT and C151S proteins, using fluorescent stopped-flow kinetics). Helicase activities were followed using a 30 nM concentra-
tion. (C) Binding of DNA analysis of Rep C151S. A fluorescent probe (F-DNA-dsDNA) was used to monitor the binding of the protein. Binding was followed
using 5 nM DNA and a range of protein concentrations from 50 to 2,000 nM. (D) Determination of viral replication in the presence of wt or C151S mutant Rep.
The bar graph shows the quantification of three slot blot experiments. The signal obtained with the Rep-specific probe was normalized to that obtained with the
ampicillin-specific probe, to normalize for input (transfected) DNA. The replication of the wt AAV2 genome in the presence of adenovirus was set as 100%. Data
are presented as means
 SEMs. (E) Comparison of the production of rAAV2-GFP infectious particles in the presence of wt or C151S Rep. rAAV2-GFP particles
were produced in HEK293T cells in the presence of adenovirus helper functions, AAV2 Cap, and wt or C151S Rep. Cells were harvested, lysed, freeze-thawed, and
treated with the endonuclease Benzonase. Various volumes of crude lysate (in l, x axis) were added to HeLa cells, and the percentage of GFP-positive infected
cells was determined by FACS analysis. Data from four experiments are presented as means
 SEMs. (F) Visualization of wt AAV2 and AAV2-RepC151S viral
particles by transmission electron microscopy at50,000 magnification. Empty viral particles appear as white rings. For each sample, 6 fields of approximately
200 particles were counted; the mean percentage of full particles and the standard deviation are indicated.
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the two functional domains of Rep68, we created several oligo-
meric models of Rep68 and calculated their hydrodynamic prop-
erties using the programs HYDRO and UltraScan-SOMO (36,
37). This approach allows us to verify the results from the sedi-
mentation velocity and TEM experiments. First, in order to exam-
ine the limits of our Rep68 model, we generated two structures.
The first model has the two domains joined by an extended inter-
domain linker; in the second model, the linker is folded up. The
first structure resulted in a calculated sedimentation coefficient of
2.9S s20,w, while the second model predicted a sedimentation co-
efficient of 3.5S s20,w, which is closer to the experimental value.
These results suggest that the interdomain linker is not in an ex-
tended conformation but probably folded, bringing the two do-
mains close to each other. Using the second model, we generated
models for dimers, trimers, and tetramers. At the same time, we
created models for hexameric, heptameric, and octameric ring
structures. The theoretical sedimentation velocity coefficients of
all models were calculated using the program UltraScan-SOMO,
as shown in Table 2. The calculated sedimentation coefficients
from these models reproduce the experimental values obtained
from the sedimentation velocity experiments remarkably well.
Taken together, our modeling results support the notion that
Rep68 is present as a mixture of monomer-dimer species at slow
equilibrium at low concentrations. Increasing the concentration
induces the formation of trimers and tetramers that slowly inter-
convert to several oligomeric rings, namely, heptamers and oc-
tamers (Fig. 7).
DISCUSSION
The experiments described here show that in vitro, Rep68 exists as
a mixture of multiple species in equilibrium. At low concentra-
tions Rep68 partitions into two populations. The first consist of
monomers and dimers interchanging slowly and sedimenting as
two clearly defined peaks at most concentrations. The second
FIG5 Sedimentation velocity analysis of Rep68*. (A) Sedimentation profiles of Rep68* at five different concentrations obtained using the SEDFIT program. The
corresponding values for molecular mass and s20,w are shown in Table 2. (B) Dependence of the weight average sedimentation coefficient on Rep68* loading
concentration. , weight average sedimentation coefficient for the entire distribution; , weight average for the dimer-monomer equilibrium. (C) Different
concentrations of Rep68* (from 1 to 18M) were tested in sedimentation analysis assays in the absence or in the presence of nucleotides of ADP and ATP. A final
1 mM concentration of these nucleotides was used in every sedimentation velocity run. (D) Effect of ATP/ADP on the amount of 27S species formed. The area
under the 27S peak was integrated at each concentration.
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population is a mixture of heptameric and octameric rings that
sediment at13S. The fact that we can detect the individual peaks
of the two populations suggests that they interconvert slower than
the time scale of our sedimentation velocity experiments. At
higher concentrations, the amount of the 13S population in-
creases and we begin to detect the appearance of an intermediate
peak at7S. This peak likely represents a mixture of trimers and
tetramers. Our data further suggest an oligomerization mecha-
nism where Rep68 heptamers and octamers are assembled
through the association of trimers and tetramers from a pool of
monomers and dimers (Fig. 7). This process is reversible, as a
purified heptamer-octamer mixture dissociates into monomers-
dimers upon dilution (data not shown). Similarly, a report by
Dignam et al., who used size-exclusion chromatography, showed
the concentration-dependent self-association of Rep68 and its
tendency to aggregate at moderate salt concentrations, although
the nature of the different oligomers was not addressed (38). We
have shown here that aggregation of Rep68 is induced by residue
Cys151, which has a tendency to form disulfide bridges. In vivo,
due to the highly reducing environment found in the nucleus,
oxidation of cysteines does not occur. The formation of multiple
oligomeric rings displayed by Rep68 is similar to the findings for
some AAA proteins and other ring helicases. For instance, for-
mation of heptamers has been described for the bacteriophage T7
gene 4 primase/helicase (39), the minichromosome maintenance
(MCM) proteins from several species (40–42), the heat shock pro-
tein ClpB (43), Pseudomonas aeruginosa Hfq (44), ClpP (45), and
Rad52 (46). In many cases, mixtures of heptameric and hexameric
rings have been observed to be present at the same time (47). Our
data suggest that Rep68 adopts a similar behavior, forming hep-
tameric and octameric rings. The functional role of Rep68 ring
structures, however, remains to be addressed, and it is pivotal to
investigate it in the context of its interaction with different DNA
substrates. In vitro studies of initiator proteins such as DnaA,
SV40-LTag, and PV-E1 show that the formation of an initiation
complex is a stepwise process that requires the binding of individ-
TABLE 1 Estimates of dissociation constants for the oligomerization of





K2¡1 K4¡2 K8¡4 K16¡8
Apo-Rep68*
1.0 NDb ND ND ND
2.1 1.5 1.79 0.16 ND
4.8 3.26 1.71 0.15 ND
9.3 2.35 1.98 0.17 1.6
18.2 1.56 2.56 0.38 0.48
Avg 2.2 2.0 0.21 1.0
Apo-Rep68* with ATP
0.7 4.9 NDb ND ND
1.8 2.0 0.43 0.04 0.16
4.2 0.75 0.9 0.13 ND
8.6 0.87 1.26 0.09 0.31
17 0.96 1.1 0.06 0.07
Avg 1.9 0.9 0.08 0.18
Apo-Rep68* with ADP
0.9 0.9 1.1 0.02 ND
2.1 1.3 0.5 0.04 0.5
4.2 0.7 0.6 0.05 0.4
8.8 0.9 ND ND 0.7
18.1 1.9 1.0 0.05 0.5
Avg 1.1 0.8 0.04 0.5
a Total concentration of the Rep68* monomers in the cell obtained from the
integration of the complete c(S) distribution from the interference data.
b ND, not determined.
c The0.1-fold change in K8¡4 relative to that for K4¡2 might indicate a entropic
effect caused by ring closure. Note also that there seems to be a general small decrease
in the values of the dissociation constants when either ATP or ADP is added; although
the effect is not large, the trend seems to be there.
FIG 6 Electron microscopic analysis of the Rep68 protein oligomers. (A)
Visualization of cross-linked Rep68* particles by electron microscopy
at 50,000 magnification using the negative-stain technique. Image pro-
cessing of the particles shows the presence of heptameric (B) and octameric
(C) rings. Addition of ATP gives a similar mixture of heptamers and oc-
tamers (data not show) but also induces the formation of large filament-
like structures (D). (E) Dimension details for these structures after the
image processing.
TABLE 2 Comparison of experimental and calculated sedimentation
coefficients (s20,w) for different Rep68 oligomers
Oligomer





Monomer 60.8 61.4 3.7 3.4
Dimer 121.6 114 5.4 5.5
Trimer 182.4 215c 8.7c 7
Tetramer 243.2 8.3
Hexamer 364.8 NDd ND 11.1
Heptamer 425.6 412c 13.3c 12.5
Octamer 486.4 13.6
a Mass and sedimentation coefficients calculated from the corresponding peak position
of the sedimentation profiles and f/f0 values determined with the SEDFIT program.
b Sedimentation coefficients calculated from atomic models using the program
UltraScan-SOMO.
c Calculated from broad peaks that do resolve into two or more peaks with these data.
d ND, not determined.
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ual protein molecules to several direct repeats. This process is
inhibited if the initiator protein is present as a stable ring structure
because of the topological constraints of placing a closed ring
around DNA. In many cases, this is what has been observed in
vitro (13). In addition, formation of rings could provide a more
stable structure, increasing protection against degradation. Sev-
eral groups have postulated that the presence of heptameric rings
provides a mechanism for loading the initiator protein onto DNA
without the need for an additional loader protein. Thus, upon
interaction with DNA, one subunit is lost with the resulting open-
ing of the ring (42, 47). The presence of multiple Rep68 oligomers
possibly provides a pool of different functional units that could be
used for distinct reactions, such as initiation of DNA replication,
recognition of the terminal resolution site (trs) hairpin for nick-
ing, or the binding to the p19 promoter. In this regard, we have
shown that Rep68 oligomerization is regulated by DNA structure
and found that single-stranded DNA and helicase substrates sup-
port the formation of double-octameric Rep68 (19). Moreover,
we determined that Rep68 is capable of unwinding a helicase sub-
strate when purified as a double-octamer Rep68-helicase substrate
complex. Other reports have found that Rep68 forms hexamers,
when bound to dsDNA (22). Another level of complexity that
could regulate the oligomerization properties of Rep proteins in
vivo involves posttranslational modifications. Studies have deter-
mined that Rep proteins are highly modified, with residues being
phosphorylated, ubiquitinated, and sumoylated. The last two
modifications are used primarily to target the Rep proteins for
proteosomal degradation (48–50). In contrast, phosphorylation
inhibits several enzymatic properties of Rep proteins, such as
DNA binding and helicase activity, and may regulate the assem-
bly-disassembly of Rep proteins to DNA substrates (51, 52). The
final answer to the functional oligomeric state of Rep68 will be to
determine the structure of Rep68 bound to different DNA sub-
strates, such as the AAV ori, AAV S1, and p19 promoter and to
characterize the effect of phosphorylation on the formation of
these complexes.
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The Interdomain Linker of AAV-2 Rep68 Is an Integral
Part of Its Oligomerization Domain: Role of a Conserved
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Abstract
The four Rep proteins of adeno-associated virus (AAV) orchestrate all aspects of its viral life cycle, including transcription regulation,
DNA replication, virus assembly, and site-specific integration of the viral genome into the human chromosome 19. All Rep proteins
share a central SF3 superfamily helicase domain. In other SF3members this domain is sufficient to induce oligomerization. However,
the helicase domain in AAV Rep proteins (i.e. Rep40/Rep52) as shown by its monomeric characteristic, is not able to mediate stable
oligomerization. This observation led us to hypothesize the existence of an as yet undefined structural determinant that regulates
Rep oligomerization. In this document, we described a detailed structural comparison between the helicase domains of AAV-2 Rep
proteins and those of the other SF3members. This analysis shows amajor structural difference residing in the small oligomerization
sub-domain (OD) of Rep helicase domain. In addition, secondary structure prediction of the linker connecting the helicase domain
to the origin-binding domain (OBD) indicates the potential to form a-helices. We demonstrate that mutant Rep40 constructs
containing different lengths of the linker are able to form dimers, and in the presence of ATP/ADP, larger oligomers. We further
identified an aromatic linker residue (Y224) that is critical for oligomerization, establishing it as a conserved signature motif in SF3
helicases. Mutation of this residue critically affects oligomerization as well as completely abolishes the ability to produce infectious
virus. Taken together, our data support a model where the linker residues preceding the helicase domain fold into an a-helix that
becomes an integral part of the helicase domain and is critical for the oligomerization and function of Rep68/78 proteins through
cooperative interaction with the OBD and helicase domains.
Citation: Zarate-Perez F, Bardelli M, Burgner JW II, Villamil-Jarauta M, Das K, et al. (2012) The Interdomain Linker of AAV-2 Rep68 Is an Integral Part of Its
Oligomerization Domain: Role of a Conserved SF3 Helicase Residue in Oligomerization. PLoS Pathog 8(6): e1002764. doi:10.1371/journal.ppat.1002764
Editor: Craig Meyers, Penn State University School of Medicine, United States of America
Received February 1, 2012; Accepted May 3, 2012; Published June 14, 2012
Copyright:  2012 Zarate-Perez et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by NIH grants RO1-GM092854 (CRE) and the UK Medical Research Council grant 1001764 (RML). The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: cescalante@vcu.edu (CRE); michael.linden@kcl.ac.uk (ML)
Introduction
The four adeno-associated virus (AAV) Rep proteins are
generated from a single open reading frame by the transcriptional
use of two different promoters (p5 and p19) and subsequent
alternative splicing mechanisms [1,2,3]. These reactions produce
proteins that share three functional domains: an origin binding
domain (OBD), a SF3 helicase domain and a putative zinc-finger
domain [4,5]. The combination of these domains imparts these
proteins with striking multifunctionality. In particular, the larger
proteins Rep78 and Rep68 function as initiators of DNA
replication, transcriptional regulators, DNA helicases and as key
factors in site-specific integration [6]. The smaller Rep proteins
Rep40 and Rep52, play a critical role during packaging of viral
DNA into preformed empty capsids, where they are thought to be
part of the packaging motor complex [7,8,9]. Although in terms of
domain architecture the AAV Rep proteins resemble other
members of the SF3 protein family, the peculiar OBD with its
additional nuclease activity and the complex character of their
oligomeric properties, set them apart from other SF3 helicases
such as simian virus 40 large T antigen (SV40-LTag) and
papilloma virus E1 (PV-E1) proteins [10,11,12,13]. In both of
these proteins, the minimal SF3 helicase domain assembles into a
hexameric ring in a process that can be induced by the presence of
ATP and/or single-stranded DNA [14,15]. In contrast, Rep40
containing only the helicase domain and Rep52 with an additional
Zn-finger domain, appear to be monomeric [16,17]. This indicates
that oligomerization of AAV Rep proteins requires the presence of
both the OBD domain and the helicase domain. This combination
imparts both Rep68 and Rep78 with a complex and dynamic
oligomeric behavior in-vitro that is modulated in large part by the
nature of the DNA substrate [18]. The monomeric behavior of
both Rep40 and Rep52 is striking in that they appear to contain
the required structural features that are present in other SF3
helicase members. The X-ray structures of both SV40-LTag and
PV-E1 show that their helicase domains assemble as hexameric
rings and that the oligomerization interface is bipartite [15,19].
One interface is formed by the interaction of neighbouring N-terminal
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oligomerization domains (OD). The second interface is formed by the
interaction of the C-terminal AAA+ domains and is further stabilized
by the presence of nucleotides [11,15]. In order to understand the
structural features that promote AAV Rep oligomerization, we
pursued in this study a detailed structural comparison of SF3 helicases.
We show that the OD domain in Rep40/52 has been hindered in its
ability to oligomerize by the transcriptional use of the p19 promoter.
This event generates proteins with a smaller OD domain as compared
to other SF3 helicases. More importantly, we show that in the context
of Rep68/78 the required oligomerization is supported by the
interdomain linker which is directly involved in oligomerization
interface and we provide evidence that the tyrosine residue preceding
the start of Rep40/52 (Y224) is critical in the oligomerization and
therefore activity of the large AAV Rep proteins. Taken together, our
results support a model where oligomerization of Rep68/78 is
mediated by a composite oligomerization interface formed by the
OBD, helicase and linker domains, with the latter playing an essential
role in the inducing the oligomerization process.
Results
The oligomerization domain (OD) of AAV Rep40 differs
from the OD’s of other hexameric SF3 helicases
As a first step in our attempt to determine the structural features
that promote oligomerization in AAV Rep proteins, we analyzed
the oligomeric interface of SF3 family members SV40-LTag and
PV-E1. As previously described, the helicase domain contains two
subdomains: a N-terminal helical bundle of four a-helices known
as the oligomerization domain (OD) and the C-terminal AAA+
subdomain (Figure 1A). In PV-E1 the oligomerization interface
spans both subdomains forming two extended surfaces at opposite
faces of the proteins. In the AAA+ subdomain, one face comprises
all the catalytic residues, including: the P-loop, its subsequent
helix, the b-strands with the associated Walker B residues, sensor 1
motif, and one side of the b-hairpin (Figure 1B). The neighboring
subunit interacts through areas that are located in the a-helices
‘‘behind’’ the b-sheet and on the opposite side of the b-hairpin
(Figure 1B). Overall, about 20% of the solvent accessible area takes
part in the interface and includes about 34% of all residues. In PV-
E1, the OD domain consists of 68 residues forming a four helical
bundle. The oligomeric interface comes from interaction of
residues located in helices 1 and 4 in one monomer, with residues
in helices 2, 3 and part of helix 4 in the other subunit (Figure 1B).
Most of the interface is hydrophobic with many tyrosine and
isoleucine residues. Similar types of interactions are seen in the
interface formed by the SV40-LTag OD domains. This domain is
a lot bulkier, spanning 89 residues that form a five-helix bundle.
The extra helix originates from an additional Zn-finger motif.
Significantly, the OD of Rep40, on the other hand, has only 52
aminoacids and, thus, is significantly shorter than PV-E1 and
SV40-LTag OD domains. The direct result of this difference is a
decrease in the total accessible surface area by more than 1000 A˚2.
In addition, the packing of the helices is less compact, producing a
more dynamic structure (Figure 1C). We hypothesize that the
smaller OD domain of AAV Rep proteins imparts these proteins
unique oligomeric properties where the smaller Rep40/52 are
mostly monomeric while Rep68/78 -with the additional OBD
domain- form oligomers. However, the measurable ATPase
activity in all Rep proteins, suggest that Rep40/52 should
oligomerize in the presence of nucleotides [20].
AAV-2 Rep40 forms a transient dimer in the presence of
nucleotides
To determine if the presence of nucleotides can induce
oligomerization of Rep40 -containing the minimal helicase
domain-, we carried out sedimentation velocity experiments in
the presence and absence of nucleotides at different concentra-
tions. The sedimentation velocity profiles offer a complete
characterization of the number and type of oligomers in solution.
The data were analyzed using the program sedfit [21,22].
Figure 2A shows plots of the c(s) distribution against the
sedimentation coefficient (s) for two concentrations of Rep40 in
the absence of nucleotides. A single peak whose s20,w increases
slightly with increasing concentrations is observed. The slight but
significant increase in s and calculated molar mass is consistent
with a weak and transient dimerization (for hydrodynamic reasons,
s is expected to decrease with increasing concentrations of an ideal
solute). The data where also fitted using the program sedphat to a
monomer-dimer association were the process is in rapid exchange
on the time scale of the centrifuge [22]. Table 1 shows that the
dissociation constant in the absence of nucleotides is ,1023 M,
which is at the upper end of detection by sedimentation velocity.
Similar distributions of Rep40 (at 36 mM) in the presence of either
5 mM ATP or ADP are shown in Figure 2B and 2C. Here an
increase is observed in the width of these peaks if compared to
those for Rep40 alone. This is a well-understood behavior for a
associating system whose exchange kinetics are neither slow of fast
on the time scale of the centrifuge, thus, broadening the c(s)
distribution peak [23]. The presence of a small shoulder suggest
that dimer formation is occurring here as well, although perhaps
its rate of dissociation is slower than for Rep40 alone. The s-value
of the shoulder is consistent with a transient Rep40 dimer that
represents ,0.2% of the total amount of protein. The relatively
low ATPase activity of Rep40 reported in the literature supports
our model of transient dimerization promoted by the binding and/
or hydrolysis of ATP [20].
Addition of linker region to Rep40 constructs induces
oligomerization
In order to assess whether the interdomain linker connecting the
OBD domain and the helicase domains contains additional
Author Summary
Viruses have to optimize the limited size of their genomes
in order to generate the proteins required for infection and
replication. Several mechanisms are used to accomplish
this including the use of multiple promoters and alterna-
tive splicing. These processes generate gene products with
diverse functions through the combinatorial assembly of a
small number of protein domains. The small genome of
the adeno-associated virus has two major open reading
frames that generate seven proteins, four non-structural
Rep proteins and three capsid proteins. The non-structural
Rep proteins share a motor domain that uses hydrolysis of
ATP to generate the conformational changes that drive
DNA replication, transcriptional regulation, site-specific
integration and the packing of viral genome into capsids.
These functions depend upon the oligomerization of Rep
proteins on specific DNA sites through the cooperation of
the N-terminal origin binding domain and the C-terminal
helicase domain. We provide evidence that the linker that
connects the two domains is an integral feature of the
helicase domain and contains a conserved aromatic
residue that is critical for oligomerization. This residue
emerges to be a signature motif of SF3 helicases and is
also present in a subset of bacterial Rep proteins that
support rolling circle replication mechanism.
Critical Role of Linker in Rep68 Oligomerization
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regions of distinct structure that may play a role in promoting
oligomerization, we first carried out secondary structure prediction
analysis to determined if the linker contains additional regions of
structure. The results suggest that the region from residue 215 to
224 has the potential to form an a-helix (Figure 3A). We
hypothesized that this region could extend the first helix of the OD
domain (Figure 3A) and the ensuing increase in surface accessible
area may be sufficient to drive oligomerization. To test this
hypothesis, we designed a new Rep construct beginning at the start
of the linker region and extending to aminoacid 536 (a truncated
version of Rep68 without the OBD domain, Rep68D200), and
performed sedimentation velocity and cross-linking studies in
order to characterize its oligomerization properties. The sedimen-
tation profile of Rep68DN200 shows the presence of two peaks,
one corresponding to the monomeric species (,2.53S) and the
other to a dimer (,3.71S). The amount of formed dimer increases
at higher concentrations as expected from a monomer-dimer
equilibrium system (Figure 3B). Formation of dimers was also
observed when we performed cross-linking experiments. Figure 3C
shows that the amount of dimeric species has significantly
Figure 1. Structural comparison of SF3 helicase structures. (A) Ribbon representation of SF3 helicases AAV-2 Rep40, PV-E1 and SV40-LTag.
Salmon color depicts the oligomerization domain (OD). Blue color represents the AAA+ domain. (B) PV-E1 dimer showing the residues participating in
the formation of the oligomerization interface colored in red and blue. (C) Structural alignment of the OD domain of AAV-2 Rep40 (Green), BPV-
E1(Blue) and SV40-LTag(Magenta).
doi:10.1371/journal.ppat.1002764.g001
Critical Role of Linker in Rep68 Oligomerization
PLoS Pathogens | www.plospathogens.org 3 June 2012 | Volume 8 | Issue 6 | e1002764
increased in Rep68DN200 as compared to Rep40wt. We
calculated the dimerization constants of Rep40wt and
Rep68DN200 from a global fitting of the sedimentation velocity
data to a monomer-dimer model (Table 1). In summary, we
determined that the presence of the linker region increases the
strength of dimerization by about 10-fold relative to that of Rep40.
Extension of the linker region to residue 215 defines the
minimal length required to promote oligomerization
Next, we sought to determine the minimal length of linker that
is needed to promote oligomerization. We generated three
additional constructs, named Rep68DN209, Rep68DN214 and
Rep68DN219 and tested their ability to oligomerize (Figure 4).
Our results indicate that Rep68DN214 contains the minimal
length of linker that is required to promote detectible oligomer-
ization, although with the shorter construct Rep68DN219, a small
shoulder is seen at higher concentration (data not shown). These
results confirm that the linker region from 215 to 224 may fold
into a a-helix, resulting in an increase of the surface accessible area
of the OD domain that mediates oligomerization. This increase,
however, is not sufficient to produce higher order oligomers.
ATP and ADP induce formation of higher order oligomers
of the extended linker Rep protein constructs
In order to determine the contribution of ATP and ADP to the
oligomerization of the extended linker Rep linker constructs, we
performed sedimentation velocity studies in the presence of
nucleotides. Our hypothesis was that if oligomerization reflects
the functional state of these proteins, the addition of nucleotides
should support and induce further oligomerization. Figure 5 shows
that the presence of ATP and ADP induces the formation of
higher order oligomers. Formation of dimeric species at this
concentration can be seen with Rep68D214 as well as the longer
constructs RepDN209 and RepDN200. In the later two, ADP
produces two main populations sedimenting at,3S and ,7S with
additional intermediate oligomers. ATP on the other hand, seems
to generate more stable species at ,7S. Again, these data show
that the presence of the linker region induces oligomerization of
the Rep constructs and that the addition of nucleotides, in
particular ATP, induces formation of larger oligomers, possibly
through the stabilization of the interface formed by the AAA+
domains. This finding is in good agreement with the unique
characteristics of the AAV Rep nucleotide binding pocket, which,
based on its open conformation together with the presence of an
arginine finger predicts the nucleotide contribution to oligomer-
ization [24].
Linker substitution abolishes oligomerization of Rep68
To determine if the linker is critical for the oligomerization of
Rep68, we replaced it with an unrelated sequence and examined
its effect on oligomerization using sedimentation velocity. The only
prerequisite for the substitute linker were a lack of structure and no
impact on the native structures of the connected domains. We
chose a sequence from the transcription factor Oct-1. This
transcription factor has two DNA binding domains connected by a
linker of 29 residues. The X-ray structure of this protein shows
that the linker is unstructured and flexible. In addition, it has been
used to connect different protein domains without affecting their
properties [25,26]. We generated a Rep68 mutant protein
(Rep68octlink), where residues 206 to 224 were replaced with 18
residues from the Oct-1 linker and tested its ability to oligomerize.
The sedimentation profile of Rep68 typically shows two popula-
tions with sedimentation coefficients of,3S and,13S (Figure 6A).
We have determined that the 13S peak corresponds to a mixture
of oligomeric rings (data not shown). Figure 6B shows that the
replacement of the linker completely abolishes the oligomerization
Figure 2. Sedimentation velocity profiles of Re40. (A) Sedimen-
tation velocity analysis of Rep40 at different concentrations (18 mM and
36 mM). In all cases the protein sediments with a sedimentation
coefficient of 2.63S. (B) Sedimentation profiles of Rep40 (36 mM) in
presence of 5 mM ATP and (C) 5 mM ADP. All the experiments were
performed at 40 000 rpm and 20uC in a buffer containing 200 mM NaCl.
doi:10.1371/journal.ppat.1002764.g002
Table 1. Global fits of the effect of concentration from
sedimentation velocity studies on Rep40 and Rep68DN200.
Sample smonomer sdimer logKa
Kd Global X2
S S mM
Rep40 2.63 3.70 3.1 730 0.886
Rep68DN200 2.62 4.71 4.1 79 0.20
Sedimentation velocity was performed as described in Materials and Methods.
Concentrations of Rep40 used were 18, 36, and 54 mM and for Rep68DN200: 4,
8, 16 mM.
doi:10.1371/journal.ppat.1002764.t001
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Figure 3. Effect of interdomain linker on oligomerization. (A) A schematic diagram of the AAV-2 Rep proteins with the N-terminal origin
binding domain (green), oligomerization domain (pink), AAA+ domain (blue) and Zinc finger domain (orange). The sequence of the linker region is
shown below with the predicted helical regions connecting the OBD and the helicase domains. Linker sequence is highlighted in yellow. (B)
Sedimentation profiles of Rep68DN200 over the concentration range from 18 to 54 mM and their comparison with Rep40. The sedimentation analysis
shows the presence of two peaks of 2.53S and 3.71S, which corresponds to the monomeric and dimeric species respectively. (C) Cross-linking of
Critical Role of Linker in Rep68 Oligomerization
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of the mutant protein Rep68octlink. We can detect formation of
dimeric species only at the highest concentration tested and in the
presence of ATP, (Figure 6C). These results show that replacement
of the linker produces a Rep68 protein whose ability to
oligomerize has been severely affected.
Presence of the linker region induces oligomerization of
the OBD domain
The above findings indicate that the linker region plays a central
role in the oligomerization of AAV Rep proteins. To confirm that
the linker region has an intrinsic property to induce oligomeriza-
tion, we generated a construct that spans the OBD domain and
the linker region (OBD-linker residues 1–224) and measured its
ability to oligomerize. We first analyzed the OBD domain (1–208)
to determine any oligomerization up to concentrations of 1 mg/ml
(43 mM). Our results show that while OBD is a monomer
(Figure 7A), the OBD-linker protein construct displays formation
of dimers at increasing protein concentrations (Figure 7B). These
results support the hypothesis that the linker region has an intrinsic
property to induce oligomerization
Linker residue Y224 is critical for oligomerization and
represents a conserved feature in SF3 helicases
We generated a model of the Rep68DN214 construct using the
X-ray structure of Rep40 (residues 225–490) and 9 residues of the
linker (215–224) that were added as a helical extension to the N-
terminus. The model of the a-helix was generated using Robetta
[27]. Figure 8A and 8B shows the structural alignment of the OD
domain of the Rep68DN214 model with the OD domains of PV-
E1 and SV40-LTag. The alignment shows that residue Y224
superimposes with aromatic residues F313 and W270 located at
the beginning of helix 1 in the OD domains of PV-E1 and SV40-
LTag respectively. Analysis of the structures of both proteins
reveals that these aromatic residues play a critical role in forming
and stabilizing the oligomerization interface. They pack against
both the N-terminal end of helix 4 of the same subunit and the C-
terminus end of helix 4 of the neighboring subunit. In order to test
the hypothesis that Y224 plays an equivalent role in AAV Rep
proteins, we mutated it to alanine and tested its effect on the
oligomerization of Rep68DN200. Mutation to the smaller residue
alanine should have a direct effect in the oligomerization of this
protein because of the significant reduction of surface exposed
area. Figure 8C shows the sedimentation profile of this mutant
protein showing that it completely abolishes the formation of
dimers. To confirm that residue Y224 plays an important role in
the oligomerization of AAV Rep proteins, we generated a
Rep68Y224A mutant and compared its ability to form oligomers
with respect to wild type Rep68. Analysis of the Rep68Y224A
mutant reveals that at low concentration the protein is mostly
found as a monomer with a sedimentation coefficient of ,3S. At
higher concentrations, we observed the appearance of multiple
peaks that correspond to dimers, trimers and larger oligomers;
nevertheless, the majority of the protein is present as a monomer.
The presence of ATP induces a small degree of stability to the
dimeric species at 5 mM and both the 5S and 11S species at
10 mM. However, the 13S complex observed with the wild type
Rep68 is not formed and most of the protein is still found as a
monomer (Figure 8E). These results indicate that residue Y224 is
critical for the oligomerization of AAV Rep proteins.
Residue Y224 is critical for AAV virus viability
To assess if the disruption of oligomerization observed with the
Rep68Y224A mutant has any consequences on the AAV viral life
cycle, we produced recombinant AAV2 particles expressing the
GFP gene in presence of a helper virus containing the Y224A
mutation in the Rep ORF. The cells were harvested and lysed,
and the crude lysate (treated with an endonuclease) was used to
infect Hela cells. Strikingly, the crude lysate from cells transfected
with the mutant helper plasmid didn’t contain any infectious
rAAV2-GFP particles, as determined by FACS analysis of GFP
positive cells (Figure 9). These results show that the residue Y224
of AAV Rep proteins, and the oligomeric properties it confers to
these proteins, have a crucial role during the AAV life cycle.
Rep40 and Rep68DN200. Lane 1, Molecular weight markers; Lane 2, Rep40; Lane3, Cross-linked Rep40; Lane 4, Rep68DN200; Lane 5, cross-linked
Rep68DN200. The arrow shows the position of the Rep68DN200 dimer. The asterisk shows proteins bands from non-specific aggregates.
doi:10.1371/journal.ppat.1002764.g003
Figure 4. Minimum linker length requirements to induce
oligomerization. We generated protein constructs with decreasing
lengths of linker that are named in the context of the full Rep68 protein:
comparison of the sedimentation velocity profiles of (A) Rep40, (B)
Rep68DN219 (residues 220–536), (C) Rep68DN214 (residues 215–536)
and (D) Rep68DN209 (residues 210–536). Monomeric species proteins
sediment at ,2.7S while the peak at ,3.7S corresponds to a dimer.
Protein concentration was at 36 mM in all the sedimentation
experiments and run at 40000 rpm and 20uC.
doi:10.1371/journal.ppat.1002764.g004
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Discussion
In this study we report that the interdomain linker present in the
larger AAV Rep68/78 proteins is an integral part of their
oligomerization interface. We showed that the linker region is in
fact an extension of the OD domain of AAV Rep proteins. Our
results have shown that Rep40 constructs containing either a
complete or half linker have the ability to oligomerize. This effect
is enhanced in presence of ATP or ADP. We hypothesized that the
linker region from residues 215 to 224 forms a a-helix that is
connected to the first a-helix of the SF3 helicase domain.
Secondary structure prediction and modeling of the linker region
supports this argument (Figure 3A and 8B). Furthermore, we have
identified a critical aromatic residue (Y224) located at the end of
the linker region that is conserved in Rep proteins from all AAV
serotypes. The bulky nature of this aromatic residue appears to be
a conserved feature in SF3 helicases (Figure 8A). Structural
alignment of the OD domain of a Rep40 model with an extended
helical linker and those of SV40-LTag and PV-E1 shows that
residue Y224 aligns with equivalent aromatic residues Trp270 and
Phe313 respectively (Figure 8A, 8B). A detailed analysis of the
oligomeric interface of these proteins shows that these aromatic
residues have a dual role: they stabilize the hydrophobic core of
the OD domain helical bundle, and are part of the oligomerization
interface between neighboring subunits. Our results reveal the
critical role of the OD domain in the formation of stable oligomers
in SF3 helicases. The larger OD domains of SV40-Tag and PV-E1
proteins in cooperation with the AAA+ motor domain generate a
helicase domain that forms stable hexamers. Constructs of SV40-
LTag and PV-E1 without the OD domain fail to oligomerize
[14,19]. Another example that shows the fundamental role of the
OD domain in oligomerization comes from the study of the
evolutionary related proteins involved in rolling circle replication
(RCR) of plasmids. The protein RepB from streptococcal RCR
plasmid pMV158 is a hexameric protein that initiates replication
of plasmid DNA and has a domain structure that resembles SF3
Figure 5. Effect of nucleotides in the oligomerization of Rep extended-linker construct proteins. ATP and ADP were added to each linker
construct and compared to Rep40. Sedimentation profiles of (A) Rep40, (B) Rep68D219, (C) Rep68D214, (D) Rep68D209 and (E) Rep68D200. All
protein concentrations were kept at 36 mM and contain 5 mM of ADP (left panel) or 5 mM ATP (right panel). Sedimentation velocity experiments
were run at 40000 rpm and 20uC. Data was collected using the interference system.
doi:10.1371/journal.ppat.1002764.g005
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helicases but lacks the AAA+ subdomain [28]. Its N-terminal OBD
domain is structurally and functionally related to the OBD from
AAV Rep proteins due to the presence of the HUH motif critical
for DNA nicking. Its C-terminal domain only consists of a 4 helical
bundle that is similar to the OD domains of SF3 helicases and is
responsible for hexamerization. Structural alignment shows that
RepB has an aromatic residue (Phe143) equivalent to residue
Y224 in AAV Rep68/78. We hypothesize that the role of this
residue has been conserved throughout evolution to serve as a
modulator of oligomerization in SF3 helicases and related RCR
proteins. The smaller AAV Rep proteins Rep40/52 with
truncated OD domains are missing the Y224 residue and thus
are not able to sustain a stable oligomerization interface and are
mostly monomeric. Consequently, the stable oligomerization of
AAV Rep proteins requires the cooperative interaction of the
OBD domain, the linker and the helicase domain. In this context,
the OD sub-domain, and in particular the aromatic residue at the
C-terminus of linker, appear to be the triggering element required
for the oligomerization of AAV Rep proteins.
The critical role of residue Y224 in the overall AAV-2 viral life
cycle is illustrated by the complete abolishment of production of
infectious particles from AAV-2 vector constructs produced in the
context of Rep carrying the Y224A mutation (Figure 9). This
result prompts the question of which specific functions are affected
by this mutation. We think that most of the biochemical activities
of Rep68/78 will be affected due to the impairment in
oligomerization. Remarkably, an earlier report by Walker et al.
on the identification of residues necessary for site-specific
endonuclease activity showed that a Y224 mutant was defective
in AAV hairpin/DNA binding, trs endonuclease, DNA helicase
and ATPase activity [29], suggesting that correct oligomerization
of Rep proteins may be important in all of these functions.
In agreement with our results, a recent report has shown that
the presence of the linker in an AAV5 Rep40 construct induces
oligomerization in presence of DNA. However, the authors
concluded that the linker effect is primarily due to its interaction
with DNA [30]. As we demonstrated in this report, the
oligomerization effect is an intrinsic property of the linker due to
its critical role in the formation of an oligomerization interface as
part of the OD domain. The presence of DNA induces further
oligomerization as seen with all helicases [13]. However, it appears
that the linker also plays an additional role in protein-DNA
interaction that may be important during the assembly of Rep68/
Figure 6. Effect of Linker replacement in Rep68 oligomeriza-
tion. Comparison of sedimentation profiles of Rep68 and Rep68octlink
proteins. (A) Rep68 sediments as a major peak at ,13S. (B) Rep68octlink
sediments as a monomer with sedimentation coefficient of 3.5S. (C)
Rep68octlink in presence of 5 mM ATP sediments in two peaks
corresponding to monomer and dimer species. Protein concentration
was kept constant at 25 mM in buffer containing 200 mM NaCl.
Sedimentation velocity experiments were run at 40000 rpm and 20uC.
Data was collected using the interference system.
doi:10.1371/journal.ppat.1002764.g006
Figure 7. Oligomerization of the OBD domain is induced by the
interdomain linker. (A) Sedimentation profile of the OBD (residues 1–
208) at two different protein concentrations (23 and 46 mM). (B)
Sedimentation profile of OBD-linker (residues 1–224) shows monomers
and dimers sedimenting at ,1.8S and ,2.9S respectively. Sedimenta-
tion velocity experiments were run at 40000 rpm and 20uC. Data was
collected using the interference system.
doi:10.1371/journal.ppat.1002764.g007
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78 on DNA substrates such as the AAV origin of replication and
AAVS1 integration site.
The use of alternative gene promoters is a common mechanism
to generate protein diversity and flexibility in gene expression. At
the same time it allows to obtain multiple functions from a limited
number of genes, thus optimizing the size of the genome. It is clear
that in the case of the Rep proteins from the AAV virus, nature
has generated two sets of proteins that differ primarily in their
ability to oligomerize. Rep proteins obtained from the AAV P19
promoter generate Rep40 and Rep52 with truncated OD domains
and are thus unable to oligomerize. Both proteins play a critical
role during DNA packaging into capsids; however, the mechanism
of action of monomeric Rep40/52 during packaging remains
elusive. Rep proteins generated from the P5 promoter, on the
other hand, require the cooperative interaction of three different
oligomeric interfaces produced by the OBD domain, the linker
and the helicase domain. This feature potentially provides an
additional dimension for the regulation of the diverse Rep
activities when compared to the related proteins from SV40 and
PV. We suggest that the cooperative interactions and the
modulation of these interfaces – in particular in the presence of
various specific DNA substrates – orchestrate the variety of
functions performed by Rep68/Rep78 proteins and may thus
represent a key to our understanding of the underlying mecha-
nisms.
Finally, our report introduces the possibility of two distinct
helicase modes for the biological functions supported by AAV Rep
proteins. In the context of the large Rep proteins, a complete OD
domain directs the formation of stable oligomers with a DNA
unwinding mode likely to resemble that of the related viral
proteins SV40-Tag and E1. The small Rep proteins, however,
appear to utilize an incomplete OD domain that retains Rep40/52
in a monomeric state with formation of transitional dimeric
complexes required for ATP hydrolysis. It is intriguing to speculate
that this unique arrangement allows AAV to utilize two distinct
motor activities with a single AAA+ domain. As Rep40/52 have
been demonstrated to be required for genome packaging it is
feasible to address the question whether this process requires a
Rep40/52–mediated dimeric DNA helicase activity by a mech-
anism that is as yet undiscovered or whether further oligomeri-
zation is induced by interaction with capsid proteins.
Materials and Methods
Cloning and mutagenesis of Rep expression constructs
All mutant proteins were generated using the pHisRep68/15b
plasmid, which contains the AAV2 Rep68 ORF subcloned in
vector PET-15b (Novagen). Site-directed mutagenesis for mutants
Y224A was generated using the QuickChange mutagenesis kit
(Stratagene). Rep constructs with different linker extensions were
generated by PCR with primers designed to encompass the
particular protein region. Primers included restriction enzyme sites
NdeI and XhoI, and the sequence of the TEV protease site. The
Rep68 protein used in these studies contained a Cys to Ser
mutation that prevented aggregation but was functionally identical
to the wild type protein (data not shown). The Rep68octlink
construct was generated by substitution of residues 206 to 224 of
AAV2 Rep68 with the mouse Oct-1 linker residues 328–346
(GeneBank CAA49791) using the gene synthesis services from
GeneScript. The sequences of all constructs were confirmed by
DNA sequencing (GeneWiz).
Protein expression and purification
All proteins were expressed using the pET-15b vector, expressed
in E. coli BL21(DE3) cells (Novagen), and purified as described
before [18]. The final buffer contains (25 mM Tris-HCl [pH 8.0],
200 mM NaCl, and 2 mM TCEP). His6-PreScission Protease (PP)
was expressed in BL21(DE3)-pLysS at 37uC for 3 h, in LB
medium containing 1 mM IPTG. Cell pellets were lysed in Ni-
Buffer A (20 mM Tris-HCl [pH 7.9 at 4uC], 500 mM NaCl,
5 mM Imidazole, 10% glycerol, 0.2% CHAPS, and 1 mM
TCEP). After five 10-s cycles of sonication, the fusion protein
was purified using a Ni-column – equilibrated in Ni-buffer A.
Protein eluted was desalted using buffer A and a HiPrepTM 26/10
desalting column (GE Healthcare). His-PP tag was removed by
PreScission protease treatment using 150 mg PP/mg His-PP-
Rep68. After overnight incubation at 4uC, buffer was exchanged
using the same desalting column and Ni-Buffer A. Subsequent Ni-
column chromatography using the buffer B (same as buffer A but
with 1 M imidazole), was performed to remove the uncleaved
fusion protein, and untagged Rep68 was eluted with 30 mM
imidazole. Rep68 was finally purified by gel filtration chromatog-
raphy using a HiLoad Superdex 200 16/60 column (GE
Figure 8. Residue Y224 is important for oligomerization. (A) Structure-based sequence alignment of four OD domains: AAV2 Rep, Adeno-
Associated virus 2 Rep; BPV-E1, Bovine papillomavirus E1 protein; REPB, Plasmid pMV158 Replication initiator protein; SV40-Tag, Simian virus 40 large
T antigen. Also shown in blue the putative OD domains sequences from Snake PV1, Snake parvovirus 1 and ptMacq NS1, Point-tailed Macaque
parvovirus non-structural protein 1. Highlighted in blue are the conserved aromatic residues. (B) Ribbon diagram of the structural alignment showing
the aromatic residues for AAV-2 Rep (green), SV40-Tag (magenta) and BPV-E1 (Blue). (C) Sedimentation profiles of Rep68DN200 and
Rep68DN200Y224A constructs. (D) Rep68 protein is compared with the mutant Rep68Y224A at different concentrations (2.5 to 10 mM). (E) ATP
effect on the oligomerization of Rep68Y224A mutant. Concentration of protein was varied as in figure D from 2.5 mM to 10 mM. ATP and MgCl2 were
at 5 mM.
doi:10.1371/journal.ppat.1002764.g008
Figure 9. Effect of Y224 mutation on AAV-2 virus liability.
Comparison of the production of rAAV2-GFP infectious particles in
presence of wt (squares) or Y224A Rep (triangles). rAAV2-GFP particles
were produced in 293T cells in presence of wt or Y224A Rep. Varying
volumes of crude lysate (in ml, x-axis) were added to HeLa cells and the
percentage GFP positive -infected- cells was determined by FACS
analysis. Data from four experiments are represented as mean 6 s.e.m.
doi:10.1371/journal.ppat.1002764.g009
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Healthcare) and Size Exclusion buffer. N-terminus His6-tagged
WT and mutant Rep68 proteins were concentrated to 10 mg/ml,
flash-frozen in liquid N2, and kept at 280uC until use.
Cross-linking of Rep40
The cross-linking reactions for Rep40 and Rep68DN200 were
made according to an adapted protocol from Packman and
Perham [31]. The reaction mixture was in cross-linking buffer
(25 mM HEPES, 200 mM of NaCl, pH 8.0) and protein
concentration was 2 mg/ml. A 30 fold molar excess of 100 mM
DMP (dimethyl pimelimidate dihydrochloride, MP Biomedicals,
LLC) was added to the reaction and incubated 60 min at room
temperature. The reaction was quenched by addition of 1 M Tris,
pH 7.5 to a final concentration of 50 mM. The samples were
analyzed in an 8% SDS-PAGE.
AAV Infectious particles assay
Hek 293T cells were triple transfected using polyethylenimine (PEI)
with an AAV2 ITR-containing plasmid including the GFP gene, a
helper plasmid expressing AAV2 Rep (wt or Y224A cloned from the
pHisRep68Y224A/15b) and Cap, and a third construct containing the
adenovirus helper functions (pXX6, University of North Carolina
Vector Core Facility). The presence of the Y224A mutation was
confirmed by sequencing (Eurofins). After 72 h, the cells were harvested
and lysed in 150 mM NaCl, 50 mM Tris at pH 8.5, followed by three
freeze - thaw cycles. The lysate was treated for 30 minutes at 37uC with
150 units/ml of benzonase endonuclease (Sigma). HeLa cells were
infected with increasing amounts of crude lysate, and the percentage of
GFP-positive cells was determined three days post-infection.
Analytical ultracentrifugation
Sedimentation velocity experiments were carried out using a
Beckman Optima XL-I analytical ultracentrifuge (Beckman
Coulter Inc.) equipped with a four and eight-position AN-60Ti
rotor. Rep protein samples were loaded in the cells, using in all
cases buffer used in the final purification step. Samples in double
sector cells were centrifuged at 25,000 rpm for Rep68 proteins
(Rep68 and Rep68Y224A). For Rep40 and linker constructs
sedimentation was performed at 40,000 rpm. In all experiments,
temperature was kept at 20uC. Sedimentation profiles were
recorded using UV absorption (280 nm) and interference scanning
optics. For the analysis of the results the program Sedfit was used
to calculate sedimentation coefficient distribution profiles using the
Lamm [21].
Structure analysis and modeling
Structures of AAV-2 Rep40 (1S9H), Bovine papillomavirus E1
protein (2GXA), Simian virus 40 T large antigen (1SVO) and
plasmid pMV158 RepB (3DKY) were analyzed using the
programs COOT [32], PYMOL [33] and CHIMERA [34].
Structural alignment was done using the DALI server [35].
Secondary structure prediction was performed using PredictPro-
tein [36]. Modeling of the linker region was done using
ROBETTA [27].
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Abstract 19 
The life cycle of the human parvovirus adeno-associated virus (AAV) is orchestrated 20 
by four Rep proteins. The large Rep proteins Rep78 and Rep68 are remarkably multi-21 
functional and display a range of biochemical activities, including DNA binding, 22 
nicking and unwinding. Functionally, Rep78 and Rep68 are involved in transcriptional 23 
 2
regulation, DNA replication and genomic integration. Structurally, the Rep proteins 24 
share a AAA+ domain characteristic of the SF3 family of helicases, with the large Rep 25 
proteins additionally containing an N-terminal origin-binding domain (OBD) domain 26 
that specifically binds and nicks DNA. The combination of these domains, coupled 27 
with dynamic oligomerization properties, is the basis for the remarkable 28 
multifunctionality displayed by Rep68 and Rep78 during the AAV life cycle. In this 29 
report we describe an oligomeric interface formed by Rep68 and demonstrate how 30 
disrupting this interface has drastic effects both on the oligomerization and 31 
functionality of the Rep proteins. Our results support a role for the four-helical 32 
bundle in the helicase domain of Rep68 as a bona fide oligomerization domain (OD). 33 
We have identified key residues in the OD that are critical for the stabilization of the 34 
Rep68-Rep68 interface; mutation of these key residues disrupts the enzymatic 35 
activities of Rep68, including DNA binding and nicking, and compromises viral DNA 36 
replication and transcriptional regulation of the viral promoters. Taken together, our 37 
data contribute to our understanding of the dynamic and substrate-responsive 38 
Rep78/68 oligomerization that is instrumental in the regulation of the DNA 39 
transitions that take place during the AAV life cycle. 40 
 41 
Importance 42 
The limited genome size of small viruses has driven the evolution of highly 43 
multifunctional proteins that integrate different domains and enzymatic activities 44 
within a single polypeptide. The Rep68 protein from adeno-associated virus (AAV) 45 
combines a DNA binding and endonuclease domain with a helicase-ATPase domain, 46 
which together support DNA replication, transcriptional regulation and site-specific 47 
 3
integration. The coordination of the enzymatic activities of Rep68 remains poorly 48 
understood, however Rep68 oligomerization and Rep68-DNA interactions have been 49 
suggested to play a crucial role. We investigated the determinants of Rep68 50 
oligomerization and identified a hydrophobic interface necessary for Rep68 activity 51 
during the AAV life cycle. Our results provide new insights into the molecular 52 
mechanisms underlying the regulation of the versatile Rep proteins. Efficient 53 
production of AAV-based gene therapy vectors requires optimal Rep expression 54 
levels, and studies such as the one presented here could contribute to further 55 
optimization of AAV production schemes. 56 
 57 
Introduction 58 
Adeno-associated virus (AAV) is a human DNA virus of the family of parvoviridae with 59 
a unique dependance on helper viruses such as adenovirus or herpes virus for 60 
productive replication (1). In order to take advantage of host pathways and helper 61 
virus for productive replication with only a limited number of viral gene products at 62 
hand, AAV has evolved to combine multiple functions into single proteins. More 63 
specifically, a single open reading frame generates the non-structural Rep proteins 64 
that orchestrate the different aspects of the AAV life cycle, including transcriptional 65 
regulation, replication, packaging and Rep-mediated integration. The four multi-66 
domain Rep proteins, Rep40, Rep52, Rep68, and Rep78, are generated through the 67 
use of two promoters and alternative splicing (2, 3). All Rep isoforms share an SF3 68 
helicase domain (HD) that combines ATPase and helicase activities (4, 5). The large 69 
Rep proteins Rep68 and Rep78 further contain an N-terminal origin binding domain 70 
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(OBD) that specifically binds and nicks the AAV origin (5-7). Rep78 and Rep52 have 71 
an additional zinc-finger domain that is involved in interactions with cellular proteins 72 
(8, 9). Differences in the domain composition of the Rep isoforms confer specific 73 
functionalities to the large and the small Rep proteins. Rep52 and Rep40 are 74 
necessary for efficient packaging of the viral DNA into preformed capsids, but are 75 
dispensable for viral replication and integration (10). The DNA binding and nicking 76 
activities of the OBD of the large Rep proteins on the other hand, are the basis for 77 
AAV DNA replication and integration (11, 12). More specifically, Rep78/68 bind to 78 
the Rep binding site (RBS) in the inverted terminal repeats (ITRs) and execute a site- 79 
and strand-specific nick at the nearby terminal resolution site (trs). This process is 80 
necessary for resolution of the ITRs and completion of the viral DNA replication cycle 81 
with assistance of the host cell machinery (12, 13). Similarly, the DNA binding and 82 
endonuclease activities are required for mediation of integration at chromosomal 83 
target loci that contain RBS/trs sites such as the integration hotspot AAVS1 (14-16). 84 
In addition, efficient nicking of the trs at both the viral and cellular origin requires 85 
ATP-dependent helicase activity for the generation of an optimal single-stranded 86 
substrate (7, 17). Finally, both OBD and helicase domains have the ability to mediate 87 
transcriptional regulation of viral and cellular promoters by two independent 88 
mechanisms conferring regulatory functions to both small and large Rep proteins 89 
(18-20).  90 
Structurally, the Rep proteins belong to the superfamily 3 of helicases (SF3), a group 91 
of multifunctional viral proteins combining a characteristic AAA+ motor domain, 92 
which couples ATP hydrolysis and DNA unwinding, with an origin binding domain to 93 
achieve rapid origin melting (21). Other members of this family include the simian 94 
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virus 40 large T antigen (SV40-LTag) and the papilloma virus E1 (PV-E1). In contrast 95 
to the OBD of Rep, SV40-LTag and PV-E1 lack endonuclease activity. The AAV large 96 
Rep proteins are also related to HUH endonucleases that catalyse rolling-circle 97 
replication (RCR) in bacteriophages and geminiviruses, as well as in bacteria (22, 23), 98 
indicating a significant evolutionary conservation. The large AAV Rep proteins have a 99 
complex and dynamic oligomeric behaviour that can adapt to the different DNA 100 
substrates present during the AAV life cycle, varying from the RBS-containing 101 
double-stranded DNA encountered during initial origin binding, to the single-102 
stranded DNA after origin melting (24, 25). In contrast to the AAA+ domains of SV40-103 
LTag and PV-E1, which readily form hexameric rings (26, 27), Rep40 and Rep52 are 104 
monomeric, due to the absence of a complete oligomerization domain (OD) at the N-105 
terminus of the SF3 helicase domain (28). Mutation of the corresponding OD in 106 
SV40-LTag and PV-E1 has been shown to prevent their oligomerization and to disrupt 107 
the replication of SV40 and PV, respectively (29, 30). Intriguingly, a similar OD is also 108 
found in oligomeric HUH endonucleases such as RepB from the pMV158 109 
streptococcal RCR plasmid despite the absence of a helicase domain (31). In the large 110 
Rep proteins, the linker connecting the OBD and the helicase domain provides the 111 
residues necessary to complete the OD and plays a crucial role in the oligomerization 112 
of the large Rep proteins (28, 32). Thus effectively the OBD, linker and helicase 113 
domain cooperatively interact to promote oligomerization.  114 
While recent findings have significantly contributed to the understanding of the 115 
determinants of Rep oligomerization (25, 28, 32), its relevance in the context of the 116 
AAV life cycle remains to be elucidated. In order to gain an understanding on how 117 
oligomerization contributes to the multiple enzymatic functions of the Rep proteins, 118 
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we took advantage of our previous findings, which show that the linker domain, and 119 
in particular the N-terminal linker residue Y224, is essential for Rep oligomerization 120 
(28). This residue is found in an equivalent position as the residues in SV40-LTag and 121 
PV-E1 known to be crucial for the formation and maintenance of the oligomeric 122 
interface (28). Here we describe an oligomeric interface for Rep, identified in a 123 
dimeric complex modelled using the Rep40 structure with a predicted extended N-124 
terminal α-helix to complete the OD (33). This model highlights a potential role for 125 
Y224 and I251 in the formation of the oligomeric interface; site-directed 126 
mutagenesis confirmed that oligomerization is indeed hampered when Y224 and 127 
I251 are altered. Moreover, we could demonstrate that mutations that lead to a 128 
disruption of the interface result in defects in DNA binding, trs nicking and alters the 129 
expression levels of the viral proteins, with severe consequences on viral DNA 130 
replication and production of infectious virus.  131 
 132 
Materials and Methods 133 
Protein production and purification  134 
All mutations were generated in the pHisRep68/15b plasmid, which contains the 135 
AAV2 Rep68 ORF subcloned in the vector pET-15b (Novagen) using the 136 
QuickchangeTM mutagenesis kit (Agilent Technologies Inc). All proteins were 137 
expressed in E.coli BL21(DE3) cells (Novagen), and purified as described previously 138 
(28). In brief, cell pellets were lysed in Ni-Buffer A (20 mM Tris-HCl [pH 7.9 at 4 °C], 139 
500 mM NaCl, 5 mM Imidazole, 10% glycerol, 0.2% CHAPS, and 1 mM TCEP) and 140 
purified using a Ni-column. The hexa-histidine tag was removed using the PreScission 141 
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protease and Rep68 was further purified by gel filtration chromatography using a 142 
HiLoad Superdex 200 16/ 60 column (GE Healthcare) and size exclusion buffer (25 143 
mM Tris-HCl [pH 8.0], 200 mM NaCl, and 2mM TCEP). Rep68 WT and mutant 144 
proteins were concentrated to 10 mg/ml, flash-frozen in liquid N2, and kept at -80°C. 145 
Sedimentation velocity experiments 146 
Analytical ultracentrifugation experiments were carried out using a Beckman Optima 147 
XL-I analytical ultracentrifuge (Beckman Coulter Inc.) equipped with both four- and 148 
eight-position rotors. Protein samples (420μl, 10μM final concentration) were loaded 149 
in the cells, using in all cases buffer containing 25mM Tris-HCl, pH 8.0 and 200mM 150 
NaCl. Samples were centrifuged in 2-sector carbon-filled Epon centerpieces at 151 
25,000rpm at 20°C. At least 200 scans were collected at 5-min intervals at 25,000 152 
rpm. Sedimentation velocity concentration profiles were collected using both UV 153 
absorption (280 nm) and Rayleigh interference scanning optics. Results were 154 
analyzed using the SEDFIT program (34, 35). 155 
AAV Infectious particles assay 156 
293T cells were triple-transfected with an AAV2 ITR-containing plasmid encoding a 157 
CAG-controlled GFP gene (pTRUF11), a helper plasmid expressing AAV2 Rep (WT or 158 
mutants) and Cap, and a third construct containing the adenovirus helper functions 159 
(HGTI plasmid) (36, 37). The mutations in Rep were confirmed in all plasmids by 160 
sequencing (Eurofins). After 72h, the supernatant was harvested, spun to clear 161 
cellular debris and increasing volumes of supernatant were used to transduce HeLa 162 
cells. The percentage of GFP-positive HeLa cells was determined 48h post-163 
transduction by flow cytometry (FACSCanto, BD Biosciences). 164 
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qPCR-based replication assay 165 
293T cells were transfected with PEI (Polysciences, Inc) and the infectious AAV 166 
plasmid pAV2 (38) or its mutant versions, and super-infected 4h later with 167 
adenovirus serotype 5 (Ad5) at a multiplicity of infection (MOI) of 5. After 72h, cells 168 
were harvested in PBS, pelleted, and the pellet was divided in 4. A fourth was used 169 
for RNA extraction, one for protein extraction, one for total DNA extraction and the 170 
last quarter for Hirt extraction of small molecular weight DNA.  171 
Total DNA was extracted using the Qiagen DNAeasy Blood and Tissue DNA extraction 172 
kit.  Viral DNA was quantified by real-time PCR using the SYBR Green JumpStart 173 
Taq ReadyMix for qPCR (Sigma-Aldrich) using an ABI PRISM system (Applied 174 
Biosystems). Cap primers (fw: TTCTCAGATGCTGCGTACCGGAAA; rv: 175 
TCTGCCATTGAGGTGGTACTTGGT) and a pAV2-based standard curve were used for 176 
absolute quantification; the signal was normalised to cyclophillin (fw: 177 
TGCTGGACCCAACACAAATG; rv: TGCCATCCAACCACTCAGTCT). 178 
 179 
Analysis of replicative intermediates 180 
293T cells were treated as described for the qPCR-based replication assay. Small 181 
molecular weight was extracted using a modified version of the Hirt extract 182 
procedure (39). Briefly, cells were lysed in Hirt Lysis buffer (0.6% SDS, 10mM Tris pH 183 
7.5, 10mM EDTA), and treated with proteinase K (Thermo Fisher) to digest proteins. 184 
The high molecular weight DNA was precipitated and discarded. The small molecular 185 
weight DNA was then purified by phenol extraction followed by sodium acetate and 186 
isopropanol precipitation. The precipitated DNA was washed and resuspended in 187 
DNAse-free water. The extracts were digested with the restriction enzyme DpnI 188 
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(New England Biolabs) to digest input DNA. Samples were run on a 0.8% agarose gel 189 
at 30V overnight, and transferred to a nitrocellulose membrane by the Southern 190 
blotting method. The membranes were hybridized overnight in 0.75 nylon wash 191 
buffer (40.6g Na2HPO4, 18.65g EDTA, 500g SDS in 3.58 liters of ddH2O, pH 7.2) at 192 
65˚C with a radiolabeled Rep probe (primers: fw 5’-AACTGGACCAATGAGAACTTTCC-193 
3’ and rv 5’-A AAAAGTCTTTGACTTCCTGCTT-3) or an ampicillin probe (primers: fw 5’-194 
AATCAGTGAGGCACCTATCTCAGC-3’ and rv 5’- AACTCGGTCGCCGCATACACTATT-3’) to 195 
control for DpnI digestion. Probes were labelled with the Prime-It RmT random 196 
primer labeling kit from Stratagene and [32P]dCTPs (PerkinElmer). The membranes 197 
were exposed to a phosphorimager screen overnight. Images were acquired using a 198 
Typhoon PhosphorImager (Molecular Dynamics) and analyzed with the ImageQuant 199 
TL software (GE Healthcare Life Sciences).  200 
Fluorescence anisotropy DNA binding assay.  201 
Binding assays were performed using a fluorescein labelled 41-mer containing AAVS1 202 
or p5 RBS sequences. The sequences used are 5’-203 
TGGCGGCGGTTGGGGCTCGGCGCTCGCTCGCTCGCTGGGCG-3’ (AAVS1) and 5’-204 
ACCGGGCAAAATGGAGACCCTGCGTGCTCACTCGGGCTTAA-3’ (p5) (40, 41). Rep68 WT 205 
and mutant proteins at concentrations ranging from 5nM to 3μM were mixed with 206 
DNA (5nM)  in a final volume of 300 μl using the following buffer: 25mM HEPES (pH 207 
7.0), 100mM NaCl, 1mM TECEP. Fluorescence readings were taken on a PC1 208 
fluorimeter (ISS, Inc.) with excitation and emission filters at 490 and 520nm. Tubes 209 
were equilibrated at 20°C for 20 minutes before measurement. Each anisotropy 210 
point is the average of 10 measurements. Anisotropy is calculated as the ratio of the 211 
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difference between vertical and horizontal emission intensities over the total 212 
normalized intensity. The fraction of DNA bound (B) was calculated using the 213 
following equation: 214 
B = ([A]x –[A]DNA)/([A]FINAL – [A]DNA )                215 
Where [A]x represents the anisotropy measured at protein concentration X, [A]DNA is 216 
the anisotropy of free fluorescence DNA and [A]FINAL is the anisotropy at saturation. 217 
The data were fit to a single binding site model with Hill coefficient using the 218 
program Origin™ (Origin Labs). Each experiment was done in triplicate.  219 
Helicase Assay 220 
The substrate used in this assay is a heteroduplex DNA consisting of an 18-bp duplex 221 
region with a 10-nucleotide 3’ tail at the bottom strand. The top strand (trap-DNA) is 222 
labelled at the 5’ end with fluorescein, and is released upon unwinding. The 223 
sequences used are 5’-F-CATATGGAGCAGAACAGA-3’ for the trap DNA and 5’- 224 
AGACAAGACGAGGTATACAAAAAAAAAA-3’ for the complementary strand. 225 
All reactions were performed in a buffer containing 25mM HEPES, 50mM NaCl (pH 226 
7.0) at a total volume of 50μl. 1mM of protein was mixed with 0.5mM of double 227 
stranded F-DNA (18ADT10A) and 2.5μM of single stranded DNA (18s), and then 228 
added to the mix of buffer described above containing 5mM of both ATP and MgCl2. 229 
Reaction was incubated at 25˚C for 1 hr. EDTA was used to stop the reaction at a 230 
final concentration of 20μM. Aliquots of 10μl were loaded in a 12% bis-acrylamide 231 
gel (30%) (19:1) using 6X-loading dye (0.25 xylene cyanol FF, 30% glycerol). For the 232 
densitometry and analysis of the bands, a Gel Doc EZ Imager was used, together with 233 
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the automatic lane and band detection tool. Lane background subtraction, white 234 
illumination and an activation time of 300 sec were used for the analysis.  235 
Supercoiled (sc) DNA nicking assay.  236 
ScDNA nicking activity for Rep68 was assayed as described previously (14). Briefly, 237 
assays were performed in 30μl reactions containing 30mM Hepes-KOH (pH 7.5), 238 
7mM MgCl2, 0.5mM DTT, 4mM ATP, 40mM creatine phosphate (Sigma), 1μg 239 
creatine phosphokinase (Sigma) in 15mM NaCl final concentration. 100ng scDNA 240 
plasmid and 200ng of purified His-Rep68 (or mutants) were added to the reactions. 241 
All samples were incubated for 1h at 37˚C; the reaction was terminated by adding 242 
10μl of stop reaction (proteinase K [1.2μg/μl], 0.5% SDS and 30mM EDTA pH7.5) and 243 
incubating for 1 h at 37˚C. Samples were resolved in a 1% agarose gel (1X TAE), 244 
which was subsequently stained with ethidium bromide (0.3μg/ml) in 1X TAE. The 245 
scDNA plasmids used in this assay were pRVK (contains AAVS1 nucleotide 1 to 246 
3536bp) and a mutated version containing a mutant trs sequence (42). 247 
Western Blot 248 
Proteins were extracted from cells transfected and infected as described for the 249 
replication assays. Cells were lysed in RIPA buffer and the cleared lysate was run on a 250 
12% acrylamide gel. The proteins were transferred onto a nitrocellulose membrane 251 
(GE healthcare) and immunoblotted using anti-Rep antibody (clone 303.9, Progen, 252 
1/100 dilution), anti-Cap antibody (clone B1, ARP, 1/500) and anti-HSP90 antibody 253 
(polyclonal, Santa Cruz, 1/5000). All antibodies were incubated in blocking buffer (5% 254 
non fat dried milk in PBS containing 0.1% Tween 20). Images were acquired and 255 
analysed using an Imagequant apparatus (GE healthcare). 256 
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Real-time qRT-PCR  257 
293T cells were transfected and infected as described for the replication assays. 258 
Total RNA was extracted using the RNeasy kit (Qiagen) after DNAseI (Qiagen) 259 
treatment for 15 minutes at 37˚C. Reverse transcription was performed using the 260 
High Capacity Reverse Transcription kit (Applied Biosystems). cDNA was quantified 261 
by real-time qPCR on an ABI PRISM system (Applied Biosystems) using the TaqMan 262 
Universal PCR master mix (Life Technologies and custom designed primer-probe 263 
mixes (Eurofins). Primers: p5 fw (5’-AACAAGGTGGTGGATGAGT-3’), p5 rv (5’-264 
CGTTTACGCTCCGTGAGATT-3’), p19 fw (5’-TCACCAAGCAGGAAGTCAAAG-3’), p19 rv 265 
(5’-CCCGTTTGGGCTCACTTATATC-3’), p40 fw (5’-GGAAGCAAGGCTCAGAGAAA-3’) and 266 
p40 rv (5’-CCTCTCTGGAGGTTGGTAGATA-3’). Probes: p5 (5’-FAM-267 
ACGTGGTTGAGGTGGAGCATGAAT-TAM-3’), p19 (5’-FAM-268 
ACGTGGTTGAGGTGGAGCATGAA-TAM-3’) and p40 (5’-FAM-269 
AGGAAATCAGGACAACCAATCCCGT-TAM-3’). Relative expression levels were 270 
determined with the ∆∆Ct quantification method (43), using 18S ribosomal RNA 271 
(Taqman pre-developed assay reagents, human 18S rRNA, Applied Biosystems) as a 272 
housekeeping reference gene.  273 
 274 
Results 275 
Y224 forms hydrophobic interactions necessary for Rep68 oligomerization 276 
Previous studies showed that Rep68 exists as a mixture of oligomers in solution. 277 
More specifically, two major populations have been observed by sedimentation 278 
velocity experiments, including a monomer-dimer peak that sediments at ~3S and 279 
oligomeric rings that sediment at 13S (25). We also showed that replacing the 280 
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tyrosine positioned at the C-terminal end of the linker in Rep68 by the smaller 281 
residue alanine, disrupt its oligomerization; this presumably because of a reduction 282 
in the surface exposed area (Figure 1A) (28). To further confirm this hypothesis we 283 
mutated the tyrosine to phenylalanine (Phe), proline (Pro) or aspartic acid (Asp) and 284 
performed sedimentation velocity experiments to study how these mutations affect 285 
oligomerization. Figure 1B shows that replacement of the tyrosine with the small size 286 
side-chain amino acids Pro and Asp has a drastic effect on the sedimentation profile 287 
of Rep68. The 13S peak disappears, and the most prominent population present in 288 
solution has a sedimentation coefficient around 5S, suggestive of smaller molecular 289 
weight oligomers (Figure 1B). Exchanging the tyrosine with the bulky aromatic Phe 290 
results in the appearance of two peaks, one with a sedimentation coefficient of 5S 291 
similar to what we observed for the other mutants, and a second peak around 12S 292 
that is indicative of the formation of larger oligomers. This 12S population, however, 293 
has a smaller sedimentation coefficient than what we observe with Rep68, 294 
potentially suggesting that the Y224F forms different oligomeric species. Figure 1C 295 
shows the quantification of the 13S population that is formed in the presence of the 296 
different mutations. Taken together, these results demonstrate that the bulky 297 
aromatic character of the residue Y224 is pivotal for Rep68 oligomerization and 298 
suggest that Y224 may participate in hydrophobic interactions as part of an 299 
oligomeric interface. 300 
 301 
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Generation of a Rep68 oligomeric interface model 302 
To further determine whether Y224 participates directly in forming an oligomeric 303 
interface, we modelled an oligomeric Rep dimer using the available structure of 304 
Rep40 (pdbid 1S9H), which spans residues 225-490 of Rep68 (33). We added the 305 
interdomain linker residues 217-224 to the known Rep40 structure as an extended 306 
α-helix based on secondary structure predictions (28), resulting in a Rep molecule 307 
containing residues 217 to 490 (Figure 2A). Two of the three molecules found in the 308 
asymmetric unit of Rep40 crystals form a pseudo-dimer. The interface formed in this 309 
dimer is similar to the oligomeric interface described for other SF3 helicase 310 
structures, but is not optimal to perform catalysis (44). We used this ‘dimer’, with 311 
the addition of the linker residues as our initial interface model, and we refined it by 312 
carrying out rigid body and side-chain conformation optimization using RosettaDock 313 
(45, 46). Strikingly, the top 10 models generated had almost identical interfaces as 314 
analysed by the program PISA (47), suggesting that our model was robust. A figure of 315 
the Rep interface model is shown in figure 2B. The interface buries a total of 1992 Å 316 
of solvent accessible area and includes residues from all the helices in the 317 
oligomerization domain (OD), the pre-sensor 1 β-hairpin (PS1βH), the β2β3 loop and 318 
residues from Walker A and Walker B motifs (Figure 2B). A closer analysis reveals 319 
that the modelled linker residues participate in the interface. In particular, the 320 
conserved aromatic residue Y224, which is at the end of the linker region, is an 321 
important component of the oligomeric interface. In agreement with the results 322 
shown in Figure 1, it participates in the formation of a hydrophobic pocket. Among 323 
the residues from the neighbouring subunit interacting with Y224, only I251 forms a 324 
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hydrophobic interaction whereas N254 contributes to a hydrogen bond via its main 325 
chain carbonyl oxygen (Figure 2C). 326 
 327 
Mutations leading to disruption of the interface affect oligomerization of Rep68 328 
Based on these observations, we generated a Rep68-I251A mutant and we assessed 329 
the consequences of mutating this residue alone or in combination with Y224 on 330 
Rep68 oligomerization. Figure 2D shows sedimentation velocity profiles illustrating 331 
that these mutants are mostly monomeric, thus validating the prediction from our 332 
model. Furthermore, the oligomerization defects, which we observed when testing 333 
the different Y224 mutants (Figure 1C) could also be explained by our modelled 334 
interface: smaller hydrophobic residues increase the solvent-accessible area and 335 
destabilize the interface, while a larger bulky residue maintains the hydrophobic 336 
pocket and possibly only affects the formation of the hydrogen bond between Y224 337 
and N254, thus causing a milder defect. Finally, the Y224P mutation has the 338 
strongest effect, as it probably disrupts the helical character of this region and may 339 
affect the overall OD structure. To investigate whether the interface we identified is 340 
biologically relevant and thus involved in Rep functions, we assessed how the 341 
observed disruptions in the oligomerization profile of Rep68 affect the AAV life cycle.  342 
 343 
Rep68 oligomerization is necessary to support the AAV life cycle  344 
First, we verified if the aforementioned mutant Rep68 proteins are stable and 345 
localize correctly to the nucleus, where they support AAV replication. We 346 
transfected 293T cells with constructs expressing Rep68 or the oligomerization 347 
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mutants under the control of the CMV promoter, and assessed Rep68 protein 348 
stability and localization 48h post-transfection. Figure 3 demonstrates that all the 349 
mutants were expressed at levels comparable to those observed for wild-type (WT) 350 
Rep68 and translocated to the nucleus as expected.  351 
Next, we assessed how disruptions in the oligomerization profile of Rep68 affect the 352 
AAV life cycle. We first compared the ability of the Rep oligomerization mutants to 353 
produce infectious AAV particles to that of WT Rep68 and Rep68*(Figure 4A). 354 
Rep68* or Rep* for short refers to the Cys151Ser mutant, which is functionally 355 
equivalent to WT Rep68 but prevents protein aggregation in solution (25). All mutant 356 
proteins have been generated in the context of Rep68*. As a negative control, we 357 
used the NTP-binding mutant K340H, which is deficient in ATPase and helicase 358 
activity and does not support AAV replication (48, 49). The K340H mutant, however, 359 
is still able to oligomerize and has been shown to have a dominant-negative 360 
phenotype (48-50). Recombinant AAV2-GFP particles were produced in 293T cells by 361 
transfection of plasmids encoding the adenovirus helper functions, AAV2 Cap, and 362 
WT Rep68, Rep68* or the interface mutants. Increasing volumes of supernatant 363 
collected from the cultures of AAV-producing cells were added to HeLa cells in order 364 
to assess the infectivity of the produced virus. Figure 4A shows that the Y224A Rep 365 
mutant does not support the production of infectious AAV particles as was 366 
previously reported by us (28). The more conservative mutation, Y224F, which 367 
retains the potential to partially oligomerize (Figure 1C), is severely impaired but is 368 
not entirely deficient in producing infectious AAV. Mutating I251 to alanine on the 369 
opposite side of the predicted interface, however, replicates the phenotype 370 
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observed with the Y224A mutant. Not surprisingly, the double mutant Y224A-I251A 371 
also fails to produce infectious AAV particles (Figure 4A). 372 
To evaluate if the failure to produce infectious particles was due to a defect in AAV 373 
DNA replication, we determined the number of AAV genomes in the 293T producer 374 
cells by qPCR (Figure 4B) and studied the replicative intermediates formed during 375 
AAV replication by Southern blot (Figure 4C). Both assays confirmed that the 376 
interface mutants Y224A, I251A and the double mutant Y224A-I251A all fail to 377 
support AAV DNA replication. Similarly to what we observed in the infectious particle 378 
production assay, the Y224F mutant supports AAV replication, but at significantly 379 
lower levels than observed for Rep WT or Rep*. In addition, Figure 4C shows that 380 
replication in the presence of the Y224F mutant results in the formation of the 381 
expected replicative intermediates.  Background replication can be observed in the 382 
absence of adenovirus due to the presence of E1A and E1B in 293T cells (51). 383 
Altogether, these results suggest that the oligomerization interface mutants fail to 384 
sustain AAV DNA replication and therefore cannot support the production of 385 
infectious AAV particles. 386 
  387 
Rep68 oligomerization mutants are deficient in RBS-specific DNA binding and site- 388 
and strand-specific nicking but maintain the ability to unwind unspecific DNA 389 
substrates 390 
In order to determine the cause of the replication defect of the oligomerization-391 
deficient mutants, we assessed various biochemical activities in vitro. Rep has three 392 
well-characterised enzymatic functions – RBS-specific DNA binding, trs nicking and 393 
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ATP-dependent DNA unwinding – all of which are necessary for AAV DNA replication 394 
and targeted genome integration. Table 1 shows the binding constants of Rep68* 395 
and mutant Rep68* proteins on p5 and AAVS1 RBS-containing double stranded DNA 396 
substrates. As expected, Rep68* and the control Rep68*-K340H both efficiently bind 397 
the specific DNA substrates (25, 52). The mutant that has retained some residual 398 
replication potential, Rep68*-Y224F, also efficiently binds the p5 and AAVS1 DNA 399 
substrates. All other mutants, however, have lost the ability to bind both DNA 400 
substrates, with the exception of Rep68*-I251 that has maintained its ability to bind 401 
AAVS1-containing DNA, albeit with a 10-fold lower affinity than its WT counterpart. 402 
These results suggest that some level of oligomerization is necessary for efficient 403 
RBS-specific DNA binding by Rep68, and that the oligomeric properties of the mutant 404 
Rep68*-Y224F are sufficient for DNA binding. 405 
To test the ability of the Rep68 mutants to unwind non-specific DNA, we performed 406 
a fluorescence-based helicase assay. Somewhat surprisingly, all mutants but the 407 
control K340H mutant exhibit similar helicase activity on a heteroduplex non-specific 408 
DNA substrate (Figure 5). These results suggest that under these experimental 409 
conditions Rep68 can unwind DNA even in the absence of large complexes, or 410 
alternatively that an oligomeric complex that is stabilized by a different interface is 411 
necessary for Rep-mediated DNA unwinding. Strand- and site-specific nicking 412 
activity, however, appears to diminish strongly when oligomerization is disrupted in 413 
Rep68. As shown in Figures 6A and 6B, the oligomerization-deficient Rep mutants 414 
that fail to bind specific DNA also fail to nick supercoiled plasmid DNA containing RBS 415 
and trs sequences. The Rep68*-Y224F mutant, despite retaining the ability to bind 416 
specific DNA substrates, only shows some residual nicking activity. 417 
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 418 
Rep oligomerization is important for transcriptional regulation of AAV genes.  419 
In addition to their role in AAV DNA replication, the Rep proteins coordinate the 420 
temporal regulation of transcription of the viral genome during the AAV life cycle. In 421 
the absence of helper virus, the Rep proteins participate in repressing transcription 422 
from the three viral promoters p5, p19 and p40, ensuring minute levels of expression 423 
of the viral proteins. In the presence of helper virus, i.e. during a productive 424 
infection, repression of the p5 promoter is lifted by the adenoviral E1A protein (53) 425 
and binding of Rep to the p5 promoter or the ITRs leads to transactivation of the p19 426 
and p40 promoters (54-56). The p5 promoter itself is also controlled by Rep, which 427 
can act both as a repressor or an activator through binding at the p5 or ITR RBS, 428 
respectively (56, 57). The net result is a self-regulatory loop that generates protein 429 
levels that are tightly controlled and are optimal for AAV replication and packaging 430 
(58). Two mechanisms of Rep-mediated repression have been identified: direct 431 
repression through binding at the RBS in the p5 promoter, and indirect repression 432 
that requires the ATPase activity of Rep (19). In light of the dependence of 433 
transcriptional regulation on Rep binding to the p5 promoter and ITR, we assessed 434 
whether the oligomerization mutants also displayed defects in transcriptional 435 
activity resulting in altered protein expression levels. As a control we used again the 436 
K340H ATPase mutant, which has been shown to lead to the expression of 437 
exceedingly high Rep protein levels under conditions permissive for AAV replication 438 
(48). Cells were transfected with the various AAV infectious plasmids, and Rep and 439 
Cap protein levels were determined in the presence and absence of adenovirus co-440 
infection. In the presence of WT Rep and the absence of adenovirus, we expect low 441 
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levels of both Rep and Cap proteins. In the presence of adenovirus, Rep protein 442 
levels peak around 30h after infection and then slowly decrease, while Cap levels 443 
increase with viral DNA replication (56). Because we harvested the cells 72h post-444 
transfection, we expect to see only slightly higher levels of the Rep proteins but 445 
significantly higher Cap expression when compared to cells that were not co-infected 446 
with adenovirus. As shown in Figure 7A, we observed strikingly high Rep protein 447 
levels in cells transfected with the mutated Rep proteins, including the control 448 
K340H mutant. Once more, we observed that the Y224F mutant showed an 449 
intermediate phenotype represented by a very modest increase in Rep protein 450 
expression levels (Figure 7A). The Cap protein levels, on the other hand, were found 451 
to be lower in cells expressing the mutant proteins: only in the presence of Rep 452 
proteins that support the AAV life cycle we detected high Cap levels, with the sole 453 
exception being the K340H mutant (Figure 7A). The same trend was observed both in 454 
the presence and the absence of adenovirus infection, although the Cap levels were 455 
significantly lower in the absence of helper virus. These results suggest that the 456 
oligomerization mutants fail to regulate the expression levels of the AAV proteins, 457 
most likely by failing to autoregulate the p5 promoter through RBS binding. In view 458 
of these important differences in protein amounts, we assessed the levels of AAV 459 
transcripts by RT-PCR (Figure 6C). Because all AAV RNAs use the same 460 
polyadenylation signal, we were not able to quantify the p19 and p40 transcripts 461 
separately from the p5 transcripts. As expected, with all primer sets used – targeting 462 
respectively p5, p5 and p19 and all major AAV mRNA – we observed an increase in 463 
mRNA levels in response to adenovirus co-infection in the presence of Rep proteins 464 
that support AAV replication. In the presence of the Y224F mutant, the response to 465 
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adenovirus is still present, but is nevertheless reduced when compared to WT Rep. 466 
The oligomerization-deficient mutants Y224, I251, and Y224-I251, which are unable 467 
to bind the RBS at the p5 promoter, have higher basal mRNA levels, varying between 468 
2- and 10-fold, and do not respond to adenovirus infection. In the context of 469 
adenovirus co-infection, however, the differences in mRNA levels do not correlate 470 
with those observed for the protein levels, suggesting that changes in post-471 
transcriptional regulation are also contributing to the altered protein expression 472 
levels. Rep-mediated post-transcriptional regulation has been observed before, but 473 
its mechanism remains unknown (59). The K340H mutant, which oligomerizes but 474 
fails to support AAV replication, has considerably higher basal mRNA levels as 475 
compared to WT Rep, possibly explaining the very high Rep and Cap protein amounts 476 
observed, and the presence of adenovirus does not lead to a clear change in mRNA 477 
levels. Taken together, our data support a model in which Rep oligomerization is 478 
important for the gene regulatory function of Rep, potentially through p5 RBS 479 
binding, which is necessary to achieve an appropriate transcription profile. 480 
 481 
Discussion 482 
The limited genome capacity of small viruses such as adeno-associated virus has 483 
driven the evolution of highly multifunctional non-structural proteins that combine 484 
several enzymatic functions necessary to support the viral life cycle. In AAV, the Rep 485 
proteins are responsible for orchestrating the entire viral life cycle, from 486 
transcriptional regulation, to replication and packaging, as well as Rep-mediated 487 
integration. The combination of several enzymatic functions, including DNA binding, 488 
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nicking und unwinding, and the ability to interact with a multitude of DNA substrates 489 
and proteins, allows the Rep proteins to support replication. However, the 490 
coordination of all these functions would require a tightly controlled system, which 491 
we envision could be provided by the different oligomeric states the protein 492 
assumes. During the AAV life cycle, Rep has to catalyse reactions on different DNA 493 
substrates, including initiation of DNA replication, recognition and nicking of the trs, 494 
and binding to the p5 promoter in order to provide transcriptional regulation. It has 495 
been shown that Rep can form different oligomeric species in vitro, both in the 496 
absence of DNA and in the presence of different DNA substrates (24, 25), allowing 497 
for an additional layer of regulation of the Rep activities during the AAV life cycle. To 498 
fully understand the mechanism of action of Rep on its different substrates, it is 499 
essential to identify the oligomeric complexes formed with the different DNA 500 
molecules. For example, it has been shown that Rep68 forms a double-octameric 501 
ring in the presence of ssDNA as well as on forked helicase substrates (24), whereas 502 
other reports have suggested that Rep68 forms hexamers when bound to dsDNA 503 
(50, 60). However, the importance of these complexes for the viral life cycle has not 504 
been formally addressed, and while it is clear that Rep oligomerization is functionally 505 
relevant, data on possible oligomerization interfaces remain scarce. Smith and 506 
colleagues identified two regions – residues 151-188 and 334-347 – that when 507 
deleted disrupt Rep oligomerization, however they did not investigate the functional 508 
consequences of these deletions (50). Intriguingly, residues 334-346 include the ATP 509 
binding site that has been shown to be part of the oligomeric interface in PV-E1 and 510 
SV40-LTag hexamers. A more recent report showed that one residue, R107, initially 511 
identified for its role in integration, origin binding and nicking, and shown to be in 512 
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direct contact with origin DNA, is also essential for oligomerization (24, 61). Finally, 513 
we and others have shown that the interdomain linker of Rep78/68, and in particular 514 
the Y224 residue, is critical for Rep oligomerization (28, 32). 515 
Building on our previous studies, we further characterized the role of residue Y224 in 516 
Rep oligomerization. Substitution of Y224 using residues with different properties 517 
had varying consequences on Rep68* oligomerization. More specifically, small 518 
hydrophobic residue substitutions severely impaired oligomerization, while the more 519 
conservative Y224F mutant retained the ability to oligomerize (Figure 1), suggesting 520 
that Y224 participates in the formation and the stabilization of a hydrophobic 521 
interface. This hypothesis was supported by a model of a dimeric Rep-Rep 522 
interaction built from the pseudo-dimer observed in the crystal structure of Rep40  523 
using an extended Rep40 molecule (33). In this model, a large interface is formed 524 
that resembles the interface formed by the PV-E1 protein and includes residues from 525 
the Walker A, Walker B, PS1βH and β2β3 (Figure 2). Furthermore, all the helices in 526 
the OD are also participating in the interface and form a hydrophobic pocket, 527 
emphasizing the relevance of this sub-domain in Rep oligomerization. More 528 
specifically, linker residue Y224 on the extended α-helix 1 of one Rep molecule is 529 
interacting with residue I251 and with the main chain carbonyl oxygen of residue 530 
N254 on α-helix 3 of the other Rep molecule (Figure 2C). Mutating I251 to alanine in 531 
Rep68, alone or in combination with Y224A, confirmed that this residue is important 532 
for Rep68 oligomerization. Importantly, because none of the residues located in the 533 
OD that we identified as participating in the oligomeric interface are part of the 534 
described catalytic sites within the Rep proteins, the consequences of these 535 
mutations on the functions of the Rep proteins are likely to be due to 536 
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oligomerization defects. We showed that oligomerization-deficient mutants Y224A, 537 
I251A and Y224A-I251A are unable to replicate AAV DNA and fail to support the 538 
production of recombinant AAV. Our data suggest that these defects are caused by 539 
the loss of DNA binding and origin nicking activities by the mutant Rep proteins, and 540 
confirm that Rep oligomerization is critical for its function in support of the AAV life 541 
cycle. We also assessed the consequences on Rep function of a more conservative 542 
mutation, Y224F. This substitution maintains the bulky aromatic character of the 543 
residue, a feature that is conserved in the OD of SF3 helicases and other related 544 
proteins (28). The Rep68*-Y224F mutant retains the ability to oligomerize, but forms 545 
the large 13S complexes less efficiently than observed with Rep68* (Figure 1). 546 
Interestingly, the binding of RBS-containing DNA does not appear to be 547 
compromised by this mutation; nicking activity on the other hand is severely 548 
impaired, possibly explaining the observed low levels of viral replication (Figure 6). In 549 
view of the oligomeric behavior of the Y224F mutant, these results suggest that this 550 
mutant retains the ability to form an oligomeric complex sufficient for RBS-mediated 551 
DNA binding, but fails to promote the subsequent DNA nicking step. How this 552 
transition is affected, however, is not clear. One intriguing possibility is that the 553 
initial Rep binding to the RBS and melting of the origin promotes the recruitment of 554 
further Rep78/68 molecules and the assembly of a second, larger, Rep-DNA complex 555 
that is necessary for the nicking reaction.  Residue Y224, and more generally the OD, 556 
could help stabilize the formation of this complex, allowing a shift in the interaction 557 
with the origin DNA to allow the trs nicking reaction to take place. The Y224F 558 
mutation had previously been identified in a study by Walker et al. to be important 559 
for Rep function (62). In contrast to our findings, however, the authors reported that 560 
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the Y224F mutant was deficient in ITR binding, endonuclease, DNA helicase and 561 
ATPase activities. The cause of this difference may be due to a different 562 
experimental strategy, or could possibly be explained by the presence of a maltose-563 
binding protein (MBP) tag (62), which may affect the already weakened 564 
oligomerization potential of Rep68-Y224F.  565 
SF3 helicases are thought to function as oligomeric complexes, as is the case for PV-566 
E1 and SV40-LTag that form active hexameric complexes. Surprisingly, all the 567 
oligomerization-deficient mutants described here were still able to unwind a 568 
heteroduplex DNA substrate (Figure 5). This suggests that interaction with and the 569 
unwinding of this DNA substrate does not require the formation of large Rep 570 
oligomers, or alternatively that the presence of heteroduplex DNA and ATP stabilizes 571 
the formation of an oligomeric complex independently from the oligomeric interface 572 
described here. Rep40 and Rep52 are mostly monomeric and retain helicase activity, 573 
albeit to a lower level than that observed with the large Rep proteins (63). In our 574 
previous report we have introduced the possibility that AAV Rep proteins have 575 
evolved two distinct helicase modes (28): one that parallels the helicase activity of 576 
other SF3 helicases, requires oligomeric rings and is performed by the large Rep 577 
proteins, and one that only requires a transient dimerization and is characteristic for 578 
the activity of the small Rep isoforms. Thus, it is plausible that the mutants described 579 
here are still able to unwind DNA through the same mechanism used by Rep52/40, 580 
but they would not support the unwinding of a substrate that requires the helicase 581 
activity from oligomeric rings. Based on the different functions in the AAV life cycle 582 
of the large and small Rep proteins, it is tempting to suggest that melting of the AAV 583 
origin, which is mediated by the large Rep proteins, requires the formation of a 584 
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stable oligomer that unwinds DNA by a mechanism analogous to that described for 585 
other SF3 helicases, while packaging AAV genomes into the viral capsids, which is 586 
efficiently carried out by the small Rep proteins, may proceed through a different 587 
helicase mode. 588 
In addition to their role in supporting AAV DNA replication, the enzymatic activities 589 
of the Rep proteins are also essential for the correct transcriptional regulation of 590 
viral and cellular transcripts. Because it is known that the levels of Rep proteins are 591 
tightly regulated – and not simply maximized – to achieve efficient AAV DNA 592 
replication (58, 64), we assessed whether the expression levels of AAV proteins was 593 
affected by the oligomerization mutants. The K340H Rep mutant has been shown to 594 
fail in appropriately regulating the expression of the AAV genes, suggesting that the 595 
ATPase/helicase activity of Rep is involved in transcriptional regulation (48). A 596 
different mechanism of transcriptional repression, dependent on the RBS binding 597 
activity of Rep78/68 but not on its ATPase function, has also been demonstrated 598 
(20). In this study, we show that regulation of AAV gene expression is impaired in the 599 
presence of Rep oligomerization mutants that do not bind p5 or AAVS1 DNA, and our 600 
results suggest that oligomerization of the large Rep proteins is necessary for the 601 
correct regulation of the transcription of all AAV promoters (figure 7). More 602 
specifically, the oligomerization-deficient mutants fail to induce transcription of the 603 
viral promoters upon infection with the helper virus adenovirus and, in addition, 604 
both large and small Rep protein levels increase substantially in the presence of 605 
oligomerization mutants. The presence of the Y224A mutation creates a stronger 606 
Kozak sequence at the p19 promoter as compared to WT Rep68, but this is not 607 
sufficient to explain the differences in protein levels observed, in particular for 608 
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Rep78. In addition, the increase in Rep52 expression in the presence of the Y224A-609 
I251A mutations is modest compared to that observed for the Y224A alone. The 610 
differences in protein levels observed in presence of adenovirus, however, cannot be 611 
explained by the RNA levels alone, suggesting that there is some level of post-612 
transcriptional control that may also be Rep-dependent. A function for AAV Rep in 613 
this context was previously suggested in a study by Trempe and Carter, where it was 614 
observed that regulation of gene expression at a transcriptional level alone was not 615 
sufficient to explain differences in protein levels (59). Our data also support a role for 616 
an oligomeric complex of Rep in regulating protein levels post-transcriptionally. 617 
Understanding the mechanism behind this potential uncharacterized function of AAV 618 
Rep proteins may reveal a new layer of complexity in the role that the Rep proteins 619 
play in coordinating the AAV life cycle. 620 
In conclusion, our study identifies and describes an essential Rep-Rep protein 621 
interface that is involved in the formation of Rep complexes and demonstrates its 622 
functional relevance throughout the AAV life cycle. Our study focuses on residues 623 
that are part of the α-helical bundle located upstream of the helicase domain, and 624 
strengthen the role of this sub-domain of Rep as a bona fide oligomerization domain. 625 
The identification of the oligomeric interfaces of AAV Rep like the one described 626 
here, and further structural and functional characterisation of Rep oligomeric 627 
complexes, particularly in the presence of different DNA substrates, will provide 628 
additional insights into the molecular mechanisms of Rep-mediated transcriptional 629 
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Figure Legends 806 
 807 
Figure 1: Role of Tyr224 in Rep68 oligomerization. (A) Schematic diagram of Rep68, 808 
with the OBD in green and the helicase domain (HD) in blue. The sequence of the 809 
linker is shown and Y224 is highlighted in red. (B) Sedimentation velocity analysis of 810 
Rep68 and different Y224 mutants. (C) Quantification of the amount of 13S species 811 
formed by Y224 mutants.  812 
 813 
Figure 2: Model of a Rep-Rep interface. (A) Ribbon representation of Rep40 814 
extended to residue 217 as an α-helix highlighted in dark blue. The Walker A, Walker 815 
B, PS1βH, the β2β3 loop and OD are indicated. (B) Model of a dimeric Rep complex. 816 
The structures participating in the interface are highlighted in red and magenta. (C) 817 
Close-up of the interactions formed by residue Y224, including the hydrophobic 818 
interaction with I251 and the hydrogen bond with the backbone of N254. (D) 819 
Sedimentation velocity analysis of Rep68 mutants I251A and Y224A-I251A (YI 820 
mutant).  821 
 822 
Figure 3: The interface mutants are stable and localize to the nucleus. (A) Rep68 823 
WT or mutants were transfected in 293T cells and tested for expression levels by 824 
Western blotting 36h post-transfection. (B) 293T cells transfected with Rep68 WT or 825 




Figure 4: Interface mutants do not support the AAV life cycle. (A) Increasing 829 
volumes of supernatant from 293T cells producing recombinant AAV-GFP in the 830 
presence of Rep WT or mutants were used to infect HeLa cells, and the percentage 831 
of GFP-positive cells was determined by FACS analysis. Data from three independent 832 
experiments represented as mean ± SEM. (B) AAV DNA replication under permissive 833 
(+ Ad) and non-permissive (no Ad) conditions was quantified by quantitative PCR. 834 
Data from three experiments were normalized to the Rep*+Ad condition, and are 835 
represented as mean ± SEM. (C) AAV replicative intermediates generated in the 836 
same conditions as in (B) were visualized by Southern blotting using a Rep-specific 837 
probe. RfM: monomeric replicative form. RfD: dimeric replicative form. 838 
 839 
Figure 5: Comparison of the helicase activity of the interface mutants. The ability of 840 
the Rep68 interface mutants to unwind a fluorescein labeled heteroduplex DNA 841 
substrate was assayed. Data from three experiments represented as mean ± SEM.  842 
 843 
Figure 6: Rep-mediated nicking of supercoiled plasmid. Supercoiled (SC) plasmid 844 
DNA containing a RBS and a trs was mixed with Rep68* or the interface mutants. If 845 
the endonuclease activity is intact Rep will nick and relax the plasmid conformation 846 
to an open circular (OC) form, which can readily be distinguished by agarose gel 847 
electrophoresis. A trs mutant (TRSmut) plasmid that is not nicked by Rep was used as 848 
control. Untreated indicates DNA that was left untouched, while mock treated 849 
indicates plasmid that was incubated in reaction buffer 1h at 37˚C in the absence of 850 
protein. (A) Representative agarose gel electrophoresis image. (B) Quantification of 851 
four independent nicking experiments. Data represented as mean ± SEM.  852 
 37
 853 
Figure 7: Rep oligomerization is important for transcriptional regulation of AAV 854 
genes. (A) Western blot showing Rep and Cap protein levels under conditions 855 
permissive (+ adenovirus) and non permissive for AAV replication. The first lane of 856 
the left panel is equivalent to the third lane in the right panel. (B) Transcription levels 857 
of AAV genes were analyzed under the same conditions as in (A). RNA levels were 858 
measured by RT-PCR using three primer-probe mixes detecting RNA from the p5 859 
promoter only, from p5 and p19, and from p5, p19 and p40. The fold 860 
change was calculated relative to the mRNA levels in the presence of WT Rep but in 861 
the absence of adenovirus. Data from three experiments represented as mean ± 862 
SEM. 863 
 864 
Table 1: Rep68 and interface mutants binding constants on AAVS1 and p5 RBS-865 
containing DNA.  866 
Protein AAVS1-41 (nM) p5-41 (nM) 
Rep68* 128 203 
Rep68*-K340H 123 136 
Rep68*-Y224A nd* nd* 
Rep68*-Y224F 221 311 
Rep68*-I251A 1438 nd* 
Rep68*-YI nd* nd* 
*not determined due to poor binding. 867 







